<SEC-DOCUMENT>0001213900-25-041614.txt : 20250509
<SEC-HEADER>0001213900-25-041614.hdr.sgml : 20250509
<ACCEPTANCE-DATETIME>20250509172735
ACCESSION NUMBER:		0001213900-25-041614
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		49
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250509
DATE AS OF CHANGE:		20250509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		25931824

	BUSINESS ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(646) 677-3870

	MAIL ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ea0239143-10q_actinium.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 09 21:02:50 UTC 2025 -->
<html xmlns:atnm="http://www.actiniumpharma.com/20250331" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-6960">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="ixv-34"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric><b>&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended <b><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-6961">March 31, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-6962">2025</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-50"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric><b>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from __________ to __________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-61"><b>001-36374</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-67"><b>ACTINIUM PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-77"><span style="font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-82"><span style="font-size: 10pt"><b>74-2963609</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction of<br/>
Incorporation or Organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-100"><b>100 Park Ave., 23<sup>rd</sup> Floor</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-6963">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-6964">NY</ix:nonNumeric> </b></p></td> <td style="vertical-align: bottom; text-align: center">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-107"><span style="font-size: 10pt"><b>10017</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-6965">(646)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-6966">677-3870</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>Securities registered pursuant to Section&#160;12(b)
of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol</b>&#160;</span></td> <td style="width: 2%">&#160;</td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-146"><span style="font-size: 10pt"><b>Common stock, par value $0.001</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-151"><span style="font-size: 10pt"><b>ATNM</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-156"><span style="font-size: 10pt"><b>NYSE American</b></span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-6967">Yes</ix:nonNumeric> &#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-6968">Yes</ix:nonNumeric> &#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="background-color: white"> <td style="width: 25%"><span style="font-size: 10pt">Large accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> </tr> <tr style="background-color: white"> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-190"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span><span style="font-size: 10pt">&#160;</span></td> <td><span style="font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-198"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td> </tr> <tr style="background-color: white"> <td>&#160;</td> <td>&#160;</td> <td><span style="font-size: 10pt">Emerging growth company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-206"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric><span style="font-size: 10pt">&#160;</span></td> </tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards, provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;Yes
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-219"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric>&#160;No</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate the number of shares
outstanding of each of the issuer&#8217;s classes of common stock, as of May 9, 2025: <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-6969">31,195,891</ix:nonFraction></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#a_001"><span style="font-size: 10pt"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; width: 8%"><span style="font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top; width: 86%"><a href="#a_002"><span style="font-size: 10pt">Financial Statements</span></a></td>
    <td style="vertical-align: bottom; width: 6%; text-align: center">1</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><a href="#a_003"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="vertical-align: bottom; text-align: center">15</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><a href="#a_004"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="vertical-align: bottom; text-align: center">30</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><a href="#a_005"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: center">30</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#a_006"><span style="font-size: 10pt"><b>PART II &#8211; OTHER INFORMATION</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top"><a href="#a_007"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top"><a href="#a_008"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><a href="#a_009"><span style="font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><a href="#a_010"><span style="font-size: 10pt">Defaults Upon Senior Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><a href="#a_011"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: top"><a href="#a_012"><span style="font-size: 10pt">Other Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_013">Exhibits</a></span></td>
    <td style="vertical-align: bottom; text-align: center">67</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#a_014"><span style="font-size: 10pt"><b>SIGNATURES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">68</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I - FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. &#160;UNAUDITED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
consolidated financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion
of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at
March 31, 2025 and December 31, 2024, and the results of operations and cash flows for the three months ended March 31, 2025 and 2024,
respectively, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance
with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these
financial statements be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s audited financial
statements for the year ended December 31, 2024 in the Company&#8217;s Annual Report on Form 10-K. The results of operations for the three
months ended March 31, 2025 are not necessarily indicative of the operating results for the full year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6970">65,325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-6971">72,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-6972">1,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-6973">1,602</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25in">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-6974">66,456</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-6975">74,506</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net of accumulated depreciation of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-6976">939</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-6977">891</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-6978">317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-6979">364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted cash &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-6980">327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-6981">324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating leases right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-6982">1,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-6983">1,685</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance leases right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-6984">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-6985">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-6986">68,647</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-6987">76,899</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6988">6,520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6989">7,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating leases current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-6990">579</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-6991">569</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Finance leases current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-6992">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-6993">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25in">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6994">7,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-6995">8,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-6996">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-6997">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Long-term operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-6998">836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-6999">984</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Long-term finance lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-7000">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-7001">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-7002">42,953</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-7003">44,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-7004"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-7005">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-7006"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-7007">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-7008"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-7009"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-7010"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-7011">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-7012"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-7013">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-7014"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-7015">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-7016"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-7017">31,195,891</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-7018"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-7019">31,195,891</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-7020">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-7021">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-7022">417,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-7023">408,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-7024">391,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-7025">375,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7026">25,694</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7027">32,758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-7028">68,647</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-7029">76,899</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Three Months&#160;Ended<br/> March 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-7030">7,700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-7031">6,635</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-7032">8,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-7033">2,962</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-7034">16,638</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-7035">9,597</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7036">16,638</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7037">9,597</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income - net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-7038">700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-7039">927</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-7040">700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-7041">927</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7042">15,938</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7043">8,670</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss per share of common stock&#160;&#8211; basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-7044"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-7045">0.51</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-7046"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-7047">0.31</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Weighted average shares of common stock outstanding&#160;&#8211; basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-7048"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-7049">31,195,891</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-7050"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-7051">27,886,486</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2025 to March
31, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January 1, 2025</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-7052">31,195,891</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7053">31</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7054">408,553</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-7055">375,826</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7056">32,758</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-7057">8,874</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-7058">8,874</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7059">15,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7060">15,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, March 31, 2025</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-7061">31,195,891</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7062">31</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7063">417,427</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-7064">391,764</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7065">25,694</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2024 to March
31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January 1, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-7066">27,634,213</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7067">28</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7068">373,934</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-7069">337,583</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7070">36,379</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-7071">1,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-7072">1,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-7073">1,752,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-7074">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-7075">14,694</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-7076">14,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-7077">10,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-7078">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-7079">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7080">8,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7081">8,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, March 31, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-7082">29,396,411</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7083">29</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7084">390,081</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-7085">346,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-7086">43,857</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flows used in operating activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7087">15,938</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7088">8,670</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-7089">8,874</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-7090">1,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Depreciation and amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-7091">205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-7092">216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-7093">470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-7094">271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-7095">1,047</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-7096">440</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-7097">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-7098">129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-7099">7,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-7100">7,374</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows used in investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-7101">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash used in investing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-7102">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows used in/provided by financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-7103">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-7104">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Sales of shares of common stock, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-7105">14,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Proceeds from the exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-7106">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash used in/provided by financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" sign="-" unitRef="usd" id="ixv-7107">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-7108">14,768</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net change in cash, cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-7109">7,576</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-7110">7,383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-7111">73,228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-7112">76,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at end of period</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-7113">65,652</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-7114">84,373</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Condensed Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="ixv-1816"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:NatureOfBusinessPolicyPolicyTextBlock" id="ixv-1820"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a pioneer in the development of targeted radiotherapies
intended to meaningfully improve outcomes for patients with advanced cancers including relapsed or refractory disease who have failed
existing therapies. It is advancing a pipeline of differentiated clinical stage product candidates focused on validated cancer targets.
Its current pipeline is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene therapies that
the Company believes have high unmet needs that are not addressed by currently available treatment options.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-1824"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-1828"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates" id="ixv-1832"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-1837"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-1842"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="ixv-1846"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2025 and December 31, 2024:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-7115">65,325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-7116">72,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-7117">327</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-7118">324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-7119">65,652</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-7120">73,228</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-1911"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-1915"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-1919"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With
Customers </i>(&#8220;ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the
transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in
the contract; and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the
goods or services it transfers to the customer. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="ixv-1934"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis,
depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606<i>. </i>There was no revenue for the three months ended March 31, 2025 and March 31, 2024,
respectively.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="ixv-1956"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>There
was no grant revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1" escape="true" name="atnm:LicenseRevenuePolicyTextBlock" id="ixv-1962"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-1982"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-1987"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-2006"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-7121">For the three months ended March
31, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units
and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</ix:nonNumeric></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-7122">271</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-7123">5,421</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-7124">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-7125">305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-7126">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-7127">1,439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-7128">578</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-7129">7,165</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-2062"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, FASB issued
ASU 2023-07, <i>Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures</i>, which provides improvements to reportable
segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires the Company to disclose
significant segment expenses that are regularly provided to the chief operating decision maker, or CODM, and included within each reported
measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable
segment, a description of their composition and provide all annual disclosures about a reportable segment&#8217;s profit or loss and assets
pursuant to Topic 280 during interim periods. The Company must also disclose the CODM&#8217;s title and position, as well as certain information
around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and
deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures
required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The Company adopted this standard effective January
1, 2024, and reported in its Annual Report on Form 10-K for the year ended
December 31, 2024.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1" escape="true" name="atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock" id="ixv-2071"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_2" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB
issued ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic
220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03
require disclosures in the notes to the consolidated financial statements and specified information about certain costs and
expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b)
depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are
already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a
qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively.
The amendments in ASU 2024-03 are effective January 1, 2027 and effective for interim periods beginning January 1, 2028. The Company
is currently evaluating the impact of ASU 2024-03 on its financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, FASB issued
ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness
of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income
taxes paid information included in income tax disclosures. The Company is required to disclose additional information regarding reconciling
items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax
rate. Similarly, the Company is required to disclose income taxes paid (net of refunds received) equal to or greater than five percent
of total income taxes paid (net of refunds received). <span style="background-color: white">The amendments in ASU 2023-09 are effective
January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance.
The Company is currently evaluating the impacts of ASU 2023-09 on its financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-2101"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $<ix:nonFraction contextRef="c35" decimals="-6" format="ixt:num-dot-decimal" name="atnm:MilestonePayment" scale="6" unitRef="usd" id="ixv-7130">1</ix:nonFraction> million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of <ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="atnm:NetSalesPercentage" scale="-2" unitRef="pure" id="ixv-7131">2</ix:nonFraction>% of net sales will be due to FHCRC.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the Southern District of New York, wherein, the Securities Complaint alleges that the Defendants made material misrepresentations
and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all Defendants pursuant to section
10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated thereunder, as well as additional claims
against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint purports to assert class action claims
on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October 31, 2022 and August 2,
2024.&#160; Plaintiff seeks unspecified damages.&#160; On May 5, 2025, a derivative shareholder complaint (the &#8220;Derivative Complaint&#8221;)
was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability for the allegations
made in the Securities Complaint.&#160; The Defendants have not yet responded to the Securities Complaint, and they intend to vigorously
defend themselves against the plaintiff&#8217;s allegations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company and other Defendants intend to defend vigorously against such
claims, however, there can be no assurances as to the outcome.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-2114"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At March 31, 2025, the Company
has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment. The
Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseDescription" id="ixv-7132">5 years 2 months</ix:nonNumeric>, with an expiration
date of <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1" id="ixv-7133">July 30, 2027</ix:nonNumeric> and current annual rent of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="6" unitRef="usd" id="ixv-7134">0.6</ix:nonFraction> million. The Company is also responsible for certain other costs, such as insurance,
utilities and maintenance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-2126"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-7135">173</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-7136">173</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-7137">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-7138">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-7139">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-7140">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-7141">3</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-7142">3</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_LeaseCostTableTextBlock-c0_cont_2" id="_LeaseCostTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-7143">156</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-7144">153</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd" id="ixv-7145">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd" id="ixv-7146">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-7147">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-7148">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><ix:nonNumeric contextRef="c28" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-7149">2.3</ix:nonNumeric> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance Leases</td><td>&#160;</td> <td style="text-align: right"><ix:nonNumeric contextRef="c28" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-7150">1.8</ix:nonNumeric> years</td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. <ix:continuation continuedAt="_LeaseCostTableTextBlock-c0_cont_3" id="_LeaseCostTableTextBlock-c0_cont_2">Below is information on the weighted average discount rates used at the time that the leases were evaluated:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_3"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c28" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-7152">4.8</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-7153">6.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-2382"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding three months ended March 31, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-7154">475</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-7155">8</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-7156">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-7157">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-7158">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-7159">1,498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-7160">19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-7161">83</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-7162">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-7163">1,415</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" unitRef="usd" id="ixv-7164">18</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_OtherRevenueTextBlock-c0_cont_1" escape="true" name="atnm:OtherRevenueTextBlock" id="ixv-2461"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4  - Other revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. There was no grant
revenue recognized for the three months ended March 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#8220;EUMENA&#8221;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $<ix:nonFraction contextRef="c36" decimals="-6" format="ixt:num-dot-decimal" name="atnm:NonRefundablePaymentReceived" scale="6" unitRef="usd" id="ixv-7165">35</ix:nonFraction> million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="atnm_OtherRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#8217;s contract liabilities primarily consist of advanced payments from licensees. Long-term license revenue deferred was $<ix:nonFraction contextRef="c3" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-7166"><ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-7167">35</ix:nonFraction></ix:nonFraction>
million at March 31, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#8217;s regulatory approval
of Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-2488"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company
entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, &#8220;JonesTrading&#8221;, pursuant
to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $<ix:nonFraction contextRef="c37" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-7168">200</ix:nonFraction> million of its common stock.
On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales
Agreement&#8221;) with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The A&amp;R Sales Agreement modifies the
original Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares of common
stock are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the
&#8220;Prior Shelf Registration Statement&#8221;). On August 11, 2023, the Company filed a new registration statement on Form S-3 (File
No. 333-273911), which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024, to replace
the Prior Shelf Registration Statement, including a base prospectus which covers the offering, issuance and sale of up to $<ix:nonFraction contextRef="c38" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="6" unitRef="usd" id="ixv-7169">500</ix:nonFraction> million
of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering,
issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction contextRef="c38" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-7170">200</ix:nonFraction> million of common stock that may be issued and sold under the Amended
Sales Agreement. On March 31, 2025, upon filing of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024,
the Company became subject to General Instruction I.B.6 of Form S-3, pursuant to which in no event will the Company sell its common stock
in a registered primary offering using Form S-3 with a value exceeding more than one-third of its public float in any 12 calendar month
period so long as its public float remains below $<ix:nonFraction contextRef="c39" decimals="-6" format="ixt:num-dot-decimal" name="atnm:AggregateMarketValueOfCommonStock" scale="6" unitRef="usd" id="ixv-7171">75</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company did not sell any
shares of common stock during the three months ended March 31, 2025. During the three months ended March 31, 2024, the Company sold <ix:nonFraction contextRef="c22" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares" id="ixv-7172">1.8</ix:nonFraction>
million shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c22" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-7173">15.0</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c22" decimals="-5" format="ixt:num-dot-decimal" name="atnm:NetProceedFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-7174">14.7</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-2499"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-7175">5,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-7176">6.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c50" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-7177">7.04</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-7178">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-7179">1.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-7180">4,891</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-7181">6.45</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-7182">271</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-7183">6.49</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c44" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-7184">7.61</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, March 31, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-7185">152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-7186">7.54</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c44" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-7187">7.16</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
March 31, 2025, the Company granted new employees options to purchase <ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares" id="ixv-7188">25</ix:nonFraction> thousand shares of
common stock with an exercise price ranging from $<ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-7189">1.06</ix:nonFraction> to $<ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-7190">1.43</ix:nonFraction> per share, a term of <ix:nonNumeric contextRef="c40" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="ixv-7191">10 years</ix:nonNumeric>, and a vesting period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-7192">4</ix:nonNumeric> years. The options
had an aggregated fair value of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="3" unitRef="usd" id="ixv-7193">28</ix:nonFraction> thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
option-pricing model include: (1) discount rate range from <ix:nonFraction contextRef="c41" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-7194">4.0</ix:nonFraction>% to <ix:nonFraction contextRef="c42" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-7195">4.5</ix:nonFraction>% (2) expected life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-7196">6</ix:nonNumeric> years, (3) expected volatility range from
<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" unitRef="pure" id="ixv-7197">90.6</ix:nonFraction>% to <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" unitRef="pure" id="ixv-7198">90.7</ix:nonFraction>%, and (4) <span style="-sec-ix-hidden: hidden-fact-51">zero</span> expected dividends. During the three months ended March 31, 2024, the Company did not grant any stock options.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, the Board of Directors approved of the cancellation
of stock options to purchase an aggregate of <ix:nonFraction contextRef="c43" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="6" unitRef="usd" id="ixv-7199">4.9</ix:nonFraction> million shares of common stock held by certain current employees and directors that were
initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated Stock Plan. Such cancellations were
subject to the consent of the applicable holders of the stock options, which the Company received. The cancellation of these stock options
resulted in the recording of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="6" unitRef="usd" id="ixv-7200">8.7</ix:nonFraction> million in stock compensation expense. During the three months ended March 31, 2024, the Company recorded
compensation expense related to stock options of $<ix:nonFraction contextRef="c44" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-7201">1.2</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2025
was $<ix:nonFraction contextRef="c45" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" unitRef="usd" id="ixv-7202">0.4</ix:nonFraction> million related to unvested options, which is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c44" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-7203">2.3</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-2684"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c51" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-7204">300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-7205">5.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c46" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-7206">300</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-7207">5.85</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $<ix:nonFraction contextRef="c46" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="6" unitRef="usd" id="ixv-7208">1.8</ix:nonFraction> million, was determined based on the stock
price on the dates of the grant and is being recognized over three years. The unrecognized compensation expense at March 31, 2025 of $<ix:nonFraction contextRef="c46" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" unitRef="usd" id="ixv-7209">0.2</ix:nonFraction>
million is expected to be expensed over <ix:nonNumeric contextRef="c47" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-7210">0.4</ix:nonNumeric> years. During the three months ended March 31, 2025 and 2024, the Company recorded compensation
expense related to RSUs of $<ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-7211">0.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c48" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-7212">0.1</ix:nonFraction> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-2763"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-7213">7</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-7214">17.33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-7215">4.46</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-7216">7</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-7217">17.33</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c54" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-7218">4.20</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" scale="0" unitRef="shares" id="ixv-7219">7</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-7220">17.77</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c54" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" id="ixv-7221">4.00</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENT NOTICE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Quarterly Report on Form
10-Q and other reports filed by the Company from time to time with the Securities and Exchange Commission contains or may contain certain
forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company&#8217;s
management as well as estimates and assumptions made by Company&#8217;s management. Readers are cautioned not to place undue reliance
on these forward-looking statements, which are only predictions and speak only as of the date hereof. For this purpose, any statements
contained in this Quarterly Report on Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements.
&#160;Without limiting the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221;
&#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221; or comparable terminology are intended to identify forward-looking
statements. &#160;These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially
depending on a variety of factors, many of which are not within our control. &#160;These factors include but are not limited to economic
conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition
from much larger competitors; technological advances and failure to successfully develop business relationships. Although we believe that
the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance,
or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update
any of the forward-looking statements to conform these statements to actual results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;, the &#8220;Company&#8221;,
or &#8220;we&#8221;) is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients
with advanced cancers including relapsed or refractory (&#8220;r/r&#8221;) disease who have failed existing therapies. We are advancing
a pipeline of differentiated clinical and preclinical stage product candidates focused on validated cancer targets. Our current pipeline
is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene therapies that we believe have high
unmet needs that are not addressed by currently available treatment options. Our goal is to create a specialty radiopharmaceutical company
with capabilities across radioisotope production, final drug product manufacturing, preclinical research and development (&#8220;R&amp;D&#8221;)
and clinical development. We are deploying our technologies and capabilities, which we believe to be industry-leading, and intellectual
property with approximately 240 issued and pending patents worldwide, to develop targeted and next-generation radiotherapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Our Targeted Radiotherapy Candidate Pipeline</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are advancing two clinical stage product candidates that are directed
against validated cancer targets. Actimab-A is our lead product candidate in development and is intended to address the significant unmet
medical needs of patients with myeloid malignancies, including acute myeloid leukemia (&#8220;AML&#8221;) and myelodysplastic syndromes
(&#8220;MDS&#8221;). We are also evaluating Actimab-A&#8217;s potential to synergize with PD-1 immune checkpoint inhibitors (&#8220;ICIs&#8221;)
in solid tumor indications through the depletion of immune cells known as myeloid derived suppressor cells (&#8220;MDSCs&#8221;). Iomab-ACT
is a next-generation targeted conditioning agent we are developing with the intent to improve patient access to, and outcomes with, cellular
therapies such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle
cell disease (&#8220;SCD&#8221;). We are also developing ATNM-400, a novel preclinical, non-prostate specific-membrane antigen (&#8220;non-PSMA&#8221;)
targeting, first-in-class radiotherapy utilizing the Actinium-225 (&#8220;Ac-225&#8221;) radioisotope payload intended for patients with
prostate cancer directed against a novel radiotherapy target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in; text-align: justify">Actimab-A is being developed as a targeted radiotherapeutic to leverage
the Ac-225 isotope payload directed against CD33, a target expressed ubiquitously in patients with AML, MDS and other myeloid
malignancies. We are attempting to leverage the mutation-agnostic ability of Ac-225 to establish Actimab-A as a backbone therapy in myeloid
malignancies, which are extremely heterogenous and radiosensitive, as a single agent or in combinations with chemotherapy, targeted agents,
cellular therapy and immunotherapy. Actimab-A has been studied in over 150 patients as a single agent and in combination with other modalities.
This clinical experience is informing our current clinical development strategy for Actimab-A. We plan to initiate a Phase 2/3 trial with
Actimab-A in combination with the chemotherapy regimen CLAG-M in patients with r/r AML based on promising results with this combination
in a Phase 1b trial. In addition to our internal development efforts, we entered into a Cooperative Research and Development Agreement
(&#8220;CRADA&#8221;) with the National Cancer Institute (&#8220;NCI&#8221;) in February 2023 for the development of Actimab-A for AML
and other myeloid malignancies. The first Actimab-A trial initiated under the CRADA is being conducted in patients with frontline AML
in combination with Venetoclax, an oral Bcl-2 inhibitor and ASTX-727, an oral hypomethylating agent (&#8220;HMA&#8221;) developed by Taiho
Oncology, an Otsuka Holdings company. We anticipate that additional trials will be initiated under the NCI CRADA as multiple proposals
have been submitted for review.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March of 2025, we initiated
our Actimab-A solid tumor program that will combine Actimab-A with PD-1 checkpoint inhibitors. We initiated this program to evaluate if
Actimab-A can deplete CD33 expressing MDSCs and hence improve patient outcomes in combination with PD-1 ICIs such as KEYTRUDA<sup>&#174;</sup>&#160;and
OPDIVO<sup>&#174;</sup>. The Actimab-A solid tumor program is comprised of several controlled, head-to-head clinical trials that will evaluate
the combination of Actimab-A with KEYTRUDA<sup>&#174;</sup>&#160;versus KEYTRUDA<sup>&#174;</sup>&#160;alone, and Actimab-A with OPDIVO<sup>&#174;</sup>&#160;versus
OPDIVO<sup>&#174;</sup>&#160;alone. The initial tumors that are being targeted are Head and Neck Squamous Cell Carcinoma (&#8220;HNSCC&#8221;)
and Non-Small Cell Lung Cancer (&#8220;NSCLC&#8221;) with a separate trial for each indication.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 is our newest
targeted radiotherapy program that we are advancing for prostate cancer. We believe there is a high unmet need for patients with
advanced prostate cancer, particularly those who progress after receiving the targeted radiotherapy Pluvicto<sup>&#174;</sup>.
Pluvicto<sup>&#174;</sup> (Lu-177-PSMA-617) is a prostate-specific membrane antigen (PSMA) directed targeted radiotherapy that uses
the beta-particle emitting radioisotope Lutetitium-177 (&#8220;Lu-177&#8221;) that is approved for patients with metastatic prostate
cancer. Pluvicto<sup>&#174;</sup> is marketed and sold by Novartis and generated sales of $1.39 billion in 2024. ATNM-400 is
differentiated from Pluvicto as it targets a different marker than PSMA that has been shown to be overexpressed in patients with
prostate cancer and uses the alpha-particle emitter Ac-225, which is more potent than Lu-177 but has a shorter path length, which
could result in fewer off-target effects such as xerostomia or dry mouth. Given the biology of the antigen targeted by ATNM-400 and
the precise and potent cell-killing of Ac-225, we believe ATNM-400 has transformative potential to address unmet needs in prostate
cancer for Pluvicto ineligible patients, after that drug has failed and even as an alternative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2025, preclinical
data with ATNM-400 was presented at the American Association for Cancer Research (&#8220;AACR&#8221;) annual meeting. In vivo studies
demonstrated that ATNM-400 is more efficacious than Pluvicto and produced a statistically significant (p &lt; 0.0001) reduction in tumor
volume in 22Rv1 prostate cancer models with 99.8% tumor growth inhibition achieved with a single 40 &#181;Ci/kg dose of ATNM-400. In
addition, expression of the target receptor for ATNM-400 persisted following Pluvicto therapy and ATNM-400 demonstrated sustained tumor
control after Pluvicto stopped working. ATNM-400 internalized rapidly, exhibiting potent cytotoxicity and prostate cancer-cell killing
via double strand DNA breaks that were produced by the Ac-225 alpha-particle emitting radionuclide payload of ATNM-400. ATNM-400 was
well tolerated with no apparent toxicities at two different dose levels. Biodistribution analyses showed sustained uptake in tumors up
to the 216-hour time point, with rapid clearance from the blood by the 48-hour time point and clearance from essential organs including
the kidneys, intestines and liver. We plan to continue to study and advance ATNM-400 and expect to present additional data in mid-2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to ATNM-400, we
have active R&amp;D efforts leveraging our in-house preclinical development and translational research capabilities that are primarily
focused on supporting our ATNM-400 preclinical program, the Actimab-A and Iomab-ACT clinical programs and advancing several preclinical
programs for solid tumor indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-ACT is our next-generation
targeted conditioning agent directed against CD45, a target expressed widely across the hematopoietic system including normal nucleated
immune cells such as lymphocytes that are relevant to this program and uses the Iodine-131(&#8220;I-131") radioisotope payload. We
are developing Iomab-ACT as conditioning for cell and gene therapies in both malignant and non-malignant hematologic indications. Iomab-ACT
utilizes non-myeloablative doses of I-131, to not fully deplete the patient&#8217;s bone marrow and immune system with the goal of improving
patient access and outcomes for potentially curative cell and gene therapies by replacing the need for the non-targeted, chemotherapy-based
conditioning regimens that are currently used. Iomab-ACT is currently being studied in three clinical trials. These trials include Iomab-ACT
with a commercial CAR-T therapy, Iomab-ACT prior to allogeneic BMT for patients with SCD, which could potentially inform a trial design
with gene therapy for SCD, and Iomab-ACT with a novel investigational CD19 CAR-T therapy.&#160;In May 2025, we announced that the first
patient was enrolled in the Iomab-ACT commercial CAR-T trial at the University of Texas Southwest Medical Center (&#8220;UTSW&#8221;).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
previously advanced our targeted conditioning program Iomab-B through the Phase 3 Study of Iomab-B in Elderly Relapsed and Refractory
AML (&#8220;SIERRA&#8221;) trial, a 153 patient, randomized multi-center trial conducted in the United States. and Canada. Iomab-B is
comprised of the anti-CD45 monoclonal antibody apamistamab with myeloablative doses of I-131 intended to enable patient access to bone
marrow transplant (&#8220;BMT&#8221;), the only potentially curative treatment option for patients with r/r AML. At this time, we are
seeking a strategic partner for Iomab-B to conduct an additional clinical trial based on feedback from the U.S. Food &amp; Drug Administration
(&#8220;FDA&#8221;) and are committed to establishing the best development path forward for Iomab-B in the U.S., while keeping internal
resources and strategic priorities in focus. As previously disclosed and noted above, Actinium also has a License Agreement with Immedica,
granting Immedica the exclusive product rights for commercialization of Iomab-B in certain countries in the European Economic Area, Middle
East and North Africa (&#8220;EUMENA&#8221;) region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Clinical Targeted Radiotherapy Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Actimab-A: Mutation Agnostic Mechanism of Action
with Backbone Therapy Potential in Myeloid Malignancies including AML and high-risk MDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0 0pt 0in; text-align: justify">Actimab-A <i>(Ac-225-lintuzumab satetraxetan) </i>is our lead radiotherapeutic
product candidate in development for patients with myeloid malignancies. To our knowledge, Actimab-A is the only CD33 targeting radiotherapy
in clinical development. We are focused on developing Actimab-A as both a monotherapy and in combination with other treatment regimens
to leverage both the potential mechanistic synergies of radiation and its mutation agnostic cell- killing ability. In addition to our
internal development efforts, we entered into a CRADA with the NCI in February 2023 for the development of Actimab-A for AML and other
myeloid malignancies.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We intend to establish Actimab-A as a backbone therapy, leveraging
the broad expression of CD33 in myeloid malignancies such as AML and MDS, which, like most blood cancers, are highly sensitive to radiation.
AML is a highly heterogenous, mutation-rich cancer with over 70 identified driver genetic mutations. However, there are only approved
therapies for four mutations including FLT3, IDH1 &amp; IDH2, and KMT2A. CD33 is expressed regardless of other mutations being present.
The Ac-225 isotope payload that we utilize with Actimab-A emits potent alpha-particles with high linear energy that kill cells via double
strand DNA breaks for which there is no known resistance or repair mechanism.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our development strategy is
to exploit these properties of Actimab-A to address the unmet needs of patients with myeloid malignancies across the treatment journey
including the frontline, relapsed/refractory and maintenance settings. To accomplish this, we are leveraging our clinical development
experience, clinical data and preclinical work supporting Actimab-A&#8217;s mutation agnostic capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A + CLAG-M Pivotal Phase 2/3 Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have aligned with the FDA
on a randomized pivotal Phase 2/3 trial to compare Actimab-A + CLAG-M to CLAG-M alone in patients with r/r AML. Based on our interactions
with the FDA, this trial will first complete a Phase 2 portion where the Actimab-A dose will be optimized in combination with CLAG-M.
We expect the Phase 2 portion of this trial to be initiated in the second half of 2025. Once the optimized Actimab-A dose is determined,
we expect the trial will advance to the Phase 3 portion of the study, which may reduce time and resources required compared to separate
Phase 2 and Phase 3 studies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary endpoint of the
Phase 3 trial will be Overall Survival. Event-Free Survival (&#8220;EFS&#8221;) and other efficacy measures as well as safety also being
evaluated. We are actively seeking potential strategic partners or collaborators to advance this trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A NCI CRADA Trials</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2023, we entered into a
CRADA with NCI to develop Actimab-A for the treatment of patients with AML and other hematologic malignancies. The NCI will serve as the
regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A, and the CRADA will provide support for
and may accelerate the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel
combinations. The CRADA studies will be overseen by the NCI in collaboration with Actinium&#8217;s clinical development team, where we
have the right to review and approve all protocols and have full rights to all data. The NCI CRADA provides for us to supply Actimab-A
and for NCI to cover all clinical trial execution and development expenses, which we believe will be a cost-efficient approach as opposed
to a Company sponsored trial and may therefore spare our balance sheet. The NCI Cancer Therapy Evaluation Program (&#8220;CTEP&#8221;),
which sponsors approximately two thirds of all combination cancer studies, will accept Letters of Intent (&#8220;LOIs&#8221;) or concepts
for Phase 1, 2 or 3 studies of Actimab-A in AML and other hematological malignancies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, the NCI announced
that its myeloMATCH program was officially open to patient enrollment across the U.S. and Canda. MyeloMATCH is a portfolio of clinical
trials to test precision medicine treatments for adults with AML or MDS being designed and led by four leading cancer research organizations
including the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG Cancer
Research Network in collaboration with the NCI National Clinical Trials Network (&#8220;NCTN&#8221;). Collectively, the myeloMATCH program
expects to open trials at hundreds of cancer care sites across the U.S. and Canada with the goal of enrolling 5,000 or more patients over
the next several years. Under our CRADA with the NCI, Actimab-A is part of the myeloMATCH program and may be included in future clinical
trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A, Venetoclax &amp; ASTX-727 &#8211;
Frontline AML Triplet Phase 1b Combination Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we announced
the initiation of the first clinical trial to be conducted under our CRADA by NCI. The trial will evaluate the triplet combination comprised
of Actimab-A, Venetoclax and ASTX-727, a novel oral HMA developed by Taiho Oncology, an Otsuka Holdings company, in frontline AML patients.
Venetoclax in combination with HMAs (Ven-HMA) is approved for patients with newly diagnosed AML. We believe this trial is supported by
our Actimab-A + Venetoclax combination trial that showed that combination was well-tolerated and showed supportive anti-leukemic activity.
The frontline AML triplet trial is expected to enroll up to 48 patients who are newly diagnosed with AML that are age 75 and above and
not eligible for intensive chemotherapy. The trial will evaluate various dose levels of Actimab-A along with dosing regimens. We expect
initial clinical data to be generated from this trial in second half of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional clinical trial
concepts for Actimab-A have been submitted under the CRADA and are being reviewed. We anticipate that additional clinical trials with
Actimab-A will be initiated in 2025 including under the CRADA to leverage Actimab-A&#8217;s mutation agnostic mechanism.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Data Supporting Actimab-A&#8217;s Mutation Agnostic Profile</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To leverage Actimab-A&#8217;s mutation agnostic capabilities and support
its broad development, we have conducted preclinical experiments studying Actimab-A in combination with targeted agents including Bcl-2
inhibitors, FLT-3 inhibitors, IDH inhibitors, menin inhibitors for NPM1 and KMT2A AML, chemotherapies such as azacitidine and in cell lines
expressing TP53 mutations.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2025, we
presented data at the AACR annual meeting preclinical data demonstrating that the combination of Actimab-A with standard of care
targeted AML therapies including menin and FLT3 inhibitors and the HMA azacitidine resulted in significant antileukemic activity in
AML cells lines with FLT3, NPM1, KMT2A and TP53 mutations. Additionally, in animal models, Actimab-A significantly enhanced tumor
growth inhibition, prolonged the duration of response and survival when combined with the menin inhibitor revumenib, and potentiated
AML cell killing in combination with the FLT3 inhibitor gilteritinib and HMA azacitidine. We expect to present additional data
supporting Actimab-A&#8217;s mutation agnostic capabilities and backbone potential at future scientific and medical conferences. In
addition, we will continue to explore potential clinical trials under our CRADA with NCI, investigator-initiated trials or under our
sponsorship.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Actimab-A Solid Tumor Program: Potential Pan
Solid Tumor Therapy in Combination with PD-1 Checkpoint Inhibitors Including KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> by Depleting
Myeloid Derived Suppressor Cells </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given the significant number of patients treated with PD-1 ICIs, there
is extensive data in the medical literature on outcomes in these patients. PD-1 ICIs have significantly improved patient outcomes across
several solid tumor indications, however, not all patients have robust or durable responses. Multiple therapeutic modalities have been
studied in combination with PD-1 ICIs in attempt to improve patient outcomes, but few combinations have produced a sufficient clinical
benefit to have been approved. To our knowledge, our Actimab-A solid tumor program is the only CD33 targeted radiotherapy being evaluated
in combination with PD-1 ICIs. The rationale for studying Actimab-A in combination with either KEYTRUDA<sup>&#174;&#160;</sup>or OPDIVO<sup>&#174;&#160;</sup>is
based on the premise that depleting MDSCs with Actimab-A will improve the efficacy of these drugs.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDSCs are immune-suppressive
cells that help tumors evade immune detection and promote disease progression. They are overexpressed in the tumor microenvironment in
several different solid tumors and associated with poor outcomes. They work by multiple mechanisms but most relevant to PD-1 inhibitors
which work by keeping T-cells active is that MDSCs prevent T-cells from recognizing and attacking cancer cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Studies have shown that MDSCs are overexpressed in patients with cancers.
For instance, a study by Bronte et al., in patients with NSCLC receiving ICIs evaluated the role of immune cells on patient outcomes.
In this study, MDSCs were the only immune cell subtype to show a statistically significant association with tumor response. The median
level of MDSCs was determined to be 1.9% with patients above that level being classified as &#8220;High-MDSC&#8221; and patients below
that level being classified as &#8220;Low-MDSC&#8221;. In this study, only Low-MDSC patients had a clinical response, with no responses
observed in High-MDSC patients and over 80% of High-MDSC patients having progressive disease. In addition, Low-MDSC patients had a statistically
significantly improvement in progression-free survival (&#8220;PFS&#8221;) of 8.39 months compared to 1.94 months in High-MDSC patients
and OS of 15.15 months compared to 3.03 months in High-MDSC patients.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is considerable preclinical
scientific evidence in the literature that depleting MDSCs could be a viable strategy in improving the outcomes of PD-1 directed immunotherapy,
however, there have been no viable clinical approaches that have been tried successfully to our knowledge.&#160; MDSCs are known to express
the CD33 antigen which is the target of Actimab-A.&#160; Actinium has also generated published and unpublished preclinical data showing
that Actimab-A can selectively deplete MDSCs in solid tumors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe there is strong
scientific rationale supporting the potential for Actimab-A to deplete CD33 expressing MDSCs and hence improve patient outcomes with PD-1
ICIs such as KEYTRUDA<sup>&#174;</sup>&#160;and OPDIVO<sup>&#174;</sup>. Our Actimab-A solid tumor program is expected to be comprised of
several controlled, head-to-head clinical trials that will evaluate the combination of Actimab-A with KEYTRUDA<sup>&#174;</sup>&#160;versus
KEYTRUDA<sup>&#174;</sup>&#160;alone, and Actimab-A with OPDIVO<sup>&#174;</sup>&#160;versus OPDIVO<sup>&#174;</sup>&#160;alone. The initial
tumors that are being targeted are HSNCC and NSCLC with a separate trial for each indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patient population for
these trials will be adults with PD-L1 expression and locally advanced metastatic HNSCC or NSCLC randomized to either Actimab-A alone
or Actimab-A with a specific checkpoint inhibitor. The objective of each trial would be to evaluate the safety and tolerability as well
as following endpoints including ORR, PFS and OS. Further, the following biomarker data would be collected including the pattern of depletion
of CD33+ MDSCs and T-cell activity in peripheral blood. We expect to present initial proof of concept clinical data from the first of
these trials in the second half of 2025 as well as provide an update on the outlook for the rest of the trials for the Actimab-A solid
tumor program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ATNM-400 Program: Novel, First-in-Class, Non-PSMA Targeting Ac-225 Radiotherapy for Prostate Cancer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we announced
ATNM-400, a novel, first-in-class Ac-225-based radiotherapy intended for patients with prostate cancer. Prostate cancer is the most common
cancer in men, with approximately 1 in 8 men diagnosed with prostate cancer during their lifetime. According to the American Cancer Society,
an estimated 313,780 new cases of prostate cancer will be diagnosed in the United States in 2025. The global incidence of prostate cancer
is approximately 1.5 million new cases annually. Approximately 20% of prostate cancer cases are more aggressive forms that progress to
metastatic disease, which is associated with significantly worse survival outcomes. Radiotherapy is commonly used to treat prostate cancer,
and in 2022, the PSMA-targeting radiotherapy Pluvicto<sup>&#174;</sup> was approved by the FDA and the European Medicines Agency (&#8220;EMA&#8221;)
for the treatment of patients with metastatic castration-resistant prostate cancer. Pluvicto<sup>&#174;</sup> is marketed and sold by Novartis
and generated sales of $1.39 billion in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 is differentiated
from Pluvicto and the majority of radiotherapies in development for prostate cancer, as it targets a different marker than PSMA that has
been shown to be overexpressed in patients with prostate cancer. In addition, ATNM-400 uses the alpha-particle emitter Ac-225, which is
more potent than Lu-177 but has a shorter path length, which could result in fewer off-target effects such as xerostomia or dry mouth.
We believe there is a high unmet need for patients with advanced prostate cancer, particularly those who progress after receiving the
targeted radiotherapy Pluvicto<sup>&#174;</sup>. We have generated preclinical data with ATNM-400 in prostate cancer models, which was
presented at the AACR annual meeting in April 2025. The ATNM-400 presentation highlighted the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In vivo studies demonstrated that ATNM-400 is
more efficacious than Pluvicto<sup>&#174;</sup> and produced a statistically significant (p &lt; 0.0001) reduction in tumor volume in 22Rv1
prostate cancer models;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg" style="height: 226px; width: 300px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
                                            mice bearing Pluvicto<sup>&#174;</sup>-failed tumors, ATNM-400 was administered on day 14
                                            following Pluvicto<sup>&#174;</sup>treatment, demonstrating robust antitumor activity and
                                            tumor growth inhibition in Pluvicto<sup>&#174;</sup>- resistant tumor models;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg" style="height: 238px; width: 624px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Expression of the target receptor for ATNM-400 persisted following
Pluvicto<sup>&#174;</sup> therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto<sup>&#174;</sup> stopped working, which
we believe supports its potential utility in post-Pluvicto<sup>&#174; </sup>treatment settings;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">ATNM-400 demonstrated
                                            greater efficacy than Pluvicto<sup>&#174;</sup> in prostate cancer models with 99.8% tumor
                                            growth inhibition achieved with a single 40 &#181;Ci/kg dose of ATNM-400 supporting its
                                            potential to be offered as an alternative option;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">ATNM-400 internalized rapidly, exhibiting potent cytotoxicity and prostate
cancer cell killing via double strand DNA breaks that were produced by the Ac-225 alpha-particle emitting radionuclide payload of ATNM-400;</p></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Biodistribution analyses showed sustained uptake in the tumor
up to the 216-hour time point, with rapid clearance from the blood by the 48-hour time point and clearance from essential organs including
the kidneys, intestines and liver; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">ATNM-400 was well tolerated with body weight recovery and
no apparent toxicity at both doses evaluated in vivo</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are progressing the further development of ATNM-400 and expect to have further updates on this program mid-2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Iomab-ACT Program: Potential Universal Targeted
Conditioning Agent for Cell &amp; Gene Therapies to Improve Patient Access and Outcomes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The opportunity exists for better conditioning regimens in the area
of cellular therapies beyond the non-targeted chemotherapy-based regimens that are used currently. We are working on a next-generation
targeted conditioning program, Iomab-ACT, for the rapidly growing cell and gene therapy market, as well as BMT conditioning for non-malignant
hematologic indications such as SCD.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are studying
Iomab-ACT in collaboration with Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;), for conditioning prior to CAR-T
therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (&#8220;B-ALL&#8221;) or diffuse large B-cell
lymphoma (&#8220;DLBCL&#8221;). This study, funded by a NIH grant is the first study of its kind to use an ARC, with CAR-T therapy.
At the 2024 Tandem Meetings | Transplantation&amp; Cellular Therapy Meetings of ASTCT and CIBMTR, we presented results from the
ongoing Phase 1 trial. No patients (0/4) developed Immune Effector Cell-Associated Neurotoxicity Syndrome (&#8220;ICANS&#8221;) of
any grade, a major safety measure of the study, as ICANS is observed in 25% or more of patients with r/r B-ALL and DLBCL treated
with various CAR T-cell products and negligible incidence of cytokine release syndrome (&#8220;CRS&#8221;). Additionally, Iomab-ACT
demonstrated transient depletion of peripheral blood lymphocytes and monocytes. Persistence of CAR T-cells up to 8 weeks and minimal
non-hematologic toxicities have been observed to date. These results prompted us to explore additional clinical trials with
Iomab-ACT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have initiated an investigator-sponsored
trial studying Iomab-ACT as targeted conditioning prior to patients receiving an FDA approved commercial CAR-T therapy at UTSW. To our
knowledge, this is the first trial to study a targeted radiotherapy conditioning agent with a commercial CAR-T therapy. Given the robust
clinical data that exists with commercial CAR-T therapies, we believe this trial may demonstrate the potential for Iomab-ACT to improve
outcomes over current chemotherapy conditioning regimens, which we are seeking to replace and provide patients better access to CAR-T.
In May 2025, we announced that the first patient was enrolled in this trial, which will enroll up to 30 patients. We expect to generate
initial proof-of-concept clinical data by year end 2025.&#160;The primary objectives of this study are safety, tolerability and efficacy.
Secondary objectives will evaluate incidences of CRS and ICANS as well as the persistence and expansion of CAR-T cells, which has been
associated with improved efficacy and patient outcomes. If successful, we believe this Phase 1b/2 trial could support a pivotal trial,
which could be initiated as early as 2026.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-ACT is also being studied
in an investigator-led clinical trial as targeted conditioning prior to a BMT for patients with SCD in collaboration with Columbia University.
Sickle cell disease is a rare, debilitating and life-threatening blood disorder with significant unmet need that affects approximately
100,000 people in the U.S. Patients with sickle cell disease have a mutation that causes red blood cells to develop a crescent or &#8220;sickle&#8221;
shape, which restrict the flow in blood vessels and limit oxygen delivery to the body&#8217;s tissues, leading to severe pain and organ
damage called vaso-occlusive events (&#8220;VOEs&#8221;) or vaso-occlusive crises (&#8220;VOCs&#8221;). The recurrence of these events
or crises can lead to life-threatening disabilities and/or early death. A BMT is a potentially curative treatment option for patients
with sickle cell disease, particularly in patients who have had complications such as strokes, acute chest crises or recurring pain crises
due to their disease. We expect patient enrollment for the Phase 1 trial to commence in the first half of 2025 and enroll up to 24 patients
with initial safety and efficacy results from the initial cohort of patients receiving Iomab-ACT prior to a BMT for their SCD in the second
half of 2025. If safety is demonstrated, the trial is expected to inform a clinical trial to evaluate Iomab-ACT as a targeted conditioning
agent prior to gene therapy for which there are two approved agents for patients with sickle cell disease, Casgevy (Vertex Pharmaceuticals,
Inc.) and Lyfgenia (Bluebird Bio, Inc.).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to continue to develop
Iomab-ACT based on early encouraging results, ultimately with the value proposition of improving overall access and outcomes for patients
who need cellular or gene therapies. We believe an opportunity exists for Iomab-ACT to potentially generate significant revenue, if it
can provide one or more clinical benefits related to lower CRS, less neurotoxicity, longer duration of response or a higher overall success
rate of cellular therapy due to benefits of targeted conditioning.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Iomab-B</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
February 2023, Actinium announced that the SIERRA trial met the primary endpoint with statistical significance, as 22% of patients (13/76)
on the Iomab-B arm achieved durable Complete Remission (&#8220;dCR&#8221;) compared to 0% of patients (0/77) on the control arm resulting
in a p-value of &lt;0.0001. The SIERRA trial met the secondary endpoint of Event-Free Survival (&#8220;EFS&#8221;) with a 78% reduction
in the probability of an event (Hazard Ratio=0.22, p&lt;0.0001 for both per protocol and ITT basis). EFS at 180 days for the Iomab-B arm
was 28% compared to 0.2% for the control arm. In the SIERRA trial, an event was defined as one of the following: a patient not achieving
CR/CRp or crossing over, patient not receiving BMT, a patient relapsing or death. The SIERRA trial did not, however, meet the secondary
endpoint in achieving a statistically significant improvement in OS in the intent to treat (&#8220;ITT&#8221;) population.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 5, 2024, Actinium announced that it concluded both its clinical and Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) interactions
with the FDA regarding the BLA pathway for Iomab-B based on the SIERRA trial results. As previously disclosed, we had received positive
feedback from the FDA regarding our CMC package for Iomab-B and were also assigned a BLA number. However, in the third quarter of 2024,
the FDA provided definitive feedback that the SIERRA trial alone is not adequate to support a BLA filing for Iomab-B, despite (a) the
SIERRA trial meeting the primary endpoint of dCR with statistical significance (p-value&lt;0.0001) and other positive secondary endpoints
including Event Free Survival (&#8220;EFS&#8221;) and safety, and (b) our presentation of several additional analyses from the SIERRA
study, including long-term follow-up demonstrating a trend towards improved overall survival and evidence of survival benefit in patients
with high-risk TP53 mutations, to support Iomab-B&#8217;s impact on overall survival. The FDA indicated that demonstrating an overall
survival benefit in a randomized head-to-head trial is necessary and has advised us to conduct a study to evaluate allogeneic BMT using
Iomab-B plus a reduced intensity conditioning regimen of fludarabine and total body irradiation (&#8220;Flu/TBI&#8221;) versus allogeneic
BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI. This proposed additional study differs from the SIERRA
trial, which allowed physician&#8217;s choice of salvage chemotherapies and heterogenous conditioning regimens in the control arm. Additionally,
the proposed new study will not allow patients to cross over from the control arm, which was allowed in the SIERRA trial and confounded
the overall survival analysis in the ITT patient population, as nearly 60% of patients crossed over from the control arm.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Actinium
continued interactions with the FDA in the third quarter of 2024 to further discuss the specifics of the additional head-to-head clinical
trial required by the FDA, including the patient population, which the FDA had suggested could include all adult AML patients. In the
fourth quarter of 2024, Actinium conducted a further meeting with the FDA. Based on this meeting, Actinium believes it has aligned with
the FDA on the patient population for a head-to-head Phase 3 clinical trial to further evaluate allogeneic BMT using Iomab-B plus a reduced
intensity conditioning regimen of Flu/TBI versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus
Flu/TBI in all adult patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%. This is a broader
patient population than the patients enrolled on the SIERRA trial, which only enrolled patients aged 55 and above. Further, the FDA now
requires that an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based
on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA
trial based on several interactions we had with the FDA before starting the SIERRA trial. We are actively seeking a strategic partner
for Iomab-B in the U.S. to advance the head-to-head clinical trial or other clinical development activity for Iomab-B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, we entered
into a License Agreement with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant to which Immedica licensed the exclusive product rights
for commercialization of Iomab-B in certain countries in the EUMENA region. Upon signing, we were entitled to an upfront, non-refundable
payment of $35.0 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. Immedica is responsible for regulatory submissions in the EUMENA region, and we continue to retain commercialization
rights in the U.S. and rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R&amp;D and Platform Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">Our R&amp;D capabilities have the potential to yield differentiated,
high-value targeted radiotherapy programs that demonstrate our experience across multiple validated cancer targets and isotopes and cover
broad areas of focus leveraging our clinical development experience across hematology, targeted conditioning, solid tumors, and next-generation
radiotherapies. We have internal R&amp;D capabilities with our research laboratory capable of executing in vitro and in vivo experiments
and translational research. We are working on several preclinical programs which include novel approaches to validated cancer targets,
as well as novel targets that we believe show immense potential for radiotherapeutic approaches. Preclinical pharmacology studies with
our targeted radiotherapeutics, such as HER2, CD33 and CD38, have shown strong improvement in tumor growth inhibition in various preclinical
tumor models.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently believe that
our targeted radiotherapies, which utilize biologic molecules, are less likely than small molecules to face pricing pressure and negotiation
from the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), given that small molecules are at risk for pricing negotiations seven years
after approval compared to eleven years for biologics with negotiated prices taking effect two years after selection. Further, a drug
or biological product that has an orphan drug designation, which our Actimab-A and Iomab-B programs both have, for only one rare disease
or condition will be excluded from the IRA&#8217;s price negotiations requirements until such time the biological products has designations
for more than one rare disease or condition, or if is approved for an indication that is not within that single designated rare disease
or condition, unless such additional designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for
selection for negotiation. In addition, regulatory barriers for generic large molecule biologic based targeted radiotherapies are much
higher than for small molecule radioligands such as those under development or approved, namely, Pluvicto<sup>&#174;</sup>, Lutathera<sup>&#174;</sup>,
and Xofigo<sup>&#174;</sup>. Generic versions of certain radiopharmaceuticals utilizing peptides, which are considered small molecules,
have been submitted to the FDA via the ANDA pathway. To our knowledge, only the biosimilar approach pertains to large molecule biologic-based
radiotherapies filed under 351(k) BLA pathway. The regulatory pathway for a biosimilar is much more comprehensive than the pathway for
generics, and it has not been proven that biosimilars are interchangeable with the innovator&#8217;s large molecule biologic targeted
radiotherapy. In addition, we are not aware of any regulations that would require us to provide Actimab-A or Iomab-ACT, including their
respective mAbs, lintuzumab and apamistamab, to any third party or potential competitor. Despite the above, we are aware that one or more
of the policies or regulations that afford our pipeline candidates market protections may change in the future and that one or more of
our product candidates may be disadvantaged by such change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to expand our capabilities
and technologies across therapeutic modalities, linker technologies and in vivo cancer models, and build visibility through presentations
at key conferences and publications in journals of high impact. Our R&amp;D efforts are centered on the advancement of key programs with
a robust &#8220;fast-to-clinic&#8221; approach. Underpinning our development programs is our expanded patent portfolio of approximately
240 issued patents and pending patent applications worldwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Proprietary Ac-225 Cyclotron Manufacturing
Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With our in-depth, long-term experience in clinical development of
Ac-225 based radiopharmaceuticals, we have developed an end-to-end technology solution for producing Ac-225 that has demonstrated radiochemical
and radionuclidic purity identical to current gold-standard methods. This patented technology has been used to produce Ac-225 in a cyclotron
that is essentially identical to that derived from a Th-229 generator and has the potential to be a lower-cost, commercially scalable
higher-yielding approach. Importantly, the Ac-225 material produced by our proprietary method contains no long-lived contaminants and
less than 0.001% Actinium-227 (&#8220;Ac-227&#8221;). Using the cyclotron-produced Ac-225 technology may allow for large commercial scale
production with estimated cost of goods sold including capital expenditures and operational costs for a single cyclotron facility to be
several times less expensive than the price of currently available Ac-225 material.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our extensive know-how related to this production technology is supported
by 5 issued patents in the U.S. and 33 patents internationally and covers:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">End-to-end solution including processing and recycling of Radium-226 starting material</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Production of up to 100 mCi of Ac-225 per production cycle</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Utilization of a medium energy cyclotron</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Expected cost 10 to 20 times lower than currently available material</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Radiochemical purity &gt; 99%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Radioisotopic purity 99.8% with no long-lived contaminants and &lt;0.001% Ac-227</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With our Ac-2225 based Actimab-A and ATNM-400 programs
and the rapidly increasing number of Ac-225 based programs in development, we believe that we are well positioned to leverage this technology
to produce Ac-225 to address the growing clinical and potential commercial demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing and Supply Chain</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Actinium has established significant manufacturing and supply chain
expertise, having delivered over 500 doses for 18 clinical trials at 45 large cancer hospitals and have never missed a dose.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe this experience
provides us with insights that are highly relevant to the unique manufacturing and distribution requirements of radiotherapeutics. Due
to the short half-life of radioisotopes, our finished drug products are shipped &#8220;hot&#8221; and must be administered within days.
Actinium has established core competencies in the process of manufacturing radiotherapeutics, coordinating with the hospital&#8217;s care
team, and delivering &#8220;just-in-time&#8221; doses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to establish our own
manufacturing capabilities and intend to commence the build-out of a facility in the second half of 2025. We believe that having in-house
manufacturing will provide enhanced control, flexibility and scalability to serve our current and planned clinical trials and R&amp;D
efforts as well as potential future activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Isotope supply is critical
for the manufacturing of radiotherapeutics, and we have engaged several sources for the procurement of alpha (e.g., Ac-225) and beta (e.g.,
I-131 and Lu-177) emitters. We also have multiple isotope supply agreements and qualified vendors in place to supply isotopes for our
active and planned clinical trials. In March 2025, we announced that we entered into&#160;Ac-225 supply agreement with Eckert &amp; Ziegler,
a leading specialist in isotope-related components for nuclear medicine and radiation therapy, to support our comprehensive development
including U.S. and international clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium has commercial agreements
with Contract Development and Manufacturing Organizations (&#8220;CDMOs&#8221;) with significant experience in mAb and final radio-labeled
drug products. Our finished drug product CDMOs are located in the U.S. and have experience in the international supply of radiotherapies.
We have scaled deliberately for manufacturing flexibility&#160;and are currently qualifying additional CDMOs to ensure readily available
drug product upon FDA approval and the ability to ramp up rapidly to meet commercial demand.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established an actively managed end-to-end supply chain that
encompasses isotope sourcing through drug administration at the point of care to execute our clinical trials. Our end-to-end supply chain
did not miss a patient dose in our international, 24-site SIERRA Phase 3 clinical trial, including 40 additional patients that crossed
over from the control arm to receive Iomab-B. We believe we have a thorough understanding and working knowledge of the intricacies required
to manufacture and distribute radiotherapies. Through our clinical experience with Iomab-B and Actimab-A, we have developed a wealth of
proprietary knowledge to enable coordination between Actinium and all key stakeholders including, but not limited to hematologists/oncologists,
infusion center and in patient rooms, nuclear medicine and radiology, hot labs and radio-pharmacies, and radiation safety committees,
among others.<b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary technology
platform is supported by IP, know-how and trade secrets that cover the generation, development, methods of use and manufacture of targeted
radiotherapies and their select components. Our IP covers various methods of use in multiple diseases, including indication, dose and
scheduling, radionuclide warhead, and therapeutic combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of May 2025, our patent portfolio
is comprised of approximately 240 issued patents and pending patent applications worldwide, which we believe constitutes a valuable business
asset. Our IP includes 48 patent families, including key patents that relate primarily to our radiotherapeutic candidates. Our patent
portfolio includes 20 issued patents and 51 pending patent applications in the U.S., and 170 that are issued or pending internationally.
The effective lives of the issued patents in our portfolio, or patents that may issue from the pending applications in our portfolio,
ranges from expirations between 2026 and 2046.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our Iomab-B product
candidate, we have four issued patents in the U.S. and issued patents in Canada, Europe and Japan that relate to the composition. The
basic patent terms of these patents expire in 2036 and 2037. Related patent applications are also currently pending in the U.S. and internationally.
In addition, we own both U.S. and international pending patent applications that relate to the use of Iomab-B or Iomab-ACT in the treatment
of cancers and non-malignant conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patents also cover key
areas of our business such as manufacturing key components of our product candidate, Actimab-A, including Ac-225 in a cyclotron. We have
expertise in utilizing the alpha emitting isotope Ac-225 including clinical experience in treating approximately 150 patients with our
alpha-emitter-based therapies, &#8220;gold standard&#8221; linker technology and 5 issued patents in the U.S. and 33 patents internationally
related to the manufacturing of Ac-225 in a cyclotron, which we believe has the potential to produce higher quantities of Ac-225 than
currently utilized methods. In addition, we also own U.S. and international patents and pending patent applications that relate to the
manufacturing of Actimab-A and its use in the treatment of cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Human Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of May 8, 2025, we had
31 full-time employees, 13 of whom have Ph.D. or M.D. degrees and 20 of whom are engaged in research and development and clinical development
activities. In the second quarter of 2025, we conducted a work force optimization that reduced our headcount by approximately fourteen
percent. As a result, we expect personnel related expenses to be reduced by approximately $1.15 million for the remainder of 2025.&#160;
<span style="background-color: white">We do not expect this work force optimization to have a material impact on our operations or ability
to execute our operating plan. </span>We believe that we have been successful to date in attracting skilled and experienced personnel
despite the competitive hiring marketing in the industry. Our employees are not covered by a collective bargaining agreement, and we believe
that our relationship with our employees is excellent. We continue to engage external consultants on an as-needed basis to temporarily
supplement existing staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Results of Operations &#8211;
Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the <br/> Three&#160;Months&#160;Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,635</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,938</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,638</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,597</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(15,938</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(8,670</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the three months ended March 31, 2025 and March 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Institutes of
Health awarded us a Small Business Technology Transfer cost reimbursable grant to support a clinical collaboration with Memorial Sloan
Kettering Cancer Center, or MSK, to study Iomab-ACT, our CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve
lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. There was no other revenue recognized
for the three months ended March 31, 2025 and 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, on April 7,
2022, we entered into a License Agreement with Immedica, pursuant to which Immedica licensed the exclusive product rights for commercialization
of Iomab-B in certain countries in the EUMENA region. Upon signing, we were entitled to an upfront, non-refundable payment of $35 million
from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible to receive certain regulatory
and commercial milestone payments and royalties on net sales of the product in certain countries that may result from the License Agreement.
We continue to retain commercialization rights in the U.S. and rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract liabilities are
recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in our condensed consolidated balance
sheets depending on the short-term or long-term nature of the payments to be recognized. Our contract liabilities primarily consist of
advanced payments from licensees. There was no Other revenue deferred-current liability at March 31, 2025 and December 31, 2024. Long-term
license revenue deferred was $35 million at March 31, 2025 and December 31, 2024, resulting from the receipt from Immedica; this deferred
revenue will be recognized upon the European Union&#8217;s regulatory approval of Iomab-B or provision of definitive feedback that Iomab-B
will not receive approval in the European Union.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation Expense</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, our Board
of Directors approved the cancellation of certain stock options to purchase an aggregate of 4.9 million shares of common stock held by
certain current employees and directors that were initially granted under our Amended and Restated 2013 Stock Plan and 2019 Amended and
Restated Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options, which we received.
Our Compensation Committee intends to conduct an analysis of our equity compensation plan and develop an equity compensation strategy
that satisfies the purpose of the 2019 Plan to attract and retain the best available personnel who can make meaningful contributions towards
achieving our business objectives. The cancellation of these stock options resulted in the recording of $8.7 million in non-cash stock
compensation expense for the three months ended March 31, 2025. During the three months ended March 31, 2024, the Company recorded compensation
expense related to stock options of $1.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
of $7.7 million for the three months ended March 31, 2025 increased by $1.1 million from $6.6 million for the three months ended March
31, 2024. The increase was primarily a result of higher non-cash stock-based compensation expense of $1.7 million and increased preclinical
expenses of $0.2 million, partially offset by lower compensation of $0.7 million due to lower headcount. In the second quarter of 2025,
we conducted a work force optimization that reduced our headcount by approximately fourteen percent.. We do not expect this work force
optimization to have a material impact on our operations or ability to execute our operating plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and administrative expense</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative expenses of $8.9 million for the three months
ended March 31, 2025 increased by $5.9 million from $3.0 million for the three months ended March 31, 2024, primarily due to higher non-cash
stock-based compensation expense of $5.8 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the three months ended March 31, 2025 of $0.7 million decreased from
$0.9 million for the three months ended March 31, 2024 primarily due to a lower average cash balance during the respective time periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss of $15.9 million
for the three months ended March 31, 2025 increased by $7.2 million from $8.7 million for the three months ended March 31, 2024 primarily
due to higher research and development expenses and higher general administrative expenses as a result of the recognition of higher non-cash
stock compensation expense of $7.5 million discussed above. In the second quarter of 2025, we conducted a work force optimization that
reduced our headcount by approximately fourteen percent. As a result, we expect personnel related expenses to be reduced by approximately
$1.15 million for the remainder of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
selected cash flow information for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the<br/> Three Months&#160;Ended <br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,574</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,374</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash used in/provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,768</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,576</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,383</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating activities for the three months ended March
31, 2025 was $7.6 million, an increase of $0.2 million from $7.4 million in the prior-year period. In the three months ended March 31,
2025, our net loss of $15.9 million excluding non-cash stock-based compensation expense of $8.9 million was $7.0 million. In the prior-year
period, net loss of $8.7 million excluding non-cash stock-based compensation expense of $1.4 million was $7.3 million. This improvement
of $0.3 million was offset by an increase in net operating assets and liabilities of $0.5 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was no cash used in
investing activities for the three months ended March 31, 2025. Cash used in investing activities was $11 thousand for the three months
ended March 31, 2024 due to the purchase of equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash used in financing activities
for the three months ended March 31, 2025 was not material. Net cash provided by financing activities of $14.8 million for the three months
ended March 31, 2024 was primarily from the sale of shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, we entered
into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which we
are able to sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of our common stock. On June 28,
2022, we entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement, or the Amended Sales Agreement, with JonesTrading
and B. Riley Securities, Inc. The Amended Sales Agreement modifies the original Capital on Demand&#8482; Sales Agreement to include B.
Riley as an additional sales agent thereunder. Shares of common stock are offered pursuant to a shelf registration statement on Form
S-3 (File No. 333-273911), which was declared effective February 5, 2024, including a base prospectus covering the offering, issuance
and sale of up to $500 million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus
covering the offering, issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued
and sold under the Amended Sales Agreement. During the three months ended March 31, 2025, there were no sales of shares of common stock.
For the three months ended March 31, 2024, we sold 1.8 million shares of common stock, resulting in gross proceeds of $15.0 million and
net proceeds of $14.7 million. On March 31, 2025, upon filing of our Annual Report on Form 10-K for the year ended December 31, 2024,
we became subject to General Instruction I.B.6 of Form S-3, pursuant to which in no event will we sell our common stock in a registered
primary offering using Form S-3 with a value exceeding more than one-third of our public float in any 12 calendar month period so long
as our public float remains below $75 million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following the
date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management&#8217;s discussion
and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States, (&#8220;GAAP&#8221;). The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure
of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored
and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base
our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known.
Actual results may differ materially from these estimates under different assumptions or conditions. The Company does not have any critical
accounting estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, FASB issued ASU 2023-07, <i>Segment Reporting (Topic
280), Improvements to Reportable Segment Disclosures</i>, which provides improvements to reportable segment disclosure requirements, primarily
through enhanced disclosures around segment expenses. ASU 2023-07 requires us to disclose significant segment expenses that are regularly
provided to the chief operating decision maker, or CODM, and included within each reported measure of segment profit or loss. ASU 2023-07
also requires that we disclose an amount for other segment items by reportable segment, a description of their composition and provide
all annual disclosures about a reportable segment&#8217;s profit or loss and assets pursuant to Topic 280 during interim periods. We must
also disclose the CODM&#8217;s title and position, as well as certain information around the measures used by the CODM and an explanation
of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources. For public entities
with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and all existing segment
disclosures under Topic 280. We adopted this standard effective January 1, 2024, and reported in its Annual Report on Form 10-K for the
year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028. We are evaluating the impact of ASU 2024-03 on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b>In December 2023,
FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, to enhance the transparency and decision
usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation
and income taxes paid information included in income tax disclosures. We would be required to disclose additional information regarding
reconciling items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory
tax rate. Similarly, we would be required to disclose income taxes paid (net of refunds received) equal to or greater than five percent
of total income taxes paid (net of refunds received). <span style="background-color: white">The amendments in ASU 2023-09 are effective
January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance.
We are currently evaluating the impacts of ASU 2023-09 on our financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Known Trends, Events and
Uncertainties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to
risks and uncertainties common to companies in the biopharmaceutical industry, including but not limited to, risks associated with completing
preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical
products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to
secure additional capital to fund operations. In addition, the consequences of the ongoing geopolitical conflicts, such as the ongoing
conflict between Russia and Ukraine and the ongoing conflict between Israel and Hamas, including related sanctions and countermeasures,
and the effects of rising global inflation, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions,
the global economy, and contribute to increased market volatility, which may in turn adversely affect our business and operations. Additionally,
recent changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may
in the future impact, among other things, the U.S. and global economy, tariffs, international trade relations, unemployment, immigration,
healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these
changes to our business, they could adversely affect our business. For a further discussion of factors that may affect future operating
results see the sections entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statement Notice.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as discussed above
and elsewhere in this report, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our
financial condition.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Evaluation of Disclosure
Controls and Procedures</i>. Under the supervision and with the participation of our management, including our principal executive officer
and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of March 31, 2025, of our disclosure
controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange
Act. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that, as
of March 31, 2025, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required
to disclose in our filings with the Securities and Exchange Commission, or SEC, under the Exchange Act (i) is recorded, processed, summarized
and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management,
including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding
required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Changes in Internal Control
over Financial Reporting</i>. There were no changes in our internal controls over financial reporting during the period covered by this
Quarterly Report of Form 10-Q that has materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8211; OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the Southern District of New York, wherein, the Securities Complaint alleges that the Defendants made material misrepresentations
and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all Defendants pursuant to section
10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated thereunder, as well as additional claims
against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint purports to assert class action claims
on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October 31, 2022 and August 2,
2024.&#160; Plaintiff seeks unspecified damages.&#160; On May 5, 2025, a derivative shareholder complaint (the &#8220;Derivative Complaint&#8221;)
was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability for the allegations
made in the Securities Complaint.&#160; The Defendants have not yet responded to the Securities Complaint, and they intend to vigorously
defend themselves against the plaintiff&#8217;s allegations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company and other Defendants intend to defend vigorously against such
claims, however, there can be no assurances as to the outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. RISK FACTORS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>In analyzing our company,
you should consider carefully the following risk factors, together with all of the other information included in this Quarterly Report
on Form&#160;10-Q. Factors that could cause or contribute to differences in our actual results include those discussed in the following
subsection, as well as those discussed above in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; and in our Annual Report on Form 10-K for the year ended December 31, 2024. Each of the following risk factors,
either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely
affect the value of an investment in our company. The risks and uncertainties described below are not the only ones we face. Additional
risks not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may
impair our business operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;Summary of Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are providing the following
summary of the risk factors contained in this Quarterly Report on Form 10-Q to enhance the readability and accessibility of our risk factor
disclosures. We encourage you to carefully review the full risk factors contained in this Quarterly Report on Form 10-Q in their entirety
for additional information regarding the material factors that make an investment in our securities speculative or risky. These risks
and uncertainties include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We are a clinical-stage company and have generated no revenue from commercial sales to date;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we fail to obtain additional financing, we will be unable to continue or complete our product development or product commercialization and you will likely lose your entire investment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are highly dependent on the clinical, regulatory
    and commercial success of Iomab-B, Actimab-A, Iomab-ACT, ATNM-400 and other pipeline candidates which we may never achieve;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We continuously evaluate our business strategy and may modify our strategy as necessary to respond to developments in our business and other factors, and any such modification, if not successful, could have a material adverse effect on our business, financial condition, and results of operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our business could be adversely affected by the effects of future health epidemics;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our business is subject to cybersecurity risk;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have not demonstrated that any of our products are safe or effective
for any indication and will continue to expend substantial time and resources on clinical development before any of our current or future
product candidates will be eligible for FDA approval, if ever;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Preliminary, Interim, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Healthcare legislative reform measures intended to increase pressure
to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system
could have a material adverse effect on our business, future revenue, if any, and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in the healthcare industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial condition and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may rely on third parties to conduct certain aspects of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We currently depend on single third-party manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#9679;</td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disruptions at the FDA and other government agencies
caused by leadership changes, changes to regulatory approach, layoffs, funding shortages or global health concerns could negatively impact
our business;</p>
</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our patent position is highly uncertain and involves complex legal and factual questions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We are highly dependent on our key personnel, and the demand for&#160;talent in the biotechnology industry is highly competitive; if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement or execute our business strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certain provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in our stockholders&#8217; interest; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a clinical-stage company and have
generated no revenue from commercial sales to date. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product
sales to date. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If
we do not address these risks successfully, our business will suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred net losses in every year
since our inception and anticipate that we will continue to incur net losses in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not profitable and
have incurred losses in each period since our inception. As of March 31, 2025 and December 31, 2024, we had an accumulated deficit of
$391.8 million and $375.8 million, respectively. We reported a net loss of $15.9 million and $8.7 million for the three months ended March
31, 2025 and 2024, respectively. We expect to continue to operate at a net loss as we continue our research and development efforts, continue
to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that the
products under development by us will be approved for sale in the United States or elsewhere. Furthermore, there can be no assurance that
if such products are approved, they will be successfully commercialized, which would have an adverse effect on our business prospects,
financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain additional financing,
we will be unable to continue or complete our product development and you will likely lose your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following the
date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required
to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or
otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred
cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms or indeed on any terms.
In addition, from time to time, we may not be able to secure enough capital in a timely enough manner which may cause the generation of
a going-concern opinion from our auditors which can and may impair our stock market valuation and also our ability to finance on favorable
terms or indeed on any terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To raise additional capital,
we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock.
We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal
to or greater than the price per share paid by investors, and investors purchasing shares or other securities in the future could have
rights superior to existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities, clinical
studies, or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may
require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights
to future product candidates or certain major geographic markets. We may further have to license our technology to others. This could
result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business, financial
condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of funding we will
need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope
of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary
to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative,
licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited access to the capital markets
and even if we can raise additional funding, we may be required to do so on unfavorable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited access to
the capital markets to raise funds. The capital markets have been unpredictable in the recent past for development stage radiopharmaceutical
and other biotechnology companies and unprofitable companies such as ours. In addition, it is generally difficult for development-stage
companies to raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often depends
on variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at all. If
we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate funds
are not available on acceptable terms, or at all, our business, including our technology licenses, results of operations, financial condition
and our continued viability will be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the clinical,
regulatory and commercial success of Actimab-A, Iomab-ACT, ATNM-400 and other pipeline candidates which we may never achieve</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the drug candidates
we are developing, or have developed, have received regulatory approval. Based on the current status of our pipeline candidates, it will
likely take several years or additional clinical studies before we can seek approval for any drug candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A drug candidate
was studied in a Phase 2 clinical trial as a monotherapy and we are now studying it in combination with other therapies. We believe have
aligned with the FDA on a Phase 2/3 trial that is intended to support a BLA filing. There can be no assurance that the Phase 2 portion
of the trial will be successful and support advancing to the Phase 3 portion of the trial. In addition, our Iomab-ACT drug candidate has
only been studied in a limited number of human subjects in a Phase 1 trial with a novel CAR-T therapy. While we believe the initial results
from this trial were encouraging, there can be no assurance that future results with Iomab-ACT from the commercial CAR-T trial at UTSW
or sickle cell conditioning trial at Columbia will be positive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As for Iomab-B in particular,
as previously disclosed, we completed the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory AML) and presented
the trial results in February 2023, which were expected to support a BLA filing. The SIERRA trial met the primary endpoint of dCR with
statistical significance (p-value&lt;0.0001) but did not meet the secondary endpoint in achieving a statistically significant improvement
in overall survival in the intent to treat population. On August 5, 2024, we announced that the FDA determined that the SIERRA trial alone
is not adequate to support a BLA filing and is requiring an additional randomized head-to-head clinical trial to demonstrate an overall
survival benefit in an intent to treat population. Further, the FDA is also requiring an additional dose optimization trial to calculate
the dose of Iomab-B based on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver
as was done in the SIERRA trial based on several interactions with the FDA prior to the start of the SIERRA trial. Based on this revised
approach now required by the FDA, the safety and efficacy data generated from all Iomab-B studies, including the SIERRA trial, are inadequate
to seek regulatory approval for Iomab-B, as dosing based on maximum tolerable dose of 24 Gy to the liver will lead to variable doses to
the bone marrow (the target organ), result in underdosing or overdosing of patients and translate to a global patient safety risk. We
are seeking a strategic partner for the U.S. in order to conduct the additional studies required by the FDA; however, we may not be successful
in our efforts to find such a partner, or the trials and studies may not be successful. Further, there are no assurances that we can satisfy
all of the FDA&#8217;s requests, and there could be additional regulatory hurdles that may result in either non-acceptance or non-approval
of a future BLA filing. The U.S. commercial opportunity for Iomab-B may thus never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed and
noted above, Actinium has licensed to Immedica the exclusive product rights for commercialization of Iomab-B in the EUMENA region. We
are evaluating the impact of the FDA&#8217;s 2024 determination of the SIERRA trial results in the context of global regulatory submissions
for Iomab-B. At this time, filings for regulatory approval, obtaining regulatory approvals, and successful commercialization of Iomab-B
in the EUMENA region and on a global basis are highly uncertain and may never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disruptions at the FDA and other government
agencies caused by leadership changes, changes to regulatory approach, layoffs, funding shortages or global health concerns could negatively
impact our business</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ability of the FDA to review proposed clinical trials or approve new products can be affected by a variety of factors, including government
budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept
the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition,
government funding of other government agencies that fund research and development activities is subject to the political process, including
executive and congressional priorities, the impacts of which are inherently fluid and unpredictable. Disruptions at the FDA and other
agencies may slow the time necessary for new product candidates to be reviewed and/or approved, which would adversely affect our business.
For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several
times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition,
the current administration has proposed substantial reductions in force at various government agencies including the FDA, which could
significantly reduce the FDA&#8217;s capacity to perform its functions in a manner consistent with its past practices and could delay
reviews and negatively impact our business. There has been significant turnover and recent changes in senior leadership at the FDA and
other government agencies including the Center for Biologics Evaluation and Research (&#8220;CBER"), which is the division of the
FDA that would oversee and review biologics-based targeted radiotherapies like those we currently develop and plan to continue to develop.
We believe these changes could result in changes in the FDA&#8217;s perception of the approvability of therapies, the perceived value
of certain therapies or therapeutic modalities, which could create material challenges for our development efforts. At this time, there
is significant uncertainty and risks associated with future FDA regulatory policies and actions that could have a material negative impact
on our business. Any or all of these factors could cause us to amend, suspend or terminate the development of certain of our preclinical
or clinical programs, which could have material adverse impacts on our business, our product candidates or our ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to establish sales, marketing
and commercial supply capabilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates ultimately become approved and we
do not secure a commercial partner, we would have to build and establish these capabilities in order to commercialize our approved product
candidates. The process of establishing commercial capabilities will be expensive and time consuming. Even if we are successful in building
sales and marketing capabilities, we may not be successful in commercializing any of our product candidates. Any delays in commercialization
or failure to successfully commercialize any product candidate may have material adverse impacts on our business and ability to continue
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business could be adversely affected
by the effects of future health epidemics.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be adversely
impacted by the effects of future pandemics, epidemics or infectious disease outbreaks. The full impact of such an event cannot be predicted
at this time, and could depend on numerous factors, including vaccination rates among the population and the response by governmental
bodies and regulators. Given the ongoing and dynamic nature of the circumstances, it is difficult to predict the impact of a future pandemic
on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A future pandemic could adversely
affect our clinical trial operations, including our ability to conduct the trials on the expected timelines and recruit and retain patients
and principal investigators and site staff who, as healthcare providers, may have heightened exposure to a future pandemic if their geography
is impacted by the pandemic. Further, future pandemics could result in delays in our clinical trials due to prioritization of hospital
resources toward the pandemic, restrictions in travel, potential unwillingness of patients to enroll in trials, or the inability of patients
to comply with clinical trial protocols if quarantines or travel restrictions are implemented that impede patient movement or interrupt
healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party
service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and a future
pandemic may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us,
which may result in delays or hinder our ability to collect data from our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a future pandemic
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB&#8217;s
or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to cybersecurity
risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are increasingly
dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks and
cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks, utility
outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systems are maintained,
repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">theft or misappropriation of
funds;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">loss, corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical data or employee data);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disruption or impairment of our and our business operations and safety procedures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">damage to our reputation with our potential partners, patients and the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">exposure to litigation; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increased costs to prevent, respond to or mitigate cybersecurity events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we utilize various
procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.
Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers, and
others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed for a period
time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have cybersecurity insurance
coverage in the event we become subject to various cybersecurity attacks, however, we cannot ensure that it will be sufficient to cover
any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA, EMA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
rigorous regulation by the FDA, EMA and numerous other federal, state and foreign governmental authorities. The process of seeking regulatory
approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the effort and expense
incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products from the regulators, we
may never be able to generate significant revenue and may be forced to cease operations. In particular, the FDA permits commercial distribution
of a new antibody radiation-conjugate product only after a BLA for the product has received FDA approval. The BLA process is costly, lengthy
and inherently uncertain. Any BLA filed by us will have to be supported by extensive data, including, but not limited to, technical, preclinical,
clinical trial, chemistry, manufacturing and controls and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and
efficacy of the product for its intended use. The lengthy approval process as well as the unpredictability of future clinical trial results
may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business,
results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve any of our product
candidates for fewer or more limited indications than we request, may not obtain the price we intend to charge for our products, may grant
approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that
does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the
foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For instance, as for Iomab-B,
despite the Phase SIERRA 3 trial meeting the primary endpoint of durable Complete Remission (dCR) with statistical significance (p-value&lt;0.0001),
the FDA has determined that demonstrating an overall survival benefit in a randomized head-to-head trial is required for a BLA filing.
In addition, the FDA is also requiring that an additional dose optimization trial demonstrating safety and efficacy be completed to calculate
the dose of Iomab-B based on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver
as was done in the SIERRA trial based on several interactions we had with the FDA before starting the SIERRA trial. The head-to-head Phase
3 trial will evaluate allogeneic bone marrow transplant (BMT) using Iomab-B plus a reduced intensity conditioning regimen of fludarabine
and total body irradiation (Flu/TBI) versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI.
This is different from the SIERRA trial, which allowed physician&#8217;s choice of salvage therapies and heterogenous conditioning regimens
in the control arm. However, there are no assurances that the additional trials will be completed or successful or that we can satisfy
all of the FDA&#8217;s requests. There could also be additional regulatory hurdles that may result in either non-acceptance or non-approval
of a future BLA filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed and
noted above, Actinium has licensed to Immedica the exclusive product rights for commercialization of Iomab-B in the EUMENA region. We
are evaluating the impact of the FDA&#8217;s 2024 determination of the SIERRA trials results referred to above in the context of global
regulatory submission for Iomab-B. At this time, filings for regulatory approval, obtaining regulatory approvals, and successful commercialization
of Iomab-B in the EUMENA region and on a global basis are highly uncertain and may never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also evaluating Iomab-ACT,
which uses a lower dose I-131 for conditioning prior to cellular therapies such as CAR-T and gene therapies. We are currently studying
Iomab-ACT in three clinical trials including two investigator sponsored studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A (lintuzumab-Ac-225)
product candidate has also been studied in several Phase 1 and 2 trials under our sponsorship and investigator-initiated trials in patients
with r/r AML and we plan to continue to study Actimab-A in clinical trials. Actimab-A is also being developed under a cooperative research
and development agreement (CRADA) with the National Cancer Institute (NCI) and we expect clinical trials to be initiated that will study
Actimab-A as a single agent or in combination with other therapies. Product candidates utilizing the lintuzumab antibody would require
BLA approval before they can be marketed in the United States. We are in the early stages of evaluating other product candidates consisting
of conjugates of Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer. The FDA
may not approve these products for the indications that are necessary or desirable for successful commercialization. The FDA may fail
to approve any BLA we submit for new product candidates or for new intended uses or indications for approved products or future product
candidates. Failure to obtain FDA approval for our products in the proposed indications would have a material adverse effect on our business
prospects, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval process in the
United States and in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other
resources. The FDA, EMA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical data, conduct
additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In addition, even if we
obtain approval to market our products in the United States or in other countries, the approval could be revoked, or other restrictions
imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA,
EMA or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and
cash flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited. Additionally,
even if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications that
we request. The Company&#8217;s products may not be approved for the specific indications that are most necessary or desirable for successful
commercialization or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Disruptions
at the FDA and other agencies may slow the time necessary for new product candidates to be reviewed and/or approved, which would adversely
affect our business and may cause us to amend our business strategy or. For example, over the last several years, including for 35 days
beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have
had to furlough critical FDA employees and stop critical activities. In addition, the current administration has proposed substantial
reductions in force at various government agencies including the FDA, which could significantly reduce the FDA&#8217;s capacity to perform
its functions in a manner consistent with its past practices and could delay reviews and negatively impact our business. There has been
significant turnover and changes in senior leadership at the FDA and other government agencies including the Center for Biologics Evaluation
and Research (&#8220;CBER"), which is the division of the FDA that would oversee and review biologics based targeted radiotherapies
like those we currently develop and plan to continue to develop. We believe these changes could result in changes in the FDA&#8217;s perception
of the approvability of therapies, the perceived value of certain therapies or therapeutic modalities, which could create material challenges
for our development efforts. At this time, there is significant uncertainty and risks associated with future FDA regulatory policies and
actions that could have a material negative impact on our business. Any or all of these factors could cause us to amend, suspend or terminate
the development of certain of our preclinical or clinical programs, which could have material adverse impacts on our business, our product
candidates or our ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not demonstrated that any of our
products are safe or effective for any indication and will continue to expend substantial time and resources on clinical development before
any of our current or future product candidates will be eligible for FDA approval, if ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplated biological
product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval, and commercialization
of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approval is received. The research,
testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product candidates are, and will remain,
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, as applicable. We
are currently not permitted to market any of our current or future product candidates in the United States until we receive FDA approval
(of each) via the BLA process. To date, we have three product candidates in clinical development and have not-yet submitted a BLA for
any of our candidates and, for many such candidates, do not expect to be in a position to do so for the foreseeable future, as there are
numerous developmental steps that must be completed before we can prepare and submit a BLA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceutical and biological product candidates under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and
the Public Health Service Act (&#8220;PHSA&#8221;), as well as their respective implementing regulations. Such products and product candidates
are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent
compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and
financial resources. The process required by the FDA before a drug or biological product may be marketed in the United States generally
involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">completion of preclinical laboratory tests and animal studies in accordance with FDA&#8217;s good laboratory practices (&#8220;GLPs&#8221;) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;)
application, which must become effective before human clinical trials in the United States may begin;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s IND regulations, good clinical practices (&#8220;GCPs&#8221;), and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with current good manufacturing practices (&#8220;cGMPs&#8221;) and assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FDA review and approval, or denial, of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before testing any biological
product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate.
The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and a proposed clinical protocol, to the FDA as part of the IND application. Some preclinical testing may continue even
after the IND application is submitted. The IND application automatically becomes effective 30 days after receipt by the FDA, unless the
FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time
period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA
may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or
non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized
by the FDA. Accordingly, we cannot be sure that submission of an IND application will result in the FDA allowing clinical trials to begin
or that, for those that have already commenced under an active IND application, that issues will not arise that suspend or terminate such
trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events
should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND application. Clinical trials
must be conducted and monitored in accordance with the FDA&#8217;s regulations composing the GCP requirements, including the requirement
that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional
review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting
the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed
consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until
completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase 1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in subjects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the completion of clinical
trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA
must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition
of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial
waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept
the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Before approving a BLA, the FDA
will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical
trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant
must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the submission
of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and
deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret
the same data. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our product candidates
or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in
part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our proposed endpoints for
any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trial process is also lengthy and
requires substantial time, effort and expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that the clinical
trials we need to conduct to be in a position to submit BLAs for our product candidates currently in-development will take, at least,
several years to complete. Moreover, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon
or repeat clinical trials. Also, the results of early preclinical and clinical testing may not be predictive of the results of subsequent
clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials
due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and preclinical and clinical
data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed
satisfactorily in preclinical studies and clinical trials have, nonetheless, failed to obtain marketing approval of their products. Success
in preclinical testing and early clinical trials does not ensure that later clinical trials, which involve many more subjects, and the
results of later clinical trials may not replicate the results of prior clinical trials and preclinical testing. Any failure or substantial
delay in our product development plans may have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay, suspend,
or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could delay or disrupt
the clinical development of our product candidates and potentially cause our product candidates to fail to receive regulatory approval:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in receiving, or the inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation in our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in enrolling patients into clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may suspend, or the FDA
or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if we or they
believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs based on similar technologies,
are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimal factors related to toxicity, clinical
efficacy, imbalances in safety and efficacy profiles or for other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result in
perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation of the
study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in the analysis of clinical
data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for
and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials may also be
delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated
by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB (Data Safety Monitoring
Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">varying interpretation of data by the FDA or similar foreign regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unforeseen safety issues; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">lack of adequate funding to continue the clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Modifications to our product candidates
may require federal approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The BLA application is the
vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United
States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products may require
additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket approvals before
we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for a particular use or indication,
we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results.
If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conducting clinical trials
and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect our ability
to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects, financial
condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials necessary to support approval
of our product candidates are time-consuming and expensive. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initiating and completing clinical trials necessary to support FDA
approval of a BLA for Iomab-B, Actimab-A, Iomab-ACT, ATNM-400 and other product candidates, is a time-consuming and expensive process,
and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results,
and any product candidate we advance into clinical trials may not have favorable results in later clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For instance, we worked with
the FDA to develop the SIERRA clinical trial to test the safety and efficacy of Iomab-B in patients with r/r AML who are aged 55 and above
prior to a BMT. Even though the SIERRA trial met the primary endpoint of dCR with statistical significance (p-value&lt;0.0001), the FDA
has determined that the analyses from the SIERRA trial do not support a BLA filing for Iomab-B. The FDA now requires an additional head-to-head
Phase 3 clinical study. We have further discussed the specifics of this additional clinical trial with the FDA. Based on these discussions,
Actinium believes it has aligned with the FDA on the patient population for this additional clinical trial, which can include all adult
patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%. This is a broader patient population
than the patients enrolled on the SIERRA trial, which only enrolled patients aged 55 and above. Further, the FDA is also requiring that
an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based on absorbed
dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based
on several interactions we had with the FDA before starting the SIERRA trial. We are seeking a strategic partner for Iomab-B in the U.S.
to advance these additional trials. Even if we are able to secure a partner, there are no assurances that the additional trials will be
successful or that we can satisfy all of the FDA&#8217;s requests. There could also be additional regulatory hurdles that may result in
either non-acceptance or non-approval of a future BLA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preliminary, Interim, and &#8220;top-line&#8221;
data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
publicly disclose preliminary, interim, and top-line data from our clinical trials, which is based on a preliminary analysis of then-available
data, and the results and related findings and conclusions are subject to change as more patient data become available or following a
more comprehensive review of the data related to the particular study or trial. We may also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all
data. Our clinical trials may be open label studies and certain of our clinical development and/or operations staff may review interim
or preliminary safety or efficacy data during routine data collection, cleaning and analysis from time to time. Interim or preliminary
results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such
results once additional data have been received and fully evaluated. Preliminary, interim or top-line data also remain subject to audit
and verification procedures that may result in the final data being materially different from the top-line, interim or preliminary data
we previously published. As a result, top-line, interim and preliminary data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may also disclose interim data from our preclinical
studies and clinical trials. Interim data from preclinical studies are not necessarily predictive of future success in clinical trials.
Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data
could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility
in the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret
or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the interim, top-line or
preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating
results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if our preclinical studies or early
clinical trials are favorable, later clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates,
which would prevent or delay regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our preclinical studies
are favorable and our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate
claims or that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early
clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate
the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are
safe and effective for the proposed indicated uses. If the FDA concludes that any current or future clinical trials for Actimab-A, Iomab-ACT,
Iomab-B, ATNM-400 or any other product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness,
we would not receive FDA approval to market that product candidate in the United States for the indications sought. In addition, such
an outcome could cause us to abandon the product candidate and might delay the development of others. Any delay or termination of our
clinical trials will delay or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product
candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that
are not currently part of a product candidate&#8217;s profile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intellectual property related to antibodies
we have licensed has expired or likely expired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The key patents related to
the humanized antibody lintuzumab, which we use in our Actimab-A product candidate have expired. It is generally possible that others
may be eventually able to use an antibody with the same sequence, and we will then need to rely on additional patent protection covering
alpha particle drug products comprising Ac-225. Our final drug construct, Actimab-A, consists of the lintuzumab antibody labeled with
the isotope Ac-225. We currently own issued and pending patents relating to methods of manufacturing Actimab-A, methods of treatment using
Actimab-A and production of the Ac-225 isotope. In addition, we possess trade secrets and know how related to the manufacturing and use
of isotopes. Any competing product based on the lintuzumab antibody is likely to require several years of development before achieving
our product candidate&#8217;s current status and may be subject to significant regulatory hurdles, but such development by others is nevertheless
a possibility that could negatively impact our business in the future. We own 4 issued U.S. patents, 2 issued Canadian patents, 1 issued
European patent (validated as a national patent in several countries) and 1 issued Japanese patent that relate to the composition of our
Iomab-B product candidate. Patent applications relating to Iomab-B are also pending in the U.S. and internationally. We have and may continue
to file patents related to Iomab-B that can provide barriers to entry but there is no certainty that these patents will be granted or
such granting thereof will adequately prevent others from seeking to replicate and use the apamistamab antibody or the construct. Our
patent portfolio includes pending applications related to radioimmunoconjugate composition, formulation administration, and methods of
use in treating solid or liquid cancers. This subject matter includes composition, administration, and methods of treatment for our product
candidates Actimab-A and Iomab-B. Any competing product based on the antibody used in Iomab-B is likely to require several years of development
before achieving our product candidate&#8217;s current status and may be subject to significant regulatory hurdles. Further, if approved,
Iomab-B would be entitled to 12 years of market exclusivity in the U.S. and 10 years in Europe, during which time no generic biologic
or biosimilar product referencing Iomab-B can be granted marketing approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Actimab-A program clinical trials are
testing the same drug construct. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A program is comprised
of several clinical trials conducted under the CRADA with NCI, Actinium sponsored trials, investigator-initiated trials in AML and other
myeloid indications and solid tumors that will study the same drug construct consisting of lintuzumab-Ac-225. Negative results from any
of these trials could adversely impact our ability to enroll or complete our other trials studying lintzumab-Ac-225, including future
studies conducted under our CRADA with the NCI. Additionally, negative outcomes including safety concerns, may result in the FDA requiring
amendment to certain clinical trials, placing a clinical hold on certain or all clinical trials or discontinuing other trials utilizing
lintuzumab-Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are currently developing, and in the
future may develop, product candidates in combination with other therapies and that may expose us to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently developing,
and may develop future product candidates, for use in combination with one or more currently approved therapies. For example, Actimab-A
is expected to be tested in combination with KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> for treating HNSCC and NSCLC. If any
of the approved therapies we currently or may, in the future, use in combination with a current or future product candidate is found defective,
removed from the market, or otherwise becomes unavailable, our clinical trials may face significant delays, be suspended, or terminated.
Any such events would likely have a material impact on our operations and the development of the affected product candidate(s) and may
ultimately prevent the approval of such product candidate or render continued development efforts too costly to proceed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if a current or future
product candidate were to receive FDA approval to be commercialized in the U.S. for use in combination with one or more existing therapies,
we would continue to be subject to the risk that the FDA or similar foreign regulatory authorities could revoke approval of the therapy
used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with any such existing
therapies. This could result in our own products being removed from the market or cause material delays in, or the suspension or discontinuation,
of our production and/or distribution of the applicable product, as our ability to market any such product will be limited to the extent
specified in the FDA&#8217;s approval, if granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iodine-131 is a key component
of our Iomab-B drug candidate. We source medical grade I-131 from multiple suppliers, including two leading global manufacturers. Currently,
we believe there is sufficient supply of I-131 to support additional trials we may undertake utilizing I-131 and for future commercialization
of potential I-131 based products. We continually evaluate I-131 manufacturers and suppliers. While we consider I-131 to be commoditized
and obtainable through several suppliers, there can be no guarantee that we will be able to secure I-131 or obtain I-131 on terms that
are acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium-225 is a key component
of our Actimab-A product candidate, technology platform, preclinical R&amp;D programs and other drug candidates that we might consider
for development with the Ac-225 payload. We have secured multiple suppliers that are expected to provide cGMP Ac-225 for our planned clinical
trials. There are adequate quantities of Ac-225 available today to meet our current needs via our present supplier, the Department of
Energy (&#8220;DOE&#8221;), who has been our primary supplier of Ac-225 historically. The Ac-225 currently supplied for our clinical trials
from the DOE is derived from the natural decay of thorium-229 from so-called &#8216;thorium-cows&#8217; and is able to produce sufficient
quantities that are several multiples of the amount of Ac-225 we require to supply our clinical programs through to the early commercialization
phase. The DOE is also producing Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that
is currently being evaluated by us. Initial preclinical and modelling results have indicated that the linear accelerator sourced Ac-225
does not impact labelling efficiency and expected distribution. In accordance with representations made by the DOE, the capacity of Ac-225
from this route is expected to be sufficient to supply all of Actinium&#8217;s pipeline and commercial Ac-225 needs and support new program
expansion by not just Actinium but also other companies that are developing Ac-225 based products. Additional routes of Ac-225 production
are being pursued by the DOE including the generation of new thorium cows and production via a cyclotron. The cyclotron production method
for Ac-225 production leverages Actinium&#8217;s proprietary technology and know-how and presents an additional path towards production
of high-quality Ac-225 at a scale that would be able to satisfy commercial needs. In addition, we are aware of at least ten other government
and non-government entities globally including the U.S., Canada, Russia, Belgium, France and Japan that have, or expect to have, ability
to supply Ac-225 or equipment for its production within the timeframes relevant to the potential first commercial approval of our Ac-225-based
drug candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract for supply of
this isotope from the DOE must be renewed yearly, and we renewed our contract to extend through the end of 2025. While we expect this
contract will continue to be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the
contract or that change its policies that allow for the sale of isotope to us. There can be no assurance that the DOE or our other suppliers
will be able to supply all of the quantities of Ac-225 we request in the future. Failure to acquire sufficient quantities of medical grade
Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates that we
may develop and would materially harm our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to conduct clinical
trials to advance our drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other isotopes we may
choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our isotopes. These suppliers
may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers are subject to regulations
and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217; compliance to these
standards. Failure to comply with regulations and standards may result in their inability to supply isotopes and could result in delays
in our clinical trials, which could have a negative impact on our business. We have developed intellectual property, know-how and trade
secrets related to the manufacturing process of Ac-225. While we have manufactured medical grade Ac-225 of a purity compared to the cyclotron
sourced material in the past, this activity was terminated due to operating cost reasons, and we currently do not have experience in manufacturing
medical grade Ac-225 and may not obtain the resources necessary to establish our own manufacturing capabilities in the future. Our inability
to build out and establish our own manufacturing facilities would require us to continue to rely on third party suppliers as we currently
do. However, based on our current third-party suppliers and potential future suppliers of Ac-225 we expect to have adequate isotope supply
to support our current ongoing clinical trials, current and planned preclinical R&amp;D activities and commercialization should our drug
candidates receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of clinical
trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain in the trial until
its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the size and nature of the patient population;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the patient eligibility criteria defined in the protocol;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the proximity of patients to trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the design of the trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and expertise;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competing clinical trials for similar or alternate therapeutic treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinician&#8217;s and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and maintain patient consents; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the risk that patients enrolled in clinical trials will not complete a clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, refractory patients,
which several of our trials have or are expected to enroll, participating in clinical trials are seriously and often terminally ill and
therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events related
or unrelated to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in our clinical
trials, delays in patient enrollment will result in increased costs or affect the timing of our planned trials, which could adversely
affect our ability to advance the development of our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our product
candidates on a timely basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the data generated in our clinical trials will be acceptable to the FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to the FDA. Certain modifications to a clinical trial protocol made during the course of
the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification
is evaluated. In addition, depending on the quantity and nature of the changes made, the FDA could take the position that some or all
of the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial. This might require
the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval of a product
candidate. If the FDA believes that its prior approval is required for a particular modification, it can delay or halt a clinical trial
while it evaluates additional information regarding the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any delay or termination of
our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required
approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays
or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in
costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product candidates or
result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays
in obtaining regulatory approval for Iomab-B or completion of our ongoing or planned clinical trials would adversely affect our business
and prospects and could cause us to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have obtained orphan drug designation
from the FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in the
future, but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations we have
received or may receive in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received orphan drug
designation for Actimab-A and Iomab-B for treatment of AML in both the United States and the EU. Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects
fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will
be recovered from sales in the United States for that drug or biologic. Similarly, the EMA grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation neither
shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory
review or approval process. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities
for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition, if a product candidate receives
the first FDA approval for the indication for which it has orphan designation, such product is entitled, upon approval, to seven years
of orphan-drug exclusivity, during which the FDA may not approve any other application to market the same drug for the same indication,
unless a subsequently approved product is clinically superior to orphan drug or where the manufacturer is unable to assure sufficient
product quantity in the applicable patient population. In the EU, orphan drug designation entitles a party to financial incentives such
as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may
be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain (or have
obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for such candidates
for the applicable indications due to the uncertainties inherent in the development of novel biologic products, and, an orphan drug candidate
may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is broader than the indication for
which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product
to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, even if we successfully
obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the product from
competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) the FDA or EMA
can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphan drug if the later-approved
drug if deemed clinically superior to the orphan drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval of
our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may
also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our
product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials
that we conduct post-approval. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker
information. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result
in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">fines, warning letters or holds on clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage and reimbursement may be limited
or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage and
reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement for newly
approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products
are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed all or part of the
product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as
a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement approval generally
does not occur prior to the filing of a BLA for that product and may not be granted until many months after BLA approval. In order to
obtain coverage and reimbursement for these products, we or our commercialization partners may have to agree to a net sales price lower
than the net sales price we might charge in other sales channels. The continuing efforts of government and third-party payors to contain
or reduce the costs of healthcare may limit our revenue. Initial dependence on the commercial success of our products may make our revenues
particularly susceptible to any cost containment or reduction efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures intended
to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of
the U.S. healthcare system could have a material adverse effect on our business, future revenue, if any, and results of operations.</i>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The Affordable Care Act, for
example, substantially changed the way healthcare is financed by both governmental and private insurers. The Affordable Care Act contains
a number of provisions that could impact our business and operations, primarily, once we obtain FDA approval to commercialize one of our
product candidates in the United States, if ever. The Affordable Care Act may also affect our operations in ways we cannot currently predict.
Affordable Care Act provisions that may affect our business include, among others, those governing enrollment in federal healthcare programs,
reimbursement changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion
of state Medicaid programs, fees and increased discount and rebate obligations, transparency and reporting requirements, and fraud and
abuse enforcement. Such changes may impact existing government healthcare programs, industry competition, formulary composition, and may
result in the development of new programs, including Medicare payment for performance initiatives, health technology assessments, and
improvements to the physician quality reporting system and feedback program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been significant
judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable Care Act since its
enactment. For example, during his first term, former President Trump issued several Executive Orders and other directives designed to
delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health
insurance mandated by the Affordable Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part
of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation
the Affordable Care Act have been passed. For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision
requiring individuals to purchase and maintain health coverage, or the &#8220;individual mandate,&#8221; by reducing the associated penalty
to zero, beginning in 2019. In December 2018, a district court in Texas held that the individual mandate is unconstitutional and that
the rest of the Affordable Care Act is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the
individual mandate but remanded the case back to the lower court to reassess whether and how such holding affects the validity of the
rest of the Affordable Care Act. The Fifth Circuit&#8217;s decision on the individual mandate was appealed to the U.S. Supreme Court.
On June 17, 2021, the Supreme Court held that the plaintiffs (comprised of the state of Texas, as well as numerous other states and certain
individuals) did not have standing to challenge the constitutionality of the Affordable Care Act&#8217;s individual mandate and, accordingly,
vacated the Fifth Circuit&#8217;s decision and instructed the district court to dismiss the case. As a result, the Affordable Care Act
remained in effect in its then-current form; however, we cannot predict what additional challenges may arise in the future, the outcome
thereof, or the impact any such actions may have on our business. This uncertainty has become even greater given the new Trump administration
and its proposed agenda.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Affordable
Care Act, there have been numerous other Congressional initiatives and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drug products. Pharmaceutical product prices have been the focus of increased
scrutiny by the government, including certain state attorneys general, members of Congress and the United States Department of Justice.
State or federal healthcare reform measures or other social or political pressure to lower the cost of pharmaceutical products could have
a material adverse impact on our business, results of operations and financial condition.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Biden administration also
introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, former President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative
front, the American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid
drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, which began on January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, HHS
released a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and sets
out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to
advance these principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More recently, on August 16, 2022, former President Biden signed into
law the&#160;Inflation&#160;Reduction&#160;Act&#160;of 2022 (the &#8220;IRA&#8221;), which, among other provisions, included several measures
intended to lower the cost of prescription drugs and related healthcare reforms. Specifically, the IRA authorizes and directs the Department
of Health and Human Services (the &#8220;DHHS&#8221;) to set drug price caps for certain high-cost Medicare Part B and Part D qualified
drugs, with the initial list of drugs announced on August 29, 2023, and the first year of maximum price applicability to begin in 2026.
The IRA further authorizes the DHHS to penalize pharmaceutical manufacturers that increase the price of certain Medicare Part B and Part
D drugs faster than the rate of inflation. Finally, the IRA creates significant changes to the Medicare Part D benefit design by capping
Part D beneficiaries&#8217; annual out-of-pocket spending at $2,000 beginning in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 15, 2025, the Trump Administration released
an executive order entitled, &#8220;Lower Drug Prices by Once Again Putting Americans First,&#8221; which among other things, included
multiple directives to various agencies aimed at lowering prescription drug prices. These directives included reports and proposals for
new regulations related to reforming the IRA&#8217;s Medicare Drug Price Negotiation Program, reducing the prices of high-cost drugs,
and enhancing price transparency. Additional legislative and regulatory changes could be made to governmental health programs that could
significantly impact pharmaceutical companies and the success of our product candidates. At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Changes in the
healthcare industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial condition
and results of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and research
efforts rely, in part, on funding and support from U.S. government agencies such as the National Institutes of Health (&#8220;NIH&#8221;),
National Cancer Institute (&#8220;NCI&#8221;) and the Department of Health and Human Services (&#8220;HHS&#8221;). Government funding
for these programs is subject to annual budgetary decisions, which can be unpredictable and influenced by shifting political and economic
priorities. Reductions in government support for cancer research or other healthcare initiatives could limit grants, contracts, or other
financial resources that we or our research collaborators depend on, potentially delaying our clinical programs and increasing our reliance
on alternative funding sources. For instance, we have a CRADA with the NCI for the development of Actimab-A. While we have been informed
that the funding for our CRADA is not expected to be impacted, there can be no assurances that this will remain the case and any reduction
or elimination of funding can have a material adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, with the change
in presidential administration that recently occurred in the United States, government spending programs have become even more difficult
to predict and may be subject to greater risk. Considerable uncertainty exists regarding how future budget and program decisions will
unfold, including the spending priorities of the new U.S. presidential administration and Congress and what challenges budget reductions
may present for our industry generally or for our company. In particular, President Trump recently attempted to place a widespread freeze
on most federal grants and loans. Any freeze on government support for our products, programs, or studies could significantly impair our
research and development activities, business, and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Disruptions at
the FDA, the SEC and other government agencies or comparable regulatory authorities caused by funding shortages or global health concerns,
in addition to substantial uncertainty regarding the new Administration&#8217;s initiatives and how these might impact the FDA, its implementation
of laws, regulations, policies and guidance, and its personnel, could hinder government agencies&#8217; ability to hire and retain key
leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner,
or otherwise prevent those agencies from performing normal business functions on which our business operations rely, including timely
reviews, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA
or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government
budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and
policy changes that may otherwise affect the FDA&#8217;s or comparable foreign regulatory authorities&#8217; ability to perform routine
functions. In addition, government funding of the SEC and other government agencies or comparable foreign regulatory authorities on which
our operations may rely, including those that fund research and development activities, is subject to the political process, which is
inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA
and other agencies, including substantial leadership, personnel, and policy changes, may also slow the time necessary for new drugs to
be reviewed and/or approved by necessary government agencies, which would harm our business. Changes in FDA staffing could result in delays
in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement
or enforce regulatory requirements in a timely fashion or at all. Similar consequences would also result in the event of another significant
shutdown of the federal government. For example, over the last several years, the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government
shutdown occurs, or if geopolitical or global health concerns prevent the FDA or other regulatory authorities from conducting their regular
inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could materially adversely affect our business, financial condition, results of operations and prospects.
Such changes could significantly impact the ability of the FDA to timely review and take action on our regulatory submissions, which could
have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or substantial
leadership, personnel, and policy changes could impact our ability to access the public markets and obtain necessary capital in order
to properly capitalize and continue our operations. If the FDA is constrained in its ability to engage in oversight and implementation
activities in the normal course, our business may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the change in the
U.S. Presidential Administration in 2025, there is substantial uncertainty as to whether and how the new administration will seek to modify
or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. This uncertainty
could present new challenges and/or opportunities as we navigate development of our product candidates. Some of these efforts have manifested
to date in the form of personnel measures that could impact the FDA&#8217;s ability to hire and/or retain key personnel, which could result
in delays or limitations on our ability to obtain guidance from the FDA on our product candidates in development and obtain the requisite
regulatory approvals in the future. Moreover, the new Administration has proposed action to freeze or reduce the budget of the National
Institutes of Health, or NIH, as related to its funding for medical research, which could decrease the ability of facilities that rely
on NIH funding to enroll and conduct clinical trials or increase the costs to us of conducting clinical trials. There remains general
uncertainty regarding future activities. The new Administration&#160;could issue or promulgate executive orders, regulations, policies
or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic products.
Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory
frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations,
policies or guidance as a result of the new Administration, there could be a material adverse effect on us and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our relationships with customers, health
care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including
administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs
such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and
earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare professionals and
third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing
approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we conduct research, market, sell and distribute any products for which we obtain marketing approval. Federal and state
healthcare laws and regulations that may affect our operations, directly or indirectly, include the following, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal Anti-Kickback Statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal false claims laws, including civil whistleblower or qui tam actions under the federal False Claims Act, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of the covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal Physician Payments Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value provided to physicians and any ownership and investment interests held by physicians or their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">analogous state laws and regulations, including (among others) state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to comply with applicable
healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance under these laws and regulations
are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight (if we become subject to
a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws), and the curtailment or restructuring
of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities
with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party payors may not adequately reimburse
customers for any product candidates that we may commercialize or promote, and may impose coverage restrictions or limitations such as
prior authorizations and step edits that affect their use.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products
and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other
third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend
in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring
that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage
and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement
may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate
for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may
not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining reimbursement approval
for any product candidate for which we obtain marketing approval from any government or other third-party payor is a time-consuming and
costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products. Moreover,
eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Even when a payor determines that a product that we may commercialize
or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitations that preclude payment for some
uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements, or may simply deny coverage altogether.
Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be
based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other
services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Furthermore, the Centers for Medicare and Medicaid Services frequently change product descriptors, coverage
policies, product and service codes, payment methodologies and reimbursement values. Commercial third-party payors often rely upon Medicare
coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain and maintain coverage
and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our
overall financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S. and some jurisdictions
outside the U.S., there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system
that could impact our business. Generally, there has been increasing legislative and enforcement interest in the U.S. with respect to
drug pricing, including specialty drug pricing practices, in light of the rising cost of prescription drugs and biologics. Specifically,
there have been U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency
to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare,
and reform government program reimbursement methodologies for drugs and biologics. In addition, the concept of most-favored nation pricing
has been raised that would seek to establish drug prices in the U.S. to the lowest level paid by comparable countries. Such policy action
could cause us to amend, suspend or terminate the development of any or all of our product candidates if a viable commercial market did
not exist, which could have a material adverse impact on our business and ability to operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If future legislation were
to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial
results. Managed care organizations, as well as Medicaid and other government authorities, continue to seek price discounts. At the state
level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biologic product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. Due to the volatility
in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory,
payor or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material
adverse impact on our business and ability to operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may rely on third parties to conduct
our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply
with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the ability
to independently conduct our clinical trials for our product candidates and we must rely on third parties, such as contract research organizations,
medical institutions, clinical investigators and contract laboratories to conduct such trials. Our reliance on these third parties for
clinical development activities results in reduced control over these activities. Moreover, the FDA requires us to comply with regulations
and standards, commonly referred to as GCPs (good clinical practices), for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our
reliance on third parties does not relieve us of these responsibilities and requirements. If we or any of our third-party contractors
fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable
foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing
practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our consultants, contract
research organizations and other similar entities with which we are working do not successfully carry out their contractual duties, meet
expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there are a number
of other third-party contractors we could engage to continue these activities, we may not be able to enter into arrangements with alternative
third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our planned clinical trials and delayed
development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors, we
cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry
out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data they obtain
is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical
development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory
approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results
and prospects would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The protection against generic competition
for our biologic drug candidates and reimbursement by CMS may be subject to future change</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any existing
or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our targeted radiotherapy product
candidates. Our ARC product candidates are regulated by the FDA as biologic products, and we intend to seek approval for these products
pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for
the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the
FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based
on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA
until 12 years after the original branded product was approved under a BLA and in Europe a biosimilar product cannot be approved until
10 years after the original branded product was approved. The law is complex and as a result, its ultimate impact, implementation, and
meaning are subject to uncertainty. Even if a biosimilar gets approved for one of the antibodies that we use, the final constructs of
our drug candidates consist of an antibody, radioisotope and in some cases a linker and we are not aware of any regulations that would
require us to provide the final constructs or components to third parties or potential competitors. Therefore, based on the current regulations,
we do not believe that the final drug product of our candidates can be subject to competition from a biosimilar as outlined in BPCIA for
at least 12 years in the U.S. and 10 years in the EU. We are aware that generic versions of certain radiopharmaceuticals utilizing peptides
have been submitted to the FDA via the Abbreviated New Drug Application (&#8220;ANDA&#8221;) pathway, however, those products are not
covered under the BPCIA and therefore that generic pathway is not applicable to Iomab-B or Actimab-A. We expect this would also apply
to other biologic drug candidates we may seek to develop in the future based on the current provisions of the BPCIA. Additionally, the
Inflation Reduction Act (&#8220;IRA&#8221;) that was enacted in August 2022, states that reimbursement by the Centers for Medicare&amp;
Medicaid Services (&#8220;CMS&#8221;) for high-expenditure single-source biologic drugs, which we expect Iomab-B and Actimab-A to be,
can only be negotiated after at least 11 years following approval compared to 7 years for non-biologic drugs with negotiated prices taking
effect two years after selection. Therefore, we currently believe that our ARCs are less likely than small molecules to face pricing pressure
and negotiation from IRA. Further, a drug or biological product that has an orphan drug designation, which Iomab-B and Actimab-A both
have, for only one rare disease or condition will be excluded from the IRA&#8217;s price negotiations requirements &#160;until such time
the biological products has designations for more than one rare disease or condition, or if is approved for an indication that is not
within that single designated rare disease or condition, unless such additional designation or such disqualifying approvals are withdrawn
by the time CMS evaluates the drug for selection for negotiation. In August 2023, 10 initial drugs were identified with negotiated prices
expected to take effect starting in 2026. In 2027 and 2028, it is expected that CMS will establish negotiated prices for 15 additional
drugs in each respective year. We do not believe there is a high likelihood that Iomab-B or Actimab-A would be identified by CMS for negotiated
pricing under IRA but there is potential that IRA and other additional state and federal healthcare reform measures will be adopted in
the future and the implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or successfully commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may never achieve
market acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A, Iomab-ACT, ATNM-400, Iomab-B and future product candidates
that we may develop may never gain market acceptance among physicians, patients and the medical community. The degree of market acceptance
of any of our products will depend on a number of factors, including the actual and perceived effectiveness and reliability of the product;
the results of any long-term clinical trials relating to use of the product; the availability, relative cost and perceived advantages
and disadvantages of alternative technologies; the degree to which treatments using the product are approved for reimbursement by public
and private insurers; the strength of our marketing and distribution infrastructure; and the level of education and awareness among physicians
and hospitals concerning the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating specific
cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide patients with
sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the use of each product candidate
from influential physicians will be essential for widespread market acceptance. Our product candidates are still in the development stage,
and it is premature to attempt to gain support from physicians at this time. We can provide no assurance that such support will ever be
obtained. If our product candidates do not receive such support from these physicians and from long-term data, physicians may not use
or continue to use, and hospitals may not purchase or continue to purchase, them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure of Actimab-A, Iomab-ACT, ATNM-400, Iomab-B or any of our other
product candidates to significantly penetrate current or new markets would negatively impact our business financial condition and results
of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our third-party
service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial
cost and be a distraction to our management and employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently depend on single third-party
manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party
manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently operate
manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturers
to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonal
antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect to continue
to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing or future manufacturers
could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory approval of our product
candidates or commercialization of any approved products. Further avenues of disruption to our clinical or eventual commercial supply
may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen circumstances that might occur
at any of our suppliers or contract manufacturing partners including an inability to come to terms on renewal of existing contracts or
new contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on single
manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuity we are
evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing partners,
however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we would be able
to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity and support
our growth plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates require
precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers we may engage in
the future to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls or withdrawals,
delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our business. Contract manufacturers
may encounter difficulties involving production yields, quality control, and quality assurance. These manufacturers are subject to ongoing
periodic and unannounced inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and
other applicable government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&#8217;
compliance with these regulations and standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently plan to build
out a manufacturing facility in the future to operate for the purposes of manufacturing our own products. We have never built, owned or
operated a manufacturing facility. There can be no assurances that we will be able to successfully accomplish this and in doing so we
may experience delays, cost overruns, or other problems that could seriously hurt our business. Even if we successfully build out our
planned manufacturing facility, we may not realize the expected benefits of these efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on vendors with
specialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered into manufacturing
and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be the exclusive manufacturer and
supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail to comply with required regulations
or breach their contractual obligations it may be difficult, or we may be unable to identify suitable alternative third-party manufacturers.
While we identify and evaluate third-party manufacturers from time to time, even if we do identify suitable alternative third-parties,
we may fail to reach agreement on contractual terms, it may be prohibitively expensive and there can be no assurance that we can successfully
complete technology transfer and development work necessary, or complete the necessary work in a timely manner. Any of which could prevent
us from commencing manufacturing with third-parties which could cause delays or suspension of our clinical trials and pre-clinical work
that may have a negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, these third-party
contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shutdowns, employee strikes, or
any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct (either
ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-party manufacturers
to consistently supply quality product when required would have a material adverse effect on our ability to develop or commercialize our
products. We have faced delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such
delays and risks in the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company,
including delays in clinical trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are successful in obtaining marketing
approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party
manufacturers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our product candidates
have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or other regulatory
agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party
specialized manufacturers to produce commercial quantities of approved products. These manufacturers may not be able to successfully increase
the manufacturing capacity for any approved product in a timely or economic manner, or at all. Significant scale-up of manufacturing may
require additional validation studies, which the FDA must review and approve. Scale-up for commercial product may require financial commitment
or investment by us, which we may not have sufficient capital for or may elect not to undertake. If third party manufacturers are unable
to successfully increase the manufacturing capacity for a product candidate, or we are unable to establish our own manufacturing capabilities,
the commercial launch of any approved products may be delayed or there may be a shortage in supply, which in turn could have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will
be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure
and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for
or market our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have conflicts with
our partners, such as conflicts concerning the interpretation of preclinical or clinical data, pertaining to the global patient safety
profile or efficacy results of our products, the achievement of milestones, the interpretation of contractual obligations, payments for
services, development obligations or the ownership of intellectual property developed during our collaboration. We may seek to amend,
modify or terminate agreements with partners, suppliers or service providers related to Iomab-B, Actimab-A or Iomab-ACT but there can
be no assurance that we can do so successfully or negotiate terms that are favorable to us. Failure of which can increase the risk of
or result in litigation or alternative dispute resolution options taken against us. Further, we may exercise our decision-making authority
under certain circumstances pertaining to global patient safety related to our products, which our partners may disagree with and may
result in potential conflicts and public disclosure of our rationale and position. If any conflicts arise with any of our partners, such
partner may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following,
each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating
revenues: unwillingness on the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration; uncertainty
regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into
additional collaborations; unwillingness by the partner to cooperate in the development or manufacture of the product, including providing
us with product data or materials; unwillingness on the part of a partner to keep us informed regarding the progress of its development
and commercialization activities or to permit public disclosure of the results of those activities; initiating litigation or alternative
dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the agreement.&#160;Litigation
or alternative dispute resolution options can be lengthy and expensive, require significant time and attention from our management and
are highly uncertain. There can be no assurance that if we pursue, or a partner pursues litigation or alternative dispute resolution options,
that we will prevail. Monetary and equitable damages awarded against us could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If in the future we are unable to establish
U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates,
we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive regulatory approval.
In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution,
managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with
technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming
and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the commercialization
of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with
third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution
systems or in lieu of our own sales force and distribution systems. If we are unable to enter into or maintain such arrangements when
needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory
approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates,
either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant
additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face significant competition from other
biotechnology and pharmaceutical companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates face,
and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academic and research
institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii)
emerging competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with
our product candidates and technologies and may develop and commercialize additional products and technologies that will compete with
our product candidates and technologies. Because several competing companies and institutions have greater financial resources than us,
they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development, or R&amp;D,
and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we do and have substantially
greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory approvals, and manufacturing
and marketing pharmaceutical products. They also have greater name recognition and better access to customers than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The drug-related side
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even if any of our product candidates
receives marketing approval, as greater numbers of patients use a product following its approval, an increase in the incidence of side
effects or the incidence of other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result
in a number of potentially significant negative consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may withdraw their approval of the product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may elect, or we may be required, to recall or withdraw product from the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we could be sued and held liable for harm caused to patients; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or could harm or
prevent sales of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon securing and protecting critical
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are dependent on obtaining
and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages of
development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether the commercial
versions of these product candidates will incorporate proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our patent position is highly uncertain
and involves complex legal and factual questions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, we cannot predict
the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our licensors might
not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors
might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative
technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications
of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially
viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and,
we may not develop additional proprietary technologies that are patentable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the issuance
of a patent, while presumed valid and enforceable, is not conclusive as to its validity or its enforceability and it may not provide us
with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors may also be able
to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods.
We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors,
former employees and current employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent rights are territorial,
and patent protection extends only to those countries where we have issued patents. Filing, prosecuting and defending patents on our products
and product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual
property rights in some countries outside the United States could be less extensive than those in the United States. Many countries, however,
do not protect intellectual property to the same extent as the U.S. or Europe, and their litigation processes differ. Competitors may
successfully challenge or avoid our patents, or manufacture products in countries where we have not applied for patent protection. Changes
in the patent laws in the U.S. or other countries may diminish the value of our patent rights. As a result of these and other factors,
the scope, validity, enforceability, and commercial value of our patent rights are uncertain and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indeed, several companies
have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems
of some countries do not favor the enforcement of patents and other intellectual property rights, which could make it difficult for us
to stop the infringement, misappropriation or other violation of our intellectual property rights generally. Proceedings to enforce our
intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk
of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that are initiated, and
the damages or other remedies awarded, if any, may not be commercially meaningful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of pharmaceutical
companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and
enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed
unenforceable, invalidated, or circumvented. A third-party may submit prior art, or we may become involved in opposition, derivation,
reexamination, inter partes review, post-grant review, supplemental examination, or interference proceedings challenging our patent rights
or the patent rights of our licensors or development partners. The costs of defending or enforcing our proprietary rights in these proceedings
can be substantial, and the outcome can be uncertain. An adverse determination in any such submission or proceeding could reduce the scope
of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, or
reduce our ability to manufacture or commercialize products. Furthermore, if the scope or strength of protection provided by our patents
and patent applications is threatened, it could discourage companies from collaborating with us to license, develop or commercialize current
or future products. The ownership of our proprietary rights could also be challenged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, our owned and
licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protection for the
full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or our licensors have applied
for and will continue to apply for patents for certain products and methods. Such applications may not result in the issuance of any patents,
and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible
that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because
of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain a preferred position, we
could become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration of our
patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we license from third parties, or subsequent
related filings, would adversely affect our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents issued or licensed
to us may be infringed by the products or processes of others. Our ability to enforce our patent rights depends on our ability to detect
infringement. It is difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may
be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product, particularly
in litigation in countries other than the U.S. that do not provide an extensive discovery procedure. Any litigation to enforce or defend
our patent rights, if any, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management
and key personnel from our business operations. We may not prevail in any lawsuits that we initiate and the damages or other remedies
awarded if we were to prevail may not be commercially meaningful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of enforcing our
patent rights against infringers, if such enforcement is required, could be significant, and we may not have the financial resources to
fund such litigation. Further, such litigation can go on for years and the time demands could interfere with our normal operations. There
has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry.
We may become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor,
could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively than we can because
of their substantially greater financial resources. Litigation may also absorb significant management time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although
we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of
confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means, these measures may
not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access
to, the same or similar information. In addition, we cannot guarantee that we have executed these agreements with each party that may
have or have had access to our trade secrets. Furthermore, if the employees and consultants who are parties to these agreements breach
or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade
secrets through such breaches or violations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our patent rights
are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents may
be terminated, and we may be unable to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are found to be infringing patents
or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the
development or sale of our products, and/or pay damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not have identified
all patents, published applications or published literature that affect our business either by blocking our ability to commercialize our
products, by preventing the patentability of one or more aspects of our products to us or our licensors, or by covering the same or similar
technologies that may affect our ability to market our products. For example, we (or our licensors) may not have conducted a patent clearance
search sufficient to identify potentially obstructing third party patent rights. Moreover, patent applications in the United States are
maintained in confidence for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the
U.S. Patent and Trademark Office, or the USPTO, for the entire time prior to issuance as a U.S. patent. Patent applications filed in countries
outside of the United States are not typically published until at least 18 months from their first filing date. Similarly, publication
of discoveries in the scientific or patent literature often lags behind actual discoveries. We cannot be certain that we or our licensors
were the first to invent, or the first to file, patent applications covering our products and candidates. We also may not know if our
competitors filed patent applications for technology covered by our pending applications or if we were the first to invent the technology
that is the subject of our patent applications. Competitors may have filed patent applications or received patents and may obtain additional
patents and proprietary rights that block or compete with our patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others,
or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases
that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other
persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the
affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required
to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process.
Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved
in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to infringement
or other intellectual property claims against us, we may become a party to other patent litigation or proceedings before regulatory agencies,
including post-grant review, inter parties review, interference or re-examination proceedings filed with the U.S. Patent and Trademark
Office (or similar proceedings before corresponding tribunals in other jurisdictions) that challenge our patent rights or the patent rights
of our licensors. The costs and efforts of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings
can be substantial and the outcome can be uncertain. An adverse determination in these proceedings could weaken or invalidate the patent
claims that cover our technology, which adverse determination could harm our business significantly and dissuade companies from collaborating
with us or permit third parties to directly compete with the same technology.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to protect and enforce our patents
does not guarantee that we will secure the right to commercialize our potential products and respective patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent is a limited monopoly
right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention.
This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making, using and/or selling
its invention. While a patent gives the holder this right to exclude others, it is not a license to commercialize an invention covered
by the patent where other permissions may be required for commercialization to occur. For example, a drug cannot be marketed without the
appropriate authorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if
patented itself, cannot be commercialized if it infringes the valid patent rights of another party.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on confidentiality agreements to
protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our
competitors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on trade secrets that
we seek to protect through numerous measures, including non-compete and confidentiality agreements with our employees and other parties.
If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. Any remedies
that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we
may have to expend resources to protect our interests from possible infringement by others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to damages resulting from
claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees may have been
previously employed at other companies in the industry, including our competitors or potential competitors. Although we are not aware
of any claims currently pending against us, we may be subject to claims that these employees or we have inadvertently or otherwise used
or disclosed trade secrets or other proprietary information of the former employers of our employees. Litigation may be necessary to defend
against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be
a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual
property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product(s),
which would materially adversely affect our commercial development efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining patent protection
depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case
of non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance fees,
renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the relevant patent agencies
in several stages over the lifetime of the patents and /or applications. The relevant patent agencies require compliance with a number
of procedural, documentary, fee payment and other provisions during the patent application process. In many cases, an inadvertent lapse
can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which
the failure to comply with the relevant requirements can result in the abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our
technologies and know-how which could have a material adverse effect on our business, prospects, financial condition and results of operation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future operations and
successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon
to manage our business. If any member of our current senior management terminates his or her employment with us and we are unable to find
a suitable replacement quickly, the departure could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the third quarter of 2024,
our overall headcount was reduced by approximately twenty percent, with a majority of departures coming from our clinical and CMC groups.
As a result of these departures, we expect our personnel expenses to be reduced by approximately $3.7 million in 2025, which may be offset
by additional hires or consultants. We do not expect these departures to have a material impact on our operations or ability to execute
our operating plan and are actively seeking a strategic partner for Iomab-B in the U.S. to advance the additional studies and trials required
by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An overall tightening and
increasingly competitive labor market has been observed in the U.S. employment market generally. Specific to the biotechnology industry
in which we operate, there is significant demand and competition for highly specialized talent that we require. A sustained labor shortage
or increased turnover rates within our employee base as a result of general macroeconomic factors of <i>force majeure </i>events, or due
to dynamics within our industry, could lead to increased costs, such as increased wage rates to attract and retain employees, and could
negatively affect our ability to efficiently conduct our clinical development, R&amp;D, business development and potential regulatory
and commercial activities. If we are unable to hire and retain employees capable of performing at a high-level, or if mitigation measures
we may take to respond to a decrease in labor availability, have unintended negative effects, our business could be adversely affected.
An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, general macroeconomic factors or as a result
of biotechnology industry dynamics could have a material adverse impact on our operations, results of operations, liquidity or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to identify, attract, hire, or engage, retain, and motivate other well-qualified managerial, technical, clinical and regulatory
personnel. This activity is likely to create additional demands on the time and attention of our senior management personnel as they identify,
hire, and train external and internal candidates to fill the sizable number of positions required to execute our business plans, including
submitting a BLA and building a commercial organization. The market for talent in our industry is very competitive. Many of the other
biopharmaceutical companies we compete against for qualified personnel have greater financial and other resources, more favorable risk
profiles and a longer operating history in the biopharmaceutical industry than we do. They also may provide more diverse opportunities
and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates than what we have
to offer. There can be no assurance that such professionals will be available in the market, or that we will be able to retain existing
professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base in relation to such compensation,
which may include equity compensation, may increase significantly, which could have a material adverse effect on us. Failure to establish
and maintain an effective management team and workforce could adversely affect our ability to operate, grow and manage our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Managing our growth as we expand operations
may strain our resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to need to grow
rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates as well
as potential commercial operations in the future, which will place a significant strain on our financial, managerial and operational resources.
In order to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities.
Moreover, we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase our
expenses and may require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm
our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us
to liability for claims arising from the use or misuse of these materials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials,
such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations governing, among
other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely eliminate the
risk of contamination or injury from these materials, and we could be held liable for any damages that result, which could exceed our
financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future
claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the
costs of complying with such federal, state, local and foreign environmental regulations are not significant, and consist primarily of
waste disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our
research, development, production and commercialization efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not have any
international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant
opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries involves
inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected changes in
regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating
intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to experience any
of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition
may suffer and cause us to reduce or discontinue our international development and registration efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to expand our development and
regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and, as a result, we may encounter difficulties
in managing our growth, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to experience growth
in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory
affairs and, if any of our product candidates receives marketing approval, sales, marketing, and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that are potentially able to obtain
regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales,
distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we
may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales or
marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be
expensive and time consuming and will require significant attention of our executive officers to manage. We will also have to compete
with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of
any of our product candidates that we obtain approval to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To manage our anticipated
future growth, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and
continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our
management team in managing a public company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may
divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans
or disrupt our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We continuously evaluate our business strategy
and may modify our strategy as necessary to respond to developments in our business and other factors, and any such modification, if not
successful, could have a material adverse effect on our business, financial condition, and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continuously evaluate our
business strategy and modify our plans as necessary to achieve our objectives in response to changing circumstances. As part of such a
process, we may delay, modify or discontinue the development of certain of our drug candidates and choose alternative approaches if we
believe such changes would be in our best interest. We may also expand or alter our research and development activities from time to time
and redirect allocation of our resources. We have implemented such changes in our business strategy and may continue to do so in the future.
There can be no assurances that any product development or other changes that we implement will be successful or that, after implementation
of any such changes, that we will not refocus our efforts on new or different objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may expand our business through the acquisition
of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217;
ownership interests in our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so. Acquisitions
involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt
and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating
acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business
concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key
employees of the acquired companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
product, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated
with some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired products,
businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business
or companies may require a substantial capital investment by us. We may not have these necessary funds, or they might not be available
to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute
each current stockholder&#8217;s ownership interest in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Ownership of Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The sale of securities by us in any equity
or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additional capital
through the sales of stock and warrants in order to expand our level of operations to continue our research and development efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any sale of common stock by
us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional shares
of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing strategic relationships
with targeted customers and vendors. In order to do so, or to finance the cost of our other activities, we may issue additional equity
securities that could dilute our stockholders&#8217; stock ownership. We may also assume additional debt and incur impairment losses related
to goodwill and other tangible assets if we acquire another company and this could negatively impact our earnings and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>Our common stock is subject to price volatility which could
lead to losses by stockholders and potential costly security litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading volume of our
common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock to fluctuate
substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating
results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and
the financial markets or other developments affecting our competitors or us. This volatility has had a significant effect on the market
price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The trading price of our common stock may
be highly volatile and could fluctuate in response to factors such as:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated variations in our operating results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">announcements of developments by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory actions regarding our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">adoption of new accounting standards affecting our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">additions or departures of key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">introduction of new products by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">sales of our common stock or other securities in the open market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inaccurate or unfavorable reports from securities or industry analysts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">other events or factors, many of which are beyond our control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market is subject
to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&#8217;s securities,
securities class action litigation has often been initiated against such a company. Litigation initiated against us, such as the Securities
Claims further described under &#8220;Legal Proceedings&#8221;, whether or not successful, could result in substantial costs and diversion
of our management&#8217;s attention and our resources, which could harm our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends on our
common stock, so any returns will be determined by the value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations
will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. As a result, the
success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common
stock will appreciate in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain provisions of our Certificate of
Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to
complete, even if such a transaction were in our stockholders&#8217; interest.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our
management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our
stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock.
Among other things, the certificate of incorporation and bylaws:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide that the authorized number of directors may be changed by resolution of the board of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">divide the board of directors into three classes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&#8217;s notice;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are governed
by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging
in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own,
15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing
a change in our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face risks associated with litigation
and claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
legal proceedings, as further described under &#8220;Legal Proceedings.&#8221; In addition, from time to time, we may become involved
in various claims, disputes and legal or regulatory proceedings that arise in the ordinary course of business and relate to contractual
and other obligations. Due to the uncertainties of litigation, we can give no assurance that we will prevail on any claims made against
us in any such lawsuit. Also, we can give no assurance that any other lawsuits or claims brought in the future will not have an adverse
effect on our financial condition, liquidity, or operating results. Adverse outcomes in some or all of these claims may result in significant
monetary damages that could adversely affect our ability to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with the reporting requirements
of federal securities laws can be expensive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission
and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with the
preparation of registration statements and related documents with respect to any offerings of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to utilize our
federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, or the Code.&#160;The limitations apply if we experience an &#8220;ownership change&#8221;, generally defined as a greater
than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period.&#160;Similar
provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously occurred.&#160;If we
have experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability to utilize
our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in our stock ownership,
which may be outside of our control, may trigger an ownership change and, consequently, the limitations under Sections 382 and 383 of
the Code.&#160;As a result, if or when we earn net taxable income, our ability to use our pre-change net operating loss carryforwards
and other tax attributes to offset such taxable income may be subject to limitations, which could adversely affect our future cash flows.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to establish and maintain adequate
finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal
controls requirements for publicly traded companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, we operate
in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporate oversight
and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary
for us to produce reliable financial reports and are important to help prevent financial fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts. We complied
with Section 404 at December 31, 2024 and 2023 and while our testing did not reveal any material weaknesses in our internal controls,
any material weaknesses in our internal controls in the future would be required us to remediate in a timely manner so as to be able to
comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section 404 in a timely manner
each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory authorities which would require
additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot
provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose
confidence in our reported financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Multiple
securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publish inaccurate or
unfavorable research about our business, the price of our common stock would likely decline. If one or more of these analysts cease coverage
of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could cause the price of our common
stock and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated&#160;bylaws, as
amended,&#160;designate the U.S.&#160;federal&#160;district courts as the&#160;exclusive forum&#160;for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated&#160;bylaws,
as amended,&#160;provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities
Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasing or otherwise acquiring
any interest in our security shall be deemed to have notice of and to have consented to such provision. Such choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees, which may discourage such lawsuits, if successful, might benefit our stockholders. Stockholders who do bring
a claim in the federal district courts of the United States of America could face additional litigation costs in pursuing any such claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tariff policies and potential countermeasures
could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">President Trump has increased,
and has indicated his willingness to continue to increase, the use of tariffs by the U.S. to accomplish certain U.S. policy goals. Such
tariffs and any countermeasures could increase the cost of raw materials and components necessary for our operations, disrupt our global
supply chain and create additional operational challenges. Further, it is possible that government policy changes and related uncertainty
about policy changes could increase market volatility. Because of these dynamics, we cannot predict the impact of any future changes to
the U.S.&#8217;s or other countries&#8217; trading relationships or the impact of new laws or regulations adopted by the U.S. or other
countries on our business. Such changes in tariffs and trade regulations could have a material adverse effect on our financial condition,
results of operations and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-7222"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-7223"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-7224"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-7225">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copies of the following documents
are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-align: left; vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="text-align: left; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: justify"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.1</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm"><span style="font-size: 10pt">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed with the SEC on April 17, 2013).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.2</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.3</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.4</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.5</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.6</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.7</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.8</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022322/ea125571ex3-1_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.9</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm"><span style="font-size: 10pt">Amended and Restated Bylaws, dated August 9, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">3.10</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm"><span style="font-size: 10pt">Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">31.1*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="ea023914301ex31-1_actinium.htm"><span style="font-size: 10pt">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">31.2*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="ea023914301ex31-2_actinium.htm"><span style="font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">32.1**</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="ea023914301ex32-1_actinium.htm"><span style="font-size: 10pt">Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">32.2**</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="ea023914301ex32-2_actinium.htm"><span style="font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">101.INS*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">101.SCH*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">101.CAL*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">101.DEF*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">101.LAB*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Label Linkbase Document </span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">101.PRE*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">104*</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 37%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: May 9, 2025</span></td>
    <td><span style="font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Sandesh Seth</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Sandesh Seth</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman and Chief Executive Officer<br/>
(Duly Authorized Officer and<br/>
Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Steve O&#8217;Loughlin</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Steve O&#8217;Loughlin</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Duly Authorized Officer and<br/>
Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">68</p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>



































































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-6" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-7" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-8" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-9" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-10" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-11" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-12" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-13" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-14" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-16" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-19" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-20" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-21" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-22" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-23" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-24" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-25" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-26" name="atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-27" name="atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-28" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-29" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-30" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-31" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-32" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-35" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-37" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-38" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-40" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-44" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-46" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-48" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-49" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-50" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-7280">0001388320</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-7281">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-7282">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate" id="ixv-7283">--12-31</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnm-20250331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-05-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah8gTxiZM6/uA6nfEBodeGu+2+0ReVEwTDC0+Z7+Xbjvy1atNxHViEapukjgsdImMcgoeTmFSA+kShLZmaIu1iIX5SOssVgjTKGBI8nXD3MPb6tJD9O0Li68lWtn3OrlHpVHcdjpaSSaLnrmFzv9UvSdPuz/3S38PVBNpoXCoCNEA==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2012-06-15</xbrli:startDate>
    <xbrli:endDate>2012-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-11</xbrli:startDate>
    <xbrli:endDate>2023-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ea023914301ex31-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO SECTION 302 OF</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: May 9, 2025</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Sandesh Seth</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)&#8239;</TD>
    </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ea023914301ex31-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO SECTION 302 OF</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Steve O&rsquo;Loughlin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: May 9, 2025</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Steve O&rsquo;Loughlin</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD>
    </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ea023914301ex32-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2025 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Sandesh Seth, Chairman &amp; CEO of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly presents,
in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: May 9, 2025</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Sandesh Seth</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)&#8239;</TD>
    </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ea023914301ex32-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2025 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Steve O&rsquo;Loughlin, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly presents,
in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: May 9, 2025</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Steve O&rsquo;Loughlin</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD>
    </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $& CP# 2(  A$! Q$!_\0
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M:1G02=6+YOW>_P"&8O@Y_P! CQ=_X=CXM_\ S<T?\,Q?!S_H$>+O_#L?%O\
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M?%D'YFVKP?'/\3?*OJW R>*_#/X-^+O^"D7@O4OA')HVI?&X^!_!7Q4_83^
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MITXWHJ\TYNG)QJ4Y*7],W_#,7P<_Z!'B[_P['Q;_ /FYH_X9B^#G_0(\7?\
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M /0VS7_PYYC_ /-X?ZL\-?\ 1.</?^&')/\ YT'S_P#\,H_LQ_\ 1OWP=_\
M#=^%?_E944W[*_[+MM#-<7'P$^#%O;V\4DT\\WP_\)Q0PPQ(9)9II9--5(XH
MT5GDD=E1$4LQ !-?0M?*7[<WPWO?C!^R%^T+\,-/\"^*?B;=>.?AGKWAU? 7
M@CQUIGPU\8>)X;^...ZTWPSXTUNUO=#TC6VM?/FTZ/7;6;0]5NHH]%UE1IFH
MW3#HPN9YI7Q6&H5<[S2C3K8BA1J5O[2QS]C3JUJ5.=6U3-*--^SA.4[3K4H/
MDM*K3BW.&=;ASARG1JU(<,\/U)TZ52<:?]A9,N>4(3E&%XY+4DN>45&\83DN
M:ZA)I1=G0O@'^QGXITJTUSPS\*?V>/$6B7]VVGV.L:%X8\!:OI5[?H[1O96F
MH:?;7%I<7:2(Z-;0S/,KHRE RD#I/^&4?V8_^C?O@[_X;OPK_P#*ROYO/@[^
MR+^TKI'ASX1:R/V</CGX8^''PL_X*(?!WXJZ%:>'/!_PJ_9D^/OCGP3!\!?'
M?@GQ;XU^+_P>^!WQ*U#X0R#PCXZ?P#X:M?'.A3Z)JWB/P=J'BO5M6\,"RDO(
MY)'\;?\ !0CX>:3XY\3_ !UU#]KCX+_ +Q5\4?V4;KQMHGBWXV^&H?BU;-JG
MB[XQ6'QK^'_[/7Q=\3^.[.*)I=0B^$TUY;^'[GX9:=XF\$66KK\._#NF7%ZX
MU'[6ID6/J5IT\#QK6J\DYP4*N:XJ5><O;TX4Z-*&$SVJZV)E1FZKI0I*"J1^
MK^WA*-2M3\"&'X?C",L1P5D\.:,6Y0R#*%3BO9SE*I.5;A^"ITE4BH*<I\W*
M_:^S<7"G+^C_ /X91_9C_P"C?O@[_P"&[\*__*RC_AE']F/_ *-^^#O_ (;O
MPK_\K*_F_P#V?M0_X*>?&S2_V4?'OA'XP_M&2?!C5/$OQ2/A_P >Q&S^*6LO
MJFB_MH>/;>9?CV--^)?@CPOXK\':C\";#POX=\,^(=0L?'W@"#P[#KM[X*TZ
M#71I-]<?HY_P4'T#]O'4OC7/<?L__P##04^@S?!30;3]FF?X&^+_  GX;^'/
MAG]J.+X@7L_B'6/VLM+\0:I83>(OA;+X2;PI]C@U.R\0^$_[$M/&U@NB_P#"
M4WVF70X<1E6;X;,*&75.,X>TJT\;.K4_M?-8PPL\'B(4'1Q'M,SAR5IN<JLZ
M?M(SH4J&*E*&(E1A#$]%+!\-U<+4Q4>"\LY82H*$/]7\B<JT:]*53GI<N2RY
MH1Y5",N5QJ3J44I4E4E*C]_CX"?L9FX\2V@^%7[/!N_!EO%=^,+4>&/ )N/"
MEK/:RWT%SXEA%MYFA6\UE;SWD4VJ+:QR6L,MPC-%&[K%X2^!?[%GCZRN-2\"
M_##]G/QIIUI<FSNK_P )>'/A]XCLK:[50YM;BZT>WO((;D(RN8))%E"D,5P0
M:_-/X>?L>?$[PA^R7_P6/TC_ (03QQ>?%_\ :<^)'[8DO@:SUW7/[;U3XDZ)
MKWPUNM*^&5YX6N]2U*>6'2=?U?6M5T[08M4O;2:.W2TM[F*SAM8\?"VG?L[?
MM>V.@^+_ (G_ +$'[(GQ2_8;71OV6?V=O@E\6/#-WHOP_P#AS\1?CWXP\/?&
M+POK?Q4\9?#WP3\+_B5-'-XA\)?":T\8:9H?Q!N/%7@[Q]XG?Q5<:%X>U33=
M3M+6\M]J& J8GZ["GQGCJ3P^)PF&HXG$YK*C@YRK9?EN*G.M%Y\\9[.>*QN(
MP6&GA*.)BJF"F\;/#<\G0BKE^2T?8.7!>1352C6K5*5'(,MJ5XJGB<51C&#_
M -7_ &'-&C0I8BM&M4I2<:Z6'C6Y4JG]'_\ PRC^S'_T;]\'?_#=^%?_ )65
MG:K^S1^R;H5E)J>N?!+X&:-IT4MM!+J&J^"/!FG64<U[=0V5G#)=W=A# DMW
M>W%O:6T;2!Y[J>&WB#RRHC?D-I'PG_X*:+IG[)OAFR^*?QU\0^%OCJ+?P!^T
M;XQ\2WD_P^\??L[^ OAO\;G^+'A_Q=;Z9)XV\;:G9^/OB!\(9?$/P#USQ0_B
M36_$NO[?!FN^)IAJ]M<M+\]>*_@9_P %-_B?H/[5GA_XRR?&'QRVJ_$WX?WM
MK\+9]"@OOA7KUGH'[<?PQ\<>"?%_P9\6:I\4=2TS2K'P=\#]"OI=7\-^$_ W
M@FWN=)6=O%R:KXVTP7-[-#*\=.I^\X[I1I1G'FY,WS3VTJ?U^>7SE&G5S.$:
M<XU*=2HE7FHNC[*NVL/B*5<=3!9!&/N\#Y:YM.W-P_D?LU+ZM'$Q3G#)I.2<
M91@W3BVJG/32=2G.F?T'_P##*/[,?_1OWP=_\-WX5_\ E91_PRC^S'_T;]\'
M?_#=^%?_ )65_/;^T1KW_!1OX1?"7]J_XGZYXM_::\!:YX)^"O[9^M?''X@>
M*?'V@Q_ >74IO%UK<_LBZG^QMI^DZY=ZAX.O-$\*KC7+FVT;PS<6%B;ZS^(4
MNM^(Y[.Y7MKGX7?\%%?&U]-I?A#Q%^WIX+^ MSXR^.&M^"T\;_%K3[/X_P /
M]F?L6W%QHMEXR\6Z/XCU+43X$\2?M9VEJ/AEITNJ7$B!YX[.'0_!VIP6L=+)
MLU]DJ\^-X4Z+G[/VKS3-90<HT(5YQA*.<?O*G+4A.C3BN>M0DJ\_J3:PTD\+
MPYSNG'@G+)34>;D_L#(HR2=25.+:>1>[&\)*I)Z0J)TX_6-:J_=S_AE']F/_
M *-^^#O_ (;OPK_\K*/^&4?V8_\ HW[X._\ AN_"O_RLK\!/%GPW_P""LVA_
M#J[T/0_%O[4NLZ!JLO[%WCCXG:IJ'B>7Q)\6X]4\3_ +QPO[1>A_"J3PKXY^
M'GB/3=&\-?'*V^'\OB[P/X,\5^&K33K=KD^'/M>A7'B*SO/7=.^$W_!2>+XA
MZ+XQU[XE_M2>);CP5XN_X)@:%8I9>(=/\$> ?'G@O7GN/#_[<'B7Q9\*=-\2
MZSH(U73?"U\M_P",X1?WAT'Q39PZ_P"$I[S4H!.<YY5F,(<_^O="2?M^10S;
M-I3DZ4:?(I1_M1*DZLYN*4Y2<*<8UGSPFZ=*HX+AZ3Y?]1\N37L^9RR#(5%*
M;ES-/^Q7SJ$8IMQBE*3=-<KCS3_9B#]EG]ENZC,MK\!O@O<Q"26$R0> /"4T
M8E@D:&>(O'IK*)(9D>*5"=T<B,C@,I F_P"&4?V8_P#HW[X._P#AN_"O_P K
M*^6?^"4OPB\:_ G]DX?"KXB>&_BKX9\8^%OC3\>UU2W^*OB*3Q3<:K::O\5_
M%&N>'O$7@S69-8UH7?@KQ!X8U+1=4M9UEM)+SQ!<^(M0O+&/4+R[FG_2:OF\
MQQV9X+'XS"4<^S/%T<-B*E*EBH9CCXQQ%./(X5HQCFE>,8U(S4DE6J)+[5[Q
MCZN%X?X=Q&&H5Y\+\/T9U:49SHRR+)7*E)\W-3;>2TVW%QLVX1UZ6LW\_P#_
M  RC^S'_ -&_?!W_ ,-WX5_^5E'_  RC^S'_ -&_?!W_ ,-WX5_^5E?0%%<7
M]L9O_P!#;-?_  YYC_\ -YO_ *L\-?\ 1.</?^&')/\ YT'S_P#\,H_LQ_\
M1OWP=_\ #=^%?_E91_PRC^S'_P!&_?!W_P -WX5_^5E?0%%']L9O_P!#;-?_
M  YYC_\ -X?ZL\-?]$YP]_X8<D_^=!\__P##*/[,?_1OWP=_\-WX5_\ E91_
MPRC^S'_T;]\'?_#=^%?_ )65] 44?VQF_P#T-LU_\.>8_P#S>'^K/#7_ $3G
M#W_AAR3_ .=!\_\ _#*/[,?_ $;]\'?_  W?A7_Y64?\,H_LQ_\ 1OWP=_\
M#=^%?_E97T!11_;&;_\ 0VS7_P .>8__ #>'^K/#7_1.</?^&')/_G0?/_\
MPRC^S'_T;]\'?_#=^%?_ )64?\,H_LQ_]&_?!W_PW?A7_P"5E?0%%']L9O\
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M-_X8CXP?_,77T!11[?+/^A;B/_#M5_\ G<'U3/\ _H>X/_Q'</\ _/H^?_\
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MP#\>M4!_Y-^_:$/T\*>$/_F]I/\ A?>J?]&^_M"?^$IX0_\ F]KYP_X>R?\
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M_".^)O\ \Q-'_#V3_@GK_P!'):!_X1WQ-_\ F)H_LG'?]$=FG_F>_P#F0/\
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M_P#,]_\ ,@?ZPY5_T<W(/_ >$/\ YY'T?_POO5/^C??VA/\ PE/"'_S>T?\
M"^]4_P"C??VA/_"4\(?_ #>U\X?\/9/^">O_ $<EH'_A'?$W_P"8FC_A[)_P
M3U_Z.2T#_P ([XF__,31_9.._P"B.S3_ ,SW_P R!_K#E7_1S<@_\!X0_P#G
MD?0.I_&8ZWI]WI.L_LV?';5]*U"![:_TS4_!'@B_T^]MI!B2WN[*Z\<RVUS
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M]4_Z-]_:$_\ "4\(?_-[7SA_P]D_X)Z_]'):!_X1WQ-_^8FC_A[)_P $]?\
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M;DOQ:_X)_G2;7_A+?#_P0^(7B==#O]+O9Y/!WQ5_L#2[BWT;]H#7K0>!HO\
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MB/6-7Q::?JFFZA%ILMG:6UXLEL;E]?0_^"B_[1>A:Q?Z_'%\,]0UB_?Q&_\
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M#39SJ"7<%I9QB*Y_M'8L/E,T9@8F1MV%TQN0YMEV'>*QN#G0H*M[!SE4HO\
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M"-2AE]6K3E.DDZL54ADK@Y4U*+G'G3AS0YDG."G_ %T_\,T?\$6?^>?[(_\
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M"63J49*ZO%I-75UJ?VW_ /#-'_!%G_GG^R/_ .'TT;_YXU'_  S1_P $6?\
MGG^R/_X?31O_ )XU?Q(>?/\ \]I?^_C_ .-'GS_\]I?^_C_XU7^H>,_Z+/B/
M_P &O_YO(_XB[E?_ $:[@C_PG7_SH/[;_P#AFC_@BS_SS_9'_P##Z:-_\\:C
M_AFC_@BS_P \_P!D?_P^FC?_ #QJ_B0\^?\ Y[2_]_'_ ,://G_Y[2_]_'_Q
MH_U#QG_19\1_^#7_ /-X?\1=RO\ Z-=P1_X3K_YT']N _9G_ ."+1( C_9()
M/0#XYZ.2?H!\1JMQ?LK?\$:IO]3IO[*<N>GE?&K39,]/[OQ"/J/S%?Q$P3S^
M=%^^E^^O_+1_7ZU[CX2GG^3]]+]U?^6C_P#Q51/@7&Q5UQEQ$_6J_P#YO-J7
MBSE55M/PPX(5E?3#Q?\ [R3^Q6+]D'_@C]-CR?#7[,<N>GE?%ZVDS]-GCXU?
MC_8K_P""24W^I\$?LY2YZ>7\41)_Z#XZ-?RZ^$KFXQ'_ *1-T!_ULG7"\_>K
MZ:\)W5UB$_:9\[1SYTGJ/]JN"KPCCZ:NN+N(7ZUYK\L<>Q0\1<GK)-^&W!D6
M[;82DUT[Y5YG] $7["W_  2GFQY/PV^ 4N>GE?$6>3/TV>-C5^/]@'_@EU-_
MJ?A+\$9>W[OQU?OSZ?+XR-?D;X3N[O=#_I-Q]T?\MI/0?[5?37A*]O/W7^EW
M/!S_ *^7W_V_:O/J\/9C33?^M>?NU_\ F)JK;_N=/9P_&.25K7\/.#H[;8&@
M][=\K\S[F7_@G=_P3,< I\%/@^X/0KXOU=@?H1XN.:E'_!.?_@FFWW?@=\)#
M]/%>M'^7BRO&-+O;P1Q_Z7<@83/^D2X_A_VZ[6ROK[Y1]LNL8Z?:)O1O]NO/
MJY7F=/;B?/'ZXNNNE^F,/9HY[D%5I/@+A)7[9=A7^>6';C_@G!_P39;I\"?A
M0?IXGUP_R\5U>M/^"9G_  3LU!VCL/V>/AO>R*NYDM-<\27+JH(!9EA\3N0H
M) R1C)'/(K'LKZ]^7_3+K[W_ #\3>_\ MUWWA[7]4TR\@NX;RY9HG1PKS.W.
M&&Y?,WJL@4E0Q1E96>*5)8))8I/.KX?-Z<9<G$><RG9\JGC<4HN6ME)QQ;DD
MWHVKM7O9VL_9PV+X:JS@JO _"\:;E%3=+*\ ZBBVE)P53+E!R2=TI-)VLVKI
MK)_X=;?L _\ 1LO@?_P/\6__ #1TY/\ @ES^P&C!D_9F\#JPZ$7_ (LR/_+B
MK[.\*>*;7Q)9(ZLB7B)F:$<!MN TD:DDK@LOG0EF:!G7#RP207$W65\O5SC/
MJ-25*IFV;1G!V:>8XWY-/ZS9Q:U36C3NNJ7WV'X9X.Q5&%>APWPY4I5%>,ED
MF5?.,E]1O&<7I*+LXM-/HW\.6_\ P37_ &&[3'V;]G7P=#CD;+_Q3Q^?B ^E
M;MO_ ,$_?V.+3'V?X#^%8L=-M]XE/3I][7#QR>.G)K[&HK)YUG+WS;,WZYAC
M'^>(.I<+<,Q^'AS(8^F398ORP2/E:W_8C_96M,?9_@UX<BQTVWOB X_[ZU@U
MNV_[)/[.EIC[-\+=$BQTVWNN\?GJQKZ,HJ'FV:O?,\P?KC<4_P ZYHN'.'H_
M#D.2Q],JR]?EA$>(6_[-_P $;3'V?X?Z7%CIMO-8X_/4C_GZ"MVW^"OPNM1B
MW\(V<0]%N]4_K?'_ #]:]2HJ7F>9/?,,<_7%XE_G6-%D621^')\J7IEV"7Y8
M9'GB_"CX?)C9X;MEQTQ=ZE_\FU93X9^!T^YH$*_2[U'_ .3*[JBH>/QSWQN+
M?KB:[_\ <IHLHRF/PY7ER],#A%^5!''+\/\ P@F"NC1KCIBZO_\ Y*K9TW0-
M'TAF?3K*.W=E*E]\TS!6V[E1IY)3&K[$+A"H<HA?)5<;%%9SQ.)J1<:F(KSB
M]XSK5)1?752FT]==4S>G@,#1E&='!X2E.+O&=/#4(2B[-7C*%*,D[-JZ:=F]
M=0HHHK ZC/U<W0TK4S9"4W@T^]-H("BSFZ%M+]G$+213HLIEV>67AF0/M+12
M#*'\H/\ @D[+>7OA#XLZIK5WXGU'Q;>ZAX$B\;ZAXG'Q0ENIO%NG:7KMCK-L
M]_\ $/XB>.].OKW3IXA87K^#K?PSI,*P6D/]DPVB:79:;^CWQK\2W'@_X3>/
M_$UIJ7@_2+C2/#6H7,>I?$!]<C\%V>8Q"TOB5_#,4VOII6R5EN'TF-[U0P,(
M!&1^7O\ P1WTO1QX!^+GBBU;PO::QXE\1:.+SPSH^O?$K6=9\&Z-HVJ>.--\
M.Z#JJ?$+PUX8^R:--;Q76O>$6L;;4-3N=,UF9]?U>]E2P9?HL#3:X<SVJU9/
M$Y92BU&\G)5*DY0D^1VI\K4_C2YU'F7,X*7F8B7_  IY?!;JEBY--Z)<L4FE
MS:RO>/PM\K=M%)K]DZ_S2?BA_P E'\>=C_PEWB'\/^)I=5_I;5^-OQO_ ."6
M/_!-;Q7\3?%'B[QYK:_#CQ7XLU";Q%K7AO3OBWH/A'3QJ&JR/=WFI6?A_6XK
MJXTZ/4[F62[:"U:+3EDD;[#;6\)$8]_@'B3 \/U\R6-HXRI'&4<-[-X/#O$R
MC+#5*TI*=*,HS491K)J:O%.+4DN:+/RWQAX'S;C'"9%+*L1EE">68G'>WCF>
M,C@*<X8VAAH0E2KU(3I.<)X9J5*7+*49J4&^243^<OX(?LX? WXW?!3X8WDF
MB>*/ 'CSQGXR^-_@_7_B5_PF&H>+-$T:P^ _PATOXR:MXFT_X;#1M)BU#4O%
M-A+J'AR+0'\36UEI4AM-234)V66*NCT#_@G7X>^(/@'P=XW\)?$KQ%I$'C7X
M?> ]<\+)<?#34=?LI=6\<^ /BA\0K#6_B5J5GX@%G\-/#)T[X>#3=8U*)]:T
MO3-1U2!+:2ZB2:4_NKI__!+W_@F=I-O;VFE?'SQ7I=I:3:G<VMKIW[3'AFQM
MK6XUO3QI&MSVT%M%%%!-K.DJNEZM+$B2:CIJBQO&FM0(J[NQ_8&_X)_Z9\--
M4^$>G_M)>+;+P)K.IZ9J.I:5:_M)^$[>:YM](T'4?#5AX=?4(;=+[_A#XM(U
M6^@;PAY__".223?:)--:=5<?6UN-J"G.6$Q>>4XSQ3J*G6R;$UHTJ%2<G.*=
M251R=./LU3IWC3<5*$73YY58_F^%\*\7*E2IYEEO"5:=++U1=;"\48##3Q&+
MHPIQIU)JC&C&"K2]K*K7<9UU.4*LU75*GAY?@]XF_P"":?@>VBM/&L?Q3O/"
MG@6YO?A;9VOA^YTF/Q'K$R:IX.^!6L^/X+GQ*+NQM]&\0ZOJ/Q:OKOX<:==:
M+/I5SI^CJFKZK:?:+-YO$="_9?\ AI8?$7]LRTD\)?%[XN:1^S3XO\/^%?!G
MPDT!AX0^)OC*U\3_ !+?P')XEUY]/T;Q1J-OHWA.SC$\DNC:/(NK7NJZ%>7S
MZ3I5U,@_HF?_ ()K?\$YY=/U729/VE/B"^DZZ^D2:YI3?M5Z,=-UI] M[>ST
M%]6L-WV747T2TM+2TTEKR*9M.MK2UM[0Q16\*(MK_P $U_\ @G18^*;CQS8_
MM*_$&R\;W:SK=^,[/]JO1K7Q9=K<VZVEREWXC@:/6+E+BU1+:=9[R198(XXI
M R(H!2XUHQA5C6QV>5G*G&%*V28JAR\N(H57SSI3]MS5*,*V&G6A/VT(U%4I
M+F<U K^%F*G5P]3#93PGA5"K.KB+\5Y=BG4<\'B\.O94L1#ZJH4,35PV.HX6
MK2^JU*E!T:[=-0E4_!?P]_P34G\:3Q2V7BSQ7\-KO7/&VN6FD^$/&_@N#Q W
M@KPEH_QR\+_!"[\-^/OB3X;U2'PJ?C99ZMXKM]6M_ NEV"PZMI>FW#K?6ES=
M10IW_@?_ ()F_#/5?$/AJYG^,WBWQUX5UG2;G4]1TG2?AC=^&?%5OI>L^!?C
MCJ'A;4=+CC\0^(/[:UBT\8?!;5DO/"L*0?VGHU[IB0:K%>W5W#:?M#8_\$S?
M^";^EZ>-)TW]HWQWI^DKX@MO%HTNQ_:GT2UTT>*[)O,L_%'V& I:GQ%:R?O;
M?6S$=3BE E2Y60!A<M/^";O_  3MT^2WFT_]IGXB:?-:"W%I-8_M6Z/:2VHM
M#J)M!;26[1O +4ZQJYMO*9/(.K:F8MOV^Z\V*O&JFIJ&9YU334HP2X=K7BG%
M*+=1RE5<HV34E+F33FW4E4FHZT/"WV4J4JF1<+UI1E3G5<N-L+RRE&<I34:,
M8PP_)-2M*$H*FXM4XPHPHTI3_G_UO_@FY>Z/X:\0Z^GQ7OYS_P (KK7B_P %
M07GPPU;3H;;3?#7P/\)?'75M.^.5VVM31_!/Q#>Z'XNM?#/A[2]0&MKJGBBQ
MO(//BM=CU^:.DN'O=/DP5#3V[X88(#.K88=B >1V-?V3W/\ P33_ ."<M[%X
MH@O/VD_B!=P^.+BWN_&T-U^U7HUQ%XRNK1_,M;GQ7',SIXBGMG :"75UO'B(
M C90 !J_"O\ X)1?\$Q]*\?>&M8\+>(1\1->T748=7TWPEJ'QB\/>)M.U.YT
MYA=1?;]!T6*UO=4LX'B6:>R>5K*YC1H;^&XM'FA?T,+X@X##TL1+&RSC&RLI
M4K9)4PL8<M*2E&4Y34$IS<;SG[L5%U9<LJDZ-/Q\?X-YQC<1@H97#AK*X<SA
MB>;BJCF$ZKGB(.%2%*G3E4DZ5)3:HTO?DY1P]/GA1I8FM^SUA_QXV7_7I;?^
MB4JWG_\ 7_3^7US[4@         X '0 #H!V HR/4?F*_!6[MONV_O;?ZG]?
MI6279)?<DOT#(]1^8HR/4?F*,CU'YBC(]1^8I##(]1^8KF_%GA'PQXZT27PY
MXOT:P\0:'-?Z-J<NF:BAEM7U#P[K-AXAT2[*!E/G:9K>EZ=J=JP;]W=6<,F#
MMP>DR/4?F*,CU'YBG&4H24H2E&46I1E%N,HM;.,DTTUT:::[B:4DTTFFK--)
MIKLTTTUY-,\9\:?L\_ _XBGQ.WCCX:>%?$S^,M5\.ZYXFEU.R,L^KZOX4T>?
MP]X?U">=94FCN=.\/W5YH*O;R0_:-%OK_2KL7%A?7=O-A:O^RG^SAKL4\.J?
M![P1<1W$VH7#*FF"U\B?5-?T'Q3?36)M)8&TZ67Q!X8\/ZHLFGFV>"XTFT%N
M8HD,;?0>1ZC\Q1D>H_,5T1QN,@HQAB\5",/AC'$5XJ-E&*Y5&JE&T80CHEI&
M*V21FZ%"3;E1HR<MVZ5-MZMZMP;>LI/5O5M[NY\XZ1^R'^S%H-C'I>D_!+X?
MVFFQ2Z+,NGC1HYK%G\.W\VIZ*)K2X>6">+3[^YN+F&">.2%GFD66.1'*GLK+
MX#_!W3_AI=?!RT\ >'T^&%^[27_@MXIKC1[\OJ,&JNM_'<3RS7L3WMM;L\%U
M-+"UO!%8M&;&-;8>N9'J/S%&1ZC\Q1/&XRI9SQ>*FU4C53GB:\FJL'>-1.56
M5JD6VXS5IQ>JDGL*A0C?EHT8WBX/EI4U>#T<7:"O%K1Q?NOJF?.6M_LB?LQ>
M(_$-_P"*];^"'P[U#Q!J>H0:K>ZC+H5NC3:I;V]E:QZB+>$QVD-Z8--L5ENH
M((YKAK6*2X>65=YO?##]EK]GSX+^,O$/Q ^%?PP\/^!_%OBNP33/$.JZ'+J<
M"ZG91_V?MBETV34)=*B?_B5:>&N+>QAN9!:QAYF&X-[_ )'J/S%&1ZC\Q5/'
MXZ5.5&6-Q<J,X*E.E+%8B5.5-.+5.5.5:4'!.$&HN+BG&+2O%62P^'4E-4**
MFI.:FJ5-24G=.2DH*2DU)IM.[3>NK#(]1^8HR/4?F*,CU'YBC(]1^8KD-@R/
M4?F*7/IS]*3(]1^8HR/4?F* %K^6O_@XT42:_P#LN1DXW^'_ (L+GT#:AX$4
MD>N,C],]17]2>1ZC\Q7YZ?\ !13X:?L/^/?ACX:O_P!MG7].\'>'="UV=/!7
MBJ+5[[2O%EOJNH6R/J>E>'8])L=6U/68=0M+&"XU32XM&U2W"V-I?RPP36EO
M<Q_2\(9A#+.(LNQDZ&)Q,82KTW1P=)U\3)U\/5I)TJ,?>JRBY*3A&TG%2::Y
M3X7Q*R:KGW!6=9;1Q> P-2I#"UUB<SQ,<'@::PF-P^)FL1BI^YAXSA"4(U9I
MPC.4%)-21_(!_P -^?&1=8TR6W$.G>$-$^$EQ\,M'\#Z/>6^BVEKK$OP.O/@
M?:_$B[\1Z3HMEXDUOQ-I.FZA>^(-&@UR_P!0@T>[NI],TJXLK20S5ZJG_!3'
MQ%'HNM:>GP9T"+5M=\2^!O%6HZ_'X\UYI[S5_ L_PPNK#5;FUO-%O5.NW$WP
MSC\W6+2XLC*GB+46U.SU>YMH+F7] _\ A1__  0#_P"CB?B'_P!_OB2/Y_""
MC_A1_P#P0#_Z.)^(?_?[XD__ #H*_89YED%3EYN%N)?=Y;<N09A3ORRG).7)
M7CSOFJ3E)S<W*3O)MJ-OYFI9'QA1Y^3Q X&]_GO[3C+)JW*IPITY*G[;"5%2
MBJ=&G",:*IQA"/+!)2FI?G-\0?\ @I!XG\>^$?C#X1/P;\%:)'\6]._L^ZU6
MVUF[NKVR:Y\&:'X(U.^UBV;1;;3_ !'</I^@VM_H-K:6WAG2O"VJS7-QIFGE
M'"5\::A\7-5U#X>?"3P!-H^FW,7PC\4>.?$^FZGK$DVNQ:X?&LWAF7^QM6T7
M4$:R_L?1U\,PP06B2R0W<%W-#+%!'&BM^\G_  H__@@'_P!'$_$/_O\ ?$G_
M .=!1_PH_P#X(!_]'$_$/_O]\2?_ )T%;X;.\GPD>7#\-\3TX^UC6LLAS&7[
MR-"6%C*\\1.5U0G*G;F4;.]N91<>7&\+<2YC/VF-XXX!KS]A/#7?%^20_<3Q
M=/'RI\M+!TXN^+I4Z_,XN:E%)2Y'.-3\2_A_^TIXO^'?Q$7XG:!X>\':)XGL
M_ ?CCP5HDW@G0[3P#%H]WXRT2\TB#Q8J:% RWNM>'9[I-0L!<*J7)MTLIY4M
MW<U[;\5_VW=&^/!UNV^,'[.G@OQ-H=Y>^&/$?ASP[H7C?Q1X)TSPQXUT/X8V
M'PSU?5@-!LEEU3PWXGMM+T_7;CPCNTXZ1J%LMMIFNK:R3^;^H_\ PH__ ((!
M_P#1Q/Q#_P"_WQ)_^=!1_P */_X(!_\ 1Q/Q#_[_ 'Q)_P#G045,[RBI6AB)
M<.<4K$4H1A3K0R/,Z=6G"+<HQA4IXE3C9RE9\S?OS5TIRN4>%N)*&&JX*'&W
MA^\'7J3JUL+5XLR&OAZU2I%1G*I1K8"5.;E&,$TX1C>G2;BW2IN/X^W?[5J:
M]X^^*OB/QG\+=(\2>"/C1\,_AS\,_'7P\MO%NM:!))9?"W3?!<'A76]"\9VE
MC<ZGI6J0:QX(L-9FBETV^LIX[V]TN>&:(0W2=WX<_;LU/PI\,;_X$Z#\)=!T
MGX%ZQ8?&/2]6^'NF^,O$$&H/9_%75=$U;3Y-)\?W%E=>,-&OO!KZ*=/=XKZX
MTWQIH^KZSI?B/2C9W,44/ZC_ /"C_P#@@'_T<3\0_P#O]\2?_G04?\*/_P""
M ?\ T<3\0_\ O]\2?_G05,\XR:I&,)\-\4RA!T)0@\DS/DC/#0]G0JQ@L1RJ
MO2A:$*Z7M5&,5S/E1=/AKB>E.I4I\<>'\:E58J%6JN+,A=6I2QM3VV+P\ZKP
M3J2PN(JWJ5<(Y+#RG.;]FN>1^=.L_P#!1W5_&=]J7_"P/@+\.M8T)X_BCH'A
MW2?"&JWWP^OO#OP[^+'PSMOA=KW@F37=/TG59]>ELM&T?PM>Z=XDU"RBNUO/
M#L8EL&%]<2*W2O\ @I!XA\.1:=HGAGX$_"^S\%1?V'X=UOPUKESJ7BO4-<^%
M?A;X5'X0>&_AY'XIU2U74-&NK+POJ7BV>_\ &-I;37NIZGXLO)?[*M(;&SB'
MZ,?\*/\ ^" ?_1Q/Q#_[_?$G_P"=!1_PH_\ X(!_]'$_$/\ [_?$G_YT%8?V
MAP_R\G^J_%'(K6I_V)FOLTTK*48?7+*?7G3YN;W[\VIT_P!C\8\[J?Z_< ^U
M=^:M_K5P[[:47)3=.57^S.:5)M*/LFO9^S_=6]F^4_$GX+_M"7WP5M-)M-(\
M(:;K<>B_'OX6?'BS>_U>\M9_MWPIMO$=KI?AB2:"UD9K/4XO$+"[UCB]MVLH
MVAMG\^0+])?#K_@HIXG\#:'#IFJ_##3?&NK1>&?'/AB7Q3K'CSQ#'J^HVGCW
MQMX^\::PNKQW.FZM9ZG:-+X\?3FM[B+[:RZ#I=U:ZI8":]M9?TI@^!'_  0(
MN94@A_:&^(DDLAVH@G^) +$]@6^$('YD5Z7HG[%'_!%'Q'Y8T7XO?$V_,OW
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M=>TG7H(;*_N;?66LK>&3Q9^Q_P#L5WCZGH/P^^(/B/2?$=KXKU70M.U7Q?\
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MYJM-4JCG4BG]44F_[:Q$>5Q37M%:+AS25Y<C7*FY)MZ-VA)SBHQ?F%[\=/\
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MXJ^RP]?,)X.51T,N=/'8+$SKQH0]MBH456@\+"+K*A^ZK/XS3_@EQ^RWX;\
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M9INM"U;PE=?M;?M-W'A[6]*M/#NLZ+-\0/#3VNH:%I.I:3\(K70K@GX?>?\
MV3;7FC:)X'?38YH[2XMM,T^RN8I[&WC8<IX"_P"".?\ P3S\&^,?#OBBZ\<?
M$3QK'H>J6&H1^%_$_B/17\/:O<P^,AX-L[36(=(\'Z5?75A+XR@_L*XLH]0M
MXKR8/;7)>RE<O]6?\/:/V0/^@SXY_P#"0;_Y95H:5_P59_8_U34;+3F\3^+-
M-%[<P6WV_4O"5VEA:F>18Q/=O:7%Y<1V\1;?-)';2^7&K2%=JFJEP)XV4J5?
M_C!?$VE3E"I*M[+!X:'-%4IJ<FL-EL:LY*GSI<BE5Y;QI^\XIQ#Q7^BUB,3A
M;^*W@5B*\*M*&%^L9EC:RA-UZ;I0B\;GD\/"#K.FVJLH8=2M*M:G&<H_<<'Q
M-^'\OD);^)]-/GFRBMU7SP'-]XHN/!-BB@PJ!Y_BFTN-$C!P!=PL&VQ 2'P:
M\^%7[&_B/QIKGC^^^'WPGU7QK\0!I\/B77[KPQ:S7WBUO$&HI\.+!]<$EKY&
MJSZCJ'AN'PRES?PRSDZ3;QR2K%!!(/K"UNK:^M;:]LKB&[L[RWANK2ZMY$FM
M[FVN(UF@N()HRT<L,T3I)%(C,CHRLI*D&IZ_&(8G"8:514:>;8:I)2I5.3,J
M5&3Y9-^SJJ&"I2DHU(1<H3M:=-^[":3A_47L,WK1IREC<CKTWR5(2_LG%U(2
MC*,6ITI/-JL+3IS;A.+E%PJ0:<X/W_@/Q-^S-^Q9\1?B;X2^)FK:3X;N[W3!
M<_8_"%G8:5:>!/$VI_$OQ)\0M&DUCQ/X?CT%9?$&I^(O$_BKQY;2'4-0:RN]
M0O;Z>]LY&E,TGI,WPN_8T\2V6GZ=/\-O@QJME?-X673;>7P/HLB2?VSXP\8Z
MEX8CM2VF!HHM1\9:GXYN8XD:.*XO]5U_[8C1:E=+<?6=%;SS6G-4X^TSNU&#
MA03S>"5*-YRBER86FW9R3D[N4K-<Z3@H1# 9K%MRKY"W.495G')<6G4?N*;7
M/FM3ENHSY4TU%N#<9.,W/Y@T3P3^R7!KG_"2Z%X'^$<.O^)M>TSQ.-7M/!VD
MQWVI^(/'6E>+O"&GZJ+C^S0WVOQ)I-WXVT>5@46\BU+Q!]L4OJEY)<X.C_"'
M]BPQ^ (]%^&?P:5/">J:%KGP\%KX,TN/^QM5\7:K+XF\.W^DG^SU,5QJ.L^#
MSK&G/(2+6^\/VMQ$+:6QLRGU[16;S"A[W++.E=-*^;Q=DH5*<%*V'CS*,)\C
M2LG!U(Q48SLJC@\W]WGQ&12LXN?+DN*C=WIRJ.'-F<N5RE&4HM\SC)TW+G=-
MN7S9XE\-_LM_$[QEX(^(?BWPK\,/&GCGPT?#<G@3Q;KWA;3]6U[2O^$ABU3Q
M#X3.EZE>Z?)<Q++_ &3JVMZ(KR%=,OK6XU"T%G?MYK^?Z'\"/V%+30]0\.:#
M\(_@A;Z%XUU'PEK>HZ=:>!]+C@UN_N],USQ-X-N)C_9XE*?V3#XDO]*M@\=K
M;6MSK$*P1+J5W#=?:=%-9C0A!4Z4L[ITX)*G3CG$5""A.I4I)0AAX02ISGSI
M0C!<[J3BH2G='U+-Y-2J8C(9R;3J2_L3%<TVXTXU6G+,YM.<8RBG)S:BZ<9.
M:@^?YZ\%6'[-G@_7-9\3^ M$^'7AO7_';>';C6]8\/>'K/2[[7S?^';_ ,6>
M'3<SVME"SI<:!I^HZ[;Q#RXV,5S>2H+Z5VDXK6/A1^QCXP\8ZO\ $37OAQ\'
MO$7C3QC:10:WXDU;PAIVHZCKT'B+X<7-Q'+?R7=C*ES<ZI\,+&ZA:^EC^VR^
M&X9=/DG$+&V;ZZHJ5C\-&<ZE-YS"I."I.HLV@JDJ4;<E.=2.&C.<(J%.T'+E
M7(N6,?=Y7]4SAQC&>)R*48M2<?[%Q?+SM+GE",LTDHN3=2SLY)32DY6ES?+N
ME>"/V1]+TC7M$T;P)\(-.T3QC%IO_"2:78>"M'M-/\1Q1QZW\;=*&K6D.EQP
MZBD)UC7_ (@VHN4E$-]J%_J*[;Z=PVAXST#]EOXBZS!XF\?>%OA;XSU^VTL:
M7;:WXH\)Z9KFIV^DCP/XB\5BQ@O=2TZXN(;1? GBWQ1J@AC=573=>U5 !+>3
M1-])44?7L+S^T_X6>?WO?_M:'M+248R7M/JO/[T(0A+WK2C",6G&,8Q/JF<\
MO*\5D5K*\?[%QG)=7:?+_:EK*4IR2M=<SUNY2E\;6OP7_8<TFXOK^T^$_P #
M;.XN=1N];O)HO 6AH3J$'ABZ^(%U>*HTO;"T7AC6[[Q&5@6.);?4[R5$%Q=3
MH^AK7PJ_8OU1[JXUSX;?!F\>.6ZNKQ[OP5I+_O=$@U7XNWLTP_L[#O;6_CC7
M?%ET2&,T7BC64E\U=4O[:7ZYHJ_[3I.2DZF>.2LN;^V5S):72D\.VM%9:V6F
MFA/U'-TFHXC($G>R_L/%6NU*S:69JZNTWLVN9)JZ:^1?%OPH_8M\3VU]!XQ^
M&?P6UBWMY/$5U?+JG@?1IS"]K!J7Q,\4.\ATSS$#P>/=9\3ZLB,$O1XIU0SK
M.VHWD+V=?^&?['.H:=J>E^(/AY\'I["WM_$UMJ4%QX-TI?(M]+GTOXD>*$,L
M6G+-$+>ZU+2_%-^T$BM)=74=SN>9I%'UC12CF5%*"Y\[M!II1SA)1=X\S@OJ
M[4&^5V:6CY;\W*TW+!9N^>V(R&\E))RR3%2Z3Y.>V9IS2;AS*ZYDII<O-%Q^
M>O#.F_LU?"S7/%OB3P?H7PW\"Z[JMO?V_B_5/#GARQT.[N[3P%IFFWNH6U[)
MIMC #;:#IVLZ9=301*(B;V*;9-<%V7SK]I[X0?LE?M2>$QX/^/\ 9Z3XBT[P
MA?>(]2LK^+4=7T37O#%YX<AT8^+'T_6M':VOK:&&UU714UBT\R:RO$GLGDMY
MY[2"2V^RO\_Y_*N<\7^+?#W@/POK_C/Q9J4.C^&_#&E7FLZUJ=P':*ST^QA:
M:XE*1*\LK[5VQ00I)-/*R0PQO*Z*;P>)A/'826$I9Y5S*=;#T,++"YC&>-J5
MZDJ6&HT<,XX&M7E4JRJJA0I1]HVZU.DH5+N$^/-L+B'E>8QS;%\+QR:&%Q>(
MS!9GE%;^S:.#P].OBZ^(Q[K9O1PT</AJ6'>*Q-:I*C"$,-6KNK1Y8U*7XZ7?
M_!)'_@EU8F_%WHOB6#^S/^$@^W[_ (I^.?\ 1?\ A%9],M?$/F8O#_R"KC6=
M+BN=N[YKV'R_,!8JMW_P2/\ ^"7EC]N^UZ)XE@_LTZZM]YGQ2\=#[,?#&HZ;
MI.O"3%X?^09J6L:99W&W=^^O(A'O&XKZ9>?\%B_V7+:ZN+>'PY\7;V*&5XX[
MRW\.^%5@N51B!-"MQXUAN%CD W()H8I I&^-&RHK_P##Y+]F#_H4_C'_ .$_
MX/\ _FZK]KCX8>.S46^"?$YIJ+?^WX&#::@W:,L1S0;7-925XMQ4E>$D_P"6
MJGCG]$N,JD5XG^!":E4C'_A(S6HDTZBA>5/!\E11M#FE3ERU%&4J<E&I!Q\Z
MNO\ @DC_ ,$NK(W8NM%\2PFP;64O WQ3\<_Z.WA[6[#PWK0DQ>'!T[7-4T_3
M9\9_TBZB";TW.JW'_!)#_@EW:FY6XT7Q+$;-M36Z#?%+QS^Y;1O$5GX2U0/B
M\/\ QY>(]0LM(E(R/M5Q&%+1[G'HG_#Y+]F#_H4_C'_X3_@__P";JC_A\E^S
M!_T*?QC_ /"?\'__ #=4UX7^.VG-P3XFO:]LPR]7VO:^)=K^]:][75[V=U+Q
MT^B7[W+XG^!*7O<O-DV;NVLN7FM@8\UDX<UN7F<9-<O,E'SN7_@DA_P2[A:9
M9=%\2HUNUXDP/Q2\='RVT_Q1;^"[T-B\/-OXINK?17QG_3)5"YB#2 ;_ ()(
M?\$NT9U;1?$H:-YHW'_"TO'65>#Q7'X'F!Q=_P#+/Q9+'H9(X^VL "8LR#T3
M_A\E^S!_T*?QC_\ "?\ !_\ \W5'_#Y+]F#_ *%/XQ_^$_X/_P#FZH_XA?X[
M?]$3XFWTO_PH9?:^E_\ F)[WMVNM[-M/QT^B7=V\3_ FUW:^39NVE=VN_J*N
MTK7:23:;25TEYY_PZ/\ ^"7A( T3Q-DNB ?\+2\=???Q6W@9%_X^_P"+Q:K:
M&.QO >?)_>TD7_!)#_@EW,T:1:+XE=IFM5B ^*?CGYVO?%,W@FT S>#F?Q5;
MSZ(F<?Z9&V<18D/HG_#Y+]F#_H4_C'_X3_@__P";JC_A\E^S!_T*?QC_ /"?
M\'__ #=4/PO\=NG!/B;?_L88!Z_^%*'_ ,1U^B5?7Q/\"K7UMDV;WM?57^HV
MO:^MM];=#SR'_@D=_P $O+@P+#HGB:0W3:<EN%^*7CG]ZVK>);KP?IP7_3,9
MN_$UC=Z/%G&;J!]V(@)"EO\ \$D/^"7=V;46^B>)I3?'25M OQ2\=?OSKNO7
MWA?2 F;L?\?^OZ;?Z9!G&;BVD+;8@)#Z)_P^2_9@_P"A3^,?_A/^#_\ YNJ/
M^'R7[,'_ $*?QC_\)_P?_P#-U0_"_P =];<$^)O6U\PP#MO:]L2KV]V]K7L[
M6NK"\=/HE7CS>)_@4UIS6R;-TVKQYN6^!=KI3Y;J5FXMWY6I<#IO_!)G_@E^
MT^G3Z?HWB266]?0SIQ'Q1\<D7#>(]6U'0]"\L-=@'^TM6TC4K&WW8'FVDI?8
MFQV]?\(_L$_L!Z)_9I\-V^L'[=_8(TXMX^\6S_:?^$FN]2L- $?G7')U.[T?
M4X+<-@EK.8R;$VLW/?\ #Y+]F#_H4_C'_P"$_P"#_P#YNJ/^'R7[,'_0I_&/
M_P )_P '_P#S=5%3PL\=*B:? _B7)>]RJ>.R^25^;EO_ +2KV]SFM;FM*UN9
M<NE'QZ^BA1<7'Q3\#(-./.Z649Q3;MR<_*_J4N6Z4^6_-R\T.;FY)<_TOX4^
M#'[+&CIIZ>'-0N"NIC0$T_/B77)_M0\4'4T\/B,S-_S%#HVJ"W+;3_H<QD*#
M:6]W\(^)_A/H.GV&F>&==TU;?4WT*6T82W,]QJ#^*+;4[KP^[SS1F23^T;/1
MM2>S#LJ1064BE8AM#_GC_P /DOV8/^A3^,?_ (3_ (/_ /FZH_X?)?LP?]"G
M\8__  G_  ?_ /-U7#B?!CQBQ<90Q'AQX@UX7<HQKXC+:L5)<_(Y+ZS%2<;Q
MOM>TG%1<HN/KX'Z37T;,NG&I@_&KP=PE114)SPN"SRA-P?L_:QA)8&;@I\L[
M*[LG34G-0DI_I9:_%#P!??8OLGBC39_[1_L0V6PS_P"D?\))INHZQH>S=",?
MVEIFD:E>V^[;^YM)3)L.T,6WQ1^']X+0VWBG39A?#2#:%#/B<:_HE_XDT<IF
M$<7^AZ9?ZE#NQBWMI-^QRJ-^:?\ P^2_9@_Z%/XQ_P#A/^#_ /YNJ/\ A\E^
MS!_T*?QC_P#"?\'_ /S=5QOP(\4]>7PLXX6]KSRIV^+EO;$J]O=O:U[2M;F7
M+Z4?I9^ ?N\WC[X5/X>;EI<01O91Y^6^"ERW:GRWYN52C?FY9.?Z60?%#P!<
MK;M!XHTV1;M=->W*F?$JZOX=N_%NFE<PC N_#EA>:O'NQBU@<OLDVQDB^*'@
M"98VB\4::ZS+9M&09\.M_P"&;CQE9D9A&!/X8M9]97.,6L9W;92L9_-/_A\E
M^S!_T*?QC_\ "?\ !_\ \W5.3_@L?^S"[!1X3^,62<#/A_P>!_ZG/KQ0_ CQ
M35W_ ,0MXX2UM>>5:*[M=K$J]E:^BNTWI=)./TL_ -V3\?/"IO1.U/B!7>E[
M7P3M=\UDV[)I-NS;_2M?B?X!=5=?%&FE76)U.Z;E9_"\GC6)O]3D!_"L4FM
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M9+TN\NM.U']IOX!6-_93R6MY9W7Q<\!P7%M<0L4E@GADUY7CEC<%71@&4C!
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MF+;Q/ILQU Z.MF%,V;@^(-8O] T81@PC_D(:QI=_809P/.MI"^R,H[%K\3?
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MEX[^"'@'X?>%_&'QP\':CX4N=/\  N@V[Q^-]>M?AGX?\6>%-+7Q+=&]U)=
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MCEE_++_P&7_R(>TI_P#/RG_X,I__ "97J:W_ -:G^\O_ *$M.^R7?_/M<?\
M?F3_ .)J:WM+OS4_T6X^\O\ RQD_O#_9J9QERR]V6S^S+_Y$<:E/FC^\I_$O
M^7E/NO[YZ)H?W5_'^8KV70^D?T'\C7D6AVEWM7_1;CO_ ,L9/4?[->S:%9W9
M"8M;D\#_ )82^A_V:^ SR+3G=->]U37?ND?K?#$X/V7OP^Q]N':/]\]:T+JO
MX?\ H5>Q:'_!_P !_P#9:\FT*RO,K_HESV_Y82_WO]RO8]#LKP[,6ET?N_\
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M/_AE_A/_ /+>OYU:*]O_ (EC\.O^AMXD_P#BQN(__EA\K_Q/5XT?]$]X(_\
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M,\-Q_P#2>'HGGJ?"/X4Q_P"K^&/P]3_<\%^&U_\ 0=-%64^&'PTC_P!7\//
MR?[GA+0%_P#0=/%=S16;S;-I?%FN:R_Q9IF<O_2LQ9M'A[AZ'P</Y!#_  9#
MD<?_ $G)8G'I\/? $>/+\#^#TQR-GAG15P?4;;(5./ _@H=/!_A8?3P_I(Z=
M.EIVKJ:*S>8YA+?,,>_7'XY_GC6;1R;)X_#D^41_PY3E4?\ TG+(G,CP5X-'
M3PEX9'TT'2A_[:4X>#?" Z>%?#8^FAZ8/_;6NDHJ?KV.>^-QK]<9C'^>+9:R
MK*EME>6+TRW+E^67HY[_ (1+PH.GAGP\/^X+IO\ \C5;M- T*PF6XL=%TFSG
M3.R>TTVSMYDRI4[9884=<JS*<,,JQ!X)%:U%1+%8J:<9XK%3C)-2C+$XF49)
MZ-.,L1*+36C3336C31I#+\OIRC.G@,!3G%J49PP."A.,D[J49PP<)1DGJI1E
M&2>J:>H4445@=84444 >9_&G5=1T+X._%C6](NY;#5='^&WCG5-,OH&*3V6H
M6'AC5+JSNX6&"LMO<11S1L.5=%(Z5_#Y?:A?7-[>7$]Y=2SSW4\T\LD\KR2S
M2RN\DLCLY:221R7DD<L[N2S,6))_NF\<>%X/&_@KQ?X,N;F2RM_%WA?7_#,]
MY"@DEM(=>TJ[TN2YB1BJO) ET941F 9D"D@'-?RYZ[_P3&^+5AK.JV5M\7?V
M<I[>UU"[@AFNOBG;Z=<RQ13R)')<:?<:8T]E,Z@-+:2L[V[EH6DD*%V_M_Z(
M?'?!?".6\<X;B7/LMR+'8[,<CQ&$GCU7I2Q6"H8#'4*L:6(HX#%\T:.,J1E/
M#RJ4[2J1KQISO*<?\M?VB?@YXL>*&>>%F-\/N!^)>-LJR?)>*<'F='A_#1S&
M.6YGC,WRK%8>KBL"\=AG1EB\NH3ITL:J%135">$=:FXQI3^;O@Y\ [KXO> _
MB'XKM/&MWIVN>#TN!H?@^TT&[UB^\4RV.@7_ (BOG2Z.J:<(K:WM+$V\D>C6
MOB'5[62XCU"_TFTT2*?4H^^T/]BSXIZEHOB?4+G6-.;4M#D.GV.DZ)J$.J)?
M^(K*TU^?Q%X9OM2N;K3;?3-9\,SZ19V]_&B7UE>'58VTW4+D0/N]N\/_ +"7
M[3GA/2->T#PO^T5\$O#NA^*8!;>)-(T7X]-IVG:Y (Y(1%J=I:V4<-TI@FFM
MV,BEFMY98&8PR.AUI?V,?VMYXWAF_:?^$,L4NEP:+*DG[04S+)I-M;WEK!82
M9L_F@CM]1OXL$EV2[N [L9":_HK,?%7+*F.S*>5^,O 6&R_$8[#5\OH8W"9M
MB<1@L'2H8.-?".I1R:A&<<17I8J<I-UJJC7=L13_ '5/#_QSD_T:.,*659+2
MSWZ*'CAC<XP>4X["YOBLLH8+!8/,\RKXK,983,51Q.:8JI3EA,+7P$(P4<-A
MW/"13PE7]_5Q?QYXI^!4?P]\7?"?PSXZ^(8BM?B'!JO]NZMX.TNX\3KX3O\
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M9)B<-@\']8Q6(A1PCS&>,Q"=;+<-&A3A0K4X5)JM%U/:1HJ-2[C']J^@_P"
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MEK')/%=>%+'P/./-2S62)G\)Z98:*)(6CE2VM(I(W2Z!G/[W?\-K_P#!+O\
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M )Y2?]\-_A7](7_#:_\ P2[_ .B0^%__  Q'@W_XU1_PVO\ \$N_^B0^%_\
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MPSJUQHVL^,_@_#=P^(K7PS";/QAJ^KQWE_'X6\8>,_$LD)TCP[?/#'X+\.>
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MJ'_"0)X@75O^$.\/#6(]OBFP\;OX?BU7^R_MT?A"X\7:78^(+GPLLXTB;4(
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M"V@ZWJ</@C4M U%[.=(?"O\ AT;_ ,%'=P;_ (94^(NY<!6^V>&LJ!GY5/\
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M6O[2J\S;:E["BK7O:T8V6E_M-K2.CMK^;/A[]H?]HKQ!^Q7\;_C5I/A:YO\
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MPGKLKKI $LLA1(C>CY9'_!,;]OD @?L;?'X [\@?"GQ4 ?, #Y TK!W@ /\
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MRYU*5%SG*'&&'ASM7OB\JDU"]G&-\<H1E*"C%U5!3YHJ:C!M\WU;XI_X)T?
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MQ^T0?^Z6>+CWSVTNN2OQ5PLV[<3\-O1[<0Y$_P LY9@\URK7_A4RW?\ Z&.
M[_\ 88? -SW_ ,_W:R)NC?4_R-?H%/\ \$Q/^"A3=/V-?VBCGT^%?BX^GII?
MM_*LR7_@E_\ \%#R&Q^QE^T6>I&/A5XN.>#Q_P @OKS7F5N*.&'MQ+PX]ML_
MR-]7_P!3<YI9IE=G_P *>7;?]## _P#S8?GY-T/T'\ZP[CJ?H?Y"OT.E_P""
M7?\ P43/3]B[]HX\=OA3XM/0Y_Z!F?I6//\ \$M?^"C!SC]BK]I$\'I\*/%Q
M[8[:9[?Y->1B>)>&VG;B+A]^F>Y*^K[9LSEJ9GEEO^1EEV\O^8_!=O\ L+/S
MINN@^G]16%<?\M/\^E?HO<?\$K_^"CS?=_8E_:4.!CCX2^+SW_[!?^?SK(G_
M ."5/_!2-M^W]B+]I8[NF/A)XP]O^H7_ "KYW%\0\/N]L_R)Z],ZRA_EFC/-
MJYCE[YK9A@'MMC<'Y?\ 44?F_=?Q?C_[-4OA3QEXL^'GBOP[XZ\">(M8\)>,
MO">KV&O>&?$N@7]QIFLZ)K.F7"W5AJ.FW]J\<]M=6UQ&DD4D;@@K@Y4D'[_N
M?^"47_!2EL[?V'?VFFZ]/A'XP/\ >]-+]Q7]#O\ P1(_X-_M<M_$6D_M6_M_
M?#N[T1?#6J?:OA/^SCXTTTP7]]K&EW+"+QQ\5M#NU#VVF:?>0B7PSX*U"$2:
MO/&FL>(+==(2RT_6/AN)^,^&LFRS%8[$9GE^.A&,J=/!8+&X#&XC&U:D9QCA
MH4*.)Q*Y:J<HU:E:"P]*DZDZTI1M2J^)FF=Y9@L+6KU,5AZZ4>6-"A7P]>I6
MG)-*E&$*M72>JG*<?9Q@Y.;:M&?]&W_!*'X]_M3?M)?L4_"WXJ?M>?"__A6O
MQ2UFS\NTO',-A=?$SPC#;6AT#XHWOA)(()O!-UXLBDFFDT*95BNA;KXATRVT
M_1M;TW3K7](:1555554*J@*JJ %50,!5 P     !@#@4M?Q!C\32QF.Q>+H8
M2C@*.)Q-:O2P6'<W0PL*E24XT*3J.4W"FG97=M^6,(<D*?X9B*D*U>M5A1AA
MX5*DYQH4^;V=*,I-JG#F;?+%.ROYV2CRQB4445R&(4444 %%%% !1110!0U3
M3]/U73;[3=5L[+4=-OK6>VOK'4K6"]L+JVEC9)H+RTNHY;>YMY$)66&>*2*1
M,JZ,I(K\D_\ @F-%/:^)OC3'K'F2:UJ,&CZW8Z_++XRLK'XC>%KSQ-XPM]+^
M(G@[P]XB^&_@72++P;JMS:W=E8W&@7-]";BSDA^Q65C_ &=<7OZ6?&S69?#O
MP@^)FO6]]J6F7.C^!_$FI6M_I%]%I>I6EU9Z5<SVTUIJ<VGZK%ITB3I&6OGT
MS4!:1[YQ9W)C$3_DE_P2+DCN/$_[0FJ+X>@\+:KXB_X1?7O&UA;^*[+QE9ZG
MXVO-3\3RZIJVCZE8?#WP);Z?H16;R].TQ'UF-_-EOXYX&N9C<?29;2D^'^(*
MO-[G-@*:2M?GC64V]9)\KC))VC).48J7*U&:\O%37]I9="VML1)O^ZX./;=-
M75VK)NUUS1/V\K^7S]IO_@YD^&WP2^.7Q(^$7P]_9GUWXIZ/\-O%>M^";WQQ
MJ7Q,MO T>M:_X9U*YT?79=)T)/ OBF8:-%JEG=0:=?76HQ7&HV\:7C6-HDR1
M#^H.O\FK]JK_ ).A_:1_[+W\8?\ U8?B*OK_  MX8R;B3&YO'.<-/%4\%A,+
M.A2CB*V'@JE?$U*<YS="4)S:A32@G-13E*3C)VMXW%N:X[*Z&">"JQHRKUJT
M:DW3IU&XTZ491BE44HI.4FVU%MV232O?^IC_ (BM;'_HR2Y_\/['_P#.AH_X
MBM;'_HR2Y_\ #^Q__.AK^/:P@2ZU#3K60L([O4;"TD*<.([J\A@D*$Y <)(Q
M4D$!L$@CBOV^\<?\$<TD^*7B[PEX#^,<V@V<OQ.\3V'@'0?%'@G7O$-M;?"'
MPG\=/"O[/NM:UXO^*>GR:=X:M_BI#XQ\41:KHOPP.FP:AXC\-6PO(=1M+N_L
M+2;]4Q_ _AOE<Z4,=ECH>VIU:L)/&YM.+C1G"%2[IXB;BXN<9.\;*'O-[1?R
M.&S[B?%QG+#XI5.24822H8.+O.+E&RE2BG?E:5G>^EMVOU+_ .(K6Q_Z,DN?
M_#^Q_P#SH:/^(K6Q_P"C)+G_ ,/['_\ .AK\??$G_!(\6ECH^K>!?VB7^)&G
M3WW@_4/$EMIOP6U[P_K?ASX?>,/#?QKUJ#QBT.N^+(-&N'TN[^ 'Q!36K.]U
MK2]-T;P__8WB+4-:03WNGV>_\4?^"1UGX%^%?B&?3/BW>7WQB\$ZE^TAJ5PU
MSX.U=?A3X_\ !GP8\-?!WQSI@D\;-<1Z%\)?$4OA3XFRQI%XBU#6;'Q3X@CA
MM-/NK+3X!J%QP+AKPJ<J45@Y.5:HJ:3Q&=QE!N7)S58SJPG3@I<J<Y1:2E&:
M4Z?/.'1_:G%Z4VZZM"+DW[/ -2LN:T'&#4I6NTD]XN+:E92_6/\ XBM;'_HR
M2Y_\/['_ /.AH_XBM;'_ *,DN?\ P_L?_P Z&OQM\&?\$MM<U/\ 8Z^*?Q6\
M6MJ6F_'71/$GB'6_ L'A[QCX'\5_"P?"+X5:YX!T'XJZMJ=YX9U?5F\5WTB>
M,_$'B/1-;\)ZA>Z#IND?"[Q:FIWB3 I'#\3_ -DG]F[X3_'CPQ\+M3^"'[7^
MI^#/#?[5.G?LG>-_BCKOC7PKX3\!_%[6/$-EI<>D^/?AWK4?@*XO/"FI"XOV
M\8Z3X*LK'QKH?B#X=W&DW-SXNTK5;U?-J/"OAG4JUZ%#*:V)J8>>(A4C0QV.
M:_V>E&K*<)5<SH*I"IS.G1]FISJ5:=5.E"G3E64O..*HPIU*F,A2C4C3E%U*
M%!/][-Q2DH82HXRC92GS<L8QG#WY2FH'[,?\16MC_P!&27/_ (?V/_YT-;?A
MO_@ZM\)7>O:3:^*OV-M>TCP[<7UO#K&J:'\9['7=7L+&215GN]/T>]^&^@VN
MIW,"$R1V4^LZ9'<,HC:]MPWF+_*G^U7X5^&G@#]HKXP_#GX1^'?%GAGP3\-/
M'_BWX;V=IXV\7V_C?Q#J-_X%\1ZKX9U'Q!<ZU:^'O#$,$.NSZ:-0M]&73'.C
MI*;,ZA?[/M#> P_ZV+_KHG_H0KVJ'AIP-BL/1K0R6M2CB:-.K!2S#,(UH0KT
MX3@VEBZL(U%"K"5N:HHR:3YK21Q5.*<_I5)P>.A)TIRA*V'P[A*5.4HR2;HP
MDXN4)*]HMJ]K73/]>GP?XKT7QWX2\+>-_#5RUYX=\8^'=$\5:#>2126[W6B^
M(=,MM7TNY>"51+ \]C>6\K0RJLD9<HX#*0.CKP']E#_DUK]FO_L@/P<_]5WX
M<KWZOY1Q-.-'$XFC&[C1Q&(I1;U;C2Q%>E%MI)-N-.+;25VV[+9?KU*3G2I3
M=KSI4YNVUYTZ<W;RO-V\K!1116)H?.-I^UK\ KWQ)X^\+VWC6\DN_AEIGC35
M?&6K_P#"%>/4\&6$'PY:-/'UM8>/G\,+X(\0ZMX.EECMO$&B>'?$&JZQIUYY
MMC+8_;+6\@M^$U7]O_\ 9.T:'X>75[\3[HZ?\4/!?A[XB>%=6M/A]\3+_2(_
M!?BOQ/%X+T#7_%.J67@ZXLO MM?>+94\.O!XUFT"]T_51);:I:V1BE*<CKO[
M!VE:YHOQ1^'9^.WQDTSX%_%+5/$^K:E\%=(G\&:?X?TB;XB>/[?XA_%"WTOQ
M9;>%(_B(MGXRU1M<L[:.7Q6\OA6R\5:\- FMY9;![#RQ?^"3OP&MKK2[^Q\5
M>/!J?@&_@U/X&:SK4VC>+M<^"-U;?&/4/C8(_#&M>+=,UG5/$%C>>)]:UW2]
M8L_&MUX@&K^&]7GT^]E>YMK"_M?I:-'A;>OC,RVCRPI49.Z>&2<JE2=)*%2.
M,ESU*5.%6E'#4Y1I5JU24>;RYSS;:G0PO6\IS6ZJMVC&,WS1=!6C*4H3=62<
MX0BG;[*^(/[3OPA^%WQ.\"_!_P 9ZCXPL/'7Q+E\CP5::?\ "WXH>(=#UJ:*
M*YNK^-?&'A[P?JGA"R.C:?:7&K:^=0URT70='B;5=7-G8_OZS/C!^UW^S[\"
MK+PCJ7Q&\=RVFF>.="\0>*O#6I>&/"GC/XA:=>^$O"EMI5YXD\63WWP_\/>)
MK73_  QH]GKFE75WKFH2VVGFWO8Y8)YD60HLG[,/@N'Q5\'?%.DZ]XULIO@Q
MXE^+'BO0;/5_$^K>-?[4U7XO>&=;\-Z\FK:GXWN_$&LG3=,77;J]T'2;/4+;
M3-+,5MIMK:Q:1#'8KX;^TS^P!X9_:BT7X1:9XS^)6L:;>_"WP?XO\$SZI9_#
MSX3:LGB73?'6G^&M/\0:C%H?B/P;JOA_P7XA5?#-M/H6M>"M-T:Z\/375R-+
M\F+RXTY<-3R&=?!1Q5?&4\/R5ECZD%)U'43K>QG1I^QJ>SC)1H\T%.O:4VG*
MUY0UJRS!4Z[I4Z$JG-#ZO&37*HOV?.JDN>/,TW4L[4[J*=KV3^H_!G[0/P5^
M('EIX4^)?A34+F?4O&6E6FG7.I)HVL7]S\/M1NM)\:2Z9HVN+INJZGIOAZ^L
MKJ._UC3[.YTA8X6NHKZ2U*SM%K'[1/P*T.R\$ZC>_%GP)-9_$GQ'I/A+X?RZ
M1XBT_P 0'QEK^M>(;+PI967AR+09M2FU9(_$&HV>FZE?6<<NGZ++-YFL75A;
MQRS)\1'_ ()3_!.>XUN'4/'WQ2U'0?%.H^)=7\4Z;<ZEH1U?5M2U;_A9<.B7
M5OXR&A_\)1HYT&R^+/BZ*]ATS48+?Q?='2M0\3PW\]G<"]VM$_X)H_#W1?%?
MA?QO%\3/&LWB2P\<>$_'GC6X_L'P!;Z?XUU3P)X^\-?$#PK:V.D6_A=++X=6
M%IJ/A>QL-6B\ )H<GB&QFNI-6EGU"07HUEAN&^:4HYIF#CRMQIO )-R]E4<8
M.KS.UZJA%R]F[1=K/GYZ$*KFEDGA,,I72<EB&TESQ3DH65[0<G;F5VO[O+4^
ML;_]ICX+Z;\59O@O<^*[T^/;-X;?58;7PAXUO_"_A^_N?#TWBVUTCQ/\0;'P
M[<^ /#&MW7A>"7Q!!HVO^)M.U.32O(O/LHBO+(W/7V'QE^$&JW7AZRTOXK?#
M;4KWQ:EQ)X4M+#QSX8O+KQ-':37EM=/X>M[?5))=:2VN-.U""X;34N5AFL+R
M*0J]K.J>$>*?V3)]8\=_$KQ/X6^/'Q=^&_A;XOQ:EJ/Q"^'/@]O!(T+6?&]]
M\/K;X:P^-;/6M:\):MXMT2[@\.Z;H<]QH^DZY;:-J&M:!I6IW-KN2ZANOF[P
MW_P2<^"NC::FG:GXY\=:YNU*VU"YO/LWAC2K\K_PG?BSQ]JUGIM_8:.NH:-%
MK6I>,M6L[J>PO$O([,6S17/VN-[B2(8?()TXRJ9CC*%14J-Z<,)+$.5:5.3K
MN3FJ,*:IUDHQITIU8SI<LE652<E2J53,5)J.&HU(\]2TI5E32@II4TE%U)2<
MH7<I34'&=UR.,4Y_H19_&7X0:A!IMU8?%;X;7UKK":[)I%S9^.?#%S!JL?A>
M-IO$SZ;-#JCQWR>'84>776M6E72(T9]0-NJDC0\,?$_X:>-KQM.\&?$/P-XN
MU!--AUA[#PQXMT#7[Q-(N75+?56M=*U"[G73;AW1(;XH+65W54E8L ?SLUK_
M ()3_"7Q1-X0OO%'Q%\:ZKJGA/X>ZU\,H[NUT#X>Z!;7?AN;2M3TOPK+_96A
M>%;#3H->\,)J<EQ=>(I(+O6O%4L4,6N7LEG!;6T'T'\(/V+_  1\%_C3>?&3
MPEXH\0VLU_\ ##PS\-=0\'V=IHFC^&=;'A?0/"'AJP\5>([;2K"V_MGQ';Z5
MX,T^WT^^=+>>QAO-1M7GO+(Z?;:?%?#9%&C4EA\SQE6NJ525.G/ QA2E5C.U
M.E*HI\]JD-?:*$5"2M*/*RJ=7,'.*J86A"FY14I1Q#E-0<;RDH\MKPEIRMMR
M3T=S[)HHHKQ3N"ORX_X*T?\ !0^\_P""<7[..C_%#P[X+T_QUX_\>^.[+X=^
M!M)UR>\M_#-EJ,VC:SXBU'6_$+:>\-_<VEAI6AW*6VFV=S9RWU_=6JO>V]O'
M.Q_4>OY?O^#IW_DTO]F__LY%O_56^/*^FX,P&$S3BG(\!CJ2KX3$XV,*]%RE
M&-6$:.)J^SDX2C/DE*C!3491<H\T>9*39Y6>8FMA,HQ^)P\_9UJ5!NG-)-PE
M*I2AS)237,E.3C=-)V=G9(_+7_B)\_;L_P"B9?LW?^$GX[_^>-1_Q$^?MV?]
M$R_9N_\ "3\=_P#SQ:^</@C\.O\ @GA<_"O]B3PC\6?#OA74?B_\>;7P7?>(
MKS2-0^(=IXCL+\?M*^*O#GB_4_B3XQ_X3ZS^&7ACP1<?![1/[+M?"<'AS3?&
M)UE])UZ+5;*RN9+N3S_PQ_P3U^ WCWP;X^^(VA?M%7?AWPY9_!>W^*'@K2?$
M=[\-G\1Z?XD.A_$?7+SP9XUTNWUV)WMKI_ ,&E:!>6%QI<WVOQ'IUI=37NH1
M""\_H+^QO#^$ZL<3PI#"QIU9TH5:N7XJ=+$.&+G@^:BZ&+J2<9582<7.$;PC
M*2E+E=_SCZ]Q')0=+.)57*$9RA#$48RIJ5&->TU.C%)J$DFHR=I-)I75OL__
M (B?/V[/^B9?LW?^$GX[_P#GBT?\1/G[=G_1,OV;O_"3\=__ #Q:^=M5_P""
M6W[.EGXE\565O^V7I"^'-)^$VE^.](N+U_")\4"]N=0\96.JZUX@\.V<TTEG
MX/TC_A&=)E-C;O\ ;=13Q39W.E>)K[3(;34M5^8?V:_AG^S%X]_9V\.^*?'7
MAR&S^(/A+]J*V@^)^OZ[\1)K6/Q5\$M*^!'Q3^*&H>&?#/A"U?29M%TZ;4?!
MVAZ)<ZTKZIKFK>)=6MK&QU#2EGMM/ETAD?AY6H3KX?AFA7A3J8:G44<OQM*<
M'BX8F=%N.(Q-+F3>%E3G[/VCA4JT5)<LW.$RQW$L*BIU,UJ4Y2C5E%O$T)QD
MJ,J49J].E.SM54H\W*I1C-K5*,OTG_XB?/V[/^B9?LW?^$GX[_\ GBT?\1/G
M[=G_ $3+]F[_ ,)/QW_\\6OSB_;&^'?@'X":9^REX@B_9K\ >$O&6I^&=4\6
M_$OPAHOQ&\5?$3X1>,M.FMO#=]X2\&:[X@C\=WGB74OB!I=E<ZC>?$_5/"-[
MX1\/6EYK6G^%]$BDOO#^IWC?1_B7]GG]CKQK^T/##I^F^"/A5X-TO]IGX.?L
M_P#A_P #>"/$MUK/@3Q%X<\:_!F3XL>,?B?\2-;\:?$#5O%-Q9Z+JL=SX.M5
M\(ZWH6E)<OIUK?7EM?6]Q]L3R'@14:&(?"6'="O2QE2-2G2]O9X.M4H2ART,
M?-R]M*G*=*I#]W[.\IJ+2C,68<0.I.DLYJJI3G1BXRE[.ZK4XU%*\\/%+D4E
M&<7[W-I%N]X_1W_$3Y^W9_T3+]F[_P )/QW_ //%H_XB?/V[/^B9?LW?^$GX
M[_\ GBU\=^)?V%?@=\)O@;XE^)FL?$S0?B-XMU_]DOXS>-M%\+2>*?#BV/A3
MXL:#I7P4\5^ ]6\*7OAC6XYM>2XT_P ?>)/#J^'M7355EU30M55FN[RPO;+2
MO4[7]C[]D_QIX1T#P[/:> OAC\._$5C^R;:_!/\ :ST3XPVVO_$OXR>.?B2V
MDC]H30O%OPRUOQE<:!ID?@.&X\7SW&FOX2\$Q^ IO"6BV^HZQJ(UT-=9RRCP
M[4?:1X8H5**KRH2JQP>)C[U.$I5'"E4Q<:U=PY9?NZ,)5:E.%6O2C*C1JN-K
M&<2M\KS:I&;IJHH.O2>DFE%2E&BX4U*Z]^<E",I0A-J<X)^X_P#$3Y^W9_T3
M+]F[_P )/QW_ //%H_XB?/V[/^B9?LW?^$GX[_\ GBU\=?#C_@G9\#?BC8Q:
MYX4^-OCO4=/U[P!I7C32M"MK?X83>*O 44WPF^+?Q!U34?BA:C70;K0DU[X8
M6WA2U@\&V%WKED?$D-UJEJ&MX%O-72_^"?G[/FG-J6FWGQ^T;4CXA\*Z;8:/
MJ6O7O@D7L@N/B[^SSX63XV_#3_A'_&;V,?@7Q+H7Q0\80^&K#QNEWKL'_"#^
M(IM3TLVXDO=)J64>&\93A_J]AG4IVYZ?]G8]2C=M.Z^LRLX\M1M6U]FW"4H2
MA6G*QO%#49?VE5Y9:QE]9PUGHK6_=*][QMKIS)-*2E!?6'_$3Y^W9_T3+]F[
M_P )/QW_ //%H_XB?/V[/^B9?LW?^$GX[_\ GBU\J?##_@FU\ ?BSXKT33O"
M/QX\?ZMI/B:?2-*L=#L;;X4OX]\/S2_$3XT>!-=\:^);27Q$NFW7@BPC^$^C
MZO!IN@Q7?BGROB'HS,ES:6L=SJ/+>'?V3_@3XH_X)?>(OB[I&H> F_:=T"X\
M2_$N\UO4?'%YIUPWP\T'QEJN@GX>Z'I4FJ/8:U\58-.T"?4-1^'G_"-VGD>%
MO$&D>.(_%5U)')I%.63>'*E3C'AS#2E/%X/!S3P.,INC/'2JPI5*JJ8J\:4)
MTG&K))\KG#E=1.4J8L;Q-:3>:54E1KUHM8BC)5(T%!SC!QHV<VIIQBVKI2NH
MM)2^U/\ B)\_;L_Z)E^S=_X2?CO_ .>+1_Q$^?MV?]$R_9N_\)/QW_\ /%KX
MO\:?L<_LO:GX1\(^*M ^*,W@[Q1K_P $;/Q59^$M*U;PIK7@X>*OAY^SM\(_
MBGXOE\6WVK^('\46NH_$CQ/XO\2>'K+2=)^SQ:9K5@]O90C[)<Z:OK/CK]A;
M]EG4-3\0:#\/_%^B:1J6H^(/BIX1E\6ZGXY\*R>!]-UOP_\ M6?#?X8^&8O
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M#,_HQT?_ (+G?M4:AM\[P5\&%W8SY?AOQ4,9 /&[QNWKWKU;1O\ @LM^TGJ
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M99)\*/'$37-[>7"06\/G7&B16\"M(Z^9/<30V\$8::XFBA1Y%_N"_P"(E/\
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M7_\ -I1_Q$I_\$WO3X^_^&PTO_YM*/\ 73Q+_P"B ?\ X+S'_P":A?V%PO\
M]%&O_ L-_P#*C^.M/^"4_P#P45C+&/\ 8N^/R%N6*_#G7 6//)Q:\]3UH_X=
M3_\ !1;&/^&+_C_C:5Q_PKG7<;2=Q7_CUZ$\D>O-?V*?\1*?_!-[T^/O_AL-
M+_\ FTH_XB4_^";WI\??_#8:7_\ -I1_KIXE_P#1OW_X+S'_ .:@_L+A?_HH
MU_X%AO\ Y4?QU+_P2E_X***25_8M^/JDL&)'PXUP'<N2#Q:]06;'ID^M'_#J
M3_@HF&9Q^Q9\?0[A@[#X;ZV&8-C=N/V7)W8&<]<#-?V*_P#$2G_P3>]/C[_X
M;#2__FTH_P"(E/\ X)O>GQ]_\-AI?_S:4?ZZ>)?_ $0#_P#!>8__ #4']A<+
M_P#11K[\-_\ *C^2[P?^P%_P5H^'VB^*O#?@3]G#]JKP?H'CBV-GXPTGP_X.
M\0Z=:^(K5K.ZTYX=1\JT\XK+IU]>Z=,]O+;R36%Y=V4SO:W$T3^=+_P2D_X*
M)(,)^Q9\?%'HOPWUM1P&4<"T'0,P [!CCJ:_L6_XB4_^";WI\??_  V&E_\
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MI*C/0<=*_L5_XB4_^";WI\??_#8:7_\ -I1_Q$I_\$WO3X^_^&PTO_YM*O\
MUT\2_P#HW[_\%YC_ /-1/]A<+_\ 11K[\-_\J/XZA_P2E_X**+C'[%OQ^&,X
MQ\.-<'5@Y_Y=>[ ,1_>^;KS0O_!*7_@HHIRO[%OQ]4DY)'PXUP<X89XM?1F'
M_ F]37]BO_$2G_P3>]/C[_X;#2__ )M*/^(E/_@F]Z?'W_PV&E__ #:4?ZZ>
M)?\ T0#_ /!>8_\ S4']A<+_ /11K[\+_P#*C^.X?\$J_P#@HR  /V,?V@0
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MZW_NJ?4]%?.4?[4?POE0.KZX >F;*P!Z9[:H?6I/^&G_ (8_W];_ / .Q_\
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M'--L)+JQM+"A<_%+]IW4/V7/"OBCQ%KOQ3T.36OVH_B/H/Q9^(OPY^$.I?\
M"TO"?[.-OXX^)L'A?Q=\/?A=KGA3Q5XALK.[M]/^'FGQ7-WX/\5^(M$\%ZQ?
M:\;'4+VT:_BR-=_:O_;"\%VD>B>!O@WXS^*EEIOPIL=9\.>)/BA\)_%WA3Q[
MXUDG^'NO^(V^(_C6U\+VFC>$O#4FD>-=-T#X<:U\)+32]+\=ZG>>(D\2V$=A
M9J+!<75XBK2BHYCE]2=#,*E://+#4J<,9@XTJ/UOVM;EH^UD\0IQIRAM#ZU[
M*G&,%&^3+::;>%Q,8U,-&$K*K.4J-9SG['DA>?(E3<7)2^U['GDY2OXAJ'_!
M(WXR>,/'UK\1OB#\=?!&M:Y-<_"OQ!XEAM_#6N?9O%'C[X0>#/!/PU\*^/K]
M[F8RIKB^";#Q_%,H$D::EXJM##(MO:2EOU?_ &5_!/QD^&?P=\'_  U^,DGP
MPN=0^'7AGPGX$\,:A\+[CQ5-8:IX:\)>%])T"UU'6X?%=C97%EK5Y+I\L\UG
M8?:;""*2-([F1PQK\Q/C7^U-^WY-IZ^&]&^&&L^$M6\/^+->L3KOP_\ A=XZ
MU&7XKZ9X>\0?&_P[?:CH6H:I#XBT;P%HEGI_A'X:ZT]KKR:CJGB&Y\<6-QX<
MO7T^(03,T3]JG]OWPE<>+Y==^&^O>.+NRO-;TT7>H_!WQM#X?\-/I?B/XY:C
MX'\.1>&?"-I!K7B/6OB/9>'OA9X'3QU8ZI-H.A#QGI'B+7K)3;W0O+QV%S[-
M<%2I8S&Y'4A3DI8>C"KA*52BDXTXNC4I3A2A"I3G&,HN,WR0ITK1J4_9TIP]
M7+\'7G.A0Q\7)-59N%:<9WO)J<9J4Y2C*+:::7-*4[N,N:?[F45^)GQ(_:X_
M;]MKI;G3_P!GR[TZ*R\5>*M9T;0O#GA3QC?7B:?X+OOB1H-MX.\?ZL4U2Q\1
M:=XHET_PQJW]H^$X?#S3QI#-I=W);:E#MZ"3]O#]IOPQ\5/A=\+?B-\._A_X
M9U#Q9\7O#GP]^TR>&O'4%Q\2-&U_XMZ9X.U36O ^G3ZW)/X2A\(>#K]/$,VJ
M^)CK&D>);F1TTN2 :??6R>%_JSF+@I0JY?5;IU:KIT\?AZE2,*4)5)OE@Y.5
MHPE=Q5HM:ODO57H?VKADVI0Q,%S0BI2P]2,6YR48J[2M=M6OOT7-[C_9(]5^
MO]#2TAZK]?Z&EKYX](*_D8_X.LM0O8_"W[%FEI=3IIUUKWQSOKFR61A;3WEC
M8?"R"SN98A\KS6L-_>Q0.1F-+N=5P)&S_7/7\GW_  =1^ ?%FK_"S]DSXBZ;
MH]Y>^$?!GC'XI>&_$VK6UO--;Z/J?C73/ UUX;2_DB1DM8=27PEK4,$\[1Q/
M=016RL9YX8W^Z\-)0CQOD3G*,4ZN+C%R:2=2>7XV-.*<K+GE)\L$O><G:-VT
MG\_Q2I/(<PY4W:%%NR;]V.)HN3=OLI:R>R6KT5U_.'^S]_P3]O?CS^S=K7[0
MP^+$7@BUT[5_BMI%O8:O\/-1U#P1;W/PIT/PIKL]KXN^*$7B>PL/".K^.$\4
MQZ/X T=O#FKW&O\ B"S_ ++5XC=)-%'XS_X)B?M1:)\9?$?PA\#Z+X<^)XTS
M6/B1IGAWQAH7BKPS8Z3XI7X7>*+7PAXEM6M)M:O)?#WBNWUK4-+M9O!^J7+:
MA9S:G:QSW.WSI8OB63XA^-Y?!WA+X?OKUV?!O@7Q=KGCSPIH(CA6UTGQ=XD'
MA\:UK2LL8ENI[S_A%M /E7CW%O VG1M;Q1%Y=_TOX?\ ^"@W[8_A;4]7UC0?
MC7J]C?Z]XB\5^+M7=O#_ (3O(;WQ/XV\7Z;X^\2ZW):WVAW%NE]?>+](L-;A
MDBCC%A<1,EB((I&2OZ>K8?B6%;$U<+C<OJTZDZ[P^%QF'G&GAX.</JR]M0BJ
MU24:<9.HI7C>;BI-VG'\JA4RJ4*4*V'Q,)0C3]I5HU(N562C+VON5&X13DUR
M-6=DFTE>+T](_P""<?[8^N2?#]-.^$ID3XF^")_B)X8NG\2Z +*/PE#_ ,(X
M%U'7;N.\EAT5[N;Q?X8M+*WG:1IK_6;:P=HKR"_AM.,\$?LOR>*OAY^TYK>M
M>/H?!?Q<_9CT_4]:\0_ S5?!^KWNNZOHOAGQ#IGACQA<2^);2_2QT:_T/6-1
MEMX].ATK75>/2=4O]9O?#^F1VM]=:>B_M[_M?^';+PMI>B?&K7-.TCP=I^KZ
M9HNBP:+X8_L5[/7+?1;34!K6E'138^()VMO#?AV.WN]9AO+BV;0M+N(Y!<VW
MG-YIH7[2WQW\->!/B5\-=%^(FJ6G@_XOW^MZE\1+-].T.[U7Q!=^*!:KXL\O
MQ-=Z7/XDT:V\816-C;^+K'0M5TVR\26EE:VFK6]S;Q",Z1I\1R515:N5P?M<
M,Z,L-'$*7LHXV4\3&M]8IUHM3P"C2C"E&,_;MSC7IV;(<LL3BX0Q<ER55-57
M3:YW02I.G[.4&N7$7FW-M>S23A*Z2^U?AI_P3'U+XH_!_P"%7Q7\/_'CPY=#
MXA>'=9\0^(]'TKP-J6O6/PSET[P1\1O&MKX7\6:[I_B8WFF^+)X? $-A/9^)
M/#7A72)SXGTZZ\*:WXM-E?6H]5O/^"/^IP?&36O@Q9?&?Q1KFO>'? 7B+QQ>
M2Z+\#](O;SQ(=#\1> /#-MHOP_T5/CG]HUVZU2^\>PR(_B.Z\%W446FO';:;
M?W5[';P?!GAG]MS]JGP=X,\/_#_PS\6M0TCPOX8T8>&]+@MO#GA$:Q+X8ATK
MQ+HFF^%]:\4'03XF\1^&O#^G>,?$\7AC0M>U;4--\-RZS=7.CV]I<"&2.GX]
M_;(_:*^)4GB&Y\4^,-"34_%VD2Z'XNU_PO\ #;X=>"/%'BRQEUSPQXF$GBCQ
M/X/\+Z+KWB#4X-?\&^&M6L]9U;4+O5;*\TP2VMW"US=&;@E@N+I5ZW+FF"AA
MY2Q"HVHPE4I1G74L/*I'ZHO:>RP_-3Y(34G)0E.<I\TCH5?)E3A?"5Y5$J7/
M><E&?+3:J*+]L^7GJ6ES2BTE=1BHV1]RZU_P24N]%^%GQM^*<G[2'AJ]T'X,
M:[^T'HNH^(+/X>7+?#U)/@!8Z!-=P>,?&4OCJ/4/!>L^-=<\06W@30M+M/"?
MBVVL_'L9\/WNK,)H+M_E']J7]B'QY^RIX#_9[\>>+]<.K6GQN\,Q7OB#3U\(
MZ]X>N/A7X[_X1_PKXTO/AOJ=UJ[_ &/Q9J5IX(\;^'->CUS09(M+NYY=5TA%
MCNM'NY*Y?4/VWOVI]5\2KXMU'XJWE[K;0?$JUU"2X\.^%WT[Q#;_ !BL- T[
MXI0^*M%_L8:1XG3QU'X6\/WNO#6K.[-QK>F0:_&8=9+WK<7\2_VG_P!H/XRZ
M-XB\/?%7XK>+/'^A^*/']M\4-2TSQ/>#5+2T\;VNG:CI$.J>&XKA'3PE:'3-
M5O;*;1/#(TK1+BW-LDVGN;*U,6^"PO%%/$498W,,%B,,JO/B*<:')4E2EA_8
MNC2E##PBI4ZZ^N1J-I5.98=QBE-RSKU<IE3J*AAL13JN'+3DY\T5-5.?GFI5
M)-J5-^P<5=Q2]I=MQ2^B?B!^PQIUEX-\$>,_@M\:K?XK6/B+X#O^TOXL;QCX
M#B^".G?#_P"#Q\?WGPMMM6O]7\0^._$D.N^([SQY9?V-;>%M)MQ>S17VG7D,
MTHN)(8-31?\ @F9\?M6\?QZ)<0V^B_#1?C9!\#M2^*&I1Z7+<Z'XAO9=4L=.
MU+5O 6G>(KS58]/OM8TB]T:$VVK72"]BW/<"V:.>3Y+/Q_\ C$?"Z>"SXUO3
MX83X3V7P-72OL.F^4/A3IWC[_A:%EX/\W['Y_P!D@\>?\5"+LRG4&N/W#71M
M/W%>TW'_  4(_;)NK.*PN/C9J\UM!XMM_',(D\/^%#/'XHL]?U/Q19Z@+L:&
M+LQ67B#6M8U6TT]IS80W.J7Q%N5F"K4\/Q-"FX4,9@*K<JL?:XJE/VL:<Y5W
M"?[BA3I2K4E+#P@G2C32IU'-5I3;2C4RJ4N:I0Q,%:#Y*,ER.4534H_O*DIJ
M$FJLFU-RO**BX*-C#C_9M\*Z=\'?A]X[\8?&B#P[\3_C;HWBGQ!\!_@MIGPS
M\5>+KGXAV'AOQ]/\-+/3]1\<Z3?Q:9X2\1^,/%FGZO9^%]*FT75[9HM/BFUO
M4M(&HVHKN=/_ .";?[7FJW&J067@?P?)'HSW%I?:B_Q6^'<>C#7-/O\ Q9I6
MN^$[?6FU[^S)_%_A;5O OBO2_%7AU;D7VAWNCS"['V>6"XE\7\+_ +4W[0/@
MOX87'P<\,?$6]TOP!))JSV5A_87AB]USPY%K^IV>M^(+#P;XSU#1+KQCX+TO
M7]9T^RU?6M+\+ZYI5E?ZG;I?2P_:6EDD[:^_;K_:TU)[MKOXP:F4OI!<7=K:
M^'O">G6$^H2'Q?)J&L/I^G:':V1UW7;KQ]XPU'Q+K7D?VEXAU37+C4-6N+JY
MBMGAUJ4N(XRJ?5ZV724J]:498J-6:C1=1.A&E3H4<.Z:C1M"<*M;$SE6C4JN
MNJ=2E1IS&66-1]I3Q*:IP35)QC>:C^\<Y5)U.:\[RC*$*45!QA[-RA.<_0M"
M_P"";'[4-]X@\.:7XAT#PUX;TG6?&^G^%=0U:'QGX4\1ZIIN@MXK^'GA7Q%\
M1],\):9K*:SXI\"^%'^*?@C5=2UK2,6DNG:]82I<1K)-);ZUM_P3$_:>EU34
M7U+3O#?A3P)#I_Q;UK1_B/XRUB'1=%UG1OA7X<\;>+[6ZFTV$ZAJ6BW/Q%\-
M> ]<U?P/:7RLEW:0337EU;Q0>9+S6K?\%%?VG]0^'W@'P19>+(-#U7P5K6MZ
MO?\ Q!T_3-(?Q=XPBOM9^'.M:#HFJ7$^D-_9.@>&)_A7X-A.D:+<6]AXICTJ
MU;Q/;7S6R!N#N/VXOVK[Q?#J7_QBUO48O"T/BZTTF+4-)\/7L;Z=XZT?Q!X>
M\2:/JRW&DR?VYHMQH/BOQ%HUAI6K&ZLM&T[5KFVTJ*T40F+G4.+IMMU<FI?Q
M*?+[+$3]V,VZ=>"UCSU8I)1JR:A";YZ?/%7T<LFC9*&.G\,K\U..KC[U.5TG
M:#=[P2<I1]V7*SUCPK_P3'_:PU3QW\/?"?C?PAIGPMT#QQJ7@RSO_'_BWQ)X
M<B\.>$8_&?C+PSX'L[+5&DU>S%WXSBUKQ;HL%MX&M+D:MJT]TL%E-A+B:W^0
MO$7PD^(.AWOC=K'P7XX\1>%O WB?Q?X;U#QWI/@;Q/-X2D_X0[6K[1M1U&?6
MX=.N='TV%7L6GNHKO4_^):)!#=RJR,Q][A_;]_;"A\0Z5XI;XTZO>ZWHVD:-
MH]G/JOAWPAJ]I(OAS7M)\4:!K&H:9J6@7.FZIXJT7Q'H.BZUIGBR_M;C7[._
MTVWFM[^/]Z)?F/4/&OC35'ULWGBSQ.\/B34M7U?7M/@U[5K31]4U'7[V?4-:
MN+O1;2[ATF3^T[RYGGNXC9^5,TC!T*X%=V#AGRJ3ECZF6.#ITHPIX6GBE!35
M>I*M-N:]JY.@Z=.FI3]ES*[@GSR?/7>7\L5AX8M2YYN4JLJ3?+[.*A%*/N6]
MISRE9<]G92:Y4OOJ;_@FQ\1M?^#OP5^)?P?\::=\9/$'Q9BTF;6?"'AKPY+9
M:%\-O[3\(Z_XVOK3Q5X_E\07L6E:IX4T7P[>OXDT_P 6^&/!KW+GS?!LGBVW
MAFD%?X=_\$L_VNO%OCGPAX7\7?#_ %#X<:!XD^*5I\*M3\6W\5KXA?P_J-[K
M#^&;3Q$OAO2]1AU#7/"]YXJ:S\-6&JV%RD-[JM_:Q1$1MYE>,:!^W1^UIX6T
M/P;X<\/?&36-)TGP+#I5GHR6F@^$XM0U+2M T'6/"WA[0?&FM+H(UGX@>'?#
MGAGQ#KOA_P /:%XUO]<TW1=)U6\M-/@@5D:.6W_;O_:]MAIHB^-WB8MHWCR?
MXEZ1+)8Z%)-I?BVYU*?69)].F;2O-LM'&LW$NL0^&K9XM!@U39>Q:>DT:$<+
MH\6J-:$,5D\E*>(=&M6I8EUZ<*E3$NBFJ5.GAVZ,)8913ISOR3]I*I-RYNA3
MR9N$I4<:FHTN>$)T_9RE&-+VGQRE4_>255MJ2MS1Y%&*5NK;_@GQ^T&MKXEL
MYM-\/Z;XN\!>*_'_ (<^).B:_P"*O"F@Z%\/X?AOX=^'_B#Q1-XC\97VO+86
MNN:(?B1H.F^(/#+6*W&C7YEM?MU[?175C:<+\0_V*/VDOA5X'^('Q \?>"-*
M\-Z1\,7U(^+M+O?&GA5O%=K8:7\0F^%$WB&Q\+6VIW&L:IX3F^(D<_A>S\2V
M-O-IEW>6EY+!*]M;F5LW5?VP?VE=<TC7M#U?XHZMJ.G^*=)U'1/$XNM-T22\
M\166L:#X*\,ZM+K6H'3?MNHZGJ>A?#GP387^KW,[ZE=KX?MKB>YDNIKN>?U7
MQE^W[\7/B'\ OB-\$_'>DZ?XNUOXKZD]SXU^+&O:D;KQ!/I,OQ*A^+%SH.AZ
M#!HEI;>'[2[\8PF]N(K/6GT3_2]2N+;P[:ZEJ$]_6J7$].I0<_[,KTI8FA'$
M1I0K0J4\.YT_K-2$JLH1:C%5O9PY9U8IT4G5G[:2A_V5*-3E^MTYJE4=-R<)
M1E42E[*,E&,G=MPYI7C!M3;Y(\B>+\;OV--3^"OAWXP>(+KXD:+XA'PC^-/P
M(^#%W9P>'[_37UJ]^.GP9N_C%8^((Y6U"^?3K3PU:VAT&]TUK:]O-3GD&HV<
MD,:BS<_;*_8\D_9(A^'&HVGQ0TWXO^&_B+8>(7L/&'AWPO/HOA&?5_#*:9)J
M5CX:\0Q>(?$VF>);4Q:I%(J7%QX?\6Z:L;?\))X+T/S[0S\3XJ_;'_:5\<>'
MO#'A7QA\2&\1:%X0AC72;74_"7@N6>ZO;7P@_@#2-?\ $FI)X>CU+Q=XK\,>
M#''A[P?XL\3W>J^(?"=C' V@:C874$5PN=\4/VL?V@OC3HK>'OBAXYM_%NCO
M8ZG:R6EUX+\#V!DO]<O=!OO$/BV6?2/#FGW$GQ#\2R^&-!@\2?$1I/\ A,]=
MT_3H],U'69]/EN+::\/1X@C5P4L1B,)4I4ZE?Z["'N^WI2I4*=!TW]4C*$Z=
M2G6Q#BI0B_K#HRE-4H3<U)Y:X5U2I5HSE&G["4KOV<U.I*HI+VS4HRC*%.]F
MU[/G27/*)]C?$#_@E9\1_#W@3X1^(O ?Q M/'/C'XKQ?#*YT[P/XB\'2_#&R
MNK#XD_"!_B_)K7@?QEK?BK5K/Q_H/@+3H9/#WCW4[;2-%72-<FT^*"*Z:]2!
M?%X/^"=G[1MM8^+;KQBOPX^'E]X5\$_$?QM'X:\6_$+0HO%7B&T^%OQ+L_A#
MXIL='T339+^9)$^(-V-"L=0U&2TTN^DB\RTN9TG@W^)Z'^U#\??#GQ,L_C#H
MWQ$U&V^(MC\/+'X3V_B"73=&OD_X5SIWA'3O EGX2FTF^TZYT>?3(_"NDZ9I
M<@EL3/<"R@N+B:6Y#2MT.J_ME?M,Z[XIN?&FL_$V[U3Q'>>%O&_@J\O+[P_X
M:GMKOPS\1O&S?$GQEIEQIKZ0=.==6\>D>*DN/LPN=.U:*WFTV6U2WBC7*&'X
MHIKD>-RVM%Q=1UJF&J1K*I*M*?U>,8J-%T(45&E&M*+JMRE+DO&#>DJF4R?,
MJ&*@[J*A&I%P<5!1]HVVY^T<^:;@GR627-JTO38O^":W[9-WXAU#PQI?PPTS
M7M3TJV\0/J$OASQUX0U[2K35O"_BZ3P%K/A";5M,U2XLH_&UOXPB.AKX;>1;
MI[EDE:2.U+3KN?!7]A[XB:S\7KOX4?$3Q/X/^&.KP?L_>(?VCKY'U?2O%VLV
M7@K1/ S^/-'TBZT'3M7T];+QAXJTF:P;3] U35;"[L+6[.H:BD4<!AE\FT?]
MN']K#0'UM]'^,>NV/_"1W7CB_P!;B32] FMM0U/XC>*$\:^+-6EM;G2IK==6
MNO%B?V]I^HQQK<Z+?-(=*DM8I9(VR/"7QY^,DWCC7/B-+XTU-_&.M?#A?@_J
M7B(VMD+R\^'C>"K?X>OX;.VV$2)_PAMG::+_ &A$B:FJQ)=+=B])G.BI<2RC
M6A5Q&54TZ#C0JX?#XAU5B&J-ISC7E.E&FG]9]V,9MWH_]/+<]>>51@I*EC)I
M33J0J5*:@Z=Y^[%PY9N37LM6X_\ +S^ZSZ_?]B_]H3PKH?B?Q+XE\->&M#T#
MP+H6H:UXQU:^\?>$FL_#=SHVL:-X?UCP?JTEIJ=T;?XAZ1K7B30--U+P. ^N
M6]UJ]D%@DC:22/[>^$O_  3EU3Q[\+O@G\18/BY;:!/\9;/P)J.F:;KWP^O[
M+P]"OCKQGXF\&1:)H7C63Q0EIXK\7Z#/X<;7-=\/0:3IBV7AZ\_M&74(TM9!
M)^?>L_M1?M _$70-6\+^-/B'J6MZ!XCTV'3O$.F-I.A6$.N;-<TGQ-<:MJ[:
M9I5G)J/B75-=T#1-1UOQ/=O+KNLR:99IJ-]/%%L;J_#'QB^*-AK?PN\1VOBB
M_BUGX-:):>&_AG>?9;1_^$4T6PO=9U&TLK.W>W:WN/*O/$&L3>?>Q7%P_P!N
M>.25HTC5,JV'XDK4$ECL!A,1&K4DY8?#3JTITE@YQHTI+$*;O+'.$ZDDH^SP
M\%RJI5<XOY^K6R6G5DYX3%XF@Z<(\M6O&G4C4>)BZM2+HN*M'"J481;ES5I/
MF<(<LE]3Z%^R#\?9[/Q-J&G^$]+UC3?"GAC2/&E]J>C^+/#FH:?J/A37K1]0
MT[7- O8=0-MK%F;&*6XNV@E7[)Y,\3EIHFCKVV#]BO\ :5TG5O$>B7GPZE.H
M^$=%LM;UF*VUC2KF,6]_!KMQ:V5C/'<F.^U>2W\->()_[.A.\Q:5/)')(DMF
MUSX!X/\ VI/VA-$\(OX%TOXA:E:^%)?#EIX2_L@:1HDR1>';+2+C0;?3K:YN
M-+EN[9?[(NI+*::"=)[B)8O.D=HE->RVW[5O[1^K17]M?_$O6IK35/#\7AFZ
ML4TW1X+"+2HY-9G L+*#38[;3+\S>(=>D;4[".WOMVKWVV95E54F<>*/:349
MY&Z?.U%RIX_G<$Z7OR4'RJ;2K-PBW"+E%*;48W^>Q$N&N3]Y'.?:<K<E3J8+
MD4_WKY8N:YG!-T5SM*349-P3E*WLOPH_9]T[X@?#O1/&^E_$JQM+V?Q-'H&N
M:!?^$M9MK?2(CIWB'6[N;2_$5Q=P67BO5-%T'PZVO>(=(TJT2+1M+U/37NM4
M%S-]FKUC2?V>SJ/B/X*:#X*^(.@>)K3XUZ5>7NB^(-1TS4?"^EZ3?Z/<7-IK
M&GW_ -JDOY94MYK20VDRB"^N8FADN]*TY9X#+\[>&_CC\6+7P'H7PVM=:M(/
M"/A_3M=TK0[6+PKX;75M*T_Q,+L>(;:R\2C2?^$B@76AJ%TNHLFIA[E7C25F
M6" 1^KQ?&OXN:YKW@OQ1J?BJ^N-<^'V&\(7<6F:59QZ5-*8WO+TV5EIUO97V
MH:HT49UC4+^WNKS5A'&+Z:<(N'+#\0.M7E#%X:-)SQ_U>G4C"HH0J8>LL![3
MEP=*<W2Q+H3G'VD>2E&M3G/%<T)GSV)Q'#JHT8U,'BIU%'+_ *S.G*=)SE3Q
M-&68JFY8RK"'M<*L13IR]E+GJRHU(1PO+.![IH7[/_CUK0LT>F2:G<6O@;4-
M*TVQU;2K]+K2?'SZE)H6I:C>1WZ#1H;RRTZ6_LHY[>XEN[;<[+;!8S-W6O\
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MA_X8_P"&7_S+T?\ #'/[(G_1J_[.'_AC_AE_\R]%%']H9A_T,,?_ .%V._\
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M$N'_ /E ?\.Y?V"/^C.OV<?_  T?@O\ ^5-'_#N7]@C_ *,Z_9Q_\-'X+_\
ME3111_:^;?\ 0US3_P .68?_ #<'U+!_] >$_P#"7#__ "@/^'<O[!'_ $9U
M^SC_ .&C\%__ "IH_P"'<O[!'_1G7[./_AH_!?\ \J:**/[7S;_H:YI_X<LP
M_P#FX/J6#_Z \)_X2X?_ .4!_P .Y?V"/^C.OV<?_#1^"_\ Y4T?\.Y?V"/^
MC.OV<?\ PT?@O_Y4T44?VOFW_0US3_PY9A_\W!]2P?\ T!X3_P )</\ _* _
MX=R_L$?]&=?LX_\ AH_!?_RIH_X=R_L$?]&=?LX_^&C\%_\ RIHHH_M?-O\
MH:YI_P"'+,/_ )N#ZE@_^@/"?^$N'_\ E ?\.Y?V"/\ HSK]G'_PT?@O_P"5
M-'_#N7]@C_HSK]G'_P -'X+_ /E3111_:^;?]#7-/_#EF'_S<'U+!_\ 0'A/
M_"7#_P#R@/\ AW+^P1_T9U^SC_X:/P7_ /*FC_AW+^P1_P!&=?LX_P#AH_!?
M_P J:**/[7S;_H:YI_X<LP_^;@^I8/\ Z \)_P"$N'_^4!_P[E_8(_Z,Z_9Q
M_P##1^"__E31_P .Y?V"/^C.OV<?_#1^"_\ Y4T44?VOFW_0US3_ ,.68?\
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M[$_[(46!'^S1\$D Z!?AQX77^6G5<C_8X_91B_U?[.GP;3_=^'WAI>GTT_\
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AEN7X>K"Z<7R5*&!HU(WBW%\LXWBVG=-I[-%%%<AZ!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %U >\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC(/0].#['
MTHI/3[[ %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***BGD6&&
M69V5$B1I'=VVHB("SN[?PJJ@LQ[ $\T6;:25VVDDMVVTDEOJVTEH]6M-0;LK
M_EJ_NZDM%?S+_P#!2#_@Y<_9D_8X\1^%/ 7[.VD^'?VP_&&K07FI>+]2\'?$
M33M/\#> ;:PU5]*ET+5-;L++6;BY\67,MM>S+I4-N(M/AA22_N4,\4 _2C_@
MG=_P5>_96_X*-?#[P?K'PN\<:)X<^+^LZ!K&M>*_V>-<\0:9<?%#P4/#FHP:
M7K5S?Z7;.)[SP_'<7VG7%AKT$*6EY9:C9/A9I)8H_P!JXC^CGXW\)>&60^,?
M$7AMQ'E/AQQ+B*F'RGB/%X50A.4%7=.MC<O3EFN58/%_5JRP./S3 8'!XWV;
M]A7M*B\1YM'-\MKXZKEU+%TIXRBKSI)^EU&?P5)0NN>,)2</M+>WZ>;V+$
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MXJ\<_$O5;1/&7Q.\3V$ U<>'[#S=2U6ZN9 L\U\+J"'\T_\ @KW_ ,%6-/\
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M$?1_^"C7_!8#_@HE_P $Z/\ @J3I_C?Q[9:1X=\2:C'\-_V//AOJMKJ^HQ^
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MT[-J]X7MTND];BA.-2$9PDI0G%2C*.L91DDU)/JFI:/J%%%%!04444 %%%%
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M44L)I+G2+]-K&73]4M[.]AP?-MTP:]PKXG^!7_!._P#8X_9C^-'CGX^?LZ?
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MT7-QK%]X'N++QG_94$8;+RZE;Z#-:0Q@DO-,BX)8 _JMMX(&.F!QT]>>O/\
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M=DWKHF]%=Z)MV75V3LNKT6MKJ7;) P#QVSCK[^V._(ST-+O.< CH.,="??\
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M/#MSH7Q O-&N?$EBNEI.[Z1+8ZK$+-93]EVHQW?*'[!?[)W[+?@K_@W[T/\
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M_8C\-:C!"^FZ_P#\%.]8T6]5'*;['5?B#X_TNZ,4T0W*7MI9(1+#\QB.]!D
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M8_V9]5<HRY::S6.-E1==<K=Z/U"JZCC%IJI&,?ADC^\%9G9<AT;(WA@I*E0
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M[-Z7[)Z/KL@^Z]G:^U^GS[=WH?SP_P#!>/X(?MU^/=2_80^,?_!.[]G7PO\
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MF[WNU"";NFT[VO=-I[IV:"BBBI- HHHH **** "BBB@ HHHH **** "BBB@
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M1N[^Z8*;J]FGF959\5_/9^R!^S]H'P _X*W_ /!6/]B_XS>#H?$'P+_X*0^
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M:HC_ /"2_$[Q3IS6_@[0=/MM"A-C:>$=&M1J"7EP;B^N$6&.)OU(&_"Y//\
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M.WL_9.I[-2?,Y)R=U:U_U9\&_P#!23P5XT_X*4?$_P#X)OV/P]UZU\1_#/\
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MS;>.WL([WQ5JVG:1X>%U'<I-%J?B"6TTUD5469I9HE?^4K]IS1W_ &*?A_\
M\$*/^"R?A>WELM$^"WP?_9[_ &6_VOKG3XXHWU/]FCXP^ M"TVRUW63&N;BW
M\"ZU>7\UL\["-)M1TY'<+;6T:>%6?PQU;XQ?\$BO^"[W_!6CXE6/_%<_\%"-
M.^)K?"2XNTN!<:%^RQ\+/$MOX3^%^GV+7#$P67B9]-_M-UA2.*]L]-T.Y"Y+
M"IQ49488^7O6RUXJABDES.->&+P>'P48V^/Z]3Q-3$4G=>SHX3%N=W3CS3AI
MPJ_V?*WNX^&&G2UZ5:6)GB(R=O=^J3HTZ=1OXWB:,H**D[?VG?"WXIW7C/X,
M^!?BS\0/"[?!F\\3^#-#\6>)_!OB[Q+X9OYOA[=:K8Q7=YH&M^*=$U"[\*W]
MQH\LC6ESJ>E:E<:5<R1M+9W,D)5FS/BU^T5\)O@S\#OB%^T7XN\7Z5<?"CX9
M^#_$'C;Q%XB\.ZAI^N13Z3X;L9[Z^MM&:SO#;ZIJUP+<VFGZ=!<^?>:A-!:1
M9ED"U_%#\9I_#7C^/_@V9_9F_:T\47OAG_@G+\5/V:=,U'XJZ5JGB?4/!'PP
M^(WQ@TCX=V*>!O!?Q+\26.H:7 VDO<2Z%;V6F:EJ4-G>QZW>H2IN&N(/OWXI
M_L>_\$<O"G[)?_!7WX!_L<>/-%^)FJ67P'U_XJ?$W]E31?C-XA^('PJ^"GBC
MP#X:?QCX!\7> ?!"WLNC>&K[2_$[6NL/K&E:QJ4LU\\VD:I/+!8#3+2L=3>&
MHX^O&5_92S2G25.+JS4LJJ4Z%2<J2:</:*JZU.,I:48PJS;C5CRQA)^VJ8:F
MXS4JM/!5:G.N2FHY@J\H*-355'1]BX3Y%[U5NE#EE&[_ **_V-_VM?AQ^VU^
MSC\,/VF/A<9['PA\4O"]IXLL-!UB_P!(F\3>&]/OYKD65IXJM=)OK^VTC59;
M6W%Y+82W!D@CD"LSE7-?0N@>,O"7BLWH\+>*O#GB8Z;.;741H&MZ7K/]GW0)
M'V:^&FW5R;28%6!AN D@(((R#C_/]\0+X#_9[_X-P_V&]6_99U"R^$_@W]IS
MXT?LVZ'_ ,%//BK\%_$M]'XZTOP=K<^MZ/XQU;QUJVE:C?ZEX)N-233+#2=3
ME$&EHUGY&F?9VMM4*3_7_P"T#\)/V-?V'_\ @H1_P2$;_@C!KOAO2_BS\;OB
MU%X5^.WPQ^!_Q4U7Q_X2^+7[,4^EZ9/KOC_XR:7#XDU_3Q+:6\NH7T'B;4TM
M+FZD2YU*-ENM(BDCW=*#Q<Z,'*--YC2RZ,I+FM5JX.GB9XB=F^7!QG)0C6^W
M#VU72-"<92Y2CAW4:?,L'7Q_+NW"EB716'B]$\1)1<U36D7.A3=Y5XRC_:/X
ME\1Z-X3T#7/%7B/4K/1?#GAG1=2\0>(=9U&9;>PTC1-&M)M1U;4[Z=B%AM+"
MPMKBZGE;Y$CB9FZ8/Q]^P?\ MIZ%^WA^SC9?M2>%_A[XE^&GPM\6>+/'MG\-
M+KQQ?Z9_:/CGX<^#O$%_H&F_%)K>T/EZ!HWBQM+O]0T[3-1D-]9:?$LEW)E\
MU\L_\%\O$OBOPE_P1\_;WU?P8UTFKR?!'5M*N+FS>6.XM= UW5=,T?Q)<+)$
M?,14T2]U$3,NU1"SER$#D?D3^U=X^_:/^'7_  0\_P""9G[-'[&_P'_:%^)'
M@?\ :4^ _P %?!G[07C[]EOP'J/C3XD?#'X"GP!X5UWXI)X/TO3 MMIGC7XH
M+K&I^'M&U;5KZTL;2&;7Y#(;Y[;'+%MTL;-Q<ITL3EF7X?W7;V^/^O5YUI23
MM"G1HX=4JLI*RBZMG[14CHY82GA*:=EB*>88RK+2RP^7O!4ZBBVTIU)SQ7[N
MFK.2479Q<G']<?V"O^"RWP!_X*'?M1_M>_L[_ [PSK;^%?V3%T_[7\;[[6M'
ME\%_$R.;6+W0=1O?"5A 1J%KHMAJ6FWK6^L:A*;;4K"**]MPL-S&1\L_\1&/
MP0&O/X__ .&6?VD6_8-3X[#]G$_\%!18>%C\&$^)G]LIX>>Z?PP=67QJ/ $>
MMO\ V>?&BV+VCN"$MC.# /PQ_P"".7Q,T#1/^"IO_!3/X ? 3]A[]I;X ^#/
MC7^SIX+^%?@7P)XA^'G]A7?[,@\%_"74H]'O_C_";V2?PI=?$/5XEN=%U6>>
M^O-<US5/,N)':X\U/ Y?BI\-6_X-.HOV5D\5^'W_ &E8OVJ5^"#_  0_M/3D
M^*L?Q</[27]MOHI\%?:/^$D:^33I8]2^UQZ<XVL )#+\HKE7[F=.,ZO)EV4S
M4924/K57$YQ++,=6C&5W",<-"E4BGS*+JKWFHSE**;YZM6%6$:,)9AC\*I:3
M6$H4,K^OX2-646N><JEJ;J148N2=HI2IQ?\ HUP7T5S;07L$]O/;36\=S#<P
MNKVTMO*@D2XBN%;RW@DB)EBE!V,A5N5;<>8B^)'P_E@TBYA\>^"I;77[Z;2]
M!N(_%&AR0:WJMO.(+G3-(G74/+U*^MYB(9K2S\ZXCF/ER(C_ "'SKX;^'M;\
M*?LS>!/"GB;>?$WAKX%^&/#OB$2,9)3KFC?#^PTS5O,=N78W]M.&8G+L"2=V
M:_SG/AI^Q5^SYX@_X-R?VQ_VW]<\/:[JO[37PC_:?\>7'P7^),GC7Q7;7?P@
M@TGXX^ M,^R?#G2['6K?1_#D>K/JVKZOKMS;:>+_ %75;F*ZFNBUC9-#%:=.
MCB,PC;]SA*=*LY12O/VF84\O@XZV2:JPJ*SLDN5;II85.O3P";7ML7-T(::<
M\<%7QTW*VJ]W#SAKKS6;ZH_TOXO%/AV?6Y_#$7B+0I?$UI;+>W?AZ'5M/DUR
MVL6V[;R?1UN#J,%LQ=<3RP"(D@!OF%?DU^UG_P %?/ _P)_:-'[&'[/?[/'Q
MN_;F_:\L_#-OXV\7_!KX!6F@6MC\+_"MY'!/9:E\3_B#XNU+2_"_A.74+:XM
M[FRL;B::[:.]TW[1%;G4K(3_ ,X/QN_9N^&/[(7QW_X-Q/VF_@X?&NF?M$_M
M.?$_X:6O[2WQHUCXB>--?\=?'BW\<^$/AYJWB2'XC:CK.M7\6LVUQ+KNI64%
MAY$5E!I,\.EQPI%;0O']R_\ !.CXC>"?V0_^"[/_  64^%_[5OBOPU\*_B+^
MTWXO\$?&/]G_ ,7_ !,U;3?"VG?$WX3V[ZY<V>C>$/$.N7%E8Z@?#NG:KIUL
M^C6]X98VT2_CAA=M*N!'USPUJM6E*:4*&+SK!5%)6EB,5DLL'&=.@TVW*I]:
M=6*>JAAYWYN:+6:JQ=-5$FY2P^5XFFT[JG1S2>+A&K5CI*,(?58PD]??KPTB
MHOF_6W]C;_@K)X/_ &K_ !C\=_@7XA_9T^/'[-?[7'[/'@]_&OCG]F?XV:-I
M6F:YJVCS6/VG2M0\&>/M.O;KP/K^EZI=26-G#?G4[)(X]3L]1>-M/,L\75:]
M_P %*+CX8?\ !./XH_\ !07]H3]G7QG\#_\ A57AWQ=KNK_ 76/'WP[\6^,-
M0?0-8&B>'=,T_P 8>"M5UKP:]WXVNY]/72T-ZTMB;U(K^&.9'2O/YO\ @I=^
MR;^TM\2?VX_V1?@+=:M\2/B#\%/V<?&GB/XG?%SP5H.F^(/@LC7/@W4K.#PI
M<?%71[ZXM+WQ9ITUY]C719@Z2&UU9+*X=M+OTM_Y5OV)]_Q@_P"")G_!(S]@
M/2WW3?ML?\%*O$NG^,=/20J;KX*_ GXH:Q\7OBE+-'&KF;3PFD>'K.\28&%X
M[MHG(7 &=*C/$TJLH)TI.ED\5.?P2GF&;XK+Y58Q;3A&%+"U)5%).2A2E4UI
M\K.B$:=.,JD_X5#$8V-6%_?A[#+%F$::=FIN;J4J<.7_ )>58T])WBOZSO@%
M_P %3]"^-?[<MO\ L)ZC\#/&7P]^(2_L>_#;]KC6M>UGQ-X=U+3-"M?B)8Z!
M=GX=7-C8JMW/KV@2Z\MG>ZI"YL)YK*=XXXXY(F;].M%\:>$O$MC?ZCX<\5>&
MM?T_2IKBVU;4-$US2]6LM,N;:(37,%]=V-U/;64]M$RS3PW3Q/%%^\E"J<G^
M#;_@J[;?MT7G_!;']OGPC_P3QT71_P#A9VL_\$J?#>G>,M:.KG1/%7A/X.:/
M'I^I>,8?A2D8)E^(_B&QL+7PKX3CMHUN[.;59+JQDAO(H91VW[8GQ-_9ZTK_
M (-V?V([C]@^/7?@9^R1\5/VB?@9\//VTK_PEJL]G\1O#FCW>I7-C\;[+XN>
M,-)5=7N?$=YXOL%C\2:Q?S)_:D!T>U2)='O;73C'/"IA<-BZ<''VTJ5%TY:.
M3QF=8[ 8;&-M*,<#0I4J.%JUWI]8I5;<BU>$(35>M0G*$HTU5GS0UC'ZKD^$
MQ]7#=WBZU6IB*U*C:ZPSIRO.[4?[B+7XA^ M0AT>XLO'7@R\M_$-]+IGA^XM
M/$NB74&N:C!M^T:=HTL5\Z:I?P;E\ZULC)/%O0M&,X/Q]^R+^W=X0_:M^)'[
M6'P2?P;K?PL^-/['_P 9;OX5?$WX=^)M3TG5+Z\T/4;5=7^'?Q1T"\TES#>>
M#?B)H)>_TAG1+RQN+>[L+X+-$GF?R4_M8? +_@FK^SC_ ,%7?^"%_@C_ ()\
M>*/"5C:ZO\=[+Q/XY^%_PR^*>I?$+X?1Z<UMHL7@_P")VI:7)XC\0Z5X?\<^
M*5;4;2\U&U-A?^);"SCNKJT<6,4TGZH_":ZU'PQ_P=5_M4:'X0!3PY\0/^"=
M/PQ\1?%2"UD4P-XDT'6="L?#&H7\:#:E\+ 6T-OYN)C!=R2(3',V:I4O;SC%
M<]JTL^PB34HN-;**&'Q"JN+5_9U(JM"VCA).\I.-Y%6IR0ERQO*%/),9&5TK
MT<RQ%2A*@]?CBW3D]'S149<JC/W?Z=E/('?]?E7&?\Y_#O+4:\X/]TD<]<$<
M'Z'_  ]*DI:W=]TVOET371V^_<TC9Q376[?^*[O;YW^X****!A1110 4444
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M,'2I*SG2S/+*\4TFHX?#+,'54=++EE7IRLW=ZM;,_G9_X-\/B#\-?AO\)O\
M@O'X9^+7BCPOX6\=^&_VG/CGXC^(]EXMU'3])U.7PF^A>/["+5+VVU6:&YNM
M*&IVVN68#>;%'<W1A8"6_B\_\'!I'B/3/^#93]EOQ5KD%Q!\-K7_ (*W:IXD
MU-Y[&Y.FQ^"/[-N=*6]GW*Z'3?[=LM7MU,A:&2?-LNZX!S_8=^W;_P &QW[
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MI]YM0I"ZC[?_ .">7_!ME^PQ_P $\?V@K']I?PQXG^+WQK^)O@]=2M_A)/\
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M?"CQ/X6T_6_"7A?2]$M!I^DP>'K2^CEFT:33+'_1K.ZTZXM[N* &)+@ U'\
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MV5-RDH0M:*DTK-MGSC\&OV2/V:_V=OAIJ?P<^!/P,^&/PF^%^MV=YI^N>"O
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MT,,1D7>#7[CU^+?_  3U_P"4E_\ P6W_ .RS?LA_^LX+7[24 %%%% !1110
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M)2?+VE9VT$_LW2:YHWYMK*2=GMHVE?R/\OG]@G]K+]I3X6_%W_@J[XA^#_\
MP2]\0_\ !1;XW_%;]I+X@:3\<O'_ (AT/5-?\,_#?X2_\)%\08]6\%;=#T75
M=6@\0>+;R2^G9%N[6);#0;)XK/4&L5C7W+]L[X[?LB?&[_@@%^S!X=_8S^!F
ML_LR?!R+_@I%X,^'G[2'P)UWQ9KGB^Y\+_$>W\/:IJFK-J?BS6YAJ>O:7XCL
MWT_6+;4;B+3)%N+:2UN=.L]2TZXK]V?VMO\ @WT_:J3]J'XT_M&?\$N_^"B7
MBS]B#3?VJM:?7OVB_A8J^*;?PYJ'B"^,\FK^(/"EUX/NE$SZC=7^HWR:5J>G
MVD^EWNH7HL?$L5K<+:P?1'A/_@W-_9IT?_@E1XR_X)I:_P#$GQCXCUGX@^.O
M^%W>*?VC)=-M(/%;_'Z)X3IGC>P\/27EQ"NBZ18P#0/[!O-6N+J_T:?46NM6
M&H:A)=)=&K%8>G.I2IM86&2.-"FG[:K5R[,:%>OAG"3=!X;$86G4E3YXN;S#
MEJ-2C.HEI4M+$5'&<TJM7-*SK5+2A!9A@ZN$IUGHJOUFC5JTXPY)<JPT94XI
M17,? G_!>/X<?#[X+?MA_P#!O]XQ^ W@SPIX0\<Z=^TUX=\#^'[[P;IFF:%J
M-[X#LM3^%B:?I#R:=! UWI5O'?70M_.69!_:%W&,_:I$?KOV>/#?AOXI_P#!
MV7^W?)\6M T7Q1>_#3]DOP;:?"NQ\46EGK,&DZ;=:'\*HKJ[T>QU&"6&)VM]
M=UC<\<4DL']JW;)(HN)37HW[#'_!O9^TE\.OVM/@?^T__P %$?V_/$'[9MO^
MR%:C3/V5OAZ;7Q1+IGAF.PMS:>'-4UZ\\77T[V/_  CZI;WUOH>D0:C]HU.S
MT^:[\13P:>D$OT%_P5,_X(@?%C]JW]J'PI^WM^P?^UWKO[%/[9&C>#(?AMXK
M\6VJZW_PCOCCPA#'<6-O+/?>&I1K.D:U;:9<RZ7<,MEJVFZU86VF1W%I9W.G
MPWM:<ZISH5%S5E+%9[7G&"7/AZ>;4*='#*:J>[*=*5/VE>-+2#JRY-4[8\OM
M(5X)JA+^SLFPE.<N;V>)J97CJV)Q'P<THJO2J^SHRJ+WW1BIZ-,_.'_@CWJ7
MQ0^"7_!1?_@XC\*?LD?!WPW\1I/!OQ>T36_A;\#)/&ME\+O FL^-IO'?C*VG
MT5?%4^GZKI'@^"+3[K5)O._LFX6W6QCTV.,*(_+_ $#_ ."?WCW]I7XB_P#!
M<K]L;7_VJOV?O"_[-?Q-C_X)[?L]V%O\/?"7Q>TWXVZ7<^&X/B]XM:P\0OXR
MTK0/#=I%=7UR]Y;R:-_9HELDM(Y'GF\\2-]E_P#!'O\ X)/Z)_P2W^$?Q)TK
M7OBOJWQ]_:#^/_CC_A9/Q\^-6MV<MC<^*O$B0RI;:9I<%]>:CJIT;3Y[[5+Y
MKO5-0N-1U34]5OKZ[CMO,CMXN#^$6?\ B(4_:_SC/_#M7]FL'C'3XR>-NOJ<
MD\XSC /"K@G:G2P.'YXUI83 8+ 5:RNW6K86G7E4Q#;L^:K[:,&Y)MJE'75"
MA>=7&U]81Q6-Q6,ITK)*C1JSH4Z="RT:3HRK:?:F_1?N.O0?0?RI:1>@^@_E
M2U!H%%%% !1110 4444 %%%% !1110 4A('7_/\ GWI::QP.>_'YYI.]G;>S
MMLM>F^F]K7TO:X &R/?GC(['UZ?YXS44LJ1J[NZQHBEV=V55554NSLY.U0JC
M<2QP%!8D &N#^*'Q2^'GP7\"^(OB9\4_&&@> O /A+3I=3\1>*_$NH0Z=I6F
MVL0 59)965Y[JY<I;65A:K->7]W+%:6=O/=2Q1/^:']D?'?_ (*32-<>+K'Q
M[^S)^P5>&*6Q\&>9?^#/VC_VL])R'2Y\;/"8-8^"/P-UF$(8_"]K/:?$GQ_I
M,[+KDOA;2+A+*Y^FX?X8KYM1K9MFF+I9%PO@*M.EC\^QL'5A/$J#K?V7E& I
M.GB,]SZO#EE0RS MTJ5.=/&9KCLGR^%3$ULJE51]V"]I5>D(;)/I*<K-1I]'
M-K?1*4G8Z7QO^U%\5_VI_&.O? S]@*YTVWT+0M0N_#WQC_;=US3HM;^%7PPO
MK:X%MK7A#X*Z7(RV7QI^,]KMG5I(6?X=^"KQ4F\1ZMJ%Z%T5_K7]FS]E3X4?
MLM>%-5T/X>66IZIXF\7:HWB7XH?%3QKJ<WBCXI_%[QE<1A+SQ;\1?&-Z&U#6
M=1E8,+*PC-KH6A6FS3- TO3--C2V7V'P/X#\&_#/PAX>\!?#OPMH?@KP3X3T
MRUT7PSX3\-:;::-H6A:79QA+>RT[3K***W@A3'F/M3?),SS3/)+)([=1<316
MT,L\\T=O;P(TT]Q-*D4,$4:[Y)99I"J1Q1H"\DCLJ*H)+UT9QQ10KX.?#?#&
M#JY+PRZL/;49SIULYXGQ.'FW3QW$N-H1A_:%6E.7M,%E&$A2R#*)2]CE^#QN
M.A4SG$Q"B^?VD_?Q7*K**?)!S=E"C)\R4Y;7BO:2NDWRN-,E&U"1C))QA<\<
M' ^;L<9).2">2<<\YXP\;^$?A_X>U'Q=XY\1Z+X2\+Z1;O=:MK_B+4K32M)T
MZ%/O-<WMY)%$A)^2- Q>1SM1&) /QUXE_;"O_'^MZC\/_P!C_P $'X]^+K&Y
MDTW7/B-<WLFB_L\_#^\1C%/)XC^(<4<S^*M1L6#>=X8\ 0:UJ;,/)N[G30WF
MK/X0_8ZC\2>(]'^)7[6'C:?]H[XC:5.NIZ#H>I:>FC?!#X=:CD.DG@'X5K/<
M:;)>VN0L'BGQ>_B'Q)A3-%=63R&%.>'#E#+J<,3Q3BI912G&%6AE-&G[?B3&
MQK14H\F7MQHY70JT^22Q>=5,.^24:E++,3%0E4^IADE/!4XXGB#%/+*<HPG2
MRZG%5\ZQ2G&,XM82[I9?1FI*2QN9U*$>67/3P5?W7/FY/V@/CG^TE<OIG[)7
M@S_A#OAS*QANOVH_C/H=_8^'KVWDRLEU\'OAA.^G^)?'EPBG-KX@\0KX=\(&
M1(]D^K1[XC^=/[7'[+GPD\ ?M7_\$U=1\;>)]3^,_P 1O&7[55_'\3OB)\5O
M$=MJFO:Q8Z'\-_$7B71M'_L>&2U\/^$O!VF>(]/T_5-(\,:1I.GZ='=0PB8W
MDS-*_P#0J+9$"B-3&J*JQA-J)&@  2-0,(N!@ +@8XXKY+^(G[!'[&_Q:\9Z
MS\1?B5^SQ\._&GCKQ#/!<ZUXHUS3KJ?5;^YM;6.R@G>9;R-4ECLX8K9)(%B8
MQ(%8XSG[3@?Q#RSA;/9XB&'S?(<D>39]E\:/#ZP.(SS'ULYR+.,FH_VKG&8X
MC+\1B:>%_M6.85L/@Y8+ NMA8T:6!YO9XBA]3PCQOEV0YM.JJ..RO*/[,S?
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M4X4I-.*K5:*D^5S4E*2C%RDU%*,I-M\J48J\FV]$DM6^BUVU7RQX9_X*1_L
M>,]<\.>&/"7[:/[-7B3Q)XNUC3= \+:'HGQC\$ZCJGB'7-9O(+#2=(TFQM-7
MEN;_ %'4KZYM[2RL[>-Y[FXFCAA21Y%![3]IG]K+X<_LRZ;H-KKMMK_COXI^
M/+F72OA'\"?AW9KK_P 5OBOX@4 )IWAKP^DB_9-(M)&23Q#XQUF73O#/AFP6
M:^U?4H(HA')_#7^S;_P7$\)>,O\ @HE\6-2^$'[$O[/_ (1'[8'B;]G[X._L
M_P"L>.[+3I;;X'>+O!NJ:QX+\!?$76M)\.^$-TZ:Y<^-4U_Q5I'A*?2;^'4-
M&T>SM-9NA$]['_;3^S)^QQX:^ VK:]\5O''B?5OCK^U)\0;&*V^*7[1?CFW@
M_P"$EU:U203Q>"_ >C0O+IGPR^%>D7 (T+P#X7\BRBCCAO-9N=9U8RWY_K/Q
MT^C?5^CCFW"R\2<HXGRR/$?"64\39+PMFF9<.8C-.(<5B<+@:^:T*V8\+*MA
MN'\@X;S3$U,AS;%UIXKB#-,92]GD>7T:52KFF#\/+LWAFM/$/ UL-4=+$>RJ
MU?98A1HPO.,7R3TJUI0@ZE-T[4+>]4;2Y9>+_#7]DSXF?'/QSX>_:*_X* 2^
M'_%/B_PYJ@\0?!7]EKPW>R:Q\"?V=)70-8:MK8N$AMOC-\:[:$K]N^(&O:>V
MA^'+T30> M)L(%35)_TQ10#N;!++UY/(SAC\Q /KQD]L=_ OC?\ M+?"/X"6
M^FV_C?Q#-/XM\1.T'@[X;^%=.N_%?Q+\:WI.$LO#'@G1DNM9U!FDPDMZUM#I
MMHK&2\O[:,,X^>X_"/[5O[4I\_XBZIJG[)OP.O,A/ASX'U>UN_V@O&NF.P8Q
M^-/B#8//I/PSL+Z$!+K0?!;:EXA$4DEO<>)+)]\0_!L<LZXJA@\WSVO@>'.&
MJ%'ZOD]"6'GA,GP."55U)8#A3(,/?&XZ]6*JXK$T*=6IB\;S8K.<_K8VK6JP
M^QP'#]5X:GC,76AEF73YG_:6/E6=?&M/]XL'A(1]OF,KZ*.%A2PT%RQJ8JC%
M6/3OBQ^V#X!\">*IOA5X T?7_CS\<O+C9/A'\+4M]4U+1EFRD-[X^\2S2IX6
M^'.C^8\9FOO%&HVET80\EEIU_(AB;S*W_9F^+G[0S0ZW^V9XVMO^$5DEM[VR
M_9A^#^JZIH_PPL@KB:.U^)?C.)=/\4_%:]5"B7M@W]@>#WE4B/1+R(B4_6?P
ME^"?PQ^!GAF/P?\ "GP5HO@S0A*;F]CTVWSJ.MZ@^?-U;Q#K-P\VJ^(-7N6)
MDNM4UF[O;V=G?=.<\^H[&SW'?IQD<@GU/H1CIC->;_;V$R?FH\*X2KA*\8\M
M3B3,70K9[6M=-X!0A5PG#Z<6W%X"&*S)4W&%3-X54^3N_MK#9;:GP[AIX>K=
MPEG>,5*IF\HZIU,#%PEALC35XM8*.(QLH/EECXN[6)X8\+^'/".AV'AKPKH.
MD^&O#FD6\=GI6@Z%I]KI.D:=:QJ EO9:?8Q06MM$N.4BC W98DEB3T.Q, ;1
M@  #H,#H,>U(BXR3U8@GTZ <#G'T_04^OEYSG4G.K4J3JU*DI3J5:DI3J5)S
M;E.4YSE*<Y2DVY2G*4I-\TI.3;/GI3J5)SJU9RG5J2E*I4G.52=24I-N<ZDO
M?G*5^9N3<FV^9MW;3:,8QQU_S_GVIIC0C!48YX^O7\Z?14679:[Z>=_SU]==
MQ?YI_-;/U71C-BJ %  !4 >VX&OQ/_X(Z_\ )0_^"O\ _P!I;?C_ /\ JLO@
MO7[9'I^*_P Q7XF_\$=CCXA?\%@"?^DMO[0'_JLO@O3;T;;T6K;VU:5WZMI>
MK2ZAN[[O77KKJ_OMJ?MG13#(@!8L, ;B?09QD^G/7T[T"1""0<XSV/8X/;UI
M72T>FJ7SE?E7J[.W>PFTM]-]_+5_=U'T4W>N<9Y].<T;UXR<9&>011==UT7S
M=TOO:=NX_P"OU_(=13/,3KGMGH>._(QD<<\CT]1D61')"G)'_P!?GZ'!(]1R
M.,&BZ[K=+?J[M+U:B[>C[!_DG\F[)^C>E^X^BF&1 <$X.0,8/?IVIP.0".AY
MHNNZWM\^WXH#\6_^">__ "DN_P""V_J?C/\ LA#OW_9Q3TYQZU][_M9?MF?
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M7MU2XU_6--AMH?#FO>))X_!'@FSM$L[K3M(UG5-0UK_A)/%FL7&D:;8S:@D
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M6SW4D^MW).,K]^:'NOHU*5[]6(A#EF.3@CG)QG!)4\#DCD   C@#)J6C_/\
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M.R3B]>9)\T6NG+:WWWLT?N*O0?0?RI:1>@^@_E2T%A1D>M-9@H)/UZ$].?\
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M74*>&IUCZW%YG#ZK#*<IPZRS)Z,HR>'@[XO'5Z=^3&9IC(\L\57BVY4J,9+
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M9^PO^S!_P2>_;F_X(9_&K]B#X8VOP=\6>)?V@M(^%'Q$B\*WNLW$7Q*T&5O
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MV)S+I^JZSXUU":PE^.?Q#TYTFTRY\3ZC<7%L'NKNS\-^$M'=[>9OG[_@C?\
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MB@ HHHH _%O_ ()Z_P#*2_\ X+;_ /99OV0__6<%K]I*_%S_ ()[#'_!2_\
MX+;]O^+R_LA'\_V;T/ZYS7[1T %%%% !1110 4444 %%%% !1110 4444 %1
MMP<XXXQCN<Y_#N,_F:DJ-AU)Z8XZGOW[=R/IT'%1/56?PM-.V]W;E2\[B=[:
M6OTN?GE^V)_P4/\ A[^QA\:_V-O@WX^^'_COQ%)^V9\5-1^$7A?QQX>.C6WA
M#P'XFM8=+FL'\::CKM]IUO%;ZL^J>7:Q6MQ)>F"SNYXK:?RO+K]"X_FRP7 ;
M!4X&.IZ<]\DC';!)SQ7X3_\ !>C]BK]F;]K/]FCP?XE_:_\ VT/&7[&7P&^
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M,\^GV4SL<L\MK!(S'U9F0ECZ9)QVJS'!#"BQ111Q1HNU(XT5$1?[JJH 4>P
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M%$$42EPW@G_#JO\ :E_Z33_\%&O^^OV>/_G-5^U%% 'XK_\ #JO]J7_I-/\
M\%&O^^OV>/\ YS5'_#JO]J7_ *33_P#!1H_\"_9X_I\&J_:BB@#\[?V$O^"?
MMK^Q1XC_ &BO'.I_M$_&K]IGXD?M-^*? _BSXC_$3XW_ /"&_P#"0RWOP]\+
M3>#O#]I9+X)\->%M,CLXM%DC@9'L&<&VC(?YCG]$J** "BBB@ HHHH ****
M"BBB@ HHHH **** "FMNXV^^?T_S^=.J)B>1GJ#VZ8)QCJ,Y&/I@FHGK%IZ)
MIIR_E5KMWW3MMIOV$]&GVOIWTV_ _E5_X.8M+T3P]K?_  3*^._[0GP^\5_%
M;]@'X(_M3W^M?M>>"_#FGWNN646G:SHMC:>"O$7BS0K.> :IH-A<VVKP2Q7,
MR0W'GS:*LB3ZY&DOY7_\%9_VP?\ @CW^W7\*_P!GKX ?\$IO ?A;QY^WWK?Q
M\^#:_L_^(O@)^S]XC^$NN_"@:1XFTZ\UG4?$'B"[\$^#VN-'@TR-HY+&T_MB
MVLYX!KMS=:?;Z.;QOZ._^"S/_!1GXB_L::+^SM\ _@+^RCI/[8W[0W[:?C+Q
M-\./AY\(/%TL2> ]0T_PUI-KJGB=_$UK<Q-#K226]];M#I<\MG8?9(-1O]4O
M8+>V59?R"^"GQ%_X+@?!/QM9^(?A7_P;P_L,?!G5]7U&SL/$'C/X<7_P_P##
M/B"+2=1O(8]7E.JZ-X[%\+=+5I)KB"T9XY1&JBVN758BL&U*<8RCST:6:O$>
MUC-P<,5AZV#E*@Y-:QC4A3I^T2:HT9UXZJJT.M>,7623J3R^5'V4]8^QJ4\6
MHUHP2YFY*<W*DVO;3IT)VO3L_P"R/PM;ZK:^'-"MM=N1>ZW;Z/I=OK-XI!6[
MU:WL+:#4KE"%4%9KR.>0$*H(;( ! &]5#2WNI-.L9;V%;>]EM+:2\MT;>EO=
M/!&UQ KY.Y892\8.>0N><Y-^MIMN<VW%MSFWRI*.LYNT4M.57M&VG*E;2QG1
M5J5)+FLJ5-+GOSV5."7-?7F:2<KZW;ND[I%%%%2:!1110 4444 0.G+>^>>P
M)QQ]>,C^F:_B0^.7[+GPI_X+!?\ !RA^T1^S;^V"GBKQE^SM^QW^RSX;;P5\
M+M+\6^)O"6G3^(-<L_!%]?:JM_X=U'3=3LI+O5O&MS?:C-I]U;/JHTG1K6ZE
MDMK)8C_;DP /L3\W..3T)Y]/Y$9K^0O_ (*3?LM?\%-OV(_^"J6J_P#!6O\
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MZ+'\6/\ Q%3]J#_YTE'_ !$4_P#!*C_HL?Q8_P#$5/VH/_G25^V?]E:9_P!
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M^%M<TW1O%NK:EX7U.UU36/A[\/[?SXH_"TNGFRU'7?MMQJ:Z[- D%M:?</\
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M\\_3M7RU^U#^V/\ L\?L<Z%X'\0?M#?$K2O <7Q-^('A_P"%_P ,]&ECGO\
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ME/ OAB3Q!XRF33;*[NMVB01Q6\LL\<9_8:OS(^/G[#_C']HW_@H+^RE^T?\
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4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #N G # 2(  A$! Q$!_\0
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M,OXI6AK@Y_V&OVSM-TWP!H%[X!\*^,KOX2ZC\'_VB4\5:/XWT?PM8>/OB3X
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M)Z1BWH5"$ZCY:<)3E:4N6*<GRQ5Y2:6T8K64G916K:6I]'T5^=_[.G_!5?\
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MKXXZ'\ O'/@'4/#Z6_C/1O&/B"Z:QL;_ /LK[47N/#JW2O!/JL+-'#*A5E)
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MN;DYK*+5E+V=.Z6CY(NUTV[7NMRCHVY-M*S;DFI7?5OFE=N[=W=VT/C+2/V
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M.T5$UY>2_N**@HV7*HQ@H122T2C",8Q2V25FGJ_E#P-^Q9^SK\-_B'IOQ/\
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M^R__ ,I>O^"B_P#V27]G#_TAU6OV,KG/2"BBB@ HHHH **** "BBB@ HHHH
M^<OCC^UQ^S;^S5>:'8?'CXP>#_A?<^)+>YNM#3Q7?26":E#:2+%.UO+Y,D1*
MRNL:HSJ\CD+&KD@'U?X=_$?P1\6?!VB?$#X=>(K#Q9X-\1VYN]$\0:6TCV&I
M6PD:(S6[2QQN4\Q&7+(IRI[<U^;_ /P6#\+^&M;_ &3K>]UGPUH.M7EK\:O@
M7!:W.JZ/I^HW%O!<?$O0EN(8)KJWEEBBG5F2:.-E25697!#5^GV@:5IFBZ-I
MNFZ/IMAI.G6MI EMI^F6=O8V5LIC4E+>UM8XH(4R22L<:C))/.2?T7.L@X8P
M?AGP7Q/@5Q ^)L^S_BS*<UAB\7D\\AIX?AK^QG3JY=AL/@J>;4ZV+6>X?G6,
MQ=6E2^IUN7G^L05#DIU:\L9B*4O9>QITZ,X<L:BJ\U7VB<9MR<&H^R;3BDWS
M6VCKL4445^='6%%%% !1110 4444 %%%% !1110 5\P_MA_%SX6_!#X >-?'
MWQ@^'FJ?%KP=:MH^CGX7Z%X-L_'VN^/]>\1ZM::)X=\*Z)X4U%&L=6U/5]6O
M;:WM8[HQP1.3-)+&J%A]/5\"?\%.;7P9?_L7_%?3?&NM_&+0[;4G\*6'AM_V
M?;[3M+^->J^/+CQ7HZ>!O#_PUU358+BPTSQ1KGB;^SM.M-1N52*QBFGN7FC2
M)FK*M_#=HN6L%RQC&4I)U:2:A"49QE4<925-.$KU'!)-V-*23J14MO>;=W%*
MU.K).4DXN,$XQ<VI)JFJCNMUZ9^QMXX\/?$/X):7X@\,?LS>./V2-)&M:UID
M/P:^(?@+0?AOXGTMM/N%B;5IO#'AV:?38++5F?S;*Y24O<HI>0#BOJY>@_/\
M^:_-S_@E;?+<?LJVFEW_ (J_:=\1>,O#'Q!\<^&/B1I?[8'BK2_&GQW\!^/=
M,OX!K7@7Q+XDT1$T?4]/T>.6TNM!N]-::RN=*U&WN(9F$NU+W[?'[27[7G[.
M%O\ ";5?V:?V<OAO\=]!\7^-=%\$^.KKQQ\75^&VI>&M1\5>(=&\/>%H?#&D
M_P!D:G-XNO=1N=2NIY[2W>W>VM[&24DH&*]-:/+B(TTG>K4H4H.\I1YJT**@
MY3DYVIRE)6J.3IJ+BTXT^7EY:+;I3G*RY(XBI--1C*U*=:4THI1O44:<ER65
M23C[S<VV_P!%J_!7]AAW\$_![]D;XPQE8=/@_:?_ &MO@7XOF*X0^'_C3\<O
M',?AV2YE#*%2T^)/A;P=;VSS%HX3K%XB*)+K=7IW[*O_  5ET3XW_'/]M/PG
M\5)/V?O@U\$?V2_&H^'W_"Q]3^.>F+XJOO$,'B!_#%Q/XX\(:W9:1:>#-#U#
M5K>[MO#VJMK%]'J5Q!]E=;>Y=8SA?L/>$K;XY_\ !*7Q%I_@G5K74I_$'CO]
MI'QC\-_$>BSQ7UM<:[HG[0/COQAX&US1+VW<Q3I/JNFZ;/8WMM*5>.5989,$
M-4--1I3^S6HTZ]-W3YJ552=.>E[*<8N4==8N+TO9:\RYZL-5*C5E1J)IKEJ0
M4'*.J3?+SI-V5I*4?LMO]N:*\T^#7Q#L_BS\*?A[\2;(!(O&?A/1=<G@"E#9
MZA=6<?\ :NGNA)*2Z;JBWEA,A)VRVSKDXS7I=(85YAX@^$_AG5M2D\2:1]H\
M'^,C$43Q5X9<:?>S'AT35K6/%CK=JTL=N]Q;ZC!*;A+:&!IEA4+7I]% 'C9\
M;^(O 0$'Q*L6O-&0;8_'GAZRN+C3TC19-K>(=(@6:]TJ9Q'&);JWCGLI;JY$
M<2Q1(67U32]6TS6[&#4](U"RU33KI/,MK[3[J&\M)TR1NBN(&>)P"""58X((
M.""*OLJNK(ZJR,"K*P#*RD8*LIR""."""".#7DUW\+;?2-2NO$/PZO?^$,UF
M[<3ZAIUNC2>%-=F7RCG5=#5E@@GD2WAMCJ.G+!=Q6P9$#%S0!\V?LS^ / OA
MS]J+]O3Q-X>\&^&-"\1^(/BG\+SKVO:3HFGV&KZUY_P2\":C-_:>H6\"7-Z)
MM1N+F_E\^1Q)>7$MRP,SLY^[:_FA_P"":7_!3#XH_%__ (*O_P#!5?\ 9F^-
M?PIT_P"%O@OX<^,_#-[X4\:&TUFULQKO@RPT+X80:)XAUW48ETO[1XY\/Z7:
M^,O#)DDM!+;V]Y;VOVDW%L9/Z7$=)%5XW5T8!E=&#*RGHRL"0P.>H)'O0 ZB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OYY?^"R/QK_:I^!GQ)\%:[\"O OQU\=:+XI^#'Q"\
M)6-O\'-/34UT?XD7[K_PCFJZO;2RQHJP -MF4,\:G< <YK^AJOP"_P""P?PL
M_;I\2_$7X0>-/V5?"/B_XC:5;>$O%G@C3M)\*^-D\'V7PU^(WBH?8;#XM^+8
M)"J:]HOAW3))9%LW+>1+$' SBN#&*JZ^5NDYJ2S&"?+R^RDIX3'4E3Q,IRA3
MIT*TYTZ3K59PHX><HUZU2G2I3D=V!<%];E4=&U+"?6(JMSM.IA<;EF*AR0A&
M4ZSC["4ZN&C&4L5A:>)PT(3G7C!Y'_!*?]H/XZ_M-?M*^/?''C7P)\;_  )X
M%\+?L^_"_P !ZE:_%>WBLK74?BOHMN(?&>H:=9VMU<0"XGN=SS2N(Y7!!*]:
M_H4^M?SH?\$;OV>/B+\)/C5\9M4T#4?%-U\#=+\(>&O!'BKQ7K_Q%E\>:=\9
M/V@M,/VCXA^//#MO++)_8-E;:C//I\ENFU9&3;CY0*_HOKW\?[)K NE[.T\$
MJT_9W475Q.-S+%5*D4]50Q#Q"Q. 349++*^6N=.E*?LUXV'J5:M?,)U8SC;%
M4J--2A3@E1P^6Y;0I4^6G*</;T(P]ACVIS_X4Z6.CSS]E*04445YYUA1110!
M^.?[+_\ RE[_ ."B_P#V23]G#G_MQU7CT_7/L*_8ROQS_9?_ .4O7_!1?T_X
M5+^SC_Z1:IC^M?L90 4444 %%%% !1110 4444 %(3CK_G_ZW3\ZS-5UO1]"
MMQ=ZWJNFZ/:-(D*W6JW]KI]LTTG^KB$]U+%&97YV1AM['HIKR3XJ_'SX??"[
MX>:SX_O-<TW7K:QN8M'TK3= OK;5KW7O%-\PATCPUI\5C+.TNIW]R\:K ,,D
M1:1AM4FN_ 95F>:8C"X7+L!C,76QN*I8/"JCAJTZ=;$UIJ$*,:_L?J\9<S;E
MSXB"IQA4G4<(4ZDH1*I""DYSC%1BY2NU=12NW:][?+>RZG\VO_!S]\4OVOM"
M^''P%^'G[-EU<_\ "):YXPTW7?B!;>&8(KOQ8/$>G:Y9#X>F='63[)H\NN>4
M87^43WZQ1L60';^\O_!//4?VFM5_8Z^!U]^V!90Z?^T)/X2MG\?VT<<45P+D
M.XL9+^&#,$>IRZ>+:2^2+]VMPS@=\?FU^W'X)OO!'[)'B#XJ?&?Q-IB?&GXP
M?'/X"ZUJ=GJ^IV-H/"'A:U^).C/HW@G0(;F:-HK#1;1RVI2PJ#<79E>Y/[L"
MOWDT6_L=3TK3[[3;ZUU&RN+2!H;VQN(;RUG C0%XKFW>2&12<@LCL,YP00:_
MJGQ4XPRV/T9/!GPRR[@[A)QX:X]\2:^-\2LOR>O1S[B+,Z%+AUYAAX9I*$:6
M)RAXC.)8+VKJU99G#AS+L92HX6C"$9^)@L/)YSF&,GB*]ZV%P:C@Y5%[*C!N
MMRODO=3<:?,U:T/:RBW=FK1117\CGO!1110 4444 %%%% !1110 4444 %?G
M#_P4UO/$6I_L^:W\/-&_9N^-7[0,7C&SN+N"?X$>,O"/@;Q]X"\6^%;[2=:\
M#ZYX<U_Q;>6UK9^*6\0I;3^&Y8DN$-Y9/!=0M#<;'_1ZORU_X*X_!;X6_&?]
MF7P_8?%3Q!\:-!T_0?C;\'[KPZ/@A\1[SX8^(]4\4Z[XWTCPOI-AJGB*"XM[
M6+0T?5VOKB6_8K92V<5U:%;Q(,Q.$ING"-[SKT*;Y9<LOWE:E34HRT:G"4X5
M(<KC)SA%*<&^973:BY2NERTZTDVKJ\*-6=FKVY9*$X3O>*A.;E&2]U]5_P $
ML?#VL>&_V5[6V\6?"WXY?"GX@:C\0_'>M_$;3_VD_&GA7Q]\:_%GC/5M0AN]
M4\=^.?$'@R5]!-YXAC>U^PZ=:QVHTW3;2SMEM8HDB+?0'[0'P4\5_%[QW^S'
MK&E^(M'TGPA\&?C;'\7/&^BZA:75Q?>*1HW@OQ1H7A6PTF2%A;VTVG>(/$,6
ML3R7BNFRQ00A9]C#PS_@FKX2^%OP[^#_ ,4/AO\ ##3?B+9+\._VC_C#X/\
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MGOHH8XU$,L@W="^+?P_\0-!#:^(+>QOKG[1Y>EZ[%<:#JG^C'][NL=6BM9E
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M]=Z7-';:I:V=[;75QIMQ-"MS%;ZA#!(\EE-+;ND\<5RL4DD+K(JE&!/YQ_\
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MZGINH6$@N;?2+'3+G4Y(;ZY:-5_9<_9K^*'P\_;0_9T\$>*M,T6TTFU^%_Q
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MK:5'J%I;G6-2L/#UCIVEQ:7<ZG!J4/AV>*TBDU#1+:QU"4;KGG]4!_CT^O\
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M0]:L),7&EZ]HE]'/INLZ7=*ES87]M/;RKE 2 >AT444 %%%% !1110 4444
M%%%% !1110 4444 )@>@_+MV_I1@<^O]?7'3-+12M_7]7 3'3'&#Z#\<>F:3
M:/0$_ECG(QC/(X'T':G44606&A1SG!YR/;V^F<^WM6-;^&_#]IKFH^)K71-)
MMO$6L6=AI^K:[!86L6L:E8:6UP^G6-]J*1"[NK.P:ZN6L[::5X;=IYFB1#(Q
M.W119?@UVTDK-:=&M&NJWN*R>^NV^NSNG\GJNSU5FV'2BBBF,**** "BBB@
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MMW=7$%G<R:A>74Z:DVH0PK.88PIM6)0Y/-?L8O  /^<_I_.OXKO@-\0?&O\
MP23^ GB_XX?##P1XH\3:UX_\4Z7X0\>>&?C9X4U7P/#H,-O?WQ\-7_AVXB"M
MK)U.P$<][&A8V;N%?&T"OW=_X)4_\%&?$G[=_P ,_B'XS^)VA>"_A]JO@_Q?
M:^'[#3M%U2X,-[97&G17@NYCJ;HZR>:QA4(0IVY ZU_//A_QS2Q%#)^%^(L7
M6?&-;!8C'5X3I5YT:N&4ZM:E4>.J*G2=1X9)3I\L7"I"5+E4DT?UC]+WZ*F.
MR?-/$?QV\&.'<MA]&W+>)\GX6RO$X7,,LH9E@<[J8; 9?F&!I\+X-XW'PP<,
MZJS>'Q<:^)I5L'6I8Z5>=.JK?KKD?3Z\=.#].>.:X_7?B'X"\+W?V#Q+XT\*
M^'[\P"Y%EK/B#2M,NS;LVU9UM[VZ@E:$MP) FPG@$U^<W_!0C]M?Q7^RQI/A
M#7OAYXX^ 176[NRL;GPU\1-=O8M=U-=0U6'3FUK0SI,CQ2:5HB2M=:JTOS[$
M(C((-?@A_P %3_\ @H!HL'Q0^ ]O=_#?]GKXYZ[H.@>'/'_B3X@^'+[5[K1/
M$4R37L3>"HY8Y5D?PXJNLD\4Y:5KF,'[H->QQ7XBY/PQ1S#VE2G+$Y=4R^-:
MG651TI1S"HX4G3E@JV)Q,Y**J5&OJJA%47&K*DZM%U/S;Z/WT,/$GQSS/@_Z
MKA,50R#C/"<85LMQN6RPL,QH5N#\$L1C5C:7$^69/DU"A/$UL#@H26>5ZU>I
MF$*F"I8F.!S.&$_LLM;^SU&T@O;"X@O;.[B6:UNK6:.XMKB&0;HYH)XF>*6-
MUPR.C%6!R&K\??VW/%M_HG[17P+T/P[^V;XG^$UE\1_' \)>// ^DZMX9BM/
M#ND6.B76H0ZI$FHP/<Z=<ZC?1Q023W+F*0/M09Z^]?L[?%_]HKXS_ +X1^+/
M /PC\#_"6PUOPMH.I+;:]JDFH:+%H]Q A">'+73BL\<*1'%I'=$E4 60U^ W
M_!2;_@EA^TO\5_VQ/!WCN3XC^&;T?'_QA:^$_#UU,+NT_L/4-(T>;4YFN+:W
M8".TCM[>18&CQ,YVES7!QOG^95.&L'C,AR+,<YEB<7E%5NG/&Y5&&'KU,-55
M2%18C"XJHJSG'".$HJ"CBXSJ*6DE]7]%CPBX+POC?Q+PYXM>+'!_AM2R3AWQ
M%P-.GC<)PUQYB,3FN483/<%/"8S!5,HS_A_#5\MI8*OQ'3Q.'Q-2NZO#LZ.$
M=-5)4JO]>GA^)+?1-&@CU677$BTVTB36IY(IIM66.WC5=1EEA ADDO /M#O%
MB-S)N3Y< ;.1G'Z]O0_EW]*^)_A]X@^//P.\'>"O!GQ&\!67CK0_#/A?1]%N
M_&?P\N)9)+&WT33+>R:>^T6]/VR\GF:#?BSR3U.6)S^'?A/_ (+X?%GQ!^V-
MIGP"O_A+X'TGX?7WQ@D\ S^(KVXURU\1V>@C4Y;$:C<V,H,46I)&GF26Y&U'
M.W (('OYKQSD/#\,IIYW5Q678C-J]'!8?#U,'B:DX8J<<.G3J37-!4H3KQA]
M8]M5INS<II\UOR/@+Z*OBWXPXGQ#Q?A?A>'N,<GX!RK,N*<XSK!\3Y'AL-B,
MAH8K.I0Q>#P\W#$SQ^)P^5UL3')O[.P6*A[6G3I4W"="_P#4T)%/_P"L9S[#
M.3CJ?2E5@PR#G\OZ9K^6'_@N;^W!??#?Q9\'_#?PPF\66MWJ6CWVK7'BC1/&
M'B/P<AL[#6;<76FQ6>GM';:I;ZG;E[>6^E0RVJ,?((<KN_:__@FG\6+GXU_L
M7?!;XC7.F3:3-KVBWA^P7&N7WB2>(6NH7$&9]9U%WO;Z5]A<O.S,N?+R0HHR
MOC?+,VXLSCA/#)RQ>386EBJM=2<J56-1TE*,%[)).DZU-2?M9IN2Y>;WG%\=
M_1=XY\/_ */WAO\ 2$SNM3I\.^).>8S(\ORFIAH4<=@*V&68RHUL14_M&O.I
M#&QRO%RHP^HX>I2C1D\2J3E0C6^\:***^T/YG"BBB@ HHHH *^!/^"D^N_#R
M#]E+XE>$_'>@>#/&MQXMTN&U\.>!O&'QFT[X#6VJZG9ZIIT\7B!?B5>:CIMY
MX7MO!=PUKXCOM:TJ22_LXK-5MXY)IHHY/ONOSM_X*>?#_P"$OB7]E+XC>,?B
MA%^SY8/X T.?4-#\5?M*?#\_$;X9Z4E_?:;#JN@ZUH%M_P 3BXM?&D$$/AYT
MT,2:L;BZM)+*WN;B&*%L<1_"E?2-X.;5^914Z;;CRWES)I6<4YK5TTZJHQEM
M0O[6%E>5WRIVLY<LK*5].5ZJ7-[MG[_[MU6M7_@FEI7CS0_V4/!FE?$C]I[P
MC^UKXEL]7\0Q'XH>"/$%EXPT#2M+-X'TKX=0>-+2>:X\93> [(Q:)-XIU<0Z
MSK1B%WJ$$4C@5RG_  4,_;F^(_[&>G_#:]^&_P"SMKGQY36[O7?%'Q/OK;7(
M_"^A_#KX1>"Y=&B\5Z\-8NK:XM-6\;W\^OV%EX'\%*\-WXGOH[NVMW#15;_X
M)5ZGH>M_L=>"-8\._LEZ1^Q?I>HZYXHN(?A!X<T1?#GA?5,Z@$7XD^%M&DM-
M/U.Q\.>/HTCUK1X-?L;374LGB34X5G7+)^WY\#_VTOC9<_ ZW_93\>_L\>%O
M#W@?QS)XR^)WAS]H'PEXL\7Z-XRETPVC^$H['3O#5Q:QL_AZ\2[U>&+4Y)+-
MM473KF2"1K*(IUXBZQ5/FNE]8PWM+*/)[.U%S]JX[4G%+VTE^_:D^?EKRQ#C
MR8=)T*FL>;V&*5-MRTJWK*FZ:M9R4_X4$_8)I.#="%%2\9_8P_X*EV_[4W[0
M?[9'@#Q#I?P9^&OP?_9@\8+X,TOQI??&/3?^$_U34UUA]&:?Q[X%U6UTV'P5
MI]Y=17$&E7O]JWD5W>V[V1$<^$/IW_!(F\M-1_8JT#4-/N[:_P!/O_C'^TG>
M6-_93Q75G>V=Q\??B)+;75I=0,\-Q;3Q,LD,T3O'(C!D8@@UX-\&/^"45Y>?
M&_XZ>./VR-6^!WQ^^&'C'PSJ'@'X;_#GPW\(K#P/#?\ A7Q#\2I/C#K&K_&R
M.Q\JP\<>-M*\8RII_AS6HXPT6BVB7-TSZE=7+GVK_@CIX>T/PC^PMX.\*>&-
M+M-#\->&?BK^T1H/A_1-/C,5AH^BZ5\=OB#9:;IEE$2QBM+*TABMX(RS;(T5
M<G%3+D]GAN72?U:G[=.3D_;*552;DU&\IQ4)N/*N2\87E\12YO:XB[;I^W;H
MWCR_NO9T;)1ULE/G5[OF;G*T4E%?J+1114%A7P'\3_AOX]_9N\?^(OVD/V>?
M#]]XN\)>++D:M^T7^SUI&//\6200[+GXM_"BR8K!:_%2RLX8HM=\/QM;6'Q
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M9=8MEO)+FRO&CD,-VL<Q5RN" <M\"?V]/V4?VA_ACHGQ9^'WQJ\ R^%M?O\
MQ'IMG_:OBG0]-U&*[\+^(=3\-:G%=65Q?+-"?MVES30%U FM)K:=,I*IKZ>T
MSQ?X7UWP^?%>B>(=(U?PR;6ZNQKVEZA:W^DM;62R->3I?VTDML\=L(91.RR$
M1E'#;2IK\X?V$O\ @D7^R#^P)\%KGX&?#OPS>?$GPI+XOUCQC:ZC\9;;P]XS
M\1Z;>Z[%9I?Z?8ZK_8=BT6E//:?;$M&C;9=7-S+O/FX'V/\ %;X12ZU\ OB%
M\&?A#_PCWPWF\6^#-?\ !^B7%IIWV/1O#T/BB"73]6OK>QTI86BNEL+W4)K1
MK=58:@UO,QP&:HGS<DN2W/RM0OMS--1NWHHJ3BY-Z*,9%047."G+E@Y14Y=5
M!R7,UW:CS6763BFTG<_.F?\ X**?'[QE^ROXN_:'^$GP3^&UMKWP[^+%]X.\
M8_#[XJ>-/$NAW#>!M>UO0+;X5>,M%OM$T*_=KGQGX:\7>'/%-U8WT$-O:6EQ
M<V]M<3RQ!CT.G?\ !27Q9H/BW]HWX0_%+X6>'=&^,7[/ES\#3';>&_$VHW?@
MGXD:1\4M1\'Z/XJU7PEJFIZ;::DO_"O-4\7VEMJ5G=6OVF6.:RN'$4-PS)7T
M3_@F%!\*_!GQT^%WP5\?:A:?#KXR^#O@3;FQ^)'B+Q7XZUO2?B!\'/$^G/<:
MXNK:O>7EQ%H6N>"=+L-&CTFVE6*RU#3[1XHHK3*(_P#:-_X)N^*?C;XA\6>-
MM!^)>D>#?&=[^TY\-?C-X:U>+3[V59OAQH'AWP1X>^(?PJ\5*F&O+#Q@OA"'
M4[5[?=%9:I9Z5=?*\<Y/3'ZNJW*Y2="7LTVU^\IOV6'HRDFU=I5J5;$RA9^T
MAB:D8N')3A'GO6E*:M&*]Z=.5O=:=7$5E2D[MK]S.EA5*5W3G2I.?/S59N'X
M/_\ !3_5_BCH?[ \\GP=31_$G[7_ ,1/B/X)\<Z+_P )$US%\'[3P'I/B?4+
M753<&U1];?Q%)I&DI80.EK^YU.:4,PM0']G_ &F?V\&^!7Q4U+X3^'OAX_C/
M5]/^#'B#X@RZQ<:K_9>B6WCE_%'@;PMX#^'MW,+>>19]??QK#K>K7<0=]+T:
M*"5(II;R-5^;O!?_  2O\1:%J7PYEUOXH:?=Z)X6U#X83ZIIGAY-<\/ZC80>
M'/ACXX\%?$:Y\'>(+">'4M(U7QKK?B'0-:M;U)+>73HM'E E$\J.)OB)_P $
MIO$]SXNN?$OPT_:?^*ESH<'A3QY_8GP[^+NKV_C?0+3QQJ^J?#K6O!\MYX@?
M1SXSU+PWI]_X#A&J)J6N:AJD4?V$6$VR*:!]7]256DY.:I.>,=51E)OE_=PH
M0C9<Z<8TZM6G**E*I4JPC+EC%IU-U8JJJ,83FH4XT77;C!U'6JR<ZG+IRN,Z
M-*HK14:=*=11<Y&SH7_!23XI2^,H_"?B+X.^"K-/A%XY\/\ PT_:OO\ 2O&N
MIW8\(>*_&OQ'OOAMX2G^%<%QI,+^*=%>]LDU[59-<_LNZ@TB]@BMXI+M9%'H
M'QD_;E^*_P *_C=\4])7P%\)[OX"?!'Q)\'/#GQ UO4_'^J:=\8-0;XL66E7
M#ZQX/\(?V6^B7^G>&9-9M9;V&YU*.ZN[*UU&:W4&W('D&B_\$\OCX?'%_P"*
M_$?C/X01VGQ^^('A;XH?M4Z?HUMXM:73/$?@+XGZA\1_#.F?!J>\B4W>F7D=
MW;>'=5G\6?9;F*"T^WVL3SRM$/JB_P#V"OA1XS^/G[07QU^)GA/P;XK\2?%7
M3?#&A^!?$4NF3R^+/ .C:7\-I? NK1PW%S(UA]JFN+J[U'3+B"W:6V,N\2I,
M%8<]:5-/"RI)2<8UYXBFF^6I5AAL.U25^6].>)=6%+EG&T92FI-4HING=^VC
M-R2F\/"D[6E"E+$5>:HVKN->-"SQ'NSBE"A"$&ZU24<J+_@IS^S?=/IMC8V/
MQ8U#Q!K>OP:?H?A"R^&NMS>+M=\(7-O/>P?%S1]!!%[J7PLETRUN=4B\26:R
MS264$LBZ<77RSS4?[>/C;Q%^QYXN_:-\)?"1=%\8Z;\<=6^"OAGP=\4[O4/"
M&@WUS#\;;?X1Z5XIU;5X8;Z^M?#T\5U'K%U<0VQD2:&[L%C4P[S\S^)/^";/
M[1?BG0;276_&?P,U/QYHFA?#SX1>"O%L%EX\T#6OAS\.?AA::U8^%_BSX'\2
MZ--!K&C_ !H_XG<MYJVB -X,U1+:+2KF<V<TK'T[5/\ @F1<>+_@_J/PY\?>
M,$\3ZG;?$R[O-.:[\2>,_P#A _&'PKU3XTZ/\7=;M_B'\/8+JUT"[^(&IE-;
MT=M9M+:1+59;.2VNXD:=*F2IM2Y9RU=))R?*U%XK#2E)146U-X;VD*JNU"5:
MJZ*FL*E*KR5FTFX^UG)*THW6%KJ--.3BJD%BN65*=H2J0I4O:JG]8]WH_A/_
M ,%']5N_CK_PSO\ '/P/X8\->,].U"#PGJGBKX8^(-4\9^!-7\<:[K^EZ?X4
ML/"]W>Z?97SZ3=Z?J>_6[O48H9]#U2VDLKB(JZN/0]=_X*8_L^/X!O?%OA+5
M-:NKV/XB3?#.SL-<\*ZY:J=?LK1]6OKV]@LHIKZ/PXFDP3S0:Y"CVKW+VL+%
M?.R///C3_P $\M0'CGX9^-/V6E^%?PJLO@WX>T23P7X#U;1M6A\,:CXPTGXG
M0^.;B76Y]&$M\FEZG8/=VL]Y$;G4UOQ:N-ULK*/GO1/^"3GQ:@6PN==^,7@B
M^NG_ &?QX'UK3;+0]8MM'F^-%W\5%\2:K\1; ,QGATN?X;10^#(+.3-ZMXKW
M+OY#8KH;PT_8V3BU3BJJUBI58U7)RTYDH5:,'3DHO]U*I3E::YA5$E1FX2DZ
MS3E"-W.,4Z4X^S;Y8R<U4G3JQ=K-4ZE-R2Y92^E?%W_!5#X2:3\0?AOX;\/^
M#OB3JW@/Q+XX\>^'?%GQ8N_ VMV'@;2?#7@3P=XE\07/COPUKLH6S\2^&9];
M\,ZAX<:]M"TJ75M=%;4C[.9OMOX!_M ^"/VB?"FH>*/!MEXJT*;0]9?0/$GA
M/QWX>N_"GC+PUJOV&RU:TMM<T&]+S6@U/1=3TS6],F$DD5WIFH6LZ,&9T3\P
M]:_X)T?M#>(/AUX.^"NI_%'X5GX9?"3Q7XQM/AA/;:)XEB\53^!?'6G>,1J>
MM^+YR[6,_C+1[WQ%I<.FZ/I\2Z%=VFE7$]Y>">^,<7WY^RK\&/B7\,K/XE>+
M_C1KOA'6OBK\7/%VE>(_%$7@"#5;?P7I%KX8\'Z#X&T#3]$&MXU29YM*\/Q:
MGJ4]U'&?[0U">W@4VMO"[8Q5+DJ7G*3YIRHMKDE*#>&=/F@DXJ2;Q,)4E.7L
MU&-3VD^:,8S.4N>GR1M%VC45[V<'74I7O?WH^PFIM)3G*5.,(QASS^LJ***@
MT"BBB@ HHHH **** "OQ8_X*R? 3Q_\ M"O\-?!GPT_8C\$?M*>+%6_GT[XJ
M>//B!J/P[TSX03-($CO;;6=%N(-6ENV;%S';PK)$S( RD'!_:>OS\_X*<:3X
MYU#]D+XAWOPY^.N@?LY>*?#,^D>*K/XI^*9KA-!T>/0KV.]N+748;5TN;R#4
MHXS:_8H-TMR7V(C;L5P9A[*-&G6KJHZ6'Q.'K5%2E&%3D56-.4HU&XSINE&O
M*OS4*E'$25%TZ-:$ZJ4NW+U4J8GZO2E3A4Q5'$8:$ZJJ3IQE5HS<>>G",U55
M25*-'DJTJU"]93K4ITZ<N3YH_P""4?[#7[:7[(=OX^O/VIOVL-9^->D>,1:2
M>#OA'<7EWKV@?"%8I&D?3M#\3ZFJZCJ5LL12VC\X$>7$&Y8FOV:K\4_^"2'[
M7'QY_:HL?'=_\5_VA_V=OC7I'A:'3=)TVT^$?A+Q'X-\5:7?1((Y=0\2:9XE
M,=U-9ZDB>?:W4$7D.S$HW(K]K*]W'^V]IAU5=)I8/#*@Z491?U;EJ>P=5U$Z
MM6M*'OU*U6I7JU'./M*TYQDH>+@O9M8IP52,WC*SQ"G.$HK$\E!5HT53?LJ=
M*$DH1ITJ="G&49NG1C"<7,I" ?\ /H<_Y_\ U4M%<.YVB8].._'O^A_'\*,#
M]<_GUZYZ^V*6BE9=@/QS_9?_ .4O7_!1?_LDO[.'_I#JM?L97XY_LO\ _*7K
M_@HO_P!DE_9P_P#2'5:_8RF 44A^N.Y[DCZ5\?\ QC_;Y_8]_9]^(FF?"7XQ
M?'_X?> _B-K%FM_IWA'6]76+6;BV?)A?[/&KE&N2"MM'(4DG8A45J]C(N'>(
M>*,=++.&<ASKB/,H8;$8V>7Y#E689QC88/"P53%8N>%RS!X[$0PV'A)3KXB5
M&-&C%J56K!.YG5K4J$>>M5ITH.48\U6I"G'FD[1BI3E%.3>B2;;Z)GV 2!U.
M,<GT '4D]AZDX^M?RS?\'$W[8/[1W@GP5\'/!7[!?Q!^*H^*MEXWUBX^)"?
M_2=3\0_8=!CTS9:V/B'4=*L-0M+:<7PRMD[B89W,BCI^R\GB/XU_M;W<VG>#
MHM9^"W[.=Q \=WX[N5:R^(_Q(M9LI)!X5LI!YGAS0[B DKJ\X-S=0R@VZQD
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MJ=WIEC-#;WE_;V3.+B:TM9[FWAN)XT:.&2>)793(N?@&S_9S_;\TRZMKE/\
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M)\6_ +B+X1?!@OL\1Z<5+>"M/U1O%J(YG$<TOA_*C48X7=X"P#+US[C^S_\
M\%QO^"??[2?Q/\7_  B^&?Q+U6^\9>%1J<EK8W/AV_B'BN#2)G@OI?"Q02-J
MFQTW1I&H:6)DD3Y6%?RU_LN?\$B/BKX._P""I_[2+Z[\&-1^*_ACX7POXT?P
M+K'B^^T;2O$%G\7GU&XL[#4_%<$L;Z]!80R3_:+19'25Q']I0[%K]>OV-?\
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M90!%""S%1S7ZZV\PGM[>?&WSX8I=IZCS45P#[C./P- ?\-\^Q/1110 4444
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MKG[/-=^.KN5S%JFEZB!(;**&-/L0('5B3^^E?S\?L=W7_!/S5/\ @K)^UCX
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M-4ZE-Q3Z*2J7EW<8K9*RT44ASV_SG_Z^*'IJ(6BJ"ZGI[F95O[)FMB!<JMU
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M+_8_A>:R\0?\+BMXY(OA%KBV-I/<6^FZ+K5Z;>+5;6*6:%E?,,Q!!KZ&O/\
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MB^?3+KQ1#?\ A32)QKMSHL:1:1<ZD[6WF7%QID<4:64SOYELJ*(F4*,:VG?
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M2MA%23?,EI2P\+Q<G&3HT72<[2UBVE2C*.SE3E./NRB+1114%A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 8!ZT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>atnm-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 09 21:02:49 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://www.actiniumpharma.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:atnm="http://www.actiniumpharma.com/20250331" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" id="atnm_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="atnm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" id="atnm_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" id="atnm_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" id="atnm_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies" id="atnm_r_CommitmentsandContingencies">
        <link:definition>995307 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Leases" id="atnm_r_Leases">
        <link:definition>995308 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Otherrevenue" id="atnm_r_Otherrevenue">
        <link:definition>995309 - Disclosure - Other revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Equity" id="atnm_r_Equity">
        <link:definition>995310 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" id="atnm_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/LeasesTables" id="atnm_r_LeasesTables">
        <link:definition>996002 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/EquityTables" id="atnm_r_EquityTables">
        <link:definition>996003 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" id="atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable">
        <link:definition>996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" id="atnm_r_ScheduleofDilutedNetLossPerShareTable">
        <link:definition>996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah8gTxiZM6/uA6nfEBodeGu+2+0ReVEwTDC0+Z7+Xbjvy1atNxHViEapukjgsdImMcgoeTmFSA+kShLZmaIu1iIX5SOssVgjTKGBI8nXD3MPb6tJD9O0Li68lWtn3OrlHpVHcdjpaSSaLnrmFzv9UvSf6JLi4xhGsa7h0m2+rAsrQ==] CSR-->
      <link:roleType roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" id="atnm_r_CommitmentsandContingenciesDetails">
        <link:definition>996006 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/LeasesDetails" id="atnm_r_LeasesDetails">
        <link:definition>996007 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" id="atnm_r_ScheduleofComponentsofLeaseExpenseTable">
        <link:definition>996008 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" id="atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable">
        <link:definition>996009 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/OtherrevenueDetails" id="atnm_r_OtherrevenueDetails">
        <link:definition>996010 - Disclosure - Other revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/EquityDetails" id="atnm_r_EquityDetails">
        <link:definition>996011 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" id="atnm_r_ScheduleofStockOptionActivityTable">
        <link:definition>996012 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" id="atnm_r_ScheduleofRestrictedStockUnitActivityTable">
        <link:definition>996013 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" id="atnm_r_ScheduleofWarrantActivityTable">
        <link:definition>996014 - Disclosure - Equity - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWarrantActivityAbstract"/>
  <xs:element name="NonCashActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonCashActivityAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageDiscountRatesAbstract"/>
  <xs:element name="RightofuseAssetObtainedInExchangeForLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities"/>
  <xs:element name="OtherRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueTextBlock"/>
  <xs:element name="NatureOfBusinessPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
  <xs:element name="LicenseRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LicenseRevenuePolicyTextBlock"/>
  <xs:element name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
  <xs:element name="EquityScheduleofStockOptionActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityScheduleofStockOptionActivityDetailsTable"/>
  <xs:element name="EquityScheduleofStockOptionActivityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EquityScheduleofStockOptionActivityDetailsLineItems"/>
  <xs:element name="EquityScheduleofRestrictedStockUnitActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
  <xs:element name="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable"/>
  <xs:element name="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MilestonePayment"/>
  <xs:element name="NetSalesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetSalesPercentage"/>
  <xs:element name="NonRefundablePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonRefundablePaymentReceived"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsTable"/>
  <xs:element name="AggregateMarketValueOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_AggregateMarketValueOfCommonStock"/>
  <xs:element name="NetProceedFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetProceedFromIssuanceOfCommonStock"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="OtherRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueMember"/>
  <xs:element name="RevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RevenueMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>atnm-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 09 21:02:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah8gTxiZM6/uA6nfEBodeGu+2+0ReVEwTDC0+Z7+Xbjvy1atNxHViEapukjgsdImMcgoeTmFSA+kShLZmaIu1iIX5SOssVgjTKGBI8nXD3MPb6tJD9O0Li68lWtn3OrlHpVHcdjpaSSaLnrmFzv9UvSz21M8eOO2Sos3TcsZtWOxw==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>atnm-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 09 21:02:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_Leases" roleURI="http://www.actiniumpharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_Otherrevenue" roleURI="http://www.actiniumpharma.com/role/Otherrevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_Equity" roleURI="http://www.actiniumpharma.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_LeasesTables" roleURI="http://www.actiniumpharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_EquityTables" roleURI="http://www.actiniumpharma.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofStockOptionActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofRestrictedStockUnitActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofWarrantActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_LeasesDetails" roleURI="http://www.actiniumpharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_OtherrevenueDetails" roleURI="http://www.actiniumpharma.com/role/OtherrevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_EquityDetails" roleURI="http://www.actiniumpharma.com/role/EquityDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueMember" xlink:href="atnm-20250331.xsd#atnm_RevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_RevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueMember" xlink:href="atnm-20250331.xsd#atnm_OtherRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_OtherRevenueMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20250331.xsd#atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Otherrevenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20250331.xsd#atnm_OtherRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_OtherRevenueTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_LicenseRevenuePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah8gTxiZM6/uA6nfEBodeGu+2+0ReVEwTDC0+Z7+Xbjvy1atNxHViEapukjgsdImMcgoeTmFSA+kShLZmaIu1iIX5SOssVgjTKGBI8nXD3MPb6tJD9O0Li68lWtn3OrlHpVHcdjpaSSaLnrmFzv9UvSznxgFFvWQPvcs3UCH8coig==] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofStockOptionActivityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofStockOptionActivityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofStockOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="atnm_EquityScheduleofStockOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20250331.xsd#atnm_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_MilestonePayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetSalesPercentage" xlink:href="atnm-20250331.xsd#atnm_NetSalesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_NetSalesPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/OtherrevenueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NonRefundablePaymentReceived" xlink:href="atnm-20250331.xsd#atnm_NonRefundablePaymentReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_NonRefundablePaymentReceived" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250331.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateMarketValueOfCommonStock" xlink:href="atnm-20250331.xsd#atnm_AggregateMarketValueOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_AggregateMarketValueOfCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250331.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="21" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>atnm-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 09 21:02:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in/provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Components of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Operating leases payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance leases payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Other revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Schedule of Stock Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">RSUs Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">RSUs Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $939 and $891</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted cash &#8211; long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term finance lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share of common stock &#8211; basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share of common stock &#8211; diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in/provided by financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Sales of shares of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20250331.xsd#atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueMember" xlink:href="atnm-20250331.xsd#atnm_RevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RevenueMember_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueMember" xlink:to="atnm_RevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueMember" xlink:href="atnm-20250331.xsd#atnm_OtherRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueMember_lbl" xml:lang="en-US">Other Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueMember" xlink:to="atnm_OtherRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Lease Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesRentExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract_lbl" xml:lang="en-US">Finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20250331.xsd#atnm_NonCashActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonCashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="atnm-20250331.xsd#atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations, Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations, Finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20250331.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term, Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term, Finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20250331.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rates, Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rates, Finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Operating Leases, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Finance leases, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Leases, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Operating Leases, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Leases, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of finance lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20250331.xsd#atnm_OtherRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueTextBlock_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Issuance of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Number of Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Operating Leases, Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Finance Leases, Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20250331.xsd#atnm_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetSalesPercentage" xlink:href="atnm-20250331.xsd#atnm_NetSalesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetSalesPercentage_lbl" xml:lang="en-US">Net sales percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Current annual rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonRefundablePaymentReceived" xlink:href="atnm-20250331.xsd#atnm_NonRefundablePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonRefundablePaymentReceived_lbl" xml:lang="en-US">Non-refundable payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Base prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateMarketValueOfCommonStock" xlink:href="atnm-20250331.xsd#atnm_AggregateMarketValueOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AggregateMarketValueOfCommonStock_lbl" xml:lang="en-US">Public float subject to market conditions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateMarketValueOfCommonStock" xlink:to="atnm_AggregateMarketValueOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250331.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price minimum (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price maximum (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US">RSU fair value</label>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah8gTxiZM6/uA6nfEBodeGu+2+0ReVEwTDC0+Z7+Xbjvy1atNxHViEapukjgsdImMcgoeTmFSA+kShLZmaIu1iIX5SOssVgjTKGBI8nXD3MPb6tJD9O0Li68lWtn3OrlHpVHcdjpaSSaLnrmFzv9UvSR8sdOKsYAXRktQzjPwF8tw==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Cancellation of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xml:lang="en-US">Grant Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250331.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Capital on Demand Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofStockOptionActivityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofStockOptionActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityScheduleofStockOptionActivityDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Stock Option Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsTable" xlink:to="atnm_EquityScheduleofStockOptionActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofStockOptionActivityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityScheduleofStockOptionActivityDetailsLineItems_lbl" xml:lang="en-US">Equity - Schedule of Stock Option Activity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="atnm_EquityScheduleofStockOptionActivityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Restricted Stock Unit Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Warrant Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AggregateMarketValueOfCommonStock_lbl0" xml:lang="en-US">Amount of aggregate market value of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateMarketValueOfCommonStock" xlink:to="atnm_AggregateMarketValueOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for license revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MilestonePayment_lbl0" xml:lang="en-US">The amount of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for nature of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Net proceeds from issuance of common stock..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetSalesPercentage_lbl0" xml:lang="en-US">Net sales percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NonRefundablePaymentReceived_lbl0" xml:lang="en-US">Represents the amount of non-refundable payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OtherRevenueTextBlock_lbl0" xml:lang="en-US">The entire disclosure for other revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity&apos;s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl0" xml:lang="en-US">Represents the amount of right-of-use assets obtained in exchange for lease liabilities which includes both operating and finance lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl0" xml:lang="en-US">The number of share-based compensation arrangement by share-based payment award, non-options exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl0" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of non options outstanding and currently exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average grant-date fair value of non-options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Exercisable Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl1" xml:lang="en-US">License Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl1" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20250331.xsd#atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule Of Restricted Stock Unit Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_ScheduleOfRestrictedStockUnitActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetSalesPercentage_lbl1" xml:lang="en-US">Net Sales Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract_lbl0" xml:lang="en-US">Operating Leases, Rent Expense, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0" xml:lang="en-US">Government Assistance [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Nature Of Business Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonCashActivityAbstract_lbl0" xml:lang="en-US">Non Cash Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTextBlock_lbl1" xml:lang="en-US">Other Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RevenueMember_lbl0" xml:lang="en-US">Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueMember" xlink:to="atnm_RevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl1" xml:lang="en-US">Rightofuse Asset Obtained In Exchange For Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueMember_lbl0" xml:lang="en-US">Other Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueMember" xlink:to="atnm_OtherRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl0" xml:lang="en-US">Operating Lease, Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl0" xml:lang="en-US">Equity, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1" xml:lang="en-US">Recently Issued Accounting Pronouncements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Net Proceed From Issuance Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateMarketValueOfCommonStock_lbl1" xml:lang="en-US">Aggregate Market Value Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateMarketValueOfCommonStock" xlink:to="atnm_AggregateMarketValueOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonRefundablePaymentReceived_lbl1" xml:lang="en-US">Non Refundable Payment Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="atnm-20250331.xsd#atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="atnm_ScheduleOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl0" xml:lang="en-US">Finance Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0" xml:lang="en-US">Finance Lease, Interest Payment on Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWarrantActivityAbstract" xlink:href="atnm-20250331.xsd#atnm_ScheduleOfWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWarrantActivityAbstract" xlink:to="atnm_ScheduleOfWarrantActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>atnm-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 09 21:02:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_Leases" roleURI="http://www.actiniumpharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_Otherrevenue" roleURI="http://www.actiniumpharma.com/role/Otherrevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_Equity" roleURI="http://www.actiniumpharma.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_LeasesTables" roleURI="http://www.actiniumpharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_EquityTables" roleURI="http://www.actiniumpharma.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofStockOptionActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofRestrictedStockUnitActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_ScheduleofWarrantActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_LeasesDetails" roleURI="http://www.actiniumpharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_OtherrevenueDetails" roleURI="http://www.actiniumpharma.com/role/OtherrevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250331.xsd#atnm_r_EquityDetails" roleURI="http://www.actiniumpharma.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RevenueMember" xlink:href="atnm-20250331.xsd#atnm_RevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="RevenueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueMember" xlink:href="atnm-20250331.xsd#atnm_OtherRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherRevenueMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20250331.xsd#atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="RightofuseAssetObtainedInExchangeForLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Otherrevenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTextBlock" xlink:href="atnm-20250331.xsd#atnm_OtherRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="OtherRevenueTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureOfBusinessPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicenseRevenuePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250331.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah8gTxiZM6/uA6nfEBodeGu+2+0ReVEwTDC0+Z7+Xbjvy1atNxHViEapukjgsdImMcgoeTmFSA+kShLZmaIu1iIX5SOssVgjTKGBI8nXD3MPb6tJD9O0Li68lWtn3OrlHpVHcdjpaSSaLnrmFzv9UvS2cEhfkCLMilRXlBNh7OJFw==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="atnm-20250331.xsd#atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesRentExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofStockOptionActivityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofStockOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofStockOptionActivityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="EquityScheduleofStockOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsTable" xlink:to="EquityScheduleofStockOptionActivityDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20250331.xsd#atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="EquityScheduleofRestrictedStockUnitActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivityAbstract" xlink:href="atnm-20250331.xsd#atnm_ScheduleOfWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250331.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="atnm-20250331.xsd#atnm_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="MilestonePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetSalesPercentage" xlink:href="atnm-20250331.xsd#atnm_NetSalesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="NetSalesPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/OtherrevenueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="NonRefundablePaymentReceived" xlink:href="atnm-20250331.xsd#atnm_NonRefundablePaymentReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="NonRefundablePaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="atnm-20250331.xsd#atnm_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250331.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateMarketValueOfCommonStock" xlink:href="atnm-20250331.xsd#atnm_AggregateMarketValueOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AggregateMarketValueOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250331.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NetProceedFromIssuanceOfCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACTINIUM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Park Ave., 23rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,325<span></span>
</td>
<td class="nump">$ 72,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">66,456<span></span>
</td>
<td class="nump">74,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $939 and $891</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long term</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">68,647<span></span>
</td>
<td class="nump">76,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,520<span></span>
</td>
<td class="nump">7,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease obligations</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease obligations</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">42,953<span></span>
</td>
<td class="nump">44,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">417,427<span></span>
</td>
<td class="nump">408,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(391,764)<span></span>
</td>
<td class="num">(375,826)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">25,694<span></span>
</td>
<td class="nump">32,758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 68,647<span></span>
</td>
<td class="nump">$ 76,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation (in Dollars)</a></td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">$ 891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">6,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,938<span></span>
</td>
<td class="nump">2,962<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,638<span></span>
</td>
<td class="nump">9,597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(16,638)<span></span>
</td>
<td class="num">(9,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income - net</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,938)<span></span>
</td>
<td class="num">$ (8,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock &#8211; basic (in Dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock &#8211; diluted (in Dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in Shares)</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">27,886,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; diluted (in Shares)</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">27,886,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_RevenueMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_OtherRevenueMember', window );">Other Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_RevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_RevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 373,934<span></span>
</td>
<td class="num">$ (337,583)<span></span>
</td>
<td class="nump">$ 36,379<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">27,634,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,752,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="nump">10,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,670)<span></span>
</td>
<td class="num">(8,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">390,081<span></span>
</td>
<td class="num">(346,253)<span></span>
</td>
<td class="nump">43,857<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">29,396,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">408,553<span></span>
</td>
<td class="num">(375,826)<span></span>
</td>
<td class="nump">32,758<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,874<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,938)<span></span>
</td>
<td class="num">(15,938)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 417,427<span></span>
</td>
<td class="num">$ (391,764)<span></span>
</td>
<td class="nump">$ 25,694<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,938)<span></span>
</td>
<td class="num">$ (8,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,874<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,047)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,574)<span></span>
</td>
<td class="num">(7,374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows used in/provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sales of shares of common stock, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in/provided by financing activities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">14,768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(7,576)<span></span>
</td>
<td class="nump">7,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">73,228<span></span>
</td>
<td class="nump">76,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">65,652<span></span>
</td>
<td class="nump">84,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of right-of-use assets obtained in exchange for lease liabilities which includes both operating and finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a pioneer in the development of targeted radiotherapies
intended to meaningfully improve outcomes for patients with advanced cancers including relapsed or refractory disease who have failed
existing therapies. It is advancing a pipeline of differentiated clinical stage product candidates focused on validated cancer targets.
Its current pipeline is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene therapies that
the Company believes have high unmet needs that are not addressed by currently available treatment options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2025 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">65,325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">327</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">65,652</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With
Customers </i>(&#8220;ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the
transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in
the contract; and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the
goods or services it transfers to the customer. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis,
depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606<i>. </i>There was no revenue for the three months ended March 31, 2025 and March 31, 2024,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>There
was no grant revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three months ended March
31, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units
and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">271</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,421</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">578</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,165</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, FASB issued
ASU 2023-07, <i>Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures</i>, which provides improvements to reportable
segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires the Company to disclose
significant segment expenses that are regularly provided to the chief operating decision maker, or CODM, and included within each reported
measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable
segment, a description of their composition and provide all annual disclosures about a reportable segment&#8217;s profit or loss and assets
pursuant to Topic 280 during interim periods. The Company must also disclose the CODM&#8217;s title and position, as well as certain information
around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and
deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures
required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The Company adopted this standard effective January
1, 2024, and reported in its Annual Report on Form 10-K for the year ended
December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB
issued ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic
220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03
require disclosures in the notes to the consolidated financial statements and specified information about certain costs and
expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b)
depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are
already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a
qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively.
The amendments in ASU 2024-03 are effective January 1, 2027 and effective for interim periods beginning January 1, 2028. The Company
is currently evaluating the impact of ASU 2024-03 on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, FASB issued
ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness
of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income
taxes paid information included in income tax disclosures. The Company is required to disclose additional information regarding reconciling
items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax
rate. Similarly, the Company is required to disclose income taxes paid (net of refunds received) equal to or greater than five percent
of total income taxes paid (net of refunds received). <span style="background-color: white">The amendments in ASU 2023-09 are effective
January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance.
The Company is currently evaluating the impacts of ASU 2023-09 on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the Southern District of New York, wherein, the Securities Complaint alleges that the Defendants made material misrepresentations
and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all Defendants pursuant to section
10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated thereunder, as well as additional claims
against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint purports to assert class action claims
on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October 31, 2022 and August 2,
2024.&#160; Plaintiff seeks unspecified damages.&#160; On May 5, 2025, a derivative shareholder complaint (the &#8220;Derivative Complaint&#8221;)
was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability for the allegations
made in the Securities Complaint.&#160; The Defendants have not yet responded to the Securities Complaint, and they intend to vigorously
defend themselves against the plaintiff&#8217;s allegations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company and other Defendants intend to defend vigorously against such
claims, however, there can be no assurances as to the outcome.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At March 31, 2025, the Company
has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment. The
Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration
date of July 30, 2027 and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such as insurance,
utilities and maintenance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">156</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">153</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right">2.3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance Leases</td><td>&#160;</td> <td style="text-align: right">1.8 years</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding three months ended March 31, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(83</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,415</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueTextBlock', window );">Other revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4  - Other revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. There was no grant
revenue recognized for the three months ended March 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#8220;EUMENA&#8221;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#8217;s contract liabilities primarily consist of advanced payments from licensees. Long-term license revenue deferred was $35
million at March 31, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#8217;s regulatory approval
of Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company
entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, &#8220;JonesTrading&#8221;, pursuant
to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock.
On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales
Agreement&#8221;) with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The A&amp;R Sales Agreement modifies the
original Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares of common
stock are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the
&#8220;Prior Shelf Registration Statement&#8221;). On August 11, 2023, the Company filed a new registration statement on Form S-3 (File
No. 333-273911), which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024, to replace
the Prior Shelf Registration Statement, including a base prospectus which covers the offering, issuance and sale of up to $500 million
of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering,
issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold under the Amended
Sales Agreement. On March 31, 2025, upon filing of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024,
the Company became subject to General Instruction I.B.6 of Form S-3, pursuant to which in no event will the Company sell its common stock
in a registered primary offering using Form S-3 with a value exceeding more than one-third of its public float in any 12 calendar month
period so long as its public float remains below $75 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company did not sell any
shares of common stock during the three months ended March 31, 2025. During the three months ended March 31, 2024, the Company sold 1.8
million shares of common stock, resulting in gross proceeds of $15.0 million and net proceeds of $14.7 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.43</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,891</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">271</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.49</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.61</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, March 31, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.54</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.16</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
March 31, 2025, the Company granted new employees options to purchase 25 thousand shares of
common stock with an exercise price ranging from $1.06 to $1.43 per share, a term of 10 years, and a vesting period of 4 years. The options
had an aggregated fair value of $28 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
option-pricing model include: (1) discount rate range from 4.0% to 4.5% (2) expected life of 6 years, (3) expected volatility range from
90.6% to 90.7%, and (4) <span style="-sec-ix-hidden: hidden-fact-51">zero</span> expected dividends. During the three months ended March 31, 2024, the Company did not grant any stock options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, the Board of Directors approved of the cancellation
of stock options to purchase an aggregate of 4.9 million shares of common stock held by certain current employees and directors that were
initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated Stock Plan. Such cancellations were
subject to the consent of the applicable holders of the stock options, which the Company received. The cancellation of these stock options
resulted in the recording of $8.7 million in stock compensation expense. During the three months ended March 31, 2024, the Company recorded
compensation expense related to stock options of $1.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2025
was $0.4 million related to unvested options, which is expected to be expensed over a weighted average of 2.3 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.85</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.8 million, was determined based on the stock
price on the dates of the grant and is being recognized over three years. The unrecognized compensation expense at March 31, 2025 of $0.2
million is expected to be expensed over 0.4 years. During the three months ended March 31, 2025 and 2024, the Company recorded compensation
expense related to RSUs of $0.1 million and $0.1 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">17.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.20</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">17.77</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (15,938)<span></span>
</td>
<td class="num">$ (8,670)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NatureOfBusinessPolicyPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a pioneer in the development of targeted radiotherapies
intended to meaningfully improve outcomes for patients with advanced cancers including relapsed or refractory disease who have failed
existing therapies. It is advancing a pipeline of differentiated clinical stage product candidates focused on validated cancer targets.
Its current pipeline is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene therapies that
the Company believes have high unmet needs that are not addressed by currently available treatment options.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2025 and December 31, 2024:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">65,325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">327</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">65,652</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With
Customers </i>(&#8220;ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the
transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in
the contract; and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the
goods or services it transfers to the customer. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis,
depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606<i>. </i>There was no revenue for the three months ended March 31, 2025 and March 31, 2024,
respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>There
was no grant revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LicenseRevenuePolicyTextBlock', window );">License Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three months ended March
31, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units
and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">271</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,421</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">578</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,165</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, FASB issued
ASU 2023-07, <i>Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures</i>, which provides improvements to reportable
segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires the Company to disclose
significant segment expenses that are regularly provided to the chief operating decision maker, or CODM, and included within each reported
measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable
segment, a description of their composition and provide all annual disclosures about a reportable segment&#8217;s profit or loss and assets
pursuant to Topic 280 during interim periods. The Company must also disclose the CODM&#8217;s title and position, as well as certain information
around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and
deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures
required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The Company adopted this standard effective January
1, 2024, and reported in its Annual Report on Form 10-K for the year ended
December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB
issued ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic
220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03
require disclosures in the notes to the consolidated financial statements and specified information about certain costs and
expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b)
depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are
already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a
qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively.
The amendments in ASU 2024-03 are effective January 1, 2027 and effective for interim periods beginning January 1, 2028. The Company
is currently evaluating the impact of ASU 2024-03 on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, FASB issued
ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness
of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income
taxes paid information included in income tax disclosures. The Company is required to disclose additional information regarding reconciling
items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax
rate. Similarly, the Company is required to disclose income taxes paid (net of refunds received) equal to or greater than five percent
of total income taxes paid (net of refunds received). <span style="background-color: white">The amendments in ASU 2023-09 are effective
January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance.
The Company is currently evaluating the impacts of ASU 2023-09 on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LicenseRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LicenseRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NatureOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NatureOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2025 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">65,325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">327</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">65,652</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss Per Share</a></td>
<td class="text">For the three months ended March
31, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units
and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">271</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,421</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">578</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,165</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">156</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">153</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right">2.3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance Leases</td><td>&#160;</td> <td style="text-align: right">1.8 years</td></tr> </table>Below is information on the weighted average discount rates used at the time that the leases were evaluated:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding three months ended March 31, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(83</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,415</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.43</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,891</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">271</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.49</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.61</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, March 31, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.54</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.16</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.85</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the three months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">17.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.20</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable, March 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">17.77</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,325<span></span>
</td>
<td class="nump">$ 72,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long-term</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 65,652<span></span>
</td>
<td class="nump">$ 73,228<span></span>
</td>
<td class="nump">$ 84,373<span></span>
</td>
<td class="nump">$ 76,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">7,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">5,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 15, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NetSalesPercentage', window );">Net sales percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term</a></td>
<td class="text">5 years 2 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Jul. 30,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Current annual rent</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Components of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations, Operating leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations, Finance leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates, Operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates, Finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Maturities of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Operating Leases, 2025</a></td>
<td class="nump">$ 475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Finance leases, 2025</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Leases, 2026</a></td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Leases, 2026</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Leases, 2027</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Leases, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating leases payments</a></td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance leases payments</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Leases, Less imputed interest</a></td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Leases, Less imputed interest</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of finance lease liabilities</a></td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NonRefundablePaymentReceived', window );">Non-refundable payment received</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term license revenue deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of non-refundable payment received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">RSU fair value</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Cancellation of stock options</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Base prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NetProceedFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Exercise price minimum (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price maximum (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember', window );">Capital on Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">RSU fair value</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AggregateMarketValueOfCommonStock', window );">Public float subject to market conditions</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetProceedFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetProceedFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock Option Activity (Details) - Stock Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityScheduleofStockOptionActivityDetailsLineItems', window );"><strong>Equity - Schedule of Stock Option Activity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending balance</a></td>
<td class="nump">5,137<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">$ 6.48<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</a></td>
<td class="text">7 years 14 days<span></span>
</td>
<td class="text">7 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years) Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityScheduleofStockOptionActivityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityScheduleofStockOptionActivityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Restricted Stock Unit Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs Outstanding, Beginning balance | shares</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance | $ / shares</a></td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs Outstanding, Ending balance | shares</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance | $ / shares</a></td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs Outstanding, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs Outstanding, Vested | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs Outstanding, Cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Ending balance</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">$ 17.33<span></span>
</td>
<td class="nump">$ 17.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance</a></td>
<td class="text">4 years 5 months 15 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Number of Warrants Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years) Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue', window );">Aggregate Intrinsic Value Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share-based compensation arrangement by share-based payment award, non-options exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of non options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non-options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( '"+J5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( '"+J5HI<&A?\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( '"+J5HD;M+"308  .@B   8
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MT+]N.$F)>,@]G4@P^%ISEX=AH@3E^#<7;12_F03N'F_5[U+S8.:9*>Z*\,_
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MR^0!N#\30F]/DA\H-K?T_P-02P,$%     @ <(NI6@%CBI^L!0  5A<  !@
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M*<1 ;@]QMS=:;.PYZ(W06E3V<LTH0#<"\'XEA'Z\,4>K[5'ZXC]02P,$%
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M\VLQMPY3W"[>4+&,,XD2MH"0WL4 9$ 4%W9%0_%U?N?UR)7B:?ZZ8C1B0AO
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MD8S$7$)@\?-"9B3+))+PXU<-:C0VI>+A]1OZ]RIX$<P39F1&LW_2A*\F1F"
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MY W%T>&:U_'EJ?[YKFVY5H>U7H<N7>%#@D4#@;42X3>)\'L3<<?8INJLG62
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MM6V[BY8Y*K;( !EOSI1TJ<)]"UN2UKC'EQI'3UDD\8DQ<,.:C,,D<TYPZ-E
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M"I] [.4 ]M<.#74_$0?]1]7\'U!+ P04    " !PBZE:[ @W-@T(  !B%0
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M2E$#GC9_T>6V$0FO@FE0XDW4MTVG U/-QH/4W,%D=B;1%H0R,+DD2<UVL!L
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MXNG=LUBO%M#T1PV<AMJ&02H@UW& (L)>7592)\="&8PL59>0J!R"0Y;IHD)
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MOQGJ7EG:@/74&-]>D(+NM>KC7U!+ P04    " !PBZE:H@/G[2T&  "J#0
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MW]5?!O5-L&4\C2]LP-D^7O+1AQP;X/W2XBC7W/ "W>?9T7]02P,$%     @
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M#*M#HUUU_>5O>->ES84L*%>(06Y2@[N%^3MEU_FZB1:UZS9[H4WO<L/2?"Q
MV@#S/A="'R=V@^'SD_X!4$L#!!0    ( '"+J5HY5N.2Q@H  /\A   9
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MBG[1AO\V"%^\*?@-_\QX7*'XXU+!%I8V8'UNC*^_$(/F?S[._P=02P,$%
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M<8$W"G1;UTP]7F EU_,P#I\FOO)5:>Q$M)@U;(6W:/YL;A2-H@XEYS4*S:4
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M3 ,LZ_M%O="BM._TE=!T0[!F2E<RE,:!SC="Z/W")&@O>?-_ 5!+ P04
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M4S*\NF-4'<D*<XC.F%1'LFFFZEH&7 /4_)PQ^=;1YW)ST0O_ %!+ P04
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M!(QWP/.MUNYH^-;N'Z;L#U!+ P04    " !PBZE:@-P/^50"  "L!0  &0
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MF@RNW;68=C:T#NDZ].-2D^ON8%9NG*+Q >Y\I34=')^@&]#Y7U!+ P04
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MSJ5!)W;+$H<K*!N ]PLIS69C$_3C.OT+4$L#!!0    ( '"+J5HH>2[8M0@
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M7;-</R\?FRAA,N.LX=_*\1=02P,$%     @ <(NI6B+@:-=[ 0  .A(  !,
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M<F]P<R]A<' N>&UL4$L! A0#%     @ <(NI6BEP:%_R    *P(  !$
M         ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ <(NI
M6IE<G",0!@  G"<  !,              ( !Y $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !PBZE:)&[2PDT&  #H(@  &
M@($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ <(NI
M6@%CBI^L!0  5A<  !@              ("!J X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( '"+J5IMG,281P,   4+   8
M      " @8H4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !PBZE:9\"W-J0$  !"%0  &               @($'&   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ <(NI6HUSD6[-!   K1@  !@
M             ("!X1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( '"+J5IOY]Y;G04  '(8   8              " @>0A  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !PBZE:ZPT?9Z@)  #Y
M&   &               @(&W)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ <(NI6@$5C/9L!   8 D  !@              ("!E3$
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( '"+J5KL"#<V
M#0@  &(5   8              " @3<V  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !PBZE:H@/G[2T&  "J#0  &0
M@(%Z/@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( '"+
MJ5K5[0XMU0D  "T:   9              " @=Y$  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ <(NI6GE]K#U, @  H@4  !D
M         ("!ZDX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !PBZE:$ZV'ZT0"  "*!@  &0              @(%M40  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( '"+J5HY5N.2Q@H  /\A
M   9              " @>A3  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ <(NI6C 91[FQ P  R @  !D              ("!Y5X
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !PBZE:S5(;
M\/$#   8"@  &0              @('-8@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( '"+J5JF'2Y1?P,  / )   9
M  " @?5F  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M<(NI6O&5UNCS @  ] D  !D              ("!JVH  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !PBZE:8;88GE8#  #6#0  &0
M            @('5;0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( '"+J5H#0="@(0(  *0$   9              " @6)Q  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ <(NI6H#<#_E4 @
MK 4  !D              ("!NG,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !PBZE:@N.'KTP$  !'$@  &0              @(%%
M=@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( '"+J5J'
M<4ZH_0(  "P*   9              " @<AZ  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ <(NI6EZ.'W^1 @  N@<  !D
M     ("!_'T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M" !PBZE:*'DNV+4(  !J4P  &0              @('$@   >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( '"+J5H#?&D$_0,  ! 2   9
M              " @;")  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M A0#%     @ <(NI6NU73=HC P  N0L  !D              ("!Y(T  'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !PBZE:RDN @:<#
M  !V$   &0              @($^D0  >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;%!+ 0(4 Q0    ( '"+J5HV!M3A-@,  $@3   -              "
M 1R5  !X;"]S='EL97,N>&UL4$L! A0#%     @ <(NI6I>*NQS     $P(
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9>&UL4$L%!@     D "0 LPD  ,2?      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>56</ContextCount>
  <ElementCount>212</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>15</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Other revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Otherrevenue</Role>
      <ShortName>Other revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Leases</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Equity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/LeasesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Other revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/OtherrevenueDetails</Role>
      <ShortName>Other revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Otherrevenue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/EquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable</Role>
      <ShortName>Equity - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0239143-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Equity - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable</Role>
      <ShortName>Equity - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnm-20250331.xsd</File>
    <File>atnm-20250331_cal.xml</File>
    <File>atnm-20250331_def.xml</File>
    <File>atnm-20250331_lab.xml</File>
    <File>atnm-20250331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ea0239143-10q_actinium.htm">ea0239143-10q_actinium.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="308">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0239143-10q_actinium.htm": {
   "nsprefix": "atnm",
   "nsuri": "http://www.actiniumpharma.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "atnm-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "atnm-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atnm-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0239143-10q_actinium.htm"
     ]
    }
   },
   "keyStandard": 193,
   "keyCustom": 19,
   "axisStandard": 9,
   "axisCustom": 0,
   "memberStandard": 10,
   "memberCustom": 3,
   "hidden": {
    "total": 56,
    "http://fasb.org/us-gaap/2025": 45,
    "http://www.actiniumpharma.com/20250331": 7,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 56,
   "entityCount": 1,
   "segmentCount": 15,
   "elementCount": 513,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 308,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "longName": "995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.actiniumpharma.com/role/CommitmentsandContingencies",
     "longName": "995307 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.actiniumpharma.com/role/Leases",
     "longName": "995308 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.actiniumpharma.com/role/Otherrevenue",
     "longName": "995309 - Disclosure - Other revenue",
     "shortName": "Other revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:OtherRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:OtherRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.actiniumpharma.com/role/Equity",
     "longName": "995310 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.actiniumpharma.com/role/LeasesTables",
     "longName": "996002 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.actiniumpharma.com/role/EquityTables",
     "longName": "996003 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable",
     "longName": "996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
     "longName": "996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996006 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c35",
      "name": "atnm:MilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c35",
      "name": "atnm:MilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.actiniumpharma.com/role/LeasesDetails",
     "longName": "996007 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable",
     "longName": "996008 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable",
     "longName": "996009 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.actiniumpharma.com/role/OtherrevenueDetails",
     "longName": "996010 - Disclosure - Other revenue (Details)",
     "shortName": "Other revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "atnm:NonRefundablePaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c36",
      "name": "atnm:NonRefundablePaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.actiniumpharma.com/role/EquityDetails",
     "longName": "996011 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996012 - Disclosure - Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c49",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c49",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
     "longName": "996013 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "shortName": "Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c51",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c51",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable",
     "longName": "996014 - Disclosure - Equity - Schedule of Warrant Activity (Details)",
     "shortName": "Equity - Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c52",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c52",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239143-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation (in Dollars)",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r69",
      "r346"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r483",
      "r803"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r689",
      "r690",
      "r691",
      "r692",
      "r745",
      "r805"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r712"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_AggregateMarketValueOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "AggregateMarketValueOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public float subject to market conditions",
        "documentation": "Amount of aggregate market value of common stock.",
        "label": "Aggregate Market Value Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r533",
      "r549",
      "r584"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r525",
      "r536",
      "r552",
      "r587"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r579",
      "r588",
      "r592",
      "r600"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r236",
      "r245"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Diluted Net Loss Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r56",
      "r70",
      "r89",
      "r90",
      "r91",
      "r119",
      "r126",
      "r139",
      "r140",
      "r146",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r259",
      "r261",
      "r302",
      "r336",
      "r337",
      "r340",
      "r398",
      "r462",
      "r463",
      "r466",
      "r483",
      "r488",
      "r489",
      "r501",
      "r705",
      "r706",
      "r763"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r74",
      "r89",
      "r90",
      "r91",
      "r146",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r259",
      "r261",
      "r302",
      "r483",
      "r705",
      "r706",
      "r763"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r514",
      "r517",
      "r529"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r514",
      "r517",
      "r529"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r514",
      "r517",
      "r529"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation - Unaudited Interim Financial Information",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r517",
      "r529"
     ]
    },
    "atnm_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital on Demand Sales Agreement [Member]",
        "label": "Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r68",
      "r445"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r48"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r88"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r38"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r121",
      "r170",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r287",
      "r367",
      "r368",
      "r369",
      "r370",
      "r467",
      "r623",
      "r683",
      "r685"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r50",
      "r341",
      "r385"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r150",
      "r151",
      "r439",
      "r700",
      "r702"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r689",
      "r690",
      "r692",
      "r745",
      "r802",
      "r805"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r386"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r386",
      "r404",
      "r805",
      "r806"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r168",
      "r174",
      "r343",
      "r483"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r455"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/OtherrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term license revenue deferred",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r196"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r556"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expenses",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r83",
      "r119",
      "r130",
      "r140",
      "r449",
      "r462",
      "r463"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r375",
      "r377",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r410",
      "r411",
      "r412",
      "r413",
      "r416",
      "r417",
      "r418",
      "r419",
      "r429",
      "r430",
      "r431",
      "r432",
      "r446",
      "r447",
      "r448",
      "r476",
      "r477",
      "r491",
      "r493",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r741",
      "r742",
      "r743",
      "r744",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r756",
      "r757"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r375",
      "r377",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r410",
      "r411",
      "r412",
      "r413",
      "r416",
      "r417",
      "r418",
      "r419",
      "r429",
      "r430",
      "r431",
      "r432",
      "r446",
      "r447",
      "r448",
      "r476",
      "r477",
      "r491",
      "r493",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r741",
      "r742",
      "r743",
      "r744",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r756",
      "r757"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r556"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r517",
      "r529"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r517",
      "r529",
      "r580"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r517",
      "r529",
      "r580"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock \u2013 basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r81",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r109",
      "r111",
      "r113",
      "r114",
      "r115",
      "r118",
      "r166",
      "r235",
      "r254",
      "r257",
      "r299",
      "r300",
      "r335",
      "r350",
      "r456"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock \u2013 diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r81",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r111",
      "r113",
      "r114",
      "r115",
      "r118",
      "r166",
      "r235",
      "r254",
      "r257",
      "r299",
      "r300",
      "r335",
      "r350",
      "r456"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r117"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average term",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r62",
      "r63",
      "r64",
      "r77",
      "r78",
      "r79",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r108",
      "r120",
      "r147",
      "r148",
      "r149",
      "r165",
      "r184",
      "r235",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r313",
      "r330",
      "r349",
      "r360",
      "r361",
      "r362",
      "r372",
      "r422"
     ]
    },
    "atnm_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU fair value",
        "label": "Equity, Fair Value Disclosure",
        "documentation": "Fair value of the entity's equity."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r747",
      "r755"
     ]
    },
    "atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "EquityScheduleofRestrictedStockUnitActivityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Restricted Stock Unit Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_EquityScheduleofStockOptionActivityDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "EquityScheduleofStockOptionActivityDetailsLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Stock Option Activity (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_EquityScheduleofStockOptionActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "EquityScheduleofStockOptionActivityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Stock Option Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r533",
      "r549",
      "r584"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r519",
      "r530",
      "r546",
      "r581"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r323",
      "r482"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow use from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r324"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of finance lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r328"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases current liability",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease obligations",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance leases payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r684",
      "r688",
      "r772"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2026",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r684",
      "r688",
      "r772"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2027",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r684",
      "r688",
      "r772"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases, 2025",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance Leases, Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Financing cash flow use from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r324"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-to-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r323",
      "r482"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates, Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r482"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term, Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r482"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r588"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r588"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r588"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r588"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r588"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r516",
      "r540"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r407"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Revenue",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r514",
      "r517",
      "r529"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r679"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r579",
      "r588",
      "r592",
      "r600"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r604"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r604"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r604"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r86",
      "r87"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income - net",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r129",
      "r140",
      "r462",
      "r637"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r482"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Lease Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating leases payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r684",
      "r688",
      "r772"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r684",
      "r688",
      "r772"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r684",
      "r688",
      "r772"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating Leases, Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r89",
      "r90",
      "r91",
      "r146",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r260",
      "r261",
      "r262",
      "r302",
      "r384",
      "r458",
      "r466",
      "r501",
      "r705",
      "r763",
      "r764"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r51",
      "r345",
      "r483",
      "r488",
      "r489",
      "r683",
      "r687",
      "r699",
      "r758"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r67",
      "r89",
      "r90",
      "r91",
      "r146",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r260",
      "r261",
      "r262",
      "r302",
      "r483",
      "r705",
      "r763",
      "r764"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LicenseRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "LicenseRevenuePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Revenue",
        "documentation": "Disclosure of accounting policy for license revenue.",
        "label": "License Revenue Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r152",
      "r153",
      "r154",
      "r155",
      "r198",
      "r228",
      "r229",
      "r230",
      "r246",
      "r301",
      "r333",
      "r358",
      "r359",
      "r365",
      "r376",
      "r377",
      "r425",
      "r426",
      "r427",
      "r428",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r465",
      "r467",
      "r470",
      "r472",
      "r473",
      "r474",
      "r478",
      "r479",
      "r480",
      "r481",
      "r485",
      "r707",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "atnm_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "documentation": "The amount of milestone payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r152",
      "r153",
      "r154",
      "r155",
      "r198",
      "r228",
      "r229",
      "r230",
      "r246",
      "r301",
      "r333",
      "r358",
      "r359",
      "r365",
      "r376",
      "r377",
      "r425",
      "r426",
      "r427",
      "r428",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r465",
      "r467",
      "r470",
      "r472",
      "r473",
      "r474",
      "r478",
      "r479",
      "r480",
      "r485",
      "r707",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "atnm_NatureOfBusinessPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "NatureOfBusinessPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "documentation": "Disclosure of accounting policy for nature of business.",
        "label": "Nature Of Business Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in/provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in/provided by financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r40",
      "r52",
      "r64",
      "r65",
      "r75",
      "r76",
      "r79",
      "r89",
      "r90",
      "r91",
      "r92",
      "r96",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r107",
      "r108",
      "r112",
      "r146",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r169",
      "r171",
      "r175",
      "r235",
      "r254",
      "r257",
      "r300",
      "r302",
      "r348",
      "r405",
      "r420",
      "r421",
      "r451",
      "r453",
      "r454",
      "r499",
      "r705"
     ]
    },
    "atnm_NetProceedFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "NetProceedFromIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock.",
        "documentation": "Net proceeds from issuance of common stock..",
        "label": "Net Proceed From Issuance Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_NetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "NetSalesPercentage",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales percentage",
        "documentation": "Net sales percentage.",
        "label": "Net Sales Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r579",
      "r588"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "atnm_NonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "NonRefundablePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable payment received",
        "documentation": "Represents the amount of non-refundable payment received",
        "label": "Non Refundable Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r451",
      "r454",
      "r459",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases current liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease obligations",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow use from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r324"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates, Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r482"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term, Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r482"
     ]
    },
    "us-gaap_OperatingLeasesRentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasesRentExpenseAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost",
        "label": "Operating Leases, Rent Expense, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "atnm_OtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "OtherRevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Revenue",
        "label": "Other Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_OtherRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "OtherRevenueTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Otherrevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "documentation": "The entire disclosure for other revenue.",
        "label": "Other Revenue Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r524",
      "r535",
      "r551",
      "r586"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r527",
      "r538",
      "r554",
      "r589"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r527",
      "r538",
      "r554",
      "r589"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current annual rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r176"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r386"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r176"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r386",
      "r404",
      "r805",
      "r806"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r168",
      "r173",
      "r342",
      "r483"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of shares of common stock, net of costs",
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r334",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r444",
      "r450",
      "r453",
      "r454",
      "r468",
      "r469",
      "r484",
      "r485",
      "r486",
      "r487",
      "r490",
      "r624",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r703",
      "r704",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r334",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r444",
      "r450",
      "r453",
      "r454",
      "r468",
      "r469",
      "r484",
      "r485",
      "r486",
      "r487",
      "r490",
      "r624",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r703",
      "r704",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation of $939 and $891",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r329",
      "r339",
      "r347",
      "r483"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r152",
      "r153",
      "r154",
      "r155",
      "r197",
      "r198",
      "r228",
      "r229",
      "r230",
      "r234",
      "r246",
      "r301",
      "r331",
      "r332",
      "r333",
      "r358",
      "r359",
      "r365",
      "r376",
      "r377",
      "r425",
      "r426",
      "r427",
      "r428",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r465",
      "r467",
      "r470",
      "r472",
      "r473",
      "r474",
      "r478",
      "r479",
      "r480",
      "r481",
      "r485",
      "r493",
      "r701",
      "r707",
      "r748",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r152",
      "r153",
      "r154",
      "r155",
      "r197",
      "r198",
      "r228",
      "r229",
      "r230",
      "r234",
      "r246",
      "r301",
      "r331",
      "r332",
      "r333",
      "r358",
      "r359",
      "r365",
      "r376",
      "r377",
      "r425",
      "r426",
      "r427",
      "r428",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r465",
      "r467",
      "r470",
      "r472",
      "r473",
      "r474",
      "r478",
      "r479",
      "r480",
      "r481",
      "r485",
      "r493",
      "r701",
      "r707",
      "r748",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770"
     ]
    },
    "atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r519",
      "r530",
      "r546",
      "r581"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, net of reimbursements",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r442",
      "r451",
      "r452",
      "r462",
      "r771"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r520",
      "r531",
      "r547",
      "r582"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r521",
      "r532",
      "r548",
      "r583"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r528",
      "r539",
      "r555",
      "r590"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash \u2013 long term",
        "verboseLabel": "Restricted cash \u2013 long-term",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r626",
      "r680"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "netLabel": "RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r43",
      "r344",
      "r363",
      "r364",
      "r371",
      "r387",
      "r483"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r108",
      "r147",
      "r148",
      "r149",
      "r165",
      "r235",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r288",
      "r290",
      "r291",
      "r293",
      "r298",
      "r311",
      "r313",
      "r360",
      "r362",
      "r372",
      "r805"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r443"
     ]
    },
    "atnm_RevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "RevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r80",
      "r89",
      "r90",
      "r91",
      "r119",
      "r127",
      "r128",
      "r138",
      "r140",
      "r142",
      "r143",
      "r144",
      "r146",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r302",
      "r336",
      "r338",
      "r462",
      "r475",
      "r488",
      "r489",
      "r705"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations, Finance leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r482"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations, Operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r482"
     ]
    },
    "atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "RightofuseAssetObtainedInExchangeForLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "documentation": "Represents the amount of right-of-use assets obtained in exchange for lease liabilities which includes both operating and finance lease.",
        "label": "Rightofuse Asset Obtained In Exchange For Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of shares (in Shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ScheduleOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfRestrictedStockUnitActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ScheduleOfRestrictedStockUnitActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Stock Unit Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrant Activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "atnm_ScheduleOfWarrantActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ScheduleOfWarrantActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r141",
      "r143",
      "r460",
      "r461",
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "RSUs Outstanding, Beginning balance",
        "periodEndLabel": "RSUs Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance",
        "periodEndLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Unit Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants Exercisable",
        "documentation": "The number of share-based compensation arrangement by share-based payment award, non-options exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of non options outstanding and currently exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Warrants Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance",
        "documentation": "Weighted average remaining contractual term for portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "verboseLabel": "Issuance of stock options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r206",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Exercisable",
        "documentation": "The weighted average grant-date fair value of non-options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Exercisable Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250331",
     "localname": "ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "documentation": "The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r711"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r31",
      "r32",
      "r62",
      "r63",
      "r64",
      "r77",
      "r78",
      "r79",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r108",
      "r120",
      "r147",
      "r148",
      "r149",
      "r165",
      "r184",
      "r235",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r313",
      "r330",
      "r349",
      "r360",
      "r361",
      "r362",
      "r372",
      "r422"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r120",
      "r167",
      "r168",
      "r170",
      "r172",
      "r313",
      "r334",
      "r366",
      "r373",
      "r374",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r453",
      "r454",
      "r494",
      "r804"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r120",
      "r145",
      "r167",
      "r168",
      "r170",
      "r172",
      "r313",
      "r334",
      "r366",
      "r373",
      "r374",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r453",
      "r454",
      "r494",
      "r804"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r523",
      "r534",
      "r550",
      "r585"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base prospectus",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of offering costs (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r27",
      "r28",
      "r43",
      "r367",
      "r422",
      "r434"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options (in Shares)",
        "verboseLabel": "Number of Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r27",
      "r28",
      "r43",
      "r212"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r27",
      "r28",
      "r43",
      "r372",
      "r422",
      "r434",
      "r500"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of stock options",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r31",
      "r32",
      "r43"
     ]
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price minimum (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price maximum (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "verboseLabel": "Stock Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r740"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r31",
      "r32",
      "r41",
      "r388",
      "r404",
      "r423",
      "r424",
      "r483",
      "r501",
      "r683",
      "r686",
      "r687",
      "r699",
      "r758",
      "r805"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r762"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r122",
      "r123",
      "r124",
      "r125",
      "r336",
      "r338",
      "r457"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r495",
      "r496",
      "r497",
      "r498"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r115"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r115"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001213900-25-041614-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-041614-xbrl.zip
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M!P^(. IKD/"*IED.$7P&-P(%322# ;2?R2I5,#\4\Z&*F698S*%(_I@)E=/
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MM]::1L78#&O^_=)VF!.A47S:L56:IU4ZZ9/4[7G;G$I+&?S5YY_N%U/*Y+\
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M>5-+-9G0TW.U7< ZGK^=_F)!<E" %F>S+QXK'B/^L@O)E93#OH+-I9E1X55
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MBS*:$A1 G[S]0P\RW/H+4$L#!!0    ( '"+J5JKECOE_2   !,2 @ 5
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M3HYF]S<J11D*J]YU\\$TT"1(3V[FLPO^E\%TL#8K/8JIUQ,YU'.\29PF"<_
M+E\>I?XL6JZ\0*ZCGUDX8!>E+PA1XMQ2F]&$N96GVUX 2 T[!4G*WC[7#1#2
MRD,:Y:>L?L;1["0.(W^. EA(%8GW!5=5F4K4O^N>'%SRB9\\US0( EJ60)5L
M\R!C_!0A2;9/NZ6T**$>%?CH+U'@,9HA.8Y&M,(;=GG*4.P1A%("-%\DS^)
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MN^%Y>9.'BB[W.N/J/+TM3Z>D T-MWG.-$QIIFU 7LE67?F6QU6]^H&/7ABC
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MK3 <9[3& 7O*$*H^14!,/V1;.G!)D0G,#%85)XV6F\@AEU]@/"G5+A@Q!AM
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MKI;Q$P>E3^U6&HH<6?;.-@[+0Q3>0YH5MSA;,8O&BOYX&F:T &!\"2SC4W,
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M-39Q(\W7 2LU5YL#/S7@,60JGCXV$\[BD%3%7ET\#+--I,ED3X'>]*ZYJ N
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MX1Z=F<II?=Q U>("WKA-R>&LX@1]&J6ZN.>U1Q\I3+ZLK3)513CQ.CZ#X[O
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M_&M+?.U;6,JO4U["<-O??DX]W;W5ZNZ#%PPA-+EKOYWSLTY,>IL[MHF=$:+
MW3&H[JI>,_7,^9%S<_KF1D/ZFMR8'>ZSE>QN(A]E48U^W0ZJN*RR;B%Z#.(-
MM6IU,ECXK=&].Q:D 57*,,+1KC(7%Y=7H[\Q^[2R4?C,,YN+2OM:&N)S;U;
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M3G?ZM(XRZD^#<D]C=U'B+N&AD ,/#@&S;+^B5<M\V\9D1&JSBF"'MA=-*9'
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MN'_%M0&0L\6< L:E-.+HTYQ]CO_&"=/%9E6UT. =Q*/[^PS?TY;@V:^XH!5
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M62;HB:1/P_ + ZB:4@[Q:I,1[8/O(I3MV;?K_7@+C)F;_7@&9)#M2-N%WL*
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MHD^$:@"J1GC1UV1;Z!\3V5:=ZNB24G4&\<FJ*G^*Z.1Y%?G3C$NVP9P/']4
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M(=^ZKW['K!0B,[GJJ6ALQ%YIHO;>!H*S#X46UM_RS'S JA=V67YQD\W(V-*
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M_O7CQ7>LMU6^,]D$36[=^]K%%A3U%.;1/)B+?9WR"&D;8O+OH$@ST14."2Q
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M]_&<)@+<CQ8DWZ\##''I)MH D103NI2!F,FQGZ+7D*J9%@O'Y$;N!\Z24DM
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M^3\NY::SOJ;&^O8!V1MTY3K^$CHU*,V&3I??BF$IE+WFY&*EFJM7%F'R??=
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M)@06 A*TF:I8/%DX/P]J@OPWJ\HB58W\==(?%&JK5A1A6Z@V5UY%LR[K2-1
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M.W.7K(QT<? ^P<%W;P_9/[&$+OO;_P-02P,$%     @ <(NI6K<6B5SDO@$
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MH=[5UJC>96DGKTV[:_MFQ^Y.:G:5'6AVS;1BIR$])1!WI[)M/7EA?[)'J*V
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M1^M0PK$6A]M$,O\,W]M:TO>5<W9-M0"3:UZ?9Z^V7=?ON(DD<CHQ3F*8<*!
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MDT%D"'#H; %KKF''+BCG85)NA(O0A!WC-CW!$Y+:>T%%&RCD23Q8@TN<IYP
M&&OE['39<YHSL6/0VN@'(*X.ITQIN=T/"%D#I5>R<KDV!1\$JZ("S.R4$*;G
MT7Z\!*QI9IF6=.PXQI?V"YPG6>%AJ L_;,Y;DDN]WCW_JZW&_[:<+:W+\Q E
M='SB R-3^R@H$2Q$OM0L9:%>(JKM4-<>.SP1UD1VB?J5);S'&$CJO.,EQ ZS
M>9J,K<:*-*TQ"+RN:+V@*3ZS'H*G1BI#5DKG43[#N%1(53A-:FGQ0G7Y@K5\
M(K$\6Q%,J3C9 "RQ?V;>:L2/'ZK9C_*HX@X%AAQ@,2IE>V [L D/E%9U/7#=
M'ED+B5:>K'G>S2G>:R2\5Y=X\5V!%!UB^8"76".,F9R/L$.'"(Z;C\O4-)(3
M4)'KBRN")_!@1(&J"Z/,>L?^'3FA?,@ %H<%8M>]3-74I"D,JA5-8L4\@PII
M.M(U@YX]K]N-_,(XM250(@^*80?SU_N:^><J?&_+\0>IIB75D3KU FFE3##]
M0*2/*S(<$;M XS@@#X*#"$<'G6PVT56>V;FLJX=1#$WMR>; BN4D^B#67$GS
M5='Z-.,PYB^"OL4I2$KWU;8EUU,[,Z;N3'-=2HI6IR20[I2T2Q,=FJ)O0NSV
M$*=(>#33G%]79!(MAM"3MMS2(DQC_V;B2DE+JRF6-0+%#A(P*&TL,>5TR!HZ
M\O)+E(+2&(G###W;%5H5$#;N6#CP[8&L<[-[^C>Z!P6>"83%+4.&$R(1Q4)'
M;Q0.HY!10Q+\0[*Y?2A_6&]=ZWDBE9YY.SFFXYUU=(]E;?NM=%++9-HZ X,<
MERD:%BXM*>L2]^139 N_I8ATZ=+8?/*YYD2#.VTX=^3*Q_6+ Z=Q.J [91)I
M9R"(8P$ITY4:0JFW88LH$8H0@2S9("%7D2DR2T7X#(1+$*B(E4^%K/2A8%A\
MR%TRS219@VZ(; Z0 $#N!@G[TV$J.!6\I6\/U8 'N5_N]D7GK[%6VE/O#THI
M1W*BRXBM3H$\M1SS<;NLZX 2D'B0%P(2G6BY=<.-.[.)*GH*WVC#'T<E]FM_
M#&%]BI K-4-PM%!$31.E6]^NM%!%J[+T%@'=A52AH$Z;,4$F7H\O]EF)W-[K
M]Z89<[UI&9E9.TMXLF,F9V^\=^7Z4J\JY4/NU7CNU<DA]VIS!V$+*5BU=:9@
M58_F]8"=I:S\@GJ<2^I)@%W&D'G.B*PV-M:4=:J>\HN/=JZTX*@RGA!(23B&
MY.LI08."'&^13IVG>(?%8(CB#FU[J>;WJ+OFE"X3LJ6?-M182"XY^E@U]!S)
M1F[T*'O0B7S1("<(8S4G-K!Q*7WL1*8:5V;WKA!WH_K^0A8()1>-7=+C/&UF
M)!:&$0LWA  !@QX&(E=: CSE_+;(%8(F1J($EE@[\1G$#6V$=SC.]Q'A,U%A
M80F[)H&ED=&QHZ3PJ/=,3#\^;BDGU;%%6H:44HH\R7M#RGM!$J\NAK;F-*84
M+\->P/_^"C0 L)=H63!3@[H)SWR"SCN:6W8CQRE/<H4Q[8WQ#TDKB6Y-K6*H
M98PGK']JA>O04TC150HV'@"?=T9IXP2U43P.FLDS$F'GP0 GTL/:_^#,C,T=
M^0(#_D2ZHF 3ILCY-NBZR'42;^%XEB@P XMC4I+LVH%>&FF,I(\S&W?$)GWG
ME!*-%I (G G7+9XLEXS_@9?H^W%NPR<6#8&_N HPQ)&"SSH'+:BVH=BYF )N
MIL.#HK F)KVU(BG ]T:F(]J6N&B"&703OEZ^QU( &^M4$@72&OI/9#VI+299
M$,KGJ_E[T:]!WTWQ>R<N*,7 C?D>TKUA ].5F 4.O@R<+\0JMJW,?<^@0SS7
MGXQK0;/JAS3)QX<(6T-1=@>V8Q/6,AS8K-AZ'&^,PZXRMCPMZR4.'BO"T8YD
M.C!,62:3R3#THJR#-ND.5+^^*.-;?6$'<8X)L#4C?3E/\A35%\@Y9- 7O7?X
M^T2X65Y<PJZ3ZH,601;Q\ZSX^UA,)HGLI8(R<0 _A^<R\43B@9YT7^Z%AW$C
MA[.V\.'<=MLK^^PB6QP8HK>RE(<9PH .,&N+C*LX"8:Z*YK4X3@1;<*=-!%H
MU)U6H,/WL0F\ZFTL1:^15UBE5XLP'@LNLA6"BX8(+LHEKAY=9,M%%XT-1!=9
MKN@B^S:!?B/5EE_+:1IGWE*15\PK:8(H4E$++(B07((4=H=HPM',"/6&?)@1
M>4(93Y)U$)0*7U)4*T?W$KUB?UMRTX03G4 SY4!1T1.Y7,62*&V>@BFT'GP"
M;4ZWL[1>[;@^G?[0RB0S41A=N&.LU$#*ER&=N"=X0385SX+X1)8!LE],'LC
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M7WJ;''66W(\IW)1!3UKBK-E&Z,!1,P)Q9J%<6@%6[-#BX^TE^S*=;B0]%/8
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M7JCU+!6'%L<*QD=V%B'DQ?["**^\%I37C\YJY?)<A,\#U$Z O$H;^ZT"N8%
MGC^X9G-':4VS$Z1R\:NT.=[X (Y5>NMOE;QP4,]AN,I"N*V_%MRVCLXJA7KM
M=/_FL:PRCXEF;3SB8.4=3.58@,A6&<WQ:K2^$]#Z6AL9T?$6T7KR6M!Z"E*A
M4&G.5SLV-GOE=63-I'W;L!(MJN-[KH>I4X-D,,.2\9A%GZL':#97-"@3;[HB
MNZMM>4,THK3>R^F5JH2+;;EXI^9Z3'I85\#;5H-?URZ[\9[%^.-JN5HKL*OV
MP\]R,(;1?OA.WQ;++>IG_<!%%=]]'%TZ%@VOJR?E#P5V/<#\!I4?[,G+R'^L
M[KR(>ZM07K&*/<3UV_;8(_SX$48@'Z&U9Y&I%;*QW- ')N=CE\RP#ZK!4S^K
MI0NF'Z':P-3C5*5SB6F[S>SW1<6+XD&P&BU!<OQ13&O;B7G_V$M?[C N#<-Z
M@9XVG0)9=$ M\\S?N<@"/K^]^"8+ 53T1%9=4+Z,  U@:2!F!E RB%P)O UK
MP[ 0S O&M@:2PAOK\J-O4NU0ZP?>BZLRU?,QG9J"EI/X*6#35F ]OAV7!\&M
M-D5-:3Z+2C-3N3 FC2AP(XH/:FCJ>%%(R6 Q$<DW)$&MU"Y5EAL/ V,8^4%D
MBOJ<F$)5?!2+"X%45#0TG6HSP!H+ E$,"((.X"(I\<4&BV(/<D,%O3& *B*V
M72&+L7)7$AT5  ET80VQEO\&SY?U($A&CNG&L;&^]Y)<$@4\T *\F*ZN'F>[
MLG\P5:$H0M"*]40#@*X(3]-3M?YU<<]9&2D&;02@1CT9['B("<-G.SP#)ZG.
MZP1#';WXFX9;0Z5$,1U/*1I%2,"-_(<M\JPF#[]*;8[1.Y8R)84'55W'/>9X
MKR?;L_W-!(KS1T:<:2OJ6B1092NFMB!+P<>P5.$*6V16RL6_Q]E:(V[Z(B!K
M3,R1WW+"[HIM!Y3<O2;>/UMZ+=:.8*DGZQI':V-2,:UQB 6^-H5CW:C4"\Q7
M)8I=*C-UH<P8<LJ7Y"_U8KE6D#"UX98N5L\\J.XEQ42U04[B\SXVF !^(2XL
MR@QUU&/,IR<0[P(%8VJ->/SQ0]0)D3L9U6JY6$<-"=B<U' 43]2?@IFP2H70
MZBNS^ZR,M5DAY@='SK7BGK[:AHVXV$3CG_+QKB<&JDV^2XS"PL0=K;L+U>'&
M/3$T&2<E=MQ$763 8XIXK&&-K5$M2JA+H5!KE'06PI#X[W@RD]84-!;2Q^:'
M).NVJZ5.%]AQYX.A)[D+7G_<_8#O,MTG&^48*0[IU'<]9T5J7 Y_-A-%CP&_
MPRL_Q[DS:O.F+$=1BJ!A.MC!/2[ZT;H7T/(M*<SD8&3V2[M]I_ 3 ,1TI5<F
MQ B%;(R"=(58].Y(U#GCOP!+.Q3E.I,:6KQFN-T4W?1M=^J6-1T7<WRTWO':
MBF!;_T7I+E_JC$0Z]E0J%?42XR*:"6DJE(+D5YKWE-;D *+ -VCIZ7M/4KH!
M]E>6@';B*G&5.)>DKND+DSW[LP[$7E;E9!?)K2H6MLW,8X5JEF5Z2I:IY../
MY@]8BS1*6\!R/TT8I<F5D\8H_"Q-QJ0L'@B;N]V1+#^11AJHX;W(<4'9QM1,
M6SPRA$=J_'4&2\9EQPIRRN1-;%BMY(;T?:&D8\=.V]&*=<2[C9 V3L/==):L
ML[!9JU1:LU:NH%N[#%URHLHM]7@\Y;XEVK#+E;E/AC ..;(;? B<4V '5/\*
M/,.EZ3]X8KL\:;$L#4T]D780.:$]%&U,@7?CLN4.CM':^Z L)QHLU!6V"!S*
MB(KLX6H#(59B#RIQ-5VM.VVC"9 4.(\Q)Y'JD'K HY.> A_R[1#I(\3(PB*/
M+K$OF!H5.XVG=5F?36 I;FJD.6*CQ"[)+T%VDBQG'&)I3!C*(7U2^&8J <3\
MXPS/$5=9GD+3POY4)II^<=8S,>L 33T<C#E&<7-X<: Q8]K7;&:,@#O+YLF;
M+GW)4-?7_H*%ZE6JAWJ5\7J52OE0L+(PW:[2>'T +(7.)HZ6IK/W! "W>9!(
MWRR;OU+>K,U_ U8/J[(BTU9( C6U1LWJ7O<$MJP!GUM4KVY=]K?(Y:S20'E0
MJ8[-94GW6U1=-H3MIQJV)I6Y2?-%=!->X8]_C<(N&+ !,.MSY/I^4AY\3D]G
M:N3EU5_/[\_I[\KG#V071;8#!A&\QP#!_VQ[D<",YSYY5)20KGB6OLFA.<!>
MN0.S PJ":DN(QD?'LT8@4>DULNLYV(F<U R/O)IW?9R 7*&7B+^K8R\QQM^1
M5IOBGAI4J4KM4T'O(K\!Q7!C\UJM)]5K=6 &" ],L6<=T_U=53D+/8C6C2-V
MX[XDANH7"7+Q3[/S2AJIZ' S5W287'9Q^R=9T1M'>9M:E#<*+#W$6P-&,IFK
MB>MV;)JKCOO#QD!4!27P@5AFWTL/Z'7V1,7M!=:ZM[7.NCA<5='*13NFE+C1
MDVJ#:?M!*"KEHQ TT3_49)0):BBQ[T,"5=P^#!NPJ.?@$PIQ!Y6X=P?\N@"L
MJ_E!?<-#:L=S)Q1&X/ QL(M5#=I#X)0I< .#K$Z ^R=5W"5ZRF0!O;0)GK,?
M?&W&1*);UQ!5 =66T( Q4"62&[ @#4<QL!BOP""P.0D[1H*0M)=D2%!C(KH@
M)D9L^M&S'7%D3<?A3ZHX2E3XL1N[;SOL[Q[^:S[A:-YTV(V<&S_@%2%-P7Z
MSSSH S3"?H&UGT'7A4\7/##M OMF6GU8BO%/8#&^_;OIF,*E!:![LCWVB^T#
MZ:;6?L%[8"5@DJ1:<4&@Q(H]H6)IS\!I  BN'0V0%0(%=WE$&5B &C"=2P6&
M;C('[67X^QR8I7'CE5CE4[51[#X7 :Z-FO)</7@1.JG(/4H9T4B;B/'?//_W
M@NC4:[M"\B3093%T)2"U(&6R#V%A8$,!7W0K#.)Z?N$1I7(T[&\9D+L*S5-.
M^2OTH&N@N4[Q9\GN:V F8@\>]D@/4^TWQ2KL7H^\@SZ.O(!OP+95",00E;8D
M/9H5<#$WO5(^[GQ0K$7;Y*4J^V]WTZC2?TAX':SH/@(>52EWB@UJW!DYPL.&
M$.;D/4P%(36+72S:T*D.#@W6J:)]-V7]#V+]<%+0LRK7KZ]-<I%8#@J,P2/0
M5TL"3P!M[&B)M7@X+K-O.KVX1I3[ ?4O<*TDZ"A:NT=P:%7'1W)ZOMBHBG2E
M]1Z3:Y  5PVHN>V&GA:0J]+CV]$3QB>K!8-B='(;=S&N \Y_Q^!BXN2V0.(#
M&:I+077Z9HY8(V$C 'S[V4QJ*N69S^8C%\G%$WS$2/C(-":A7,P2)>.%GA8
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M-?;0I,L:!=DYR'H*0=H##+?9\7QW<9L'0I^8@RDO ]DO>G_$D^N3SFL%"M_
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MX:$,YG/^E:!P)U]S!1;-M910BQ\3:CA?FL'ND9=CA&?#NQ*Q-A[*7:VV*4Q
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ME 8RR3RA(;YS96!57CL$MK[!_M2P-)+(TO@VE9JDKHPFVV6K7@%+VR&!IDW
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MF.!XI/.N2"?Z,FKHI(1._(/6E:A=L"3LYW[='NT:O7OT^"=?I)<4QMA<]BU
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MK/CW,F_9^*C15@34TN*X",W92Y\M\T2?63/M)+@BN^ 0=5\P*'&')2XH,/@
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M'/@4:N639N-O% )Y=!<"60N![-V%0&YEHR*OM;55K)C 9!(DCC4+8M8L#,>
M$<=YI0C:I3CT2VL5\)W0$?8&2&M5ER/'\E@.?,+S6'!TE]-6G(5B4:EA%?=
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M*^9/(!TNE28!9F.<)S8R+M*0(7WW=N:-@+*[6W= V36@[.,[H.PMO (,;#N
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MIRG)8R4'LY'0VT;%0BC$ZGA&23:I2S\M$_!N8HBB^DI1%9SZ6-&"_57+;M!
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M;6UM;=_G!D9T@=GY8V\1CR=WEHYI] +<4#9@V!U-@W?0$H7T!L64T8EP51.
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MS"OY1EB;>G[1H\R1CB^7;;<"J521NY/^"*/G!/_E;<TTAR,PH'NB8K18<I$
M5T/F5J\)U#25@P6SG&>BVR[G61^3GZ\LK9!]K4X0: [<M&Q4A*'"R(W PX5!
M(POW,L0'[Q00^.T\=EOG(XWZW!X#$Y5M^:XB!JDBN-:\A)2>;1=PSM.1X'<V
M4^+Z3E.>A&I4G*.!!I1 ']+D(W<!P+JL/NL7^#"[,OM$\2GJ#8-NIW,=GE ^
MI5S>?+*XK1GHX;#J<1I;2LQ4J1V6J\_S]YXUD< UB44_.U2#%&&0\5,H?69
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MX)M00]'\=JK35),*O"HTH9$& MMP*VJ11*4$J^S 2OH/H*1*+26K/>UGN]+
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M-_#)'+S$27RA//Z(4"/SCZ#I2JE#']M?]R 6BJ3)=J"DUT"UI"*#3[[^MQC
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M=,ED F@ZTN.,.(BD>&1\<L3OO(+/;<&,R/@B&/*U)NI/2WZODLBH<490VK#
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M]Y.'[#$=8-\+!BTQAXFP[8]+P*JT1YPOP00!0;N[(5M-?31<0>83W%KJZ'!
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M3-@/DD,;;EDU]($HV$L8^DJD<4T\SJ?KLCWG\T/ VC);K0ONO +=#)2UIP$
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M^/Q4%AR7!3]_>BH+_KZWP#>"L1\=O2F<>"=B"+$%NQ15UA(!\#0UP\<UN"-
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M!CHS:%85[A(NE6@_9Y\1ZI;'N60TT1R0U9,A4J(=;[-.V,IAM=/=2GEG=B4
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M4C45:C&Z0(3"EJZ$VE7ED@>5GA7;I\^EU7N_V^[Y5JY+_8&=E.YJ6JM+IM\
M0JO*&4]NJWZ6^Q4]RDIX4@='Q@T&U$R@1-K;P&@'H$X4@MI#1.-9OJ9 T]Z=
MR0>P6<*Y?G! ?C!&':JCO/D&H[P 1<"<>8% NRX#VE]8]VT2HI]I!U9]GBUX
M21=*N\47H='8>/0XJU?(;)]6Y"(H;1QPY\TSUW$1$M!L(7C[.[';+7PX;PBG
M<?B5SF^'SE8#%.B##1W/!CI4.ONZ;ZS)%'7L[<E'B#"A&95H,< Y$(!SCCL/
MR;XTX.(6^>WYA3: 5KC6)=@T;HW*J(WO\S#%&JP>Y3&Q4[3K6J0W2!!&\J>
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M+C[@:5)2;U3@F5;#I%3ZN1.=S%%'T^(DG^SX#YNX=_,F60RQ+;*3YM)NY.C
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M+>IC1#CU['&L"]:%=)&+.K'H**H7*GRM?UK2Z.NN>V/MTKQI)B6*T]#NMIY
MR%@' >DES^*6VC%C2RE!T,P'Y./@ JL> .E,ZL3VY\0D[GWD<>!U9@$IQ"B!
M[M<HX+RI]6VZR[WL<2&^C(N_3K^68'2J^MMOE'_+F8EJ@1-"N7_C<*0=LT#?
MD&U8(=Q4[;4#N+7>>T5?)%Y<RNLL(H:6SR@OA27"F^@7[0.&+ _!"VZFLN9J
M1+VA;#<_ZAHP3PDQ&YHKEF[O"/PFGLN/R$''175R$+DYN"-!;V*.*01$SR(2
M+W9S;<V@LRE %5AV,$'AR;KH4CA[S[B]T/OC5ND>U8<<,HU+MZM]7Y:VBJAX
MM3#+#]*K-*&:TD$;2&UZDD<@;X-P4_X;1$,>48WJD5#S6DJYW%>BQ].)NPUH
MR5NQ1+R7;<A/@'FC"C3/_K?UO'<DK_IS.]U7/!X/%II*N]F:@=/63'#IM6Q$
M@$.X#K&H@Q$2HA_!>IB0%C+&6$%/BE$] 2:B$<MA8%>RJ!*' 9-<V T3-X6^
M?0X_\]CAAXQ\[4AAH+58+,AH'N= 0X1*:1GU\:"30%*<V/8>2(&#8)N<PS^5
M(K0L@!@UNXDRT8JPHP<G9YL69)L++U$)6JHD@YL)X";SOP$9-'&#(Q/Q*-0[
MHU_%IJJPG-!QY#]_<]WZ,QW.O'/>1&ME[@/2@$-Y#G!7@BT5'C44Y)AQC!_%
MJM%;;T)0NRKH8$QOG]6N[&=#462R.PQ?MN]C@.&P+>)Q/@(&&O# A0L_0Z[H
MG#(\5!IRMON#8Z?82I7S9>U!*%LQF0(%).H$@)%V6J@P<O.\[G86S.W6EDI_
M'C^)73N1"3BJV%$"5/GH*[%AE__]7T^&@\?/ ]!$+,KC9*H82]FZV1U;X:04
M3JJ]XAEQ7@9D!W.DP!KY4MF3L5ZL#*0[Z8;?J9+#/.($A2_[QSN,.0/4A0*!
M9UG6X&;)UB>R@S9"XK1-L!W^N9?J04,BR!7K5ICG9(P]<O_CJSV'BU-Q,R9:
M@<.*^U91(A$YE1(U$B6W27A-_397C(BFB67.U5J"8>4:?V#W<B_>+N::G16E
M1;!22]5<*$_K(>1$F8X-QF[M%G'D<@'/J3FDDGEV[CNOJ%+E*\+3D-%8M&>+
M]4!49HY7*$X38@-&$Y8?TOTQ0D"WA.-I)-%5#ODKUKA0H=9S&X8I925F9!)B
M&H_JT?PB4+^8]\;W*!*XBO+BUJJ\V"HO#E?EQ;N]! B42HEQSUD-K+.J]F!)
MY5K&5.C+A\3]!-OM\^R(?CB,LWB<B *N=?O-(0*"3RC@\Z6..),#$18")D[-
MQ8ZI9&%W*Q'E[=L<4NX1)6DB][S=(WO*61-A>:)(JM4KJ_)*V KC6HW*?)1@
MVH]25U[WGS[>-;P7![&AHZ,26CC6G+@]M!C?1A*'ZQ)A94_!PHG7E7T;B@HA
MCFW>!(Y7&"(=)70TX34BCU;B2Q/K6R/P'L&=>=X#Z&:0L.&)4 \(2(N4E=#D
M*_.PE2\:7A=# ZBL%.W6&?,&-M7X E9;;FORX3M@8.@'H"+'0-TJ>!-X(E:A
M,<8=%K%J6HI9GX?U7?*,W.YF>1L<\P"4%+J\<^M*M+USB2-WK7/^PX98;<)!
M.QIFM,$;WZ4!WH>1NU\1BN[?$45YYXC3BD'GURQ*\M,QU6L<<HD:(8748+8F
M+S\7]1;;Y^L%CNAE7BS!&(?8/+'JM%''*&LD(_-OH[VO#!R.7Q((7,8=TQ10
MZ(B5:=3RJ311 IP"BO8V,_<'[C>( 5FNVZFUZ1VMW7\7Z/3%@B?P&D%5&@09
MA/R<L2?->I$.L7L?=4"A1U:V/DC,V@YX;5O>2DB]?<>"!N@6AY..P@O+T"K:
MUZQS>.2)8*9MVH1K=OA:[92)UZAO70HQ.EO[9N^*F)4MRH$>7ZCSA!@ 3H62
MO*\*NH\1,&Z&UWABO&6=&-\.M14T) 43)^0RY+(J'?N 5/<P=G>I99M11QEI
M/3"\TZJ-V$OFI<+[T9&(X\FU![[O@X"O.&E0H!QRW1A2+MQY@PL(8GX$D."Y
M"?[.49Y'!(EP"'BH(H#K8ZZ,R0:B$!NQ1Y9I58L9)Q828;)2A&A"7J5V^X6%
MHQ]P3=LK6V%-;[FB(*-M2S0[O+&P$U!7I[!">86!U(UY!L');!Z\NNV]K%*;
M?9LIQ8K5<2OH#-:4ARW##'D]L7 $;X8LNV-7\>80MJ@*&DS2F<W (<1GFL.E
M1[A0':>H=/_01-OF0W4[V&FX(R0.5.0#:5:Z9XAL_S%QL]I"L$O<RBV T76J
MXT(5J^IJ(M0;,X6@8%99:!<4#IU +]AN11N4SG7DBXV!=34#%?*H<IEPZME*
MA;TN$>SA)D,<]XK>@#*AMN;EU<Z)(F6.KDY=,J646FHPS\=AU*!^<"ZKF[W
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M'DJYR5-.+D'RGK-#UDN*>E$^JI7@'U#%\(03 )-H]KHA+O?GD)4=YH/O>M2
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M2,%(Y^.8_A:?F2@<2K:PD]43_C:'[7XGELA9I!"?!Y".YL":]S34EB08=Y%
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MJ#TP"W@\[DV-#S62"$2+E=6P9B;&:X9<;,#U"4I^2VSAR(#*HI[2S!^E^2'
M8VHL'9NUF62^U]W6HN/S3<L=* FZU6%D^1UB*(2:;?G [ %3K"W+A$3]@%1>
MX5<14@:8GQ+B?#'FCMDBK>AI_BW?I:.%-_<*K<*FW,"-(8H/2K*:,$P*[_@G
MM)Y9[R@/TY*VP$"N@%EV/$T\2^HU+$EK-Q98=Z?,J63>)E,3/4*24<E&\X[F
MC*3?88*!-D&Z&((/] YAKT#T%6D:0UW:YNR$P&>:ER5J+^*^2WU3F";DUY=Z
MMD8F.3SV+*!0NO'AQCAPGL*1E*WW7L;VS*60.9IEX209E7V71(3T8)3P(A)M
MQ[&FVY'[57G@'%/IE"FL=IR9I,)L \*N(C&O)]<I-21W'Z W1MBA@\ 3< 08
MVEV-"FU%;A;8FPD6P:5&^!"U\ !M3%BR].ZBY-C.E3;NPH@'W;E3M!57^+Y&
M <K6E?&_PEX2_?U!^/\V-IY"\!V^N++;FIU_[^#UN]YPO??Y_:?7O^SM'[S^
M]/I5;W_G[>O]WH<WO=?_\WGOX%^0:?_\:>]@S_QRY_VKWN?]U_#'CY\^[+Y^
M_6I_/5AMQP]>O,]O+@%TN4'PC6BP<:5&--^G0,O:7.^]>OUFY_/;@_W>YX\?
MWAM3>K_WX9.RJ/65\=PAXQE<TPZTM=Y[M_?^M=EYWKPV&\ZKO?W=MQ_V/W]:
MV<?=LH_A-=G']GKOP\&OKS_U]MZ_^?#IW<[!WH?WUV092S'A?TO.GF5Y]K[&
MB);H#LZJ3_'X[P]&&P\8Z/GW!\E9]6R<G,71VMBXR/&#GG$(S?/%H^B9,9E/
M=1H/-@ZW!SM%<5!,LBIZDX9'#W"RDK.3M<?#X? J;G6!^VQ>PROMD%/9NM?6
M5;_3O!MMT\(T :F^VXO+_GPS'N5%:C5/5K6:5JWFT:I6T[DMRW-T;<&-0V'S
MF@Z%1^N]U__\=>_EWL'^33@)9&M+<3SLYE-NZR96'*$WM_U/ 0(:"<>)O1;Q
M&7.P8(4A*;E\3@E0QCSN5?&D]VAC -?]9./JWO[:;\OI>UP1*U47X=3(#&DX
M+<V*E7\MYJ):R/"4QF.SQCMHJNR]G_ZEM5D>=FR6"PFBS*IX39-,X_4^9P?I
M8C14YS_DX"\+.;+.>_[VQ>FC;A!@_+^!&<N\^"OD?T 1P.8[6]:GA81A9OC-
MXQX5>9U%,/EY\:Q7'!W^--S8Z@\WG_2'V]L_MTG%FN-WWI-NK@\N,QT+A[M[
MH,+><0%>SG%539\]?'AZ>KI>QJ/UH_SDX4XQ.DY.XO)A'!V%Q<,HK,*'@\TG
M3S:'&P\W-HSK/MA\:OYGT_SGZ6#P</SDZ\;68##8C,\VD_\'1;XLJ2?KQ]7D
MO+?T2:9[/LDT5&GX6KV/ $8,1W&-LV$6I/GH>N\G1VPKK*/CN,!#U^Q1;.(]
M,Y2R_>TV1!K> $G8D[7?H%M6"%<8+PK9OYUID:2]P6. _PXV?W:R&^'W&LP?
MQTD57\1*+CBMWV8#ZO/+9?O#I;?]+?/O1QM;#\?EP-C&EK'\D^^Q_!VH56-A
MP!CNHE7A5[;);/\19C54-\A.MRZ\++;A1UP"^VL#OI:Q>KD<P=X'6RN[OS&[
MW[P;=O_D">[YPXU-M/SOVO._R_+?Q(<%V2J9ZF6.!+%]M_T;V[<7?+RR_1NV
M_:VEM_UM^,_V)MG^\-%@^U9M7UOK\!&:Z_;WFO\[Q&]OT<56MG]CMK^]]+;_
M9,.8_.,-:_M/C.VO#9;)^)]<V=XO%UPM@!M; (^6?@&8_VP-'SU].!YL? 7C
M /M_?)OV3WLUF>K3"]O^8VO[@XWVSC_8ILNM+/_&+/_QLEO^$+R>@0EUXW P
MW#2_]'?^*69F;L'^_U%G<6^ ]C_<^-Z]W[O8ROIOS/J?W 'K'PXWAT.T_NWM
MQX-;]WMVZB.031AL7(WER^6V5K9_P[;_=-EMWSC]@XU'&YO@\_QGXYM\_AW5
MH_-)>G1><H].A#^Q 3[]9B?>.#+_T[+GIRL7_J;K51O+;L_@R0PVMFDO'VQN
M#;_1GF7SOH!QOPLYE?C]&S5<:GNU2=^L50_6!__[ALPZ#C>&FT\'6YL;X&,,
MOMG)4)*+N\=)/#:6%8]J[ ?]0-U['I)#Z'<V-X8+R)B8%VQE=S=F=\/;LKOA
M]]O=Q\)L=<DT3'MO/)JD'<?7M3+%NV**0[,%WHXM#F]J#X0FL]UU:W^#S>T-
MC+VX%:W+1I]N/#K?1O_WRD9ORD:'MV:CM[=?KLSV;IOM8&.POO=^_[H-=^$S
M[&5 1]7[Y\M/;WM[&3!KFG#D%6.#KP8<>6$;.'^T]G=_79K1.@C/\BR?S'K[
MH^-X$E[QH%V/M>WNO%V^\=L-TY$ R-\FV==#:&I?6A-\]?K-\@WA*U!*2*YS
M!*_''M_NO%R^P7P;'L9I>QQ[2V>*'S^]7K[1^TBZTM>ZG*_#&+=N=2AWD:03
M>[!0AB4D\O)7814:GS"->S]1(V)%+3IZY$4,($2ME"2SF41C(BI1.%?5>M6E
M<U6*\<.MZ=EY$WUA*[N@X;S!]/!Q7,30O'"!Z;[VUN?[,(E7/HLDH;8L,WF1
M!N"GJP;@5@/PXU4#\/<V &]=(^6,=.6:)]K?^^7]S@&0AMRS=N"/*BG45&,(
M)#/D>%X]*4NBY=SJ\Q=)8S&KD#LNJH$P#4C'(J]IF(0E@-^6JIC05WP8'X?I
M6!B^D 64/P D7W&=57F UV,]AC_CZ]!1H?_^L1R23J_47!^.DK\_&%Z@/79G
M]V#O_=[G=[V/O^Y\>K>S^_KSP=[NSMO]?F_O_6ZK2_AB+OS<L_;1QN(^8?[8
MYL4^]?@OWY#I4V.W>&R,*V[^#45XA)8,.R'[YUSCY>R9/.!\]^&[F[N3%P_+
MA[U]$Q?$)8C:5,?$@_GMT]8U^IV_6_QD_B/=^N/L'H>)B:F(X7%.F>AOA\7#
M%\%/KV WVK&[D<W&FV_2)UP&OW6)GV_D5;_'\"\_=,:0;\*$JQB&D;NUW^;U
MT;$)>Y?%F.<\W*T_&%FR*R2))=_^DUUF&9U7".M>53<5'UVE>WP-C$[7]*CG
MNJ]=T=9E[W9.7/;HR4)-$>#B6M.13,-) !?L@?<';:4J#L6GZ A"90SPQNT@
MJG7_[YK6;X]>/0.XYO]KQ[% ))^&LV>]+,]BHE@[CD,SK"]ZO0!_2B(3E<A/
MYE-O"M8&\/C7AL2A1I]>&YN/K&T(\UI=KAV%X?09BM%7&+_L9-$NLE0?F;#;
M1"\/3&R1T*7J,GK0.RN39UF2&CLM:GBLA_Z]7YSS-)OMIQG<WM-TC,VP^30?
M$6%:Q!'2Z&.ZYM)/<=X<=8S*YFT\QU;[.;::S\'"YI>?BG/NO=V^]_9-W?M1
M^]Z/;NK>C]OW?GQ3]]YHW_O)3=W[2?O>3V_JWH..A3]H[8H[$62!<!\ZR'<L
M;?W',(GVLMUPFE1ANG\<%O%+D   6J0X*[%FATOT _)CE9\@.50F56S.HQ/C
M=7TTQU(>?8I'^1%5F[]A%9_W>AWK>-#:9N_NZW7-7FO??A]7>RC&_C8OO\&
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M?R-=*?7IBV#Y-\/H"V1_ U!+ P04    " !PBZE:3+J0?70'  !N)@  '@
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M[+H)<0/ 5!3))!'BA2HSUNASZ'T@X2 I*9>.@&UPNJ6B@;]T6%AEI/B<2BS
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M$*%C[ISOJ(=AO4&&L79DBKUL=,6+GF"[^:CVO+,<B)>@(*I3O?4,.,=X3JO
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MZ9&\=O>6I-,UE1Z3*P?_N'(R0E?VF?71=$W6057ZW>Y8VMSY-,4$$MK/)$E
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MXO25B*,"W21_22ZXF(,HZ@4NB/M[PWH64[PQOMM0B!:%@4?W^-=8V+:EWYY
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M,,AY^.P?=9,P;HL[,X7Q]A.-X! ]^';M#DR/6\EXZM'$@=YBI%F3&4SMTIV
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M?'*G'SGNTXND:?Q[R95>CR$6X/OL$U,F'Y89)KGPU\E;MAI._N,OJ9,T#@,
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M\TI6H@-4R[V>@K.MG30W'W\2/5\6Q+/))UM!W'WN.HHBME+EV^N:QSON5&V
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MT:P("O+VERA2(=V8O_/LS\G'CF[EOZ?ZQS4F6<1G.2P%(:Z?9.%]1F.8-ZG
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M^XC7-13O<'D\"-6_]P0NZL^10B _JA.NH+^!?[J<(>4([;F5P9]N:_KC% O
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M+OTHG9J=:W1_U1>EBZX;6;_Y+[@@S?^D\; C\(76S-_C#^-HB=+U5\ICD(F
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MO7<('RL-A^+DN Z<R=^[?,FKBDH+M_-(0'].@;J0GJ$.?[(\W3BUV#%+[)3
MG3W"I\[;XZ/2XZ-\^G8#:]D\(WS"W_[U?2OMS&N7/UXWF!#/F7C_7I#=W25'
M%6+CF33*"P]UG<)Y(&_/A)TXF4SOTUL#=G&+)I^^Z=0$/5XS 7+W\A9UA*C]
M_DH\QHC.U;_\WND50Y*(2O34K:-E$]%BZ^A+^V!@WZ 7<5&L]SBNKIHFU&O(
M2?%!X9"B&SGZ36/^T6?&-+A/]Q]*>G=1+Z6KY@L<9M>X;AQGI0;\&8F.WR>P
M 'Q<?&-1E:=9@-="%&PM8>5ZR[&#IP0NF'_E&<P!,Y2WKO/#4N"^$-0NMRU#
M%#JD]K8?&AV:/'SCIS%"M_]^Y9^;EM.4']]*/ZY87*ZHQ%62-J:2GM2 7:VK
M1!3D[=V3PA98 '"5%E0EP#OTK733\\5.EV)'K]07TNE]+I59DM05;Q; ,VOY
M6$9IC\^6G<J_\EL2IQW0C>%<O<MG87I!+Y8;8C^5^I"#$N?%&$:S!S5^WP8^
M,#FI#S6/3?*%>C:MXFYL:&4O:=:-KXP%=5U?V*3_'KD_*<W;]QB93GG[5.UZ
MUM7["HI8(-BA0A)JF?LUWW?LY9^5EA(3)1M3L=JV+T(S2HOJ Y E L'J3Z@E
MF^ ^!S\>1$/:-_O.DKP\+U7G?IZ,4AU7!16/>2NIPT**VG8^&33/1YY]%<T#
MGQPX!O:,QJ/K,XX*@)3:%[6T^'O)_4A1F %PQ<_U#O$$:#E9JV] 'N5U]K.&
MGVWD O%Y$ [-9"ATZ'C#B$(-1 (*$L3[<HL=FE#Q+_2MZ%X,Z=9Z&H9D!4 $
M4OI*=/$]9KOZDN>?=QB1)?GAS7U+0E1@_*..@CZ&=QG-WQC5]S3E2AX%L@S5
MK"9OKR7[#$A2[$$Q!<*4@0086*Y[F>\ '$DX9$I-:@3(V5*V"S(Q<%.R8(ID
M7^E[RGD4+$$C"HR+LG-JI2FM% H<Q6_I.Y4MS'U>\+ (Q=M,;N]X1+  9QU/
MWN("="U&>3XC+,=V4KXZYGC$SKX,T%_F7S"J0IB-PTY">^JYPXS+?3W%.FD6
M*Y@IZ:XH-<?VIDD5MS\F-/Q3[*R:T.O0B=%,<3E9(R%]:4>)6'/X,\.))W!=
MVK.NI6R9H.JAJMX!_JHI2_N-B6)MT,,5EY\A!9!1M]P;?AKHQ@H1^XIAH>WU
MZ?B&?-)6AH.<\61JVDN,B&H8$<O@H,[V1>FYGQ0RY,C--"K,:T62AY9L?9*W
MPU2D>>X0>K/63&G!/E$K8&[ASP]F)BVHV;F@N .CD"ZNV3^G'F]U<'.:8C9N
M@-:R,B-_S0BC_J Z?$+!Z%[NB(>_'G9'G U#"_E>1[UP]+P<?^@Q%HA0J(#S
M[NR9Q$A1"R#S%Q86!OQ)^>9[#F]S^YYLBB)T']NT1;]R179;X1^I.+GBQW&G
MJ>=[[=:7E&;U56?;K%YN+UME#1-$A7HA/'!L'_7+TJ8F.(@$N>3,D*%^GKY4
M>"4[P3.*5XW-NT!(=\4ZW_(#8W:[_D6[1:Z1ZQ:"<'8HK.#%_*)5J)"_U -L
M^^E@'.4 _9RALX)/6CI#@WB3V5S5L^?0J#D[:Z@WN<O0\WJ7$AAEZ;Q@.?V5
M\G48IE+6@MQ^;&!^ )I."CD>F/8P3BH5, <"C60^KIDK\E/YORLV%LO$PX)Y
M[%Y-Y18[*D:9ET 'Z(X6<W0'22^M436HYF+KHR^EE@[B4-Q&B-U3O^&"*^=[
MJB +5BZ4[.VW90P7JD0^D05(M/,_1DB>08 I>X2<IG:B@9@%\GG!J0Q/QLUQ
MPVO:4QKQJ'Y,+T<% 6L1^D _</Y]JD@8K1@7]+9Q._+P8PLE?&O%7QJ)*XBG
MGG=!'0904AO)*B!"6T$IN^ZS[K1P$@L0Q[A/W2,C^T>!\$B"[E(5.7?YLO^S
MG0;*,H$IM% &][>E&M1--6ZF@"PH7V=G6  8''OX-[41OWVZ@B%,BZ*TWZ9:
M)E*.[M+\:QE>5%0B4]:%QGE$. [O2S'MG4?&LK7U:<KV<MP!O ,6^K! 8$H-
MUK*K,<K9<Z^IS01E6%%M)E,-DJ>%,CDUJ!!["C"IPZ(R>H0I_J+W*>@4#CV/
MZNZ2H.SV<[&CK#$9$I.MVX\O\ZNJ,#M/X#+PND-+P=3^M;< ?\3-YS2V6]@5
MF4ZN\H_B<O6]T5/=$T!66!6YM^)""N8IW;Z.BTK#QF!B2C(5Z&8]*7^4K_B8
M5)<*5R95YV 2*FZ98[GY*X9%7EERUF@9FD_K+.K^P((B0BHLU0I>^IS)77WB
ME*G="PH$BC%G#95R#P.H^"V/(*KN)J'M$$5%F5(_Y19_'\;,5[!'YF67..U6
M+U.Q?F8[+5)O-%ZTK+.:<7?,T4K> AC;J!33[$@T87I0?%8D&0*_71'[@^9/
M1L;JIN3ER,92@#U29$QJ!["<E@OI0%FWTP(*:2MDQZ[#9SNQI314;_CQTQKJ
MZ5Y#Y3%2@ %"#$G*E>V,TU8K4,*WZ9^B/_!]-MM7 R&A4;A13H3NY*]Y515J
M?/<N__#*@H'E*#GZ+=7">B8,+'9WHAA]=WQK!W'G$K8(QSM/@UA3+7,E#[/R
MO54Q$B6CCZ,M:2MLD)A1M;J1*:#_Q=A[!S6QA^^C\:@@(D2E@Q ]@'10:0*!
M6$% B/1.CB B1$!ZD$"47N6H% 4DAQHI(0J$)B1""!Q%>@\U042:)-050K@Y
MOYE[Y\[<[]SY_K$[F<QF]RW/\[[/N\E^(DDZ9[IOV) $E67BH9[%2]%7C=19
M[JD!#+@4RGM.!1TXM,6WS4^.#V9#/T0]59RDB#8;9G18>';Q&:@3Q>+4Z[Z_
M='A\+G#[$46IE!)A?Q'U%"QB1KIH9;=H5G^AP@:5 S54M3.[TA'E;MM4QJ K
MCI1*6&=ZBA3("&5?B2A0S_2UM?6V?!7]51-GH4?PZK8.*=:&TY1H2N6WV_TL
M=..90_,8MG#NBOV'T1939J3M4%VK20<,O-TGBO)T!J*JIENRFWL_[NL#8E0:
M;UPH']2"'W73=# DXPS:$4BS=W$+,S<@GUH^\_4A,8&UL+5.4^B:;0B((3_"
M)*LQ%=IS^Y(YDERE=!*9J^H\%J,!=:/[M%C0-4ZB[<>V-4ZAG.H.D-?R+,>@
MH03*W/JI%8>:*<0;ZT5SI('VISL3+:\MN#V9P+[%6H_E: )#=(W5:;I?I!D@
M7\SF&6ZY,7,)&(JDWQX)B%:[C:&OB_VDJ39CVF?/RC60^4DJ2\X-E#5+TPZ=
MO:X=X]+*Z_*9 R:EYDL8(HXM3$8<O((Z(9F;5,31QVBK>;S)3LA@M(J/J+Y8
M1V*L\0A'R1W5NT@9.P2=5 TU7S]>.N13[RX]T&(W?Q7JK?Y6FCJ31__T*9Q)
MK&TJD';GUXR(5PZDM[QU*#<1NKEOI+UD>I7J!;RUQ?,Y_(C[:5U^O;UD^?:^
M\K;Z;&U6H4-[E=;WS;O!.(E![*B;'BZ,I97I\\6F+LNT$Z=EZ[R(DY+_1MA,
M["!('8+:+-5:I A \'7F+!6Y5*U!4D?U48PN,G=CJ\^S,(E^/U@!:Y!2P.6S
M?CS-]RP-53,J#3$#[!C@4W6TL+Q0D8+*PO$S(;63;ETT"U8LYZ3]C!Y<W&?F
M".M=7\)6+</%4(JBR59M&:Q#I(KFPA(PCT: \ I4,26W !],0,M^8KG7EJ*O
M8*GV87OQ=<U1(XL)C.%?JVJAYH^*]O@[#D%,.\AS&F^*)_.@(1&*K+I9@FR@
M::3BAE95"=7U$(&5W++8]RA)0]U[Y"&TDR"A^I$N229W=->.^:.TU.+8)F*\
M8T6@9>._7^G9&1W]F=,\">2UD879AO1I'8U3+DY(W:<ZSPU_%3+4S#89T^2T
M%EWUYWX,/0W5 -(Y%[84RXOSZ5+N+P&/&;!".\ZY-<>B?G@).FH[1QYF'VN:
MU].8,O+I)-3&X8_;7UG,M9V*"+7Z46EA_7[16NG RI2\5G4KPM7&?<!9_=R@
M0XZL:WG3Q9ETVMG@E#3$&W=V"!=Z&=- 0!>M,YFY-\H?P(O2-2<S+48_,54Z
MGWHG&:G#,:Q@-^;(3-&,8-U8R\UJE!#5G@S6VE<+&FO3?6I9D;VK&];<V13H
M531;HD,NQ1Z/EG-CFS+=XCE-_Z!BVTE:@UJ'( %'8)_B+ML_>X/4CT94H PH
M).7ANL*3,[YA8OQ>D"2_N0(W%8>1*CS!>L5R']V@XW D^@ZWF<SA$+79STM1
MN\[#6GW)2_?G9*.>]*)52MHTTK3<9*D<':;E)P;DCTEW('=PWGTHQ,*3V[*2
MY5OK4*NAO[=64 $AK6)6IBE=M6)L8<2<6V]3%#U=A0(1W0XXTX/O^0>E<&NH
M1>RO )+R<GVTTC!:MI(Z!ZX#$D9I"R%^<+.6/&MLQYB,>/)C*V]B9!/?LPCQ
M*9G[J47%,E(O^-K1+'Q"7#D)X04O$&E:N6J;J+*S\3KD(&W1&CYAA=,/,5!T
MH%B]FWFT4FZ2-50I+Q\=$?3UW =+P96)DJ:FP137H4POF_4*C@O7RWF#MYYC
M,*\W:8,';[7@J39OCGY,_;8?_BS6[,_>ODLECTI9C17*BW^0(Z-/18]#>(T,
MV&9 +!/W.4=&SD@%\#M5BTS&/X*7.4ZE"MBB,(A42^R:9F^#NR1+@M,VJJ:-
M=%/^.:MB47:[W"=V_QJ'APO$SI?K+-[5FI)+3EK@5*M?H'GN&'@DX4C29",/
M[[F7?]]I(\"?/QEAMGAF6W<,E-\@U%!M=T(]NV'>#AJ5^L&F#25T><5/RU@+
M*Z;,Y9%XA,#FTD"Y1!=MX>\?L2T1Q7ET3\5Z?-TK:WC%2B'PD8$9Q\YW):(E
M"E%CED-H;=8?LTYP7N)Z0K3$2GCT)597')ENQ+3KZX#S98@!'@(R@_-WW6S:
M=AQH% M/HTKD?8&LL9VTG9A+/8RP61Z.QLRLCZ07MIV0U/ T(TEKLM7[^L=Z
M9EBK86]MR?B;V[]*RVY+IVHOI)<WUVW^NC]]EK_[3Q>Q^K( _V&87T:&9'4Q
MSJ(<E1+9)_@3PZN-B"&=8YYKKFZ$BM%;>5T!;CI.YMB-;5E(:Q\WAPF[ U$X
M<BY;TS@469GCF#WH7>^_Z/#?0CQL'Y9.3C& H3:+Q;28TBMAQUU0FBY,]F('
MS2(G.;L=]L?M,E2,2_I1MR$-MD'5A (EX$0E]I2;3_WNBL_3G'+5\/?UY*8;
MN-,V*7:7?H==:+*T#,1;Q^+$>NGPE\;W*A6=3P=9EY5-MA1[:_X6Q:L+XI7,
M7F@:M!E?+CTQ5"":<$6[PF3"F!C@NW"R3FG$'W]G*%/%\E6*F>8/VYP$1/2W
M67'5+3!X973FG%\87&B)(S2\A1$ ?-5<7%D/=@HN#T&=*I<Z_43[[@34NB[M
M&)T<*QE[_+#99?I2FY2X0N*:D(L'^!E,7*[AXS[L&=0FHGH6A>TH.!MP; ((
M[] $9BBVS+*7A<CF%AHVL?.5S!#<PJ##V;7?]:#,%-'+XX*ZGSWH0O#[<- 4
MK>I#DD3PTQZY"R0,A$C!P:7#EY$?W;O\O.? *0C!^XTI 6O>H<V2&E3RZ>D(
M@AQA9U_ZHG'XK6:7U(WH&80P00N)/;4B(\34(=+?V??ZP3J<#2FH@J\63[^P
MY9DY[=DL4[R/\UIV0VG/HVA^0-?%O.?BWN"RWW6B"S)9;H@@.G.Q8O'K;OO<
MPRSCH3U*;,BZBKJ=C,M&8ZF/<5!^:*:LSMP[P=-9^#</MR8+A<>&BZW/$+KA
M;\N;E.I^5+@UFF4J]00-E>L'VD'%K@%'6,&(^A%"1LQV!MB'!N=.]M+HNYPA
M5C2V' BP'&G19#)&1W>IR'^F9\=/$-T\>OF['R::)974_DYQOE/\((SU(>B(
M] G>3<(G-A=GQX\#Q'G(L:XY\W4>]M6AD/=L\'S D<2!->AMGA[=+M+) 39O
MM?ODI#NRH7]R^:AI?\C*^ ,UI3PGW8;=];"QM)?L\SR@HQ^.;E1/";,V[4HS
M"F\*_F:\MRETF=Q/MK7.7';6R(5/:,O8%J_+T2:[>Y0>;!5(ZAFKB*5EU.91
M[:ET4L5!98CT59OB'JW"8ZPSP8O^83@EQ6[C.JO;806._ZTXCB_$_.O<S?FD
ML4T86G\.VY@',*O$W['_KW=GGQL^3JSA-')ILQD,^6]=^ZJ=#<0\V6X/4H,Y
M1IZ?AJVD'()^_D&^:22$FKW'+)VZ+^^C]3L%/U)9&P&7,:6 Q*L'O['^31F\
MMO!.],[WQH9&]B8@?PB263H$N7*I=LUY?Y^.B2-"1!"W WS.;)Q6F>K=C[MT
M\U69TYN_DG:5[.S^-/W.(WY'1?5#M%=!A6!\:/+WG7,U._E<BS(B?^6&+03N
M-C5%1*TH["_R=8N=LS\S%T48_3WW/E*J^87?1$E]8. /.V%RV-+F/CQ0A[0_
MN&UNZ-&K,JET[.6=?[+DT?_FO_<\5U'Z[*\3YRNOW(E_D#RC8.(G^6__EKD:
M3[L*O[R!K5+V0Y IM%#D5$;=\7LB(K+IU^X4V::#[$0(B+21G>C!:.J7P<6<
MVN":O/B#&:1/)'J'U  K8W*F^TM8RKD=D5<CO4P;+&P77)<%5I!L0J2NB.A7
MQ:)_QO^GKVW^_S:5HQ9,7/R6'\*-Q9/!+6:F8RWW1C48?DB+0:U]:9<.>)E\
MAS-RI3D=W^+PM':)->UF\F!WTU6[*ERHA$<[BQ(P8&%F:JIDJJ1BJJ15\MK:
MS%2K)//5*^O_7KPV+1D,\[LXU,S=:ATLRH9J?9=[>RHGZD0 /U8&AT_B$'1L
M'XAE@;MDC$@L0@;[:$3EBHSJ*-2$/GL22+R32&EV)Q1'93BP,INCJ@ET:8^-
M3G[XVB3_EU594G9O3X!G[-T4*5MS1U@0<HZ0C&5:!TRXT!'IH;-'D#,JH]MJ
MD12'(9^G \S%Q,41K15#ZY%O#LWA.[%PI "U)[W]"S)B!V$DKL[(G2C=I&<)
MK35*J3#8DY TRI,PFXZ)SBOBSJ$?0Z[ZGMLNOR]ZX2:-\9LYGGNY9-E\HC_+
MQ-*L+A>W%K6'W.@3V9P5 #"*W8$D>1;XZ),?3C80%X%L!L @U%#&OBG$9IG<
M5 ]AC:O>7>F,,ZQ7%K9[!%7]<T49TES%T80#\EVK#70R" DYJ7;(W=."C0%O
MOT"& =[[<S;Y;(@+0N"V;L)ZG2&\H]W-"/Q'_ M^:6LNP(>W^:]*/UX<?E!+
MUMF<ON5EB?UOJ;<P-!_6L6EL>WW29J>V:4SK3CRQLS**96*<NPO/H(<G:ZW9
M:Y_%'GF708>)K#P-JWIM?(I+/MTO[[5R=(__0/@<@A+KHO^%;$FP^CAG!0Y!
MW<HP^AJDAO> !QU\"(J+Q6Q\)=\^!"5%S=N@A^; 9^45%)1?<?JZFW!*%;YU
M!-4*>&Y%?*F2WI=2"]M0PP)R*J;CKST-8VAF"X)IF2\KWIX&JP^N=GY2M )5
MU;O?<2GCHO1(RX430VDN53\[4RM_ :^X,D//Z,A/(^DQMKS86MZ^@T^T&/;6
M,%N#H<8#3J:=DWQ @C 37\Y%F1LWQV@<.;(C?19RMHM>+'RWS$#-(_+J6[R_
M^I'B2"ZR>@_RZ9%=K0>$0Y#O@^Q.R)D)MZ^S9^ODLVDS7U?:9L%LBX ?77/G
M627!/]V/,Z?7,S_7/=5)/'LYX8L<//)_$8A,M"&KU)<-8\FLE5MTJ7>_SL2+
M*,$ 4[_ZS%=!03Y7R[X7_<YGW]_3^.*$:IO#J<HJ6J=M5OTRR]?#*=[6V(Z7
M%V_@F3]NJ6X6E!*;'P%-V>7PL9AVVDC\P]V=L8,J&\>8D;J5RGF6 J4\4 07
M1[KH8EG?LX V=!P(@:7LI4GF"R;)QU)U:Y;[_WW8U-B$=L+,Y<[6=NB')]:9
M8AXC:.5:A#_Z&$I0C3+=CFEA&LI_WGI4&YS@+A>E(SMWXP(RW:9CKR'.^]B_
M'[JJEW6RBZ0,)B9:9SDR _OG,?W>73#@CNXA2/7]_S<25LS-SK@<-G+]3!:>
MN=#TV+K.-6KDX/6O_9IR$;]B76F;5UGFG;#B4_E8MK'&<:QFUN_-E@T+W-7A
MW=F]CB:LH;[FZZ?ZF?,&2L:"$)@KINT*[&$>GM^>F36VYK=O,86*=!G$0PVJ
M?M:BKS&':,N2HJ_+?6 G\"$J,=&0B$/0A,Y8KD[R7/B09ZZ!>:J?)KRF*252
M"C4>5/ 'EP%Z7 !!V5+S$$&@:*4+<@:*E$FL</0] R Z.+(#" JM]9O1%1F!
MVKK1"X-02"G"S=%\7A'VH5JU>%B-T?+&D/@E4LF5/()E[F1,'.7$&G'/UWZ=
M_-O+6=*!+>*] QO1EE+3:X$S>K3<I]K\=@[,VQU\[OMZO_04FFXMI2YTA+%$
M9[5>3IHO=.(ON%7XEGXNT+$N17 N(81\;#*5S1IJVNB%/2)FOD%(@>S.JN_E
MFZ7_ECIDLW#K5W&G68B?Q*0.>@"CX;EC"K/23!Q1]="1]E4H=*GY7FKGXFM*
MNV!M&:U2\?XP7GD4)_$5%MC&TJ6S23=< *R%441-RK1#WY&>W11UJ)!'RBEE
M7BPCSSS][*4GQZ=4I1Y?NX.6W*0[K 8P8)+( A@)B&)B[5B$CB,X"L,M>H4B
M6HM $5NNO\=14GG'CF63C"N-BM^C_"&G2GO85WHM7P><>U5U[_KYO?;19=K>
M*&WG*T/JDT$WRA^OCO]NBO_E5RWK]$]CS*-N$U7-6TMRUK)7]*_4O"J1+""+
M)RCP)63=-B[P2RB75[;3TU2V??#[P6QM16%,J9+B<)QKH8%SR.PGOA+ZP>U5
MS:<#."7/(/VM6?D[YOL*8M9GTXI%<69PG4I^R_S).,:"V,F_?7K!LP"X8[96
M=]6))<8(X%+#EP9/^+4>TA:\ SOA-.YC7W",I8-C:71@3]?Y:&<( =&&Q[U8
M/#B&AA!0V94]*'WS'E*E]<;.7N2DGJ2-5L%KW?;U\:&.>N?H=S!*0*PD/FL3
MY10R&8$&%_W["O,8H'3JYR3($M7*>%+43#J=L2_\/9,EKU9K;+MAUI(&?!W,
M [??B;1L.@?;SJ]I?K**C3^VB9(WT\TORKDHFA<69&GYRYHKF*\JWKHD4>42
M1/B[0<_8+C_(U3D4TE@V9H2TR5[67+#0%IV;>C"O"WNC!3_&^?($B66^^NG.
M"Y@(DAE^D7=95T?6H-(E75'E0&R7LT-JRP7<<M'\OI8NC6U:,@U,FF0]O]V2
M:LWBG10FE4?(]PIF,!-W5"\#?QB*T;%MI7"^Y5S1)B;3&= TS]B7LF.%56HD
MMQA@2K"KVY==??7[8GL_XJ!QJ2[K8-K4+;72C[5*VVLB>=\4(Z=J>K.&S'ZW
MN+V*-WMB72\#_7H)*VOVI6TXS=;30/D%6'<W@B4A7,58['[%* Y_&O2>WO.V
M.^NK56;1K&;:.UWU<(LF] 0#(<#IQ@BU>,UE)$6K,0D4L"1JD6)""4()49MW
MX^L.7-P'R?0+J;8L<%QO3KG[TH9K1\TAZ,$R;2:)<,'MRM[H_+TZT?"U'V3L
M3\P?L/OF%N![S!^QS(RY>%+\O)M)N_-,,<X9!3%_(>#/6;\[!K68FTS.V$%E
MXG;N&LF1!_&Q74@_9'#5C0^WFK.F=!$^ Q8/M2X<M\RL;0Z9>X6SU.NP/5^H
MGZ4D?^(^_5AY+WKIQB777R6,0J5IB'7/]^$*CRL27^J6S?>%1'ITYBVUG8.^
M_1C*]U3$*>@4+75:^H*QBX3CCM$]!> Q;:P0P'\+"*6W8KK\Z)/I 8[,W<2J
MK4]KZ%D@[!!$+9#6U:1-W.C-D>3!OE^I9X'5=2Z[SIC%[#GX7,5[TDU6/>?!
MXLN'H#/:ZXD0WI;;\W!QVFV>!H:%2[MD6/'[E7Y4*IW:TQ$T^R7<4]EU:AE[
M2M6_$+GDN?^8))7@9F3:H>J7MU*A; \3D.@MU<UO+YDKUT_5B2E7MFJ0UQM^
M(:F9_V>A97_0@FMJ]N7=",2(9J)X)RH_Q2K5.I!#I6YLUC4MG.C6>I7Z.E1U
M]7OFX.NLTIZ-7UES&1,0\T'M-2%CID*[@,$M5IIS %LNURTQIB[2 M81:"+3
MP&HPDR26Z+L^65;B&]7F:@2=H@7YT[.^8GLI:Z1WE$>HOFL'V9P_5RZA\KIF
M1 &7></H27-)M_H&1@;?4NX/7$!)QE$@E>K1R3]M;MG8F#" YF/,"OO&B$_;
MA4Q'VET[UO#ZUJRIE<G8AQ;.$$<TXF =L^\L,SAHE993MT> M9ZX<787K]A^
MV:?S<AJ\PAO:0A!YZ?R5Q:%V!KFYX;H/RI%*9D%F8ZY]+DUF""EGMMA!HE9>
MZLH^/.X0=/3Q+_50J5;_C4<MQPL+]>-DQ)N!YZ&H"JW6#W7NXJ/K+<;VQU_(
M-PROR]\2$[,I_HE$G"1['%C]JM;N2YCE"9#1\Z\FR*RW.9MS=F_%V@&?(K4H
M^P:".Z.<JV-HIY [GEKNBJ/6".U0\WV?Z*8BPK[EZU>ORPOT5-0#UK*^9>>8
MP05I TY(K[)<H>USTQ>+D_X]&U[#H5"=U\QZ2M]65M;-]%0_R&U&?D>(LA4/
M4M%PORC>M&@)MNBHVMIWELC(QG(![P#N4FN59$Y'G[#!OR%]EX^VS4][=^S5
MR!YKE5$:.;5BX*O[=^L[#!V[&OS>AU:0PP G8GEQ'QH:6-KUI<>[8D-*-]2V
MFK;(R3**-U6=@WI.-S0/UY&%9^O.JIB&ADKW+KXML=I.%RY^:V7&CS6HD_0Q
MN6IZ>P;:R[^\=IWD\# [(YL]A==5%?7_O9;T;X"\7'[-7=MF^.N"B=Q@T\9@
ME>H'93D:6J[13YF]>?O::-4QJ L#SOL3(<#FKUZNW]WA:(Q ]>C=TH*_?@U]
M=GZ8%_G>Q?U+V?AG@?I8'%+?:[C_5M&? 1YY#\:.3Z!7=@J Z_ORT<,%0C)@
MX!#D70*D6C+C=Y.V550 HC3BUEC+Y0CZOR&>C*ZA;;PTGH O3!BS&[!QK-N\
M6--BNEI@'K%8%V,>4$/N^\VNS&=A4M&&<S#^%8XFZV&I8 :=?,K'(;>76#[%
M^ZAJ:U_<&9EL=HN@2B"&48\IR0U]_7+J<DMU2@!O<AQKW/2^DG=6L-(HI;^]
MF_]-)XJ6M6R6+9E^3O,%#S'"ME*Y(OZDU4YZ\_"2HNVG.&#SL?J%A8BTX,<(
M_JZ+"6)B2=]$O3/M.3W%L90A0BHAJ:MYHO6<UA/ US$\I6.T7/E2W*61RN:Z
M"$_KG/G26?99$PY?J$< =2:5X0BKA='/[T<?@E*BN0*%J\CC[*.NC'48/=0
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MD(6T(9 5?6P:M&A#GZTS*JJ'S]8[^MLNCMQP?+V=?S]=<G=G>Z .B1%D'PN
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MJP&'FZW]:VS^>>'^K<I&8IZI%M:_6DHH[IVK&QH&_IK_TZZ]!=: =SA1'(M
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MJ54^'%$F^=EKQ!!4",-(13SC7!AHT2Z?=EL>"U[:9!LQ.84L,(6C2?KPVG)
M>U;TD;LBD22ZVYQ>F/@S(WW/86V=54LGK#85HI0W78#[+%D[()TU9@)0"3ZT
MAE2., H)9R[&;\&2GT(H" G@%8*OC8''P(EC&EI]O"C*=>;GW,7;8\1W-_I,
MA@DV)LW>YS*ZP+2,G1HFMC,CI1D22_0+04;+L#)2V;ITR 0'_'Q,O_-Y*-/
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M%V7O&=74%O7]YAPK"J+T'J6(=.E%)$<1$"(@O<-11#J1)D$".8+TIE3I4D.
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MVHHF,AME4^?Q9U+47TQO> ]@9&2^H8\E1B"_GRC\PLZA74>WT%>^V3L!VQ@
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M17_\$N@J[!HUI\*%*MD7<8&\F'QHJ"-SG8Q-:&=Y0C)EAS;TJBE1(Q=U(QD
MW'%Y1U\V$=SR(1676U$,%Z:([A$NFZ=/3[3":=<<2+7OPGR1ZZ F]JWR<B_K
M 'Z?0V%U4E%<C<*VQ*VQ'%^('$R*N[<]1ATZV"NJ:! T/'5]]SN\ZWH$:-T4
MT9E]$D0?;G5=/_]M70Y!>T%I3/>$STQ-9]F_P"<WQY:HW>\>?#PANQ7=G"'G
M"]GU76)AF_C) (0D#HEI+4Q?R"/=IAP9B70W&18^O15(* F^6W1T3E-*7=I7
MU<& [=]E*3VZ0?:+4WL-E^KG^:K1?2.;5ZIZB=#2:+)MHV&KW.-@^-3Q: 9'
MM,<,,7VENESOEKX_U>'/WD(AM'\G7:PQ#901G%VC+R>17DRY;(XG=5!DF^IF
M'+Q$-.K&,;:J!Z/8.H5@-$<O>:WW..4==^9D#\L3A'CS. &S\K2#F:7/SE-G
MV(]H8]1%HO<Z77"T,1QL-JG0& [_IXE.&%O%))A>=M EL;$;M[6UM/%.U=M1
M$\8OI[(^$GE@;/PCTLJEV8<!6'J+Q8CDXW4*3E[21]38 Q$&98Z-V?T@(?O&
MX7=LO4-S6E:X>\0#Y?4Z)^>%N7Y7J;!GA4=[9E?#D 23J%XXV6B7$-9'EYC2
M=B&YS,X>!790SG=4C)1L9+]D /C;'2IP:M$!5QVI$3)L()S:E%HAL.66>)YN
M8Z2<O!WXZU&%H7 >;R[I]\&P5)BZ\"+;VMR&8=^ZWK-UC8% N_V3+,.J%)M4
M1VC(7UL==-[>,#<UE(@Z4=7$<LY]4%*])\4L0V)KH@2)]<G/=].[/ZG#38;0
M.!-)-]%A_KR)VN'$$?;NUI0<A*=:E@ D :( ,Y7;:2,C##(QF^LJO'5XV6L1
M\AY*>JCY61>[T*,0\M#?/8DO(LRITV297M#?NT%WU7L%IE*17@*]G[(V1@RB
M>AR"9)K'#YQ>L:FM64^J&"O?GUX)Y^RQUYO=T.&8".Z0OQ/O)UO1$A,67A_1
MU<OT3]9I&='W+O&TD_YW#\&D,"A9JI3Z>_G 5]D0]'0X&Y$YVE6/3SWRRS7.
MQ&;[%FA]_AW:T*RX?XRF74,LZW= R@C>V*:BK=Y:^Y]JO@@/Z]:1/B"/5];Q
MS<*]4)1KV;UP8@X)[T-P65!MS,5=UF!]_%:Q25 ]7V:?U&!C'V5LE*P=I5.&
M-_.2YPP5RIT:SPWQ;4HW2W*5=X2P5;48@/_"U7>3\"8:532G;F@<9HW?1%5*
M7BHR8E=;JJ6RLIS?2 FI.0R,;EL\V68 PH$4]'8@_:)5E9=]ZI:4.]OIZ?R6
MEFEOJO!ZJV.(Q8"6YW'8#-3;TEOFGICZ.Q]"2GFE"Y\%RU'U;$Y=I[LDY06\
MZUJ$Z#-XGUW$E_RW&M1WJ/2!_C/T:R*F'W:\C_^LKX=%?!TX$:$/.0M3C263
M?+1#JYR\M?J3#A<Y/+X,?'#R*KSN<.N-"%")4YM@7%& \#PB+SA>7)F0!"?N
M^S[/EG*#[$6(K?Z.D+F.B"ZWKJ%P*PO)&9DA([^]H&_SD23LC:!SS>?8Q,Q9
M*DT"85/^9FV@!V2#F(8:;)*W*T7#2^5C4(!CN,"AU/,<-;F31U:/A%Z,9@HU
MW/FVT2B=X35@A)(.(BW]J-)LY-S.N>WZ]C9KN:#TO1LQ^+?_G'UK<!9@* 0P
MY?Y]YL]FQ^U.<$LF7(?$.C_<V6*"-.Z57X-OE7$9E;-;3422DK[. +!WBFP<
M]_>.B'AQ4-G!'2T=6+S/+DULJ4!?$VV'%LTTGS4>AYM'W(0QJ;?;)79!F9JW
MW/9;!7T>RH[+12? S)!ZGH'A$C&QI03#T,IY5$%^P+QC>"%!2D*Q2_"+E<D%
M[M]_PN^ &KHT<IEVGZD4X&=@SE3VY7FQ7K4(P5!M57+@LEMJ7]NVZ,_-")D)
M!H!X@R)QVARM+0&*F;9KG$#Y;*L\C[5I"L7,?EJ:V!,6IZ$5, &/#K^JBE;)
M<DE9'5FYF5@@[$Q00$\!"X2)'[?4T*?A;!6.J(QEB0NG>O'3PMEEI-].H29"
M8^9FF7?T8;7^&27E_ 8/A\=#,/8!("OO/?S1Z],F^!.7,[#'%-XW=%&8QD=J
MZC*<?;C5-.YP$!+C?(DB.NO%\_#C0!D81<W:Z-L[6@;/'MV);K;;EI-, (OG
M#T&T']/+IRFJ)Y8<<$\XX8PDB/(J0BJ8 :C;=$8O1"1%"/R($/=7X'P\4O?I
MB)T][8?&(Z>+9+I__!>*ZJ9K P1I:-/_[W9\D)1YR>I'LG^T?7U251/R'K"W
MR 0K2$5WF5Q8\G%A<8-)O%_6*$H,9,7RRM\FMK-S__NQQ0<1BVT4D[UID^-R
M1LCI%373<%E:W^H%%6K"%\QO4RUQXL+T\I_U0_[PL38< Q#C0@0Q '+,XA(;
M!>_2P/Z<9[(M3H',1/"L0]K&])26P=:0G\[?5,CRKP2:1:VGUOE24IP8Y7QB
M"57+V-5L7$?0V3N$?K6!LEH0&E*UKN5<':R>'#1SH$8^F'X%>S<[Y%Z9MYJP
MJ@*:MOLS>[D;EL GM1KZ*]X2A/$_"&@_IP%]W<N]^;2!54]6SY[/7J5R:-A*
MNI_-7-&W6V0<^BH@WSV^>(0>1%X;9P#6+_<&!VK9 2]2@0GTWJ_^FCN^UHBH
M.98WN"6E)&&8") [I8>D>#M9PZQ8VU?*6,\$78=(1#$#(;)7"XX&D<D0JB3O
MJ6 [B.I&YV0 ]A92J5!U9F*F)R\ :4K_LV#@-\3ES]*ZLPS >+LQ"<A'A1!'
M>GT=>K2R<;OQA>>I<%*B'.3SD;U(<; GR9*W4)S"&RV[#;.K-JS56QKB"7/R
M.S%-WPKAM0]Z5=#]7NPC^UUC93K+OC]RO96GO8AS3!M421.CC/0(FYKI\+,2
M3!/:%>7P/T7^5DQ^)KM/;0:_/@R[^ZA=GS \: FI,SWZ9YSFL 0L_>;*:Y-$
M Q=KZN<7"!GP4SJ$'G#[J'$*QEC=WBN6SEA)[%[^V$CV#X%66J:5K)BGB":S
MXVT2L8]RAE^4$K-??W]_WZJD3L.%M5VNY]^-< ?A]VXM,V:].'X![B?9KGOM
M?KQ*&:'6?Y=K!?3T<?EK/-)7.)"AB[ QS4!B $I#8AD 5FPWG.XP]K^,G<T]
M,!&]Y4XQZ(^X0$$GJZ) MN1KHS8X:SK76#N8F/P<_YA26XRFIG<3Y.::D/[G
M&M;I(J,J# #W.J&OM':0:W1$N+>QXXT-<#W0_M4;^,>F=R&5[B;4GFD1X2ET
M,=D],C@L]>\1WW 4S$Q'G#+R9D?[;HTG&#UT&DM\WPB//<8@26_:)B2S<&;C
MY0):PPH?F@\4"WFA%_[K(7W,;,'W2&=^M'+3Y3S4 9'FNI.U*,4&G-(@V\\&
MW+%(L\<HZ7Q,M95U]W/%M:.<EVH%"D YRN9Z8.[21_X809S"^9_$?:UKO?]:
MNQ'98W/T13MYH#4FES2*D*L-GUVES*#MVK<"IW&/83,QQI*F,^YV;C"#G[LT
M;4$Z"S/1Z>^RT_GA;Q@ 6C-JA&G.KGM,KBF007O*>9.M@:Q.<J?5#M H.M<T
MKA)>M\9Y(_&QLD=K] **=\;%9^%Y@7<@-$_= 2?^VI(!4/=!";;[J;7[45I_
M"*,%N?S?O7WQ.2F%W:S7E*FY@5E%A_L7Z,E&)_&G?-J:*),@;)/V0R.,A&D.
M-;9H,L'J*?';^E3&3^:9_/ID$M+2)OKAU_S5HI47QU H/KKZ$@.PL1AIGB50
MYKVG<)ZJ_Z9<5GO26<^%70":P.&7*HVZ7R8SEF[E,<R--,^ MP]>/I&S[ANT
MP-<6=^ /!<'>)Y<'/7D<PMIDOIB3IC98+#/3!./$4VS+S*W&)E]W58=?^(B6
MIPKW=[E$+;T $6U@S+"9,#5$/_:+_0G/A&?DQ AH:.. 46_*-?ZE4+>$),4S
M$$(WU06CDWZ4[B!--&R'C70V,GZ4EAB<GGU&G5D-U3'+L40(6"G+(J2_>9E'
M910;53S)7'E_G%$L=;(7K;F,,.'([KAE$97=_D..R\PQML1?YRXUF[Q,=$YE
MC^N4I#)=X7(EZ'(B-:@M/+ _0GJ4)E8Z@IS3TR9[CFXX7^_$;ZUTYE[VSBG!
M&.:&WF@NM$HJ4U(Z%'B.J-A\Y5=4\Y,0G8(N\YJR;LW*KEK/?OGKV*\<X?)/
MMIK-<?AA31IAP<[9 2S<BYK$U-_S/QLO:Z[M5Q/QY+0*_OPA ^ Y"XHZEEM,
MUC98"I<D+O9"Z3<VM6*C@KUWV:&=]&X% '6W&SBC(T(1?JW\,YM774>N.8N^
M]C73#P-5%5:_UK@W!/SRBAE2G%H[_?J3[7?(I235YM=!/)2Y;!V.L9WGE-5B
MSR5L[!$#< $&) ]VZ1J&N?#9.F)3(JYN$G@Z*)R?E8<TR=LC<>W@\)L=3U1[
M8G[?35+CE$+%?-A\GM[]=$VKDY!/3JN.11A:_BB;- JP$C;4TZI/E2TI=@M6
MY_*W0B5%VR<4<JA65N+2S&J*K2W\5PN6Q9>_%GPHP >T-23XG#JT3AS,"B9K
MC?]Z7-_0.KGSK'[<M[9VJ;EE8O=&PZ>)FQA\<=:#M*-5F<LR@^O7F^S<P'?
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M>W_^V:6'%U1IGS:QY$>01&N!X6HW7TK(44#APO3CMDC^VDZIV?5II5ZN/?$
M1\]? JZF;LJ5;')E-;M^*\6>XK><L,WT.%A(%TPLBS(L&!^XU2S:[]H@E'KM
M3>%=FW)9ZTLQ9X3OUW@^O;6D"!LK34+RF[)+9VQ+OT,+!+8C@'O31_%435)_
M O]:]/M%]A9@/'16>F#/6:IK-0@*9Q/JT_1S3QK:J[$6J97YF_+=7=^VO?7-
M^GA?%3?7) M1V,M/L1R4UWD%=J:5VK$$BHN0P5!0"P6UT+ORYV.73HS/[]IV
M4AXU:3'#-@Y=()^"1%Q$H;9EC=O?_9SJO#&Y_:PE]3%VW%?E(6*B=!<#^MY
M*BPOH18]_C2ELCJ!T;Q2Y%KV,_>-5HD+->$KWJ6HQYF_<Z+6#S,;KFQ'_G:L
M5]!!\\B>LHFU2L;,W__QSTG''Y#YF+VM2;PKYCRJK7"B!^,@[\22WI]KCE=)
MYEW&>Q)>?@*D/'Q@7U".RG@Q+Q7IB?K^I3QWP>[?Y[>__ PN/TV">X<N0Y^?
M(NA7![E:'05DD9+;YY1E<XT;.U9J>#B>CZQ&W@G7I\MR.*7M+-VI>YM+3_@&
MLQJ4=FV06HE0(O,(*O2X?IS<.^:;N^D;W_/OQZ#*?Y==+FZ8#53J^_?8E"?D
ME\U[5:G.UW$Q ,&F[+3 ]%,!C>XLJ[3QD8@$$0W7P"01BY3N56I-?<SE<U'?
M]J6I-7VVCWK->E;?5V6LO.F>_GS_MAGNR1SYG2F+S:]#?[@(%+%D"6>'.9&+
M<#I:U!C11FKL^>K3MFKH'7 +18MJP@ 84?KCM"_X5Q!FG;SLKU)8CX[[WI@?
M/R@RCKF01I0K/)*!ULJW&;L>W:/TKB6K@J[05"EZS8DJ,L+N/2+ J)Z(F]9D
MRVD!Q)MVMS+HF1[GEQG9A=?!X#L03F\UI.L+0E*]\[JW_ >R?;V@UR\X1T07
M X#I3PIF4[:FN&RSD)5[7E4DGGU)T"^N@06FT'<?1<I\4CV;\#7T8"TLF'=O
M\-6#9WYM60Y9-SV%9[WZCY1.:U4&PV:=[AP544%NODAO&V>QB1M-IQ]$;NVJ
M;FZV*.P&AT4[7!7'MG4V-7=\:@%I3[_0"[SA^<Y1JU#:388]LCJ6DATIXL;*
M#=/1*91A?S\QL$G:?&Z;KR<;S*K*&I.BQ-F]LM^]A!S/4E/Q"N/_BE+7U'Z0
MR5YJ(P#FSQGM"^>D>=A)..)9DKY6_WL[0\J?1_"OV($7&H_T;1+Z2 WM)D[F
M*2!U1,JW:IL8!VUC[CC$)>Y2D\LLIC].BF9D2/-U]>\WZ6?S#-L:(W<@5QVH
MG21CP4>ICS'D\)V8W S$(X<O%116Y[ODJG6I<\G#SR:Z%QO_:_KD4>U55)_:
M)P<TIDAL'ZY%3S$ W2*<&$IVO+8RA.2YJVU6OFZ#)?B>-5^W;N(,G;XO+'),
M(F[[2>)]2 \C9BJ[).8Q :=NKB=<]"F!9T?96O!M9;+?U["+W]0"9F$1'KD$
MA:T\MHL&/+-7N7GUQS$=JKQG#;PKONN_CACX*Z4=])$!V#:%\)2>!6*RNSQ*
M)C'>D"L;7D4B7]0);/F<A%E/=?8CH!*8S]>O%F4M_%G0H3KON1SK7ND$S.&S
ME&Y>'SL;XJ)17AK]VW"QUIAME1*2OX4H(2!O"ZJQ6"LIF[I!1%SLOMHC/3/X
MLZLW(-K$I:1__%*F_5L4'\@[RPH1@Y2](JKB96'QH_"&KM)Q@8M[0H8H^5W?
M.%(K4YHH$4-K/K$: %(HFA?H>8:1H-TJ>A9V*4-'GB+<OX4-=P^L=G)R\%CD
M;#>H\'P\][% 95N#&M9U'%_7P%$=RH.%3"B@M3.Z+R<.QO_#)N.^-PKO4M&Y
M_>)"+WP&_1$ <ZD[!EPX<EFZ0'1AVF%QJZ$R8GCQ[VUM81+ZJF?K#K86&L,
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M/*AXVCD+><!]@SJ+?@B'IP72+%R0]L"D0'/"!/I-Y4.!AI'GL$K ^E0&9V1
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M+?3:(Y.;G?(=CB8W:S9M4.KF*,.VK^;I)VD.^E*W^J3TI<3?G:)??R8JS8D
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M\@\F2 !^P72%FSOL 0SKD2-FRCY'TVDF:Q-GYX','?RB#"4(^33,;7;[19B
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M/$_-1-X"GN87H@/%"\YDVR^S0D9C##*%M2:O6U(47C%!IR0CEQ=$-*$7PNR
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M/[I"9(_;SQ5<A&D2,<E8'@+I+K0]UWS\69ALD1W,TW),R1D1M+LP;^?>J+%
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M^%!,9Z3:KYB D=B382IBBUX=Q).-AC4"-OI+ERL:4@TT<TYYV\2<MTMKY.6
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MQ"B"\<T8G7%Y]X;F5*0D@2CYAN5(T./#S69W+AO78V<R2'MP=8WM.U!)%!"
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MTS#S_S1G)?^AAN@(!O*STTQ$5_ 3HA+XLA9]?0BCB&I![J9S=%%3ID!CH2K
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MW<93%**,&\IN0N3@9X^E;//NO[X&9!?C9MP&/+0Y?+]V3/P'JOQ;BJ"-0=?
MN*ZVH-BTJD *D4_ZC4!:$JEA,":#&4R&@^;LVUMG0>GN-ND>$9DK/!62+YMN
M/\0^SCF9AQ@9:$W_:5'E<TR^%Q&WW1$;KCI56+3UX**E0= %?.V'3\9-\HZ4
MR18^2[$8_P^]K"NV.5M9GBZ!LE&^0KZOFDAA^,A>ZL+'#$O+&TCG_QHS50"9
MP]<$'&(,)FY87^B"'3/&UOB;G"ZZ-E(;=D$^.$:;21,9T.Z&IQS;3T$',MPL
MT%?;@BA/-11!>,DBX-\FZ(1172>>F/_X/M0_4.%323\J8@L.BC/20*6?\42M
M!;FXQWE;!4-:QE8LK1]N8^B0AQ7N!N2!0[VN=4\QQ^8?V>>6? Y$2OXYVLBW
M*61.GV,K/B@TCR%<*D4Q8)(>%D=S3<_?FCY:A4A&A0JIPJ6?=0X8"^ODE1B'
M57=E65:7J['*^$9":DX5J>>?][@ZJW:SEZ5?.NWOH&36X=<47Z)DIR=QE'E(
M[EQH@'^O9DV9>F5C)G'LOR5ID-1;5#^XW%$%FG>9J V9J S,K$D$\AS&';:#
M+UU3W1$H;YJA,_!Q10TM7;!$C'9.3PN5% _MD6I+ZTX3!TG=A<?>C(05-?24
M!SJ*!/L<WE'ZE$ML8.(_NVVYC.G#COC!1-C(5_YRV24,D<1"T9R>MJ)4M+KR
MDXVOP60NI,F7C(TUD4UZUQR!T4A%"L-%R")B2##1@&6"9R0)(2PBDW[H$9 N
M5SX87W"O GIDO@[ \_8D6>:<FN4[;\' J4SG?_&Q*GK9TWLFJ$JB/O_Z+UR>
M]:1IS4V5%BV_JE,Y]=:P1P9V/ =\?T>Y_;\?GI]UG'?8-X/DFC31^7JT93OX
MI,[?E5,4P7N5=#S;=F8'*X2*Z.0H[V9PCK-MWPRCK>DX ?N1<'7\D06LI/'Y
M8+J?_H[ E)Z'E]Y7'2[DLL5TE-:/@3HN9*:HJ"$B3O/N9K 89Z3P^-N11KS@
MZ1*A[#A85X(^KV=[V.& 02<UHAN^%]MC6NE,96NS=-!N+*&)YT$,R;1>QQ&V
M'F6VO3']XY>"BV0>U[UJH[>IZ;0T<"'17R*S/'VD\KV.(C(1<RD=)<^F[6Z4
M9[E4>1L6&AF/1#A]YT("R&7RYPJ^S9=N!:W37MG8_92>)/T'5?+[3^A!#J[U
MK.UW9NN"#2QS.O$E0SY8VK](A'@2-=II%)RD,7&@D6521,>*!AAIYL1K9D\P
M5L?_G-"L?36F*$6)<*3?A3QE^#5?FW[HN6MR8*:Z<6$\3MBG3M*_JU:^+#[I
M7M5A^V<AV9J6FEVE;LGIF6XAZ=9ZA(60@Y$\+OC(LKR16:(T:$VUS7PU/BY5
M6/^H?/3KN=S@;=/_%N><NY4U7,@-E"XGX2.O6 <FN)#O;[ 3&C\XL2_P;/XB
M+D055OH?'& 3%LZ%/,LGW4VJBKZ/UMO-E\1. D6I#5,4ANKF0EHO*;?M\S")
M^0U;N&2^_:RS:,-ZM@C4(G$AY_C1IH4J'R;+-2]<?%C%A:P_V_[]>X S3-H4
MXL8M%Z("9_"#\)<7;'7FI9\=!NA+%PWQCL.DF1DD=>>&VFD ^J[I?><Z^RR#
M13G*GC;69W]">:]53!AM0[OZ=EU@T_LY62*/07TDYRRA(1#_E;)*V3WX" I+
M87PZ55[VOL"[)) Z6C9*$1R<[S/GN; YS+A<+.U")_*@] /=63"XYXHLA-7>
MN[(TW>%FQGN^'S/RZ/$56#1&_/3:KSGZFIA@)'I:)WB0G?9.1# LC;./"_D;
M%R5*3VN7IK,786,VPKPJA6IP(9T./*._>.:7AN]15O31MX9).BG-39;JI-U+
M#3\O_'[G.C9FS+C!@#?D=3_8<E+$LW]=1#M/DSAMFT'R''XK5LD-E=-#QI#V
MME^/M-[ -*=/ZX,#]&?=^[["YUK8ZO-%@E'S))%9\^V$3MJ&C0^OMBV\VD*5
M4EG0U(66]STN!/U(!_*O*;0 S&4#.]7"R/[;Z=,P^^C;7G2'(D+AFNPOPN7I
M#ICK1C^4NM3W\TS"J5&"'I]AEW_$NQ!*7>OTUUU,UJ\J>FH]%_(.NZ&$?\CK
M$7, 0QK)V8[K_,2%L%)G:X*J)E:X$*\[OZX')Q8J(DC*,G,AE+([.DM<R,VM
MJ 21%0_F6_<3HVPC7=J.SH\Q[%@ ,0.$LW(I?=?TOOH$A>U&GGKW.C9V8C>D
MM4_P_H#NE;!G(4=>EDF+JF9+36>01;[K5VS3-V ?G<I1F._?1QC42(/G6J+,
MLS))-3F"97M??&@-HEOJZ/R3*LGT>>X0-\!2CONBC]QGEWI(BSS[(N?8(\-:
MO=ME_,_M0AP4U493+.T>V3^S:&WOM<V\.?AJAB2#FCN42Z]W*8](&;QG>;=0
M7?NC\F7[I1MYB7EE=H5BT?,W_\0;26:6R0S<'ZLP0N0B:\.<^( E)THX29#J
M&;@5*Y N^>?;F_L6SS'TU!^P(.?.WAR6M3]<MQ55O=_9YY+'5ZS>36"TDQ%(
M#[#,7_1:_)0Y:QE0=MY2S+_5QDB/8Z/%2K=+3N=\[P_9:+A^4.1L,?_&///>
M6+U>%</O4PSJ<J,$4ZZQ/+-8"6OX_O[8LRRCS-F3B2IUH8TJKQ(A_^<^.-XX
MH.LZLBFDZ#IZ)[Q V:ZA]<U88X'-")4+L1F[4Z?HMZJ!OX-7S!Y9I3).^Y6W
MO$V\YF.F>E(G79W%A7#X?.@UFMK=6/G@F:$@MEYV\[9T="-<T" F/$U@"7,(
M(,8QD+(>"QA^EO':SD6TY+"Q$VX!7FUE3%2.BF!(=40$AP9+;+<M)'A'5&)*
MV5Y@1BGZ*(A@01F]).^:@$?*Y+0#J)S>MKJ"XLLY<CV;:7%Z>3C'[Z/6J2XG
MGJV$]MT9OJ+T$7!]]U&YK5  -9MELF\WEB _LQ:+E</H@\I76:9K"9L%<#J^
M"Y9PW],_U^EQ4)BL\44F+I1A^BG?.(@!A00^^H"^!/9[5[DL-ILH@L\8]B-K
M; 0=W%!?D1MA7O\1?&I;L V1:E%H_C,_JR3FF[_UZ'WR>)G1 M7]>4B9Y[/,
M;R7*LF:J8W'ZA@\_9TFGO8,] ,+?UHVD.YQ0&6W.'S@_6G4K+]&_N43=@E-,
M^17+^0*M-U_QF(%3F5L)(^%(GD8P)O[.C>N%QA<J#8>G"8/[>DQ.#NFO":/R
M>JC$EK^7'IUK*O&/: O?3"TKH[FYJ\;2RYJ??VOH2)W>GOX^K;VQCN^%IW$A
M@"<65.Y;7F$A>[B00\9P!BG>4XOE^W@SDB0,ULW1:4^ED<!6%D/SW)7@&K\K
MKJ2)L&O::QM)W=ED.Z.;GBY3R*DODWG-K2TOQ>?9%P9U/^8IO.!-XBT'W5^,
MUYG>">21+5;!8=ON\R.X%97R$FFC]'*FW8>@.O,!J33MA'LR@@^@0IOLKO-A
M_HYY98Z8@>KT GU9Q&R>=9-,586"M^] B3D (;WA0E;TDNN*&@;[KH;YA(6#
MULR9?^8[GX_'/LFZ]:>L\_W:/4<3-P\"6+:$+"Y8PXV,;;Y4/V;L%<02YG3/
MDV0'LM;2EF=;"D=[*0^*O'<N]B7BZC0UM;PH/BE-^]L:F]Z*_]H:>@_=RN!"
M1%5Y/&K086+"BV6O1[B07XT\4X+@<6?P(W04%T+V*N,9%7]D#3RYE5'641$;
MOGB?;3+BL'A_"1M!M2UH"EH(<HM<1$??-XXUF&7DAA#9U?G!2_V&M+E0L*$>
M0+(E#EW/I3*M ?S*DXHO+LV%$QF?P0CF@=KF@=+3[<>ROKT_\%1'R @F@<J]
M<.J0#P%SDJ*8XJ#O-I[[J9Z.!56"X\.TCX!NR"'LG8%@\C&M? ]4 SFW+HWU
MBF=M6-9#4OM63!1'ZH).O9E8E?%_].?#)I6[MYZ'+2D]?QGT2F"WF.>[++&
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MUE"4[E66@1V07V*&[PO*!V)VW.RZK4=K_']!S,@WCWF,;-8DR^^:1D_Z3MR
MW)O:_?5+81XL;:";!THR:U^>K9YS'6%$ S!/EDXPZ=URJPU@3T#O<R6>93_E
MT"M_\$#WGW;CV#:)U>='I>=VA8)1T #WD0 >Z/<C!U5^Y<QW]<"7LGZ40"**
M$W0DG<H5N]3-3#3"VK--\MYH=L5H?G1T_V.\)MEQ!(;HC];3Q[,EYKV.U1A"
M1:_E/CON]6M98!D8F8"'(J6#,D./<IG/].V(YI;"1Y0MM(<)MOV.&9,6.EHE
MECGXXS?%W_Q0Z0F\8F)OE[JI:N%[RK<\USZPN:!@MM#C!/1+77MC:!L]=L:
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M.Y'77>J;AE":C.'[W)'FAKR(^F1<YJ4;;8,5OX?^S<"IIF<9%]^>71Y..L]
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M/M+0VWSO5-+<VCJAGJ"@JOK00Z-WZ<'OWW\>0[/Q@"57_!Q7/PY41-,$AB@
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M2C%%RBDFHR2B_"1/14S"N9 <U)NT"^!)*BM-NA[D6H9)^K2@DCM$UY]!^3X
M#<U$-;%0?Y/)).;!KDYK-)(%/BCKVY1V'W#/U]O\@-_6J*Y?5\Q;B>YQ*!>U
MK8X;N1!7,E5HSI6]\L,U7/YZ>ZU0O..[?A_J9\LK.6V^_2*3 :\KZB?7O\>X
M*97D9B)[KE9FM:KHE-W;&,O+^(37DO[[.-_0?X-T<WH/S>V3\[C]PT;+P^:/
M"(&L@T-+["?\W$:+?;G'DP*_]M_H<L=A@_SMXF\/S$\.UW^Y+OV +[6NO^OA
MZ(FG1L?$PZ_I#)#VI?AI/U!=&'<5LLSJEAH9MZSZL<SW178DS@L^[T%Y ^H
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M^>YU<93IC3 J=%OLCIB2J@_505\46:' 5#QB-1DZ&15]EI^2&Y5XBQ1*4=Y
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MH[M;DL -]-QJ-_2,VA'$0^TU'G# )#%.,K\B?,/Y&68YCL'N1A, N.(,U<'
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M#$L8-C:13Z)[CB!OM+@7W69=3:O71=HI;RH'*EPYM$;>%T+G+TA4XZ6T#TC
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MQX((J'008@'I1*77C#J @!#IG8P@TH2(M @A&06D@TH;:5%I4B.0 -(B74!
MN@0E34":)(+A2@I??'_O^O[XZA\WN5FYZZRSS]EG[^?99^]S!<%W"MRK?-5\
MN",#8:S&%YOCIG=6P#Z?$>Q6@Q]3CRK%BETZS<2#[]^B7PG74[V_Q-K[L1I
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MH[!R W,,@/7-QG@7O[*L7&-A%KPOO&TA=+9-Z@A0FR5N=HZBGR#;>8+/V6H
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MV? :L/*8VI?_O;$!^Q?CBR.EO2,3E ;!I%VZWF8*#?=0=ZX-OC%'Q24_@54
M"*I?O,>(;X672?-+&D("%HMYZ3JJ'F.2F05-XACXQ:K"ZY\JL)KOD,E02@V<
M<06;A&78X=)*CG-?FTKQ/F)%H;Y$TDCWHDQ2MP@SGII$\I=78\2U?X[+LF;*
M93['(5W<L^RGU+<(LD9ROM>90NG/ K<S]!P(1'P+WB/.RW6B^-B3Y=H:G_#A
MF5*=8<;'T0"'TBL.(22'5]]4<STU/JP/JQ5,WM&(=9VMA'[1_^>RIZ+,T[D%
MY^&&R :GZC&5@(:;]=_,=Y=8%Q'F=;^\^&KP.)]NB^6#('7^V*<1J4_PV$3#
MRI1-WL5O68P1<^!I'"X0?.B[,0I]!CF#N,54W(K7"/T9;*388+AN?2$E4*?7
M6T'UQ%^6X#B^B8)N88*-]D& IL5F&G2S^ 7G(&.K?PN(;ME@Y15@-JAUR!7O
MW\EX1U,Y7LS R:6279IX9C&NOB.4Q$7<\L"\4?_CT\+[_B+L1S*@"..<:J%4
M<DZ54OR3>>(H+:9%FND%8(X&32UC[@Z(I)L:!DCV0T\8N[)ZQJ1O$YHO7ZL(
M:+MM&A-8$-C:U2[J!8<'&69P-[^V''EG>I*"Z>XA-H,.5G)$75AWP3=-+P-D
M^<^Q!^PWCTD=-U984Y>'Q[\;:[+5['BS4VV86RZQ]<#I=6G=EDR0A\ZM<-C)
M+)S^CS@$.'7@*O9R?F-&X&2Z2L4S9U:$E_E,G6JC1P6:#KFR Q[.>QHC\H+G
M2%!,_/][M9Q<8.T"3'\ .F32L,=VEDPVMGX)N)C/=)C10GRM&+M)>#7!.IC'
M'*%F/01B,;&SH.P>VWG-81I1WH)O;&I.]';['JJ8*?54T.AAO.TQ)U6'TJ.V
MD4'3&:K:+P7&RH.R<WR/VE7:ZJ@Z%2TI#YRH%+"U#S07PA?<M]0EV67\*OM2
M*HO1BH$\?[W9&:7ZY(/(G_\P'KQ7TO^J*:)0=.(O_7V0 02 1'/$15C-4QC*
MZ_@>N# GO!)IW;,/>K/;IP%VXV)IC.^%K]96);,@*.F*RI0.C]HOGQ?@Q;%.
M73:(FXR9Y20C0E[^K7:8[B5OG;X?F%MZF%.\WYDJ9I!RQMS&=BVRB87FIMK,
MC":E$8.N;WS]V*6)GG!'"2EVKB3M@^X(Z3DU2WH?!S#5Z!^S;/H SJ=EK^YI
M!!!>T1I&.\JI9(UP<XC^X(0",N<4[AWZ$*#%V+9F[#[>!R$@!P/:8KR 8)O9
MR. THZTDJ!@ASM[&WWM68RLR(X;M/KM1^W,T_.8L#K&E$W*')&3[([">FGF;
M1]L[R\3\ 1R@]8YQK"C&N/[3NSJ41=WA>Y\%4TH.WZ, <U3O\Q\N/:^(S.BG
MAOU":=5.J0V'=1@X)*E0&_[CU&B,-ZD[AZ2.A/_9&+G]@ 4^6>C'^4_=Z8:B
M(;) _'Q*1<6LJG"=5*6-1=[]2H$Q'2>;\^-FRE]BUW?B66K 2^9Y.GRCD&W$
M\0)ZJ;D,3#\D>1\D@!*E;<DC(]67IZ9LF/(-I0N>Y#_?M')_IGZ1\%AJS(<$
MM)PC@\Q!>T]CA"]MID=7OSYY-.,/S4L$\3]>.QVP$P.)J;X^=N2O%\(]=:"_
M0$4%/+6Q2Y]NC!N--9T^[!+_GF&0&?S?LI1Q_D%[@J>N7>+@LM1&J*S:2\,Q
M)\6DD7M M=1IHQH5I]SCBBK3J,F /9FP>XGZ;9DUZ6<%'*/:<_7-3V6[!]M;
MCGF)%6?[3)B)OPL0D[\BWU4<\.I?*(08) (H(?IA)"7:<B43VD-DV(,7DE@A
MDSIRY\VFS@%N#,B J< $&KS:%.@\B@BK=G5=1PO-XNC3.DDJ8577=^L;;SS_
M^V:?2,D^B#J.E=L'K6IA&(Y0C@'T^#[HUX++=PVQ []3KH51P-8^R+*0[VE?
M\A\= OSW06.D+"!\91!-9KB- ZKR<3P%U.7SS"/4YJ,LD^!=B500AZ^+CVRP
MZ;P_N15\ZU]);H+V0T@(.F+S&I4\/T7#;FR7H?2928,9_E:S'+_RU2XH8 !)
MYURIC*LTF]S),';7;;IWP]0IY\;'WI-/H^/AK3^!%KXY_;D/RLGGJWG(/FBC
M"?T>LS<F",?G_-\B6O_GJ7JA?QV/]9?[=4:D_M(.=+;L5;973,W\^FU2<\WK
M@L[V2*\YA 9L*9PGR&_W4 A3[QTL?A_4?&0CG+(U#V<-8\2"P <V+WPD!A,?
MRTL0FX!+E!"+_EG=71:)0.[SNDQ;W/T;<UR<;=KP(%C=P?WS]7,6Z<UF"."L
M"$?<=A_$*@54V.=Y_5 QZ&TH:==E9I,'NK%X@5O%TP7.P4Z@A("'T52Y"\$I
M/Z]SHFE'II68IY!EM"GSUH[%W:;O#Y\_NKT/NLKOCR3?/6(79%G_  ML36"\
M3X:<:*S"''Q7T-++C>WSEO'0FXLHUG*YI+X;8Q]TXK,K@51[R]?CM5]*B^[7
MT$-*&XEL7:0_RX3[O.L8;X1WG"G<3LL2X(@P)+(9^Z!>WEGFI4897EW%MX8.
MW3GWZL"/[I_26IP5^^OP=D*E0<<N/DT$U\<&J&8V=K_V^!SI9^D+T;Q=KJRN
ML'ZU\EQCW=B6 CW,Y_;*3T48S%<]O+ID(B/(-: '$AJ=G&N@,,?P4MA4O+EG
M."M5MTEK>:1,>71T\NBM1 GE5X\57&F9RD_^S-3.</+- #G^50TZ*.Y3\!_I
MXOV+!NLE1PRV>!9!D<>VG!="VEMN+^*\M.<PXQZ9JA.I5D,*=;&DH4",1A<?
MP3I(V9E=76B,RJR;9DD9G*]4X$/6=Q1F7TM(2&3Y9DU[CL\SK\A<\NU"T5C-
M>O8WO$TSV48\/VIR[;J3[>4#@S!$944L77K+7(Q>:9P90]^+C1@,XL41*2_(
MC/M@CN@"3V"%64%G(9D=^R Q]&64.^-+_R.4]4=3062LU5R=J:19S-/A5=IH
MN/N<MH;VNK-$^+4'<=0OFL%<\V$5'P]\R]NG9Q&=?$A(J8(V:,QM*.V#1,!I
M=+ED;DY^KP4<(]69^&GN3)>7&=Z?<:-$3#DRDKD'),F?EA>[R.U8/^0KW>+7
MJC4J;ENAQ/-T:"O&/.BEL^Z%61K8:E4A5<PL#?I[C+=WS:??TLWMGM78JSW+
MXG3>O^<D)A-BKA5!*BY7#$)SWM[: K^Z<-%#7^[*=Q&I#?W-.9P<LE+<WMS"
MF%X2\P^=>%[ZYQ9\?.NWM,*_*RQ^%YZ:H?EWO7HH(U@J\1A:+1A#FN+H3*(O
M(_UO?-S9!Z5&R1B+/# "/)PG(C>C)H7<0TS5BLW'_YJ%PZ9Q&B$0F5F5\N:
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M:G&ERW"D>\2M\LA7CXWLIW6S2Q6.3$_N;&161]26C\A6#UV/@E15CMF=TY;
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M0<:_6"(_;@T %H.(@+Y[A:@+2>CR@W$?*],GRXW._J=EVC57/FP41E2$RH=
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M.'!P[4F#P9_\IOL(Q'2^<X;\\I2?IB1.UOV+[@B7-6]TYT1"DI]0[NZJC%U
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MSR!\7K<O@$"M\OU^=HW'R&RV%< KK/.<Z0G5[\;WYT1U?_'6Y:-*(2+(KT>
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M7-+BQY9":^:/PBKXU#\J/G;ANC_$])8/W9^=O03L'C#X&W&$Z\3"<"5-J35
M(909V0'AU>E##A!I%/%FQ<6D'ZRC?-#8399LFA<UF^-]I8AM?OG3BX#PQDN2
MJ67[/LNJ;#47N#H6E5RE1?S=DD&WOD]LCJCAC^7D9)^JH*MK#&F6IB%K'GST
M+YL\%)*3X7/OXZ+#5#;>%B<>Y&S5VEG_,$0#KZ0??>L'(;/4X'_Z&G4>@83
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M$LK\7I#**N[:_JJ8 )CVR7EX%#TLBHJ+MW$:-[/ZZYCUL,/X3WUM%1CS[?M
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M4*T"\UZ-D;* >00U[-851^HQ@_J."=T8B_)@N0\GMDEV'/O TDW1J\2/Z//
MOF/(T K@UC4/.:E@:%9)]9]Q;6I&WTF>/T<#W7F^PP I(I#R"VH>MON'IS1
MH Z5,U/8%4SQ9#/M!9CH4B%TH]1LM'XC#KVOYP%?M:EM+&PC6+N?V4.WT<'4
MS#?43=8\?S6C[?\XZ76@6^B7L\ER>TI<:AVG0N5$W"H32FB$1-\:MR4K@Y4
M#5I-_R6//(R?UGS=<X^JB<6GW8'NKP=/13G80;RS1D,J3]<:F^<K.)<K]>8%
MH"TP3*@NH&'#@#,7V=U _ YHWSL SKF+M.>]X!_E"O%*N7MKN&&\&CUP,LI
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M3&$DRU!82S^EMCNJ]+R4[1C_<XGBN1);+35YCY<A@]8:7S+R-2,#<L)^/9A
MQ$XL:D3TJ:&&<QFWJ$^KS<QTXYI=$Q/@C24O*T_/97\?\."EHL.&!0AJA*!@
MH8#08G^=1()9>G![SF5P*M,'T:'5CP[RKI="Q'5/41H&S"N2-_T;F?F,PB2R
MRHD1$7BGLY^$(FG[[,W[CRZS]^)!AR\\_KP6LT@F/'>:'>8?'.!$<5T$IGJ+
M@/!%+#EB*%+'01Y&1Y^P#P&F8GL&CL5=FX103SL) 0&_1A ICB/D@8NDQD&T
M(RLK^U9@6 0\=EO[>\GWYL ),ZR8^ 8[C>J9KQ;R4_-L9=-"_KZ2<N/CDO<.
M*N@/.N *OC?J5$\0K=LUF=!FR)O)?&-L'?6,VB2\=89SE:8ZGO>R%!<P;RKG
M98'PO!$S7F2K#GUI7FFLFOLCZ\1D;4-:8D; F)WJA+.5[?_C2>K_E^NO"V%]
MS7L)KN/_0NRXWP![@:>J 5HL ;4_Q;FV2^W-#*,"U;H),PU4-'$8O*J8MO+/
MYX[C!)9;UKPV<S*I[/7M-B >7HLXZ?!W3([M(J+RUJ]RQ7BBYU()[:M^XRI<
M\]+#4;NFA@$IIT.&VE)O) ?_,@O3L]6PSCE5<')%)%7*-(7)$[@;L$MVD3<!
MR Y(2)@_#I%Y2PC+A/5 )"S^6D8?A@3#4K?;**(Y7V;I69D<W_KN]W2G9')^
M.6**B0B_-EHV>G$LZDJNUSG[P[GWP[!0B^>I\D);1]H>]S,>ESZG*V,IJCR'
M_9=42R/^"&*Q?@>TTB.<6:[0IU;:EA.S/!3+WL!>W^>BBWZ^:/QMX7!Y]L58
ME.HB_C.D$;\FS%%$S2B? .)I&'(N^P$ 9XW[ 1Y1XH G:0=T)#)&_QFU8O+M
MQ@#/<7YJXFM/8$00.J9\.7?>:T66]+ !5Q&J:B5:'I_RZ#YC[!_0X8M]?S:6
M7>CK&JIOV[^K1:L[P!5<EP_@PZ#KD5V_/+_G9DY6AL:QXGJCO6/1Q%M+T /I
MU#JP/7,K);+$\"*3GX*=68;JI)9[0>%%UL\JEUDV^[-*JN!-USN#;OG#PX\^
M9#<5C/2%AX<K$J6#'XF,GTOP--OJ5XWN_[2YO3C^N,?^\1+DA+70T<AEI_G6
MNXYW';Y$%+=]UQX/?ULWSYN=;.K/B''Y;F=66W#.\[MSK+G>U#SL]9['$QB7
M>%2)$!5F@(SG9>]V=LGV KQI8++X BD1I14*WM?F"<Y"28<H:^%:FS&?.G32
M:+TKYN@K!J2' \=^^<!C__XR_F;IU ?\/Z>7ICKR_GV$T+.X33?R<L.>,G&)
M]LE707E5X1S-QAH<].8S[WI:M]@:#0SI6K>#W39.N'T"O3?N%%(S5LV)(!D-
MF\5&#CID[(!,KATV6OY462G_JU:[$;>U&B=PHA_"WK_\TD,S1?:HWG-2DU>P
MP(+^<KI69/!X=6,;_3)N:[$H2N;BV>-[PXV6E[F/=D"KAP]H?+K5#%G,,KD'
M4EBUMP*=4%#)[<.B;ZV85[?*[;_XR:+T1;_\<N/BOEORV-&+!Z7W9-Q?'KD_
M_OCQMLO?\GU& BP/]HG[46(%,@S>--\!7:!,<T8;[_?W&0\;_S1>.1M#5UAW
M+'NDA,^XS4>R>+$1I,>7+L:8,6T68EDCB]7#XUCI%?4]KT#+&/Z[7M#&WKWR
M/:<[$\Y/JZD]8S H1_EZV^I[6@]$#,5NKJ^N ]_BG-\I,S#7KZZ_O/^8-%M:
M8H1UOGA(0@#K]^R3F/ZVJ7*T=,:,;X3=\T@(6Z_7^/\M)5R]<1@+?LS/PQW*
MT51IS;_B?NK;G3T2TN>" N[]I9E\)^ >2)6I&7CJF+>MU\H<SOG!:F"@?'\K
MCDE>891[C$$%V&$@<'(EYW=H].UOA["/T)?-.6DNGZ*X\1\N\+1^1[/E!'%>
MCOJ/PKSNI,0?G?\+D(&DGY@BW!D^BNY2J\>G;Q2'R5+Z3*3)I<VOII%V0/1W
MRMQ@/=)L4I\B%DIV*&A5]4CZN78P+M)K 6Z>?H/7T'$TF-"TE4"XR:D3[_F
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MV@$)XV9+/+V84_F\YUG,U=A&J:>1?WX^G"&>%3>M"9,Q1K_'NNI&87Y.F:;
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MES]&.80\P4I9<,=F$A:J!#*Y[8"F\>QM@@##/#K38< 5@-*$YT"X+TE0<G=
MF= M=F4)OIN21'9**1_=0.\'[/I\"#GK#DS8T[HVIPJ;\M3(OM0[65[[T/-Z
M^_3\D\].J\"_Y&N>=?N64'&S6FC?D9@AI]\.= R@NL65W@&Q*YE.R81 R&PN
M^Q>OM.,,O\]/:<I,2 =/TSV(&G2JX$_"I+G&S'78:)MEQ1)Y/0O7'NTR8B91
MM^JZ9!)IH<Y")]553>F2&)E*0H27^(WBBAO><&A@5F&00MK M<:F\;6RH!A%
M+7LM!*.N'*YZVN8<4?'$LYFBRZT#DI-ME0JN#@]Z.-9TD1 [B90&K-+K_N;K
MZ2\#!Y*CM*PE%U^>VC<1]+F,[J+1;.K26&DH^[6]HB*G6KXGH%+>-H+DMM38
M?.*4<]/RLK.5S+/7_^<HNO\?KCV_/1G[.<?Y V!<?')Q!6H<W##<.9RU_3#=
M&&.52,,0U\40_1LIAWMV0 TZ4246*RO]JD'1B+H?66K/\"T70#;52'W BTE:
M(#UIA*40A,WV+*PG^^T;\0\6('^$*#'6)LG,L++762:I-+,,ZG7CRMA!TF#^
M3<DOG_2R_KM@)2/%FSA9S4ES=;0ST3"VG6ML#)N;:X^*3?/[[0C%X;:A4^:'
MT]1KY?]OO>W.S/\"4$L#!!0    ( '"+J5HX3O H1LX  *W4   -    :6UA
M9V5?,# S+FIP9[R[!U!3[?LV& LB6)#>X55Z[SV2UP(("$CH-2I2 M);E$!$
MZ?65JE3I0@@1"" UTE] :H H/8F(@$"BE".$\/'[[\ZWN]]\N[.SW\P^<^XS
MDSG//.=<Y]SW?5W7G).3+R<KH&LFAL:&H#-GSH#^:YS,@^[\Y]?_TOC/(O^K
M:YPY^01BOPC:/AMP[LP-T%GV,^?8SYST@41!H#-,_]L$T/\^SIP]=Y[I O-%
M%M9+IQ.:KH'.GCEW[NSY<TQ,Y\^?'HT\/0XZS\[$<5WEU@5.RT?,-P*Y5*-?
MEUP4NUW?S0V=I(JK/0YZR<+*P\O'+R A*24M(ZNNH:FEK:-[YZZ!H=$]8Q,K
M:QM;.WL'1[<G[AZ>7G#OX)#0L'#$L^>O8F+CXA,2DS(RL[)S<M^\S2LM*Z^H
MK'I?7=/0B&MJ;OG8VM;3V]<_,/COT/ 487IFEOCEZQR)3/FV^GWMQ_H&[=?O
MW;W] ^#/X7]PG0&=^^_0_Z>XV$]QG3U__MQYYO_@.G,V_#\3V,\S75>YP''+
MDOE1(.<-U>B+7+=?E]1WLXBI0:G<CX,F67G$U4D2M/] ^R]D_^^ O?S_A.R_
M _L_<,V!+I\[<_KPSK&#(" &0[HT"?3_7V3>["I,1_V>S9Y:?(&SO,<G$M^,
M8E5L?\>39-:;]GSWX 2DC_,3Z:1-K.F_V;S/5)H9L'<"TAG\?0+2+@O8$UT3
M.[0,.7R!@SX)'6?&^X^W4 Q)&]ITO'Y67?L)R(GQMP+76U$B_L\):#-X*B4M
MLA4L AFO<GRHP)4?C\63-M,ZU[64L#]0/=E$U#IH0Z8]E[@+(1FNKA6]&:=\
MHJ\OHF#$O>_GWM?YV-+28W$*L#L3&JD1]PFA6$XS!7S\[DC[>U+'K%0T>*B4
ML!(DLDI.7WOM=MDFRJT_I*G\QVP%JX;L%-J\2)(#'5]H8B/3RVZN(6%B(VT>
M$.-CE6H_G%5E8G-=X'6VCK&YZDL[,UR>K^.Z^EQ;6YO9W'HEUE<@PIO+TL!#
MN31)&O0_#VQH*%,V[B <6LXS.S$:&*B>PJ/][J54'MPE_8Q8*O^7HB06,"O4
M6V;83+I?Q[B3(\7*MV52/-^_U&Q7P R7T>XKGK/5\B07#>>1QH[[PABLL*.;
M#HB(%50R$D+:23T!L8-5CNYX/Z^+IQ)=@$!J?%^7W(<.VH5D5,T7&(!RC'AT
M.>]"(\>/YUVES8Y9@>IYML6!SVLM;^=OGH"85(__<:=*]> 3;4] U[#;=$%:
MVH$1 <F-=@0\'0LE\+-=DD;4N$LW7;F:U;Q:>*+T,X]$K=..;^@&E2TY<S?!
M-''6&WJ.G+XSJ5RM+HL.P\JQ>GKZ\+& &!N,C+E*2G[&_<;&;"PW_^B0=Q9\
MH+S&N"G4RS#;V+3&^OO/:2=8I"5,!Q&Q7P=<)[N([L?0>(K)XU*WCG/!5N1B
M9J37K(;@I9$KD%[=Y9=T/4]R,8<XKQ9[C7=S7EAZY'GLLZH_$V"RD_W7M=0)
M1!3F%(W\<2XN&9WO,8,,?U]#UZ42^WQO_#8&(LAR1Z+<_>1CWCLTJ7@D&TGO
MS=:,QGAB7MPKLLLE6XOS\[$S'".6B=]8AV0'954S.MQD%.W-:<FY[=""&D+&
M*K2MVD2U0'=,!9ED863"&7[@OCW\("<'MT*NXHUPZ!X#'TP)#8WV>W<=EW:=
MGF&KA6K:BV+I$J$_&D]#&I0@'R1]I_3H"U!SHYO&K]%OM[9,7<];ZP^&(10'
M>&9"?M#9_'V>*:4XKG(>L3]=,SZ?>9&<.>_+T$"*%_?,::7FDRU>RG?(D2_)
M*=RY1]2 <?XX-(A=;2X)]7_D?;<M>[$E6\U;R_;P2<[OBVOQT&SU/VZFO=\F
M",X'%@O%C7F+ V$6V5_;]8S5&;PA6?D38^M!B_-YBI9=!9/)WF:NRY=2LG)2
M'5JX,E^O[]J]!)3VBP%F"JWF!-2C07/Z=,#AQ="D[?2VY_N,<_PX#)UFR ./
M-XK A) CGY%_/::9X[AS(ATC[N;(Z3U6]/0B]18E;5+B>^:ON%E-[K$)(GS,
M(V5P<O ]X3M] MQ%Z9I8LK%'L@%UJ[(L\/T@]V#"WH4$05\^IHZ/#IC1CJ _
M(W?,'-?1_<8N-Q]36"IQ,R8:,L.:[1G55ZT7R&_F'#5S.\KP<[[H2%KV7L-J
MN/?84KT!\H@ZOU\."-)@-D#L.P R>'CY\/3B"XWN3G7=\ H_S"EVJP9,']"X
M4[M*RN8W]G^YM'P=_<D;MLZ9JZ(Q7?I9I^T*Q_%YG9)*3 A1W4TBM"R%,LHO
MU0A-AB:;53:9H;^8W<23BM)&]33*+*QQ\#V[TYYXAU6Z],7_2IR;.-C?PXXI
M 3+Q6X-DBR_!^Y$THS[8.20_D$B+'_1_MT$ H+T]KMS3&B>@*W"!U"0QE!?B
M.^/3SN0NPO)SI5D&F,3ZU_EK*"/OIIE"S!YN/[R9ZO)UT4"<5[/%TBC0-_!\
MC:V]YTMW1&62@82K#G=VUC^&VMB*E9_$O_[]B/YK#%$6=WT "<GQ> /V\^F9
M"7;V,#8"=Y,VI]!V2IBW*]+$?M)[LI@9H?9'SQ[</,13VPH-#1QD9VV2GJDR
M;)G9&.-(D8O0G@[Y1C#QYO!6]3ZP>ZY>A!$_ 17X S>TZ#Q&E$$ZUPT8#Z"W
M'P.PD"&7?>;"T-+4M;YQ)D#-L05XI%!K6TE>,R3N^?P2(S2]M_=M,5"5^+='
M<Y"$]-]?/*X[ ?F:H@!IR" J&G]&7X8QH;),UZ-">CH]5PYZBF-$+^(@@DC]
M6;H%V6'$6QGI07/_9O&,%'D!J!SX:"SV2Z'E<^HOXAX3"<L,V'7G1<#UKU&_
MQY,B5;YGK.Z>@-C6;1T-\A=,;N6$M]3'7<RS&QP5NQZ\F,!7>U.0Y-F[PX:@
M]$,X<!"6'W.P=*2_9R6<H4"S*2SM10,O1PQMS63GK5JMVK[K,84YN2/_/$K3
M)<XB.@>$F 9%I#R0;J3EN#<P5NT[7!5@WK/N?Y:4P#T/ZR]=>5DA,%UOO_$@
MC8>[AK1IBXXIL>"/+9$W\*_!+H]:/GOB\[ A)8R9W^G(5#"QY':L4*BC<N6/
M7Q2;YX2 Y#4_^X@)Y\P*G2X;W7]B(G?6<DG+=*Z=_7=4YG[_:PA3BB_Q!;;H
M]_X'JG\W&^?<1F9OA9<HZU,EAFA_G<]^L\!GU3O^X->;+++SXS7WN%_O*P;(
MQ4*H+A;I>=9=?$VS^AQ(\'3I<2DRE&(1 VG(30!#PM$P+WTYH(*4+C)"^HB#
M<3@/RN?++]^QV'+85N#_^S%K2XY9%!W8W%<[SF%(_%C2I)Z TAC, '/?G$6?
M/Z<C@C PFY>6DGX"8N%-EG]LKX"\@U+W%^[U_N=V,E>XY8A@PL#4/7)Q2=3
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M['7,37\]GMA4J/CC;-1,S=AW)V!507C(XS)7,^D/EBK%N,A++289)K^'=]T
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MM3=6636DH=4>N?+UW-+0RKU9$R#)ST0&U^:-R4<S:9FUFZ@7>E9,569[5"A
MD_QB[TG)B*^Y1U5M\1C>VY;KQWOAKR(V!U#GNJ00:B1TOS\%QH\PM:+&I:(T
M%L+$[HE(IQ\Q0XG76]^ZJK=/AN0?'=OVFT#RG\'/WW+ZW$V/!MR. AF$4XZ3
M[Y)%P"BVL<$4?QZ$77<U.?WB.O[:ZB1=@G(%<@_70KTKPE</O.*-72DVB>]G
M2#31,$5E%+8/>G/PO,+&6VY\:2[H!40Z@]6*QG,"&BP2G-07HFM/-OFB^@YM
MJGHM+OTX7$O^3D!R*FV=B2"/7_ JDIZ@PX+]RQ<V;'6-HCV(HF;Y-HVY6V=_
M;S4'VZN7B-QD5$-K3&2L4^^9FV;3 V.>U=P>JH89F2 ;X.;0EX5$%>N:W[H-
MR98Y(IW/H5D%SVSNJ\940%5]<D*FO:TPYL[-!="HT7+">A1/5)^H(..R5@\V
MGD=?IA4HI/XF0;9<]=6\7&_2S [BU6%<S@BE?E$FI 5IG&/]P)$W#M<I=2^)
M8@!$H_@)6S_E%>;V!^V+&(]_&P2*%XL;GQ)LUW$9;ATL15ID-J8^$;U:!1BO
M1!K93A#[;#\8KZ2GST9)=TS30R/+E3(F77[,T7-$^&CW6INMV8&7E]8Y5!1Z
MVX_L7IR 5LJ6<18Q&CN)]4@?()+ZVY(ZW@M+U6U#6G926Q*:4BULJ$H]>':
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M?PLME=,2==9'L\TW/2'OC%#;0-S<A\F#L8?&^BHTR,\F&IJ<WL>6P) Y?:2
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MGZ(5:0*BUW7G=>9^<;\V(GC4#;K@;&C?WK)U6YPM(LIFWIJ?#"#*)GCA3_/
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M\HQ&Q6,E3Q\.#&QCD0V=IP_5LY<J7')57OZS(N[J_&;C6*P'RD-AA6MF#A
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M;IO%IUG;3.?,U! ?ZNK=C4IRUQ.O: Y9VS6OI@S:WP+X4=O(VJ;!WIV:U[Y
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M1:YSF4S"/C>DV1Y_X7S"2K-UW %- Q,LO!EE^Z +:W: SWJP!K^[((]BOD-
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M>EX'RY0P+W7X:6ZV5:8'*U=TI%.\!X^.:-U,:J E[$=UBN7ZC'.!1&P1O%&
MG]A7^:_C+.&]$*;#9<W>C;IT=Q6X"-UV%]Q W[28IF+ T =-"LJ'2?Y;KCYJ
MV8ZL!:26W-O?+?,IMG?+H^D44O@;* ]_U#*3?\<.KCNSN()M;6YLC:F'.9M/
M.4><5EWG&G6":Q*H/R,!D:#=0J+Z /+BS52L3O1NGEZZ=I5L;/?-G^W.2^/?
MK0?_O=DU<6F)"OPP9;7K] 8TQ'"P+YFU>TZ,[_-80#=+*9AS2X)&/R?:%<]U
M8:$1 BS3BAW\%KC50;.ZE&G#1PM^ETND)_KB.+EQ*VR]<4NU?O;_UMO5S.X%
M\R NNJ\U?.52H]2"7$3SRH &(R#X6;?,'%D(FR.SJQ< V0WES- ?DODU)_FX
M*I,502R^4< "30(J<!HN$#&\(<=ZKD1E)[CW>8,4%^WW#UX>YH1?G@S9W!^P
M*D&@/H?2,3,_OGFY"/$70"7.#-%@4>U@4>2B<P7"&(TZAD38\_D!2Y_)\C@Q
MIA=6MIST"?7E(*1>MZ6)2N55W?#!J4Q6;?_?= JW?4TP1GU&Q5%5%@I$<WX^
M146+[EL?G?O/#>@V>OW3JMAIZZZ&D"Y>D WP-ILG"Y+$\AX0UL(/F9ALMCA;
M@BR9GRX/E=K;&6:ENC/W-KQWI/.T2E,%S>\^)U"!-\&HWS6XCG7E/D&>\_Z$
M*1=A:'PTANDRK+!O<3Z9;%H,: [F<@,+6 /+SX2?=Y;6U@09H4 @[D9598[A
M9YU[NZY6"QV1<,^+Z"#D>CJ88)S'BE@Y]RJ4F\ X+C!R'1V]6!-.AGI@3QC5
MM69E&)2;+7G\+=_^<BQK5QOZ41?YD!GE=7\'.JXA2!R5TF+(BP3BN9X2$U]R
M"O';LQ7;^[MCT[;GBHWQY1+^.3I1NH9Y4K82#\W:S%)U#I.G_OXL2QKZ#6$A
M!Q(<HWV_A?'ZKHH- 3:2?5@_AOHHYS=CVPZUW B'-ZA>0#EQ$$/-L%VY*LC%
M V29UP:4.9[WOEV!:/\>IM'IOWZJBL_"'Z[%("X2NM:^@?3Q$#H 0?XLHY71
M@&.4?-*AM+MD$=#2U?[6(J+EXOULVG4VZ,<U@E'R$K0?63^0BF4,Q6XF:5S@
MF/NU6^D%5R2RV77%V\W,&\TZ3&=;3XRE"O6+IA<(5P64-Z(U^F[=I5$$;IX;
M(>3?OY1SK84; 4S>080U4@BP6?U3C3H:A,1!8C3XNF=_-4)8GJ3:]ZW2)5EM
M/!7$Q%770]@WBCW>]YQ\FJ_K1]SZ3I;3N4-*%Q]ARS0;P5OG.!M/I?G1);'G
MJ#ZK>.XCGQ)79EQ37JIE[%,A85C%9?K;N_#O!*8OC^^W!M-Q-1N'Y@T\2.RZ
MQ8A/V\O:VJ^N%NMDUCY'"Z5,MHT/&@8/(XB*M2JW=5W2=RS+WC\LH<L05>$;
MNP[9K9^CC!LWOB7UXNB7U%LS/&PJGA:V-K=&/6A7_90K"BM.G&=(2C!_\\6=
M'';: K)!%B FH1?_@*]1%KK%  -GHN#@I5Y[$$$CM0+V0A)R;8M3360N_UH9
MJ_N=>V,Y?J5K.NRL$-\?XI?V'N1V'YZHPZ&G!=WRY(N #FZ<BBQ$ /?:,'KW
M+EXK:EXDE8GF%_07+M^/$(N6]L<U#-(]\G'CGQ0QNO+/_+HRF3V;0NMPHD^V
M/*T#\>/;-(2 %W_@2&)D303Y7L"=CD8*9D8A4<#3\$5K<\LSH<:DU56M-X5]
M8X&9BCT#1Q1GTZA:V-?H6U_]/CSW"=:RV!KG3=>^'G)X9];\L9E5@HQ$0>4F
MGU!$P:?"^(1M<3>10Z16,DVK+#T>R4K8C+>7>H6,FJDWY"=R73+,5:;%V ;'
M]/UHTV:[UP.A3>@Q&Y:G"&(L1]R>51#Y08:";"8=%9B&P@C_65V3BM,0&$*X
M95+!56C6>9Y56FE*> Z5(EXRFZ$.FPW@=HZ@<4HA,#6J]\<L#[5IV%YH>/<1
MT=7%M+$V=;Z^83BF9/"E3O[UFJMP;0)'9E(CF & ZDQZD5T(![BGPG7G_8Z$
MBN:>:'6!7W;FO@A'2!U 3#/$P-$(MG-S!.!/B=1[B27PBVA ?SU,#'OX=X 6
M= D<4^.E. )E6?@I9)K1YZZL=#><W3I%.]<IX[NGCOHKFANA1S5\WT%@AI+<
M($N.S.?R[G]>6<'O/1$0+<+&?7RU-5VF.'I%CZWF>ICCDGG)[G))GB)::%VV
MH"8><0<'U^P'H)'87W)# +7$UU:4RE@M'/(.6_LM(2I*4BU-#@8"+<O)#^)>
M'=F]?.+KO;O+*2$PEZ-FMBSV\(QJ9N+=^3&J=-' J*ILAXF;AS.$YXT<OT!G
M" (RWGL]882U_CQJLC*AUYO3>F7;^AZIR@>7R#8@($3PY55G?+%LYU;W=&N/
MO[G,NVPILR7CV.SN8J'@C6C)#A*:0HLB/M_$0W?M"#8XQ;$/2JE*706K@K6V
M'IFKPKDW/4IM'WPXS-%:)1U;?K/MW/W:=G#P,.YNM_*(O)?4F J$X6-=L!)G
MAD15@)B$N:/QE$D"5[VNFF&3HMC>B^R4C1]_/T+Y3[E@F^<"5O@WZHSJ\9-?
M36IP=9QA<,*7 W))"0^[SS>Z;\[OAQ-?:D'V>'Z7,;ST[;0MQ6RKA*05:D-8
MRU2-$KT[70OB3C2//O[?B8@00%RC@W# M*"/LXP@!WV"R0^T"$A/89L(FV\Z
M'8C9A@"C9_EV8$A)#LC^!C36,BLI.Q@;ZGUE6;$F9K^I2D)7=A?78-Z2I%L2
MIZIQ4C.V!HC_.\2(;I'3M&XAV" N MJP$0Y<TLPSFB";G^C!P6"6;NXM7618
M":;\I]K<&\\S*K;X>"C/@\L: OX3?5EUK>V-*<.K/W#7\U_Z"/:F_TE<_S%[
ME&:VU8P?"?833?]HFC4[;5A>R.WYD#+':9F^)A'8D"E561RF:E]NN[J7ASYI
M,:^" J(9Z?A1)I(1X44Z48B42TC>\\#9W(/VR0G&"= 0KV0F*#!*ZBN_^5,3
M;02;F@JN!CDKO]Y-L!9>%9_M4QMK?,X5$L'R>-U2_-SO,IRV=0M1!D*0&(^U
M\X5O:&XC;BAV= 7U"[+M5S5](<OFD]4 K?4V?]=.RQK&Y]N+N&D+8A?Y^#0R
M\PV9O89Q+7:_L*.YY=6D.1H0L4?E[R#KYM\J)E^C#(7H[$*+M]4VXV1N @^P
MHRSG:!IFJO;Z'(^PGCSZ!F#3.L)F<N'CPRH!1L3 M)V^6*RBBD7 B-C>$0%,
MF@(6_ AJ:R13XOXN$>O-!!,<O L;P05%@UT%:6$-_<?*"<73C(6 GCJ_.L:2
MLZX!""'*',*>SWQ/&6W2FJYV>JM='X.RO[7# <G:"G-DW),J'-K=TQI?;-W3
M[9?U%#DA%1T=>8PPXX>B=2?**H.[HL1-/4?T6BK+VMWG?$TI[&PDVJ+U%1IC
M$V+>-PR%+M/[Q!0Q@6S6>0W2+"9S QX$).D9\2T@KT\L_CMP3YG"=FIJ:N?P
MYT7>8/>564__;W .U*J=EL_5]-#3BF".E;V.!18^0'-KC? X>\1 AR0QH<BH
M\6OQC J"!@9/=%>MUA8@'+,Y>SF#@VLQ*4MVUG;WQQG[&XEWAQ@FU0=OW7%Z
M3J.XOG85O)YFF9G'2U&#X4E?9KNIX0C  2_(L"UP ? F;&*0-)4@)L8SJDBX
M)E$"DJ V4$.L5Q>4P P**$UU.DJX4?CF"A,4K*4+;%?DMRTM9<(J*#1;V#VF
M7G!M2WBG.#919EJ3,!^%D*!,\C!%_S'0D.>(2B[8@O)WWUAP:W=.>U07-S4\
M=;UJ/:'A92*'KX^I#,0E:F,*:8':FTY-)0V;FV6G&G>B.&A;#ZKU![@R^TQ^
MD%KCF[=. G^N@M#M)/^7:0'UIIN6'3^\?!M-C*&EC<9:#QR@%\@0P!N_MM Q
M2+EU6@1VR6-:@W7TVDNU\;3L<9W<<[O^F_Q4F'FW#6@A% S%]7@038;'KA?,
MP\&\-E;P^].?+O0AA-[.;6_N#]^^--K-!K<%0HF8SXO@/FB4O4@]$1S9]'YM
MN+U)FG\E<I=Q8^WGXFKV'?T]+ONIZDN+[NT:A5>Z3A.G0*:?T>+>NC4QW;<1
M(]VB$Z#_P=A[1C7516&#\55!04!$>HD-:0)*$01,+"]@0'JO$1 Q($::! F)
M2H< KU2E1>D=I7>$$! 0D"ZA)A$1$$D4XI44)G[SS9IO9LVLF1\W*VMEW9.3
M??9Y]O/<[+V/7R4ZF)V&MBI&*P+ME;>0'0$KB\ZD,,PQ=%!+LE;R);HX@<'/
M2%+HHQP*#P># <2IV5.(4-\7OI^2$M4)R'F;WN8NI3K C'D-\+)A9W?IC# 3
MX4=1G(UYSG&N>AZ66_5;CEX^X?F3I4[5YX])0)RJ2_XZ!G\F6M@VD5'H<T>H
M2;'(WL'R0T_&4V_OTQD93T^G/[]N+7A=1O@#)?/_DC@A];&LZD>/W?5[]TXI
M5SQW3$6!0#"%IP?.=SR&D\ZN7#COH=./C+DD':28"Z-B!4M3[RRN'=7Q/>B1
MZ!5_\$ZY_:%_CM1Z!CN)OIC2TZO3>WO8R?'XT'O:S7^N\SX7%$"/4_=!G_=!
MC# Z-R2R$"OS*=%=1S_Q)G7H4, "BT B@2-*8V?%-330Y?)"2]TVVB"O]QXL
M>\^H9OXTS5'I3[XI0!JXY*#R_, P^BB[$^H-)H')R?%T'_+O_EK0,-D?LP_J
M>^*/9]0F!%_5L4K8[N6<GF)IEQ-#O /0]3<PB\4C6H>GCE:?;\K32"VO+6T8
M$P?@;K0_=/=XBNQ9!]I@8UN[%".KS'EY7=7_;IWVEW6L_[FF,=FW,5;Z%Z*,
MK C^RGZ_8ADGN),WY'R OE7H\<,_PPNR-,/H"KVI0+<C/:FFD)XY3UC2I,OE
MA-<0[V7M1217LF,]QQ$65TOG3XP7^F<YZ&AL0Q[R<LT@VB5L6HW^!XBF^9"%
M6&>7!;[2D9':?P]GSA++#OV\@Q2Z28F3G]SUVPR75?*X7Y/9^]LR>[QZVM%7
M *DIP^,;_RO0-'6!57V#&:0U]7 I0=E<S>Q;H:3H87%=I>%,02N;+#M>^8^S
MCPM'O&?,E1KRQD9?_2W@PX,[O)DJ0#LC%H#1+,B-39VT;0KQ=V2'%XU)*4TR
M,'VSH/.L<0MYK0FPHZJ*,?_]5+M8@_8AUXJC@H@Z]CJ?;B(1B( @I'^ P3N>
MJX)Y7."7I]^+I"R3=,A"1/7H?-GQKDN8L2SHP=N/EZ3IEPM#5_#Q4L9$5>.>
M/6A"(_RH;W9^#J)<G:4R8D-D9)(R\J9K2=[)?BJQPC<??<S8L0#.GP3SL23I
MD^30'CC85PPOV*4!Z*^8M;X#7E#418%-EPG,*;0,'9+[6XJR0>I<7>US%FM=
MR5,C&*7 FC(\ZZ:TF,8)BM4:<?L@D@[G:#L%G]1UFNZ3U ".?V(<B?8)9YJC
MM8$1<K6[*H1AET/N?T9>/H0*IX![:T65/6HO&-SI.AYKTQ@>,>[DF_G$;G:(
M/FIQ&U-3&=@*^Y15;];('$+.>7P;@C4^SO"U>Z<1C6^(.5_D21XT%U[K1)CX
MCB?\+C6W_^T<$B":H:3?U!VDYVBGY#:9IVR.9DW?(P-0KL6@TQS%;]BW!C_1
MLF;@/GPCUW$MXCA'Z:.)^Z"C(JY$&F;R_1.+^%U^-]L%:=L(?Y;A^1=%Q5&"
MF=VM4U_3-?DM_[8P0>#G>[H.HVVGND2 <#(5&'.8Y!Q#15*.M1'[*]E9!2ZH
M59;5"I(?)43>6NA="A.+B&#Y"397NO7)[G1**<K?*LG\J0W/Z1#?!QVJI8M%
MEZ.O9+D ;TH7O^6+34$D+"H0^7)F082]I"@Y&<"+FG(8;=1*"XV[H!!K/:$-
ME]K$G/ZD7>DRE;KDIJ<J9RDO,I1\'HCGCE5"OSJ66(,VI4TR\$!YT)L>LH4<
MUA.MSX6^>6#Y6@.]O[8"K3?3 59=BP,;0S2G.G1*EP%!X8KSQ36^4D56["A'
MLSJEUQ'PJ0QG<W/?M/Q+TU;I.:OL!<4;EUW7^[4VIDL5RTV*3=[B6KW$\LRF
M$RK*^D6RHW7'0^9QLL;.5;D;@>M#5#VM"A5#HSRE*:N@%_5OL#TPB)(I59&E
M0%&/[.*KMXAROT+;!Q$L2%W[(!-Z3>EC@].4;BF6<1?@3U;BB/8$%/5RE,;=
M&8/:6_9F04RU#8$SC"/5E-2MNU;?P)+0A_"$?1 ?1P=M,^'P'G[T!^<?M#!=
MH6=,$'UM9A<*WL@.[1>XWG7!">$@5(6"]H+GD 7P]27)-*?&3(9TGHE^9;N*
MFY%?",_"LR]2ZBR182J93MP');",J= H81(W%C\C(Q/ C>;X0A=48_&D@?&*
M>OQ>;!_VV#J>I[0CWFSI59CL8G-LB!/+B>'R\G4#,Z+*PJ#Z^-[?^EP^P(H*
M3<$WB _ X_-%:,@$%HSN8$;KCUV!"YN66*@G&APL1& %BFEJU3(ZXAK:L:22
MEK;VJ>#A.%62BY<:7?FV:.Q5A(T%OS(,UJ^]%E>2LUIN+_% WS;C#](<E65_
MLM5'VL@Z.\VV(*<T=*M0YUP)C5:TA;B1_DXTK.)R#=5=ZP)=[CLE7?'&\8>-
M,&-E=4!I[/MR\)Y_4E(*,>EFG]12-P_^#7!CF%S3K)/8N'S$=7XLG)<X KY^
MR'T#SB\_J?HPY%8'[%[=B'SZB0]M 2$_Q[3!6U0J4A@SD*_&+D3+TUX$PR76
MNV5"D,^[)&FA1/W.F[U2 KL?H=+^'.%U=Z7I1I1'5U<C;8?N9ESEYGKSP5W8
MF_:WCE.$#M88A0LP8UOBE#R>"3=D/_:@-E3N?K8X82S*G8_^0,S=X)-V;2Q4
M$"/A[&</$0?J5[ GODU>K[K/#;-02JCJU^H"T-*QZ1,D5>6O03Y:51'ZMG\S
MB%Q1W2N<0MK:P-)%"Y&-Q\LB:MM:7]OI"KA]$/D@/;:WTX9JGD(/=6D&8FD,
M_DJW?[8I/"4V+N/S3@U-+U3M7:ZHUE",\I3OEC>J.0T[P!04AJ;<50248(:&
MC3HQC/\J:J;DG2L+2MZ6F]3*WYMX")D)-)E(FA%K2]+Z0JFX[MGJ;?(XJN)&
MAKIO.=MK\1M'Y._SVUV7[N1NVN@^2(8E1$X10(V93YVBY9=3:F,@IZ8-?%;,
MX -2/[J+USDGW](Z%W_@O=%[9DOX\NV9'[L2;_ WIU6+ZEKB*BM3;LYB5TJ@
M]52 YS>QZ\2T=F7E9\X9,]KH*,&55M/J6PJO:XAPWF,P^!5+NE((\44]!I_\
M_BLD=0Z3>HGH[RD&P"07$WY.\29C)(%)AC,\&LM7U24 A/^;UH,Y.-W@[PP^
MY@NY.(%1N$G-B0]IW?%0_8EXDA>Y2!H+$VZ=FF$YMRP^J"I<ZQ3A'+U"]SW\
MMG46<PEU9F]]'^1#7XGP,ZO[M)OH+X=,$L>*BO=EU_:Y@#[ZQ)KBR0V6@ ;_
M%<TGS0F_U3@W/=ND"1:?YW0;S94K9KC"T6YPV/SN&WN<[!7%[D63XBO.?B_M
M3MC>(ROIC5RYH1.$LRG695[^XZ6@;1V\022-V)2;#:HYF:[#Q;$]MI 3".AQ
MC#2 )' $@;1*E%!?ERY].Y:K\3VWWY,68Y\UX 50(CU+\O3#8\DL[9HAL;&^
M+DF\"VWT#;F_LT%5V<W%3;3Q[/>OR";. <XGR!%V 5JI#%78T^2N_*GDTV[6
M)P,8&2H+/-GNS=>@S50RI%6=)^9=/R%-1^YK7Q6WF=3NU/ X]\)M/3NZZEO/
MJW'HQ=U:0,%X2X B%.LN"*B4LZP >XPD^AP=CO/G KE_ 2I37=1B!2Z+6+HD
ME=],^3/<B.-HC&^C#8L))=_VT*9OW$@(!Y$E]Z/;N("(/TQEE@2011L:^YMI
MHN77)3S3I<QRI3_.H$!/&JX<T7;!'EX7ZY*@82)7_ ]:C/,T)UG[Y)C06,[Y
MQ5>G O!; C?"42=)\[U;.#LUDZS<HC^ERJHU,!,!<A[D_CE*44Y?KVWZZO<I
M+QN21?8EW*CU6NF@M"%)6W3;A]?-Q*&3_8UYM+PA?4W)!G=6(FAL4UFQX/6G
M_TM9(-V+PS=($QG8!S6HL+1I/MR53>D!-Y0FBB+7)KN44;\H/(6T[=O =<U;
M)_3G_7T,6R+M,[=RQ"_-]];]^_&IQG^/L(C-7[\X? %%P)HE^[^NTTNL*\#F
M:\RHNQ+MXYYQ0A5'"2CQB_H4C-I1^;S]4#5$PM]-#7EJJA!'8B<(3"QD?8Z;
M?^<J&5N7)!5269&<"1:)K;:R3O>P>6&7=,5$6QJWWF95J\R:4K;J@UD%?YN)
MVBA66^BT+8_?ZU2RB;YM)V,D)5)189[K;8];"%OOU;2S@UDGR9DT5%IV>NM-
ME9KGMD*XB//<BD. -V5]CT52-\=(.8RW,QCM=;E+8JDH?;(L<76I\S7ZM&,1
M FS^B6517K&AEU'79TV"Z@JO]DEGGN^^5TFWX!P]S71%A[$K+J!#L70X(Y:=
MU\4=0BS6;")XWB(*<X(.CD3;%2__^_Q*B- )1+[\I44SG_(S88QF2\,O^I<4
M%Q+85;6AX*W.$EF[X&Q' XW7ZT966/O5\N^R#E9ZC7XF<FR3:5^'2JM1R$3#
MFJ0BJD7]WHQ2CRUN2:.^3VGT1$+?3TN[0D,;S%">(DR1BW#!2OU6.:5&%W-=
MAVX<V =!8J%K^Z!I4\-'/Q['IYCKT[?WP .TPH.[8VNS-4^8GID)]FY/_]?^
M$LQSW?6QG/\V&IF2\&1LW3Z(5;S)X5/?!]W-8CS:!TW(VG=[*3VUNH5I^1&>
M"LG@"HU^Z/P:XRH;CSF#P!_%7$)C@8@5:!R)F+V\OB0\LQN2Z-32A'X)_TZO
M3/=+Y9LW/@U3\!05K?S\H24T#E4H>Z$^)E!F,^Z7HL<[B;G5/X)V+WTD/M^A
MO;6[Y-A*#OPHIR]\[++<"9O:N R)\4*Q8OLJD=8\YZDRX_Q&Y^#7JQ*_[,KY
M KZF-7@67S&\HE, :]H['_'TEJSYI<$=4,@YAEP1=1,^K,.2,6/>X8PO':4Y
M](P=QO1@CV.44Q*:W'5FU"#G%-ZS%6SH0I^#)79&,IL@IZ>"*P5N3) "T!I-
MYA2/O(\)>ICA00HT"=O8N4 *C2R8P?!C1D./&X1B]%OMZX 4^IF9!T7_H>R'
MKG]%!=UL>9K:UK&RL'A3\?*F)&BZF\0_ .7M7LD#UR%Q7:<!;&^;77[62C5$
MZ/L\_TO2MB7=.$ZM./D(M#'DBKW+UDW+KK2@D;"@LTVLNQ4K0I\-=*B"HGMZ
M 4TW*7#91QP81<RK5SO@2I,"P76TA%>88$G8!]VCTG9/]W_>>'EADX]^4DQ^
M)E;HSD5'EJ&,G128A/HHZXNU=7."\OMPSMS[8W'X40U8%*Y/J9I5_Q#HB_)6
MI-!?Y7OCWD3W>M#>/<Q2KG0N.D,75>"S*MU2AB[V6O_-A;D!/X2^#70RE0 7
M!HY=IPXYA39B%\&)<BKC6R%P7&;;<S^(\*=J=4]3:565?Z?]54^_"W4=^KU^
M[U[&6\]7%Z^Q78 1I@AG&-R@GJ#*0M#Q*]V17:> @DFSQ%O-,XW,*VKJ9R;O
M>-*=58K&4Y0OW_,^] A6P^596. =>3D9SL.19;G0^@((1:AM@IY/W)GG$E$W
M9L*'[W]I:PCF*T6+;,>E:CP2.C5;/[N6KQJP)-2?KTTQU^V[RS7H"SH$ =<;
MU#7EMQ!*("])#+U+BU$YD/H%=>7.HY8+E]V>1CM%V$N@ZP_E5%H7K;=-EEN[
MSUC$4:%\]1WN0LJC+8E1J.;8S7NNT%?4G[A9C0^_VG2K+I]I<LOQ4*'6=3SF
MEVBE2TB.]TTXMEI7E1%>F<O$?L5O+3//(?(UV:DL)%GHF=Q!/7@?7@B0;U"/
M.8XZ3^_0*9\?D"HZOF[I/C_V4&IJOC8KL5PF>D4CWX*[4UG'!QA6[$JLSU47
M:LCVEN;*F @JA&7F]]J0/#QVT@]1X[J0:+8/\HU9NAD>?DZXY/H=-[M1C"MN
M=L?A:3@6_XN#.MD(C"H\K^LP%EDUL)%JJ5)35R38]8[WD+W-D^'.HJ?U3% )
MPE%A%3:ED%NZ9:2+)8U6]NSNLWOF]*]F*Q9QD /V[^^&;0L!B7DKOSX.Q]=_
M_BH9*^$=0GN9>U[#T16O59E05K9"1W6H]%'6/17@I%FBY\:<>4,.JYV+I^\P
MQ&5AZ$/HW,!MP(+6;D?[FD2)T!]XHAX/F:0@UIHG\WN)YY._GI9OT&C)BXKS
M.OPXJ;03%<HZ,<\Y&EO+&<3S<N195]EO5FAP7"-8$C4Z[SJI0%N<9OU'*+E9
M/'#ODZMY[\3=K%&'X*.]*LTV(QC2G2="0SBA3>#7V*;S[$I'K##Q.&7O\Y/&
MH 24>%:IW@]'XYC@4L-^1YA-\"K$))5-S=+>;1R#7M@S0S6GH43C]_16P_KA
MSVC+HD0KJA)!(-,H5GARE)K\YF5%NFY"LD;^Y4Q1RMNIT@L7[NL%)CP*JF_C
M.')5?B/^;5:O]#>.H"^&=UI[FW>C333G_F/,$=IV),N*:E7QK:VF_<#T[MJ4
M*O';6P[AV9>V3!)"M,;*91AN7F_"M93;&*7[>7?]93PMA6S\'I^4+TL[\7E3
MK[EO+"&1 CZ$:A[(1NN$CH2LC)@2Z'/Q#W;P&F03L\!#'_VG,@@..V/:&<4$
ME3%_I/ZIT[<_&2I9+MYX)9H0N: $HN=G7'A$X+L08"AC];JWZ/Z[@N05Y<.6
M0H]X5'JJR;%"E* JJDZU412V\=O*NFUA+.'&B<)=O73?TJ.>D-:81H1EX9:=
M@8"2[@3.P_I2'FJ&[7-A+QCH3D5YD+MCPQYZOW(H)R_Y]+V*D=8<U<PU5X[Q
M;$GA?W5GS5386#'KV%JR4X3,_"64$@6H!,.F!^QJXWL=JJ.&?+T7% A@06RO
M/.U7SY($1&[<0($=2V9#N<X<Y4.H@T$BWS1V'!!\562F7)7J2&HZ^QPFZO3?
M/P%I^"R. 8; $07V071IPO*)CIMT'RHX)L2"=V%^ W)R@G6:LC:A92'D^XD@
M7]76A+_W5J]Z=;&JSF6A79,WZ0,HE(D]^ F+IVVMD[+ :\VK$UV;(ADK 2TF
M*!EW.5V<JHYA;WKN.M%4\'79T.<G+^_FZ9B?2$C G54D]O-G\D&'PA1DZ ['
MZ#PZ":A0G=JTM9>[V3>Z](4L!!(JOJUI]'4,/<_TCQK-?9,0HRYBU&A2TW2^
M6FK:PT'4:K9O6/A%,6( -J&UI;X5FAWIZ#C_.6?S]Z]:I$"'$B^I]AS)8#A^
MZ$\:!(20C#NHS6I (3E'7C#-UK'-U2E;5\J 6G+(\M,WP#:TKS))Z<=VC3:L
M03(DK)98Z0R[?\J/<.S9,6_2U<W_^AQV79Y-@K-.MFRYZP@_PI@2-8;D<VSZ
M;,/D]"1C#GZF^-Q,$[;X_+.M*=K8'<^\JM_[<'2B'3V"+P8T=Y+IT/?.F#.3
MM%_2:1Y8BM*CKK-1NDUA3;"8$1^X M%@9"89KOP2=V8XP-RI2WM )!97S*OL
MFKY2-FGZ2X3!793G*,0^J(D J/*TK]3R$L@23<6<TA53^/'-V_8<Z=WZMQV(
M+6)R5K#715_[1.F(@O.G-&1\MH3FULA:X(-=PB@=<D3+I\LH&XMP#8[$N V!
M="[58%L3YE58E%J<"F%U^)WU_@T)G-YRE(O\>;+Q&_GGA5K^'*^@-@E'@L9'
MQ8DW"7WEES<F"I$^@N9V$F4_!QS;AY9^910.TE\-)+#"\31> 10\QV<Z "W4
M*QFCJ45F90;?*7PZX,6NG=ED^Y!&.T.=9LH6_!3X'II-V.96A'L5G[1R[_GS
M^?_LD]3-$A4GRBG0%+XCZ"(#2_PS$*G[^<HTM5;:/HBXISK;K^K %"'G$9>>
M4?U/,)DZ_5*OQW?G+NSDF4M\K0M[/7FO!58:__I^\=$SG"B'?G@S'+=K(<@Z
M.FMP=64L&7J(\P_+EI[MYH+6H\<.=!^[3L4?2*P5<!JAC)V,Z.X)7'2^W"T;
M&]40X6699VWG<F2%^0!WZ)I,Y>7R9C&J;EM08E)N6K1SB%IZMOE0^I=MAI?5
MW,\&!,QP*B';&I=.51QB!.3I_8>8NUR[==*F*35=VZRDG@M@>'S#/B@!ZE<[
M-W 3&*1*0(1<-F<Y9^ERD6'B[[OE-L G,'*%]W5@]P_')FA?/7NS(QO0U%B>
M,RVM_>S]C\C9ED#(HAQG'S26,M&MW;V2_LG)'3/8%IJLVGT?&;/<L#5&M(B3
M,P#B*]$6 '2%"Z_DQ$V]T;+,K#VAR X^H)TV@R\<+*EP=8)7N(^46X2'*U<L
ME&!-#FSEYG?'H&HZ;N!\AR[A/-,1S1*_ LM-DB3-C%\IZ?X:0M<A@LX7U60C
M,Y/^2*<%_MXH5G+^(5QM?[$S!U9&/%\;3)FL'U?C?5T[H@Z<JV6]JLG8!WG7
M,E[N@V:> HGPXE<RX3N<D#^E_T]UI[)ZTN#BAO^C[7,/VAAPH:U1]D$Q-1VR
M])L]$&GZ<HSZ$40#4@1AWU9<,-0R%^#/B".YZ+?0F97#5TZU)7*</K9J+XU?
M W\<^^Y"!@-*2\^8CSA+F .TB-H^Z'-P74I4A\4;7WB=>0[SQGH65@0B@OI-
MZ)*K@XC,[ER%$L6EI@=2.DYE_WC=)*<ZL3KY0SVZZX4H,:Y!]?@]MF\3N^3O
M,\E8$9?/Z CV?RR[\'M(U>]W@4BF@=\>DBATS(#__L_ES;W8&'6P$3TKMN'E
MFL5Y"375$)6O2SBO4ZG=&*MK8!' E,-WEGD*J&&:CM=@U!%+!^GGFT,"O(M1
M#I22M!JT!EU^=Z1JY'#?XS8'W,[6&;]G,A\^W(T:E/9ZHF]D-S:])Y2,%J6\
M7NOEJ-.ZXP\A5TV"P<<1>MT9YS57!]GXT(!W]$&CO\E-5D#.>P@/O2 ,HTY#
M1G=8%ER.QY)/?=+J=$O5D78Z&\YT6CIE#&[W/OM.].=2)W=!?K&3&X?=GI"6
M5U)BT:>6SK>Z+#[^31[YT4JC6D^IVQ&JO\]RCDYKZ;]X+.&S=>E#VG%'S?\"
MKH'OC\,/PO=!/1"6N%^!\[=N00P$,XT_,C%X)GGB5P]6NK%RLV7EZ0?/IDRX
MU!Q07?-:[I[L0RF8MRT.IG+X*S'E>P9]@.!\(1L9A7W8G3*Q?&1-K&V@SU_A
M/?1X#3G;^FXRC!K!?_WY^JF<PQY*4@V@^4Q"V-.#VU(?LOJD9*16\3$ETPU
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M$L'[(.E"CO@VZ^1!#H[9NP\" KSV0=208$6"T(TD/H1RL))UX:'4E%:3/+V
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MV*-J_4'- /B[@>3N>U P2S;+GOVB1LMO.3(3+@R1__;6'?68_UNP?K?D9]2
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MV&#>F"G<'!FSI^/_/:_6S\]OOCKE(W;>AO$6V*:!J6O?W]&6N1@IT"%2B98
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M+GAS9%!+ 0(4 Q0    ( '"+J5ID=@^"APD  &=C   5              "
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M+3%?86-T:6YI=6TN:'1M4$L! A0#%     @ <(NI6DRZD'UT!P  ;B8  !X
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E!0!I;6%G95\P,#,N:G!G4$L%!@     -  T = ,  +L_!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>ea0239143-10q_actinium_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnm="http://www.actiniumpharma.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnm-20250331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2012-06-15</startDate>
            <endDate>2012-06-15</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-6960">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0" id="ixv-34">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-6961">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-6962">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-50">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-61">001-36374</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-67">ACTINIUM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-77">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-82">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-100">100 Park Ave., 23rd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-6963">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-6964">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-107">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-6965">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-6966">677-3870</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-146">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-151">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-156">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-6967">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-6968">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-190">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-198">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-206">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0" id="ixv-219">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-6969"
      unitRef="shares">31195891</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-6970" unitRef="usd">65325000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-6971" unitRef="usd">72904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-6972" unitRef="usd">1131000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-6973" unitRef="usd">1602000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-6974" unitRef="usd">66456000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-6975" unitRef="usd">74506000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-6976" unitRef="usd">939000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-6977" unitRef="usd">891000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-6978" unitRef="usd">317000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-6979" unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" id="ixv-6980" unitRef="usd">327000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" id="ixv-6981" unitRef="usd">324000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-6982" unitRef="usd">1530000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-6983" unitRef="usd">1685000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-6984" unitRef="usd">17000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-6985" unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-6986" unitRef="usd">68647000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-6987" unitRef="usd">76899000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-6988" unitRef="usd">6520000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-6989" unitRef="usd">7568000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-6990" unitRef="usd">579000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-6991" unitRef="usd">569000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-6992" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-6993" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-6994" unitRef="usd">7110000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-6995" unitRef="usd">8148000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-6996" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-6997" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-6998" unitRef="usd">836000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-6999" unitRef="usd">984000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-7000" unitRef="usd">7000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-7001" unitRef="usd">9000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-7002" unitRef="usd">42953000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-7003" unitRef="usd">44141000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-7004"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-7005"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-7006" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-7007" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="0" id="ixv-7008" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" id="ixv-7009" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-7010" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-7011" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-7012"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-7013"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-7014" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-7015" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" id="ixv-7016" unitRef="shares">31195891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-7017" unitRef="shares">31195891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" id="ixv-7018" unitRef="shares">31195891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-7019" unitRef="shares">31195891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-7020" unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-7021" unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-7022" unitRef="usd">417427000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-7023" unitRef="usd">408553000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-7024" unitRef="usd">-391764000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-7025" unitRef="usd">-375826000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-7026" unitRef="usd">25694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-7027" unitRef="usd">32758000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-7028" unitRef="usd">68647000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-7029" unitRef="usd">76899000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-7030" unitRef="usd">7700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c8" decimals="-3" id="ixv-7031" unitRef="usd">6635000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-7032" unitRef="usd">8938000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c8" decimals="-3" id="ixv-7033" unitRef="usd">2962000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-7034" unitRef="usd">16638000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c8" decimals="-3" id="ixv-7035" unitRef="usd">9597000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-7036" unitRef="usd">-16638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c8" decimals="-3" id="ixv-7037" unitRef="usd">-9597000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-7038" unitRef="usd">700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c8" decimals="-3" id="ixv-7039" unitRef="usd">927000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-7040" unitRef="usd">700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c8" decimals="-3" id="ixv-7041" unitRef="usd">927000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-7042" unitRef="usd">-15938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" id="ixv-7043" unitRef="usd">-8670000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-7044"
      unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-7045"
      unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c8"
      decimals="2"
      id="ixv-7046"
      unitRef="usdPershares">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c8"
      decimals="2"
      id="ixv-7047"
      unitRef="usdPershares">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-7048"
      unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-7049"
      unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-7050"
      unitRef="shares">27886486</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c8"
      decimals="INF"
      id="ixv-7051"
      unitRef="shares">27886486</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c9" decimals="0" id="ixv-7052" unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-7053" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-7054" unitRef="usd">408553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" id="ixv-7055" unitRef="usd">-375826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-7056" unitRef="usd">32758000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c13" decimals="-3" id="ixv-7057" unitRef="usd">8874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-7058" unitRef="usd">8874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" id="ixv-7059" unitRef="usd">-15938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-7060" unitRef="usd">-15938000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c15"
      decimals="0"
      id="ixv-7061"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-7062" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-7063" unitRef="usd">417427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-7064" unitRef="usd">-391764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-7065" unitRef="usd">25694000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c18"
      decimals="0"
      id="ixv-7066"
      unitRef="shares">27634213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-7067" unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-7068" unitRef="usd">373934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-7069" unitRef="usd">-337583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-7070" unitRef="usd">36379000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c23" decimals="-3" id="ixv-7071" unitRef="usd">1378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c8" decimals="-3" id="ixv-7072" unitRef="usd">1378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c22"
      decimals="0"
      id="ixv-7073"
      unitRef="shares">1752050</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c22" decimals="-3" id="ixv-7074" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="-3" id="ixv-7075" unitRef="usd">14694000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c8" decimals="-3" id="ixv-7076" unitRef="usd">14695000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c22"
      decimals="0"
      id="ixv-7077"
      unitRef="shares">10148</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c23" decimals="-3" id="ixv-7078" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c8" decimals="-3" id="ixv-7079" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c24" decimals="-3" id="ixv-7080" unitRef="usd">-8670000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" id="ixv-7081" unitRef="usd">-8670000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c25"
      decimals="0"
      id="ixv-7082"
      unitRef="shares">29396411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-7083" unitRef="usd">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-7084" unitRef="usd">390081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-7085" unitRef="usd">-346253000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-7086" unitRef="usd">43857000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-7087" unitRef="usd">-15938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="-3" id="ixv-7088" unitRef="usd">-8670000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-7089" unitRef="usd">8874000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="-3" id="ixv-7090" unitRef="usd">1378000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="-3" id="ixv-7091" unitRef="usd">205000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c8" decimals="-3" id="ixv-7092" unitRef="usd">216000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-7093" unitRef="usd">-470000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c8" decimals="-3" id="ixv-7094" unitRef="usd">-271000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-7095" unitRef="usd">-1047000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c8" decimals="-3" id="ixv-7096" unitRef="usd">-440000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-7097" unitRef="usd">-138000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c8" decimals="-3" id="ixv-7098" unitRef="usd">-129000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-7099" unitRef="usd">-7574000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c8" decimals="-3" id="ixv-7100" unitRef="usd">-7374000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c8" decimals="-3" id="ixv-7101" unitRef="usd">11000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c8" decimals="-3" id="ixv-7102" unitRef="usd">-11000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" id="ixv-7103" unitRef="usd">2000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c8" decimals="-3" id="ixv-7104" unitRef="usd">2000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c8" decimals="-3" id="ixv-7105" unitRef="usd">14695000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c8" decimals="-3" id="ixv-7106" unitRef="usd">75000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-7107" unitRef="usd">-2000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c8" decimals="-3" id="ixv-7108" unitRef="usd">14768000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-7109" unitRef="usd">-7576000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c8" decimals="-3" id="ixv-7110" unitRef="usd">7383000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-7111" unitRef="usd">73228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c21" decimals="-3" id="ixv-7112" unitRef="usd">76990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-7113" unitRef="usd">65652000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c28" decimals="-3" id="ixv-7114" unitRef="usd">84373000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-1816">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1 - Description of Business and Summary
of Significant Accounting Policies&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;
- Actinium Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;Actinium&#x201d;) is a pioneer in the development of targeted radiotherapies
intended to meaningfully improve outcomes for patients with advanced cancers including relapsed or refractory disease who have failed
existing therapies. It is advancing a pipeline of differentiated clinical stage product candidates focused on validated cancer targets.
Its current pipeline is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene therapies that
the Company believes have high unmet needs that are not addressed by currently available treatment options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Segment Information - &lt;/b&gt;The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#x2019;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2025 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;65,325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;327&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;65,652&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease of corporate office
space.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With
Customers &lt;/i&gt;(&#x201c;ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the
transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in
the contract; and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the
goods or services it transfers to the customer. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements
&lt;/b&gt;- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis,
depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606&lt;i&gt;. &lt;/i&gt;There was no revenue for the three months ended March 31, 2025 and March 31, 2024,
respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue&lt;/b&gt; &lt;i&gt;&#x2013;
&lt;/i&gt;The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;b&gt;&#160;&lt;/b&gt;There
was no grant revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -
&lt;/b&gt;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share
&lt;/b&gt;- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three months ended March
31, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock units
and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;271&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;578&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,165&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2023, FASB issued
ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures&lt;/i&gt;, which provides improvements to reportable
segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires the Company to disclose
significant segment expenses that are regularly provided to the chief operating decision maker, or CODM, and included within each reported
measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable
segment, a description of their composition and provide all annual disclosures about a reportable segment&#x2019;s profit or loss and assets
pursuant to Topic 280 during interim periods. The Company must also disclose the CODM&#x2019;s title and position, as well as certain information
around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and
deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures
required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The Company adopted this standard effective January
1, 2024, and reported in its Annual Report on Form 10-K for the year ended
December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2024, FASB
issued ASU 2024-03,&#160;&lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/i&gt;&#160;(Subtopic
220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03
require disclosures in the notes to the consolidated financial statements and specified information about certain costs and
expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b)
depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are
already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a
qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively.
The amendments in ASU 2024-03 are effective January 1, 2027 and effective for interim periods beginning January 1, 2028. The Company
is currently evaluating the impact of ASU 2024-03 on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2023, FASB issued
ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, to enhance the transparency and decision usefulness
of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income
taxes paid information included in income tax disclosures. The Company is required to disclose additional information regarding reconciling
items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax
rate. Similarly, the Company is required to disclose income taxes paid (net of refunds received) equal to or greater than five percent
of total income taxes paid (net of refunds received). &lt;span style="background-color: white"&gt;The amendments in ASU 2023-09 are effective
January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance.
The Company is currently evaluating the impacts of ASU 2023-09 on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <atnm:NatureOfBusinessPolicyPolicyTextBlock contextRef="c0" id="ixv-1820">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;
- Actinium Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;Actinium&#x201d;) is a pioneer in the development of targeted radiotherapies
intended to meaningfully improve outcomes for patients with advanced cancers including relapsed or refractory disease who have failed
existing therapies. It is advancing a pipeline of differentiated clinical stage product candidates focused on validated cancer targets.
Its current pipeline is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene therapies that
the Company believes have high unmet needs that are not addressed by currently available treatment options.&lt;/p&gt;</atnm:NatureOfBusinessPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-1824">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-1828">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-1832">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-1837">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Segment Information - &lt;/b&gt;The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#x2019;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0" id="ixv-1842">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2025 and December 31, 2024:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;65,325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;327&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;65,652&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease of corporate office
space.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-1846">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at March 31, 2025 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;65,325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;327&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;65,652&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-7115" unitRef="usd">65325000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-7116" unitRef="usd">72904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" id="ixv-7117" unitRef="usd">327000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" id="ixv-7118" unitRef="usd">324000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-7119" unitRef="usd">65652000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-7120" unitRef="usd">73228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-1911">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-1915">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-1919">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With
Customers &lt;/i&gt;(&#x201c;ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the
transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in
the contract; and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the
goods or services it transfers to the customer. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0" id="ixv-1934">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements
&lt;/b&gt;- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis,
depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606&lt;i&gt;. &lt;/i&gt;There was no revenue for the three months ended March 31, 2025 and March 31, 2024,
respectively.&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c0" id="ixv-1956">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue&lt;/b&gt; &lt;i&gt;&#x2013;
&lt;/i&gt;The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;b&gt;&#160;&lt;/b&gt;There
was no grant revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <atnm:LicenseRevenuePolicyTextBlock contextRef="c0" id="ixv-1962">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional. There was no revenue for the three months ended March 31, 2025 and March 31, 2024, respectively.&lt;/p&gt;</atnm:LicenseRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-1982">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-1987">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -
&lt;/b&gt;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-2006">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share
&lt;/b&gt;- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three months ended March
31, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock units
and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;271&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;578&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,165&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-7121">For the three months ended March
31, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock units
and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;271&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;578&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,165&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c29"
      decimals="-3"
      id="ixv-7122"
      unitRef="shares">271000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c30"
      decimals="-3"
      id="ixv-7123"
      unitRef="shares">5421000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c31"
      decimals="-3"
      id="ixv-7124"
      unitRef="shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c32"
      decimals="-3"
      id="ixv-7125"
      unitRef="shares">305000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c33"
      decimals="-3"
      id="ixv-7126"
      unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c34"
      decimals="-3"
      id="ixv-7127"
      unitRef="shares">1439000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="-3"
      id="ixv-7128"
      unitRef="shares">578000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c8"
      decimals="-3"
      id="ixv-7129"
      unitRef="shares">7165000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-2062">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2023, FASB issued
ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures&lt;/i&gt;, which provides improvements to reportable
segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires the Company to disclose
significant segment expenses that are regularly provided to the chief operating decision maker, or CODM, and included within each reported
measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable
segment, a description of their composition and provide all annual disclosures about a reportable segment&#x2019;s profit or loss and assets
pursuant to Topic 280 during interim periods. The Company must also disclose the CODM&#x2019;s title and position, as well as certain information
around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and
deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures
required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The Company adopted this standard effective January
1, 2024, and reported in its Annual Report on Form 10-K for the year ended
December 31, 2024.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="c0" id="ixv-2071">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2024, FASB
issued ASU 2024-03,&#160;&lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/i&gt;&#160;(Subtopic
220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03
require disclosures in the notes to the consolidated financial statements and specified information about certain costs and
expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b)
depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are
already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a
qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively.
The amendments in ASU 2024-03 are effective January 1, 2027 and effective for interim periods beginning January 1, 2028. The Company
is currently evaluating the impact of ASU 2024-03 on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2023, FASB issued
ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, to enhance the transparency and decision usefulness
of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income
taxes paid information included in income tax disclosures. The Company is required to disclose additional information regarding reconciling
items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax
rate. Similarly, the Company is required to disclose income taxes paid (net of refunds received) equal to or greater than five percent
of total income taxes paid (net of refunds received). &lt;span style="background-color: white"&gt;The amendments in ASU 2023-09 are effective
January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance.
The Company is currently evaluating the impacts of ASU 2023-09 on its financial statements.&lt;/span&gt;&lt;/p&gt;</atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-2101">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On
March 27, 2025, a putative class action complaint (the &#x201c;Securities
Complaint&#x201d;) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#x201c;Defendants&#x201d;), styled&#160;&lt;i&gt;Kohil v. Actinium Pharmaceuticals, Inc., et al&lt;/i&gt;., Case
No. 1:25-cv-02553 in the Southern District of New York, wherein, the Securities Complaint alleges that the Defendants made material misrepresentations
and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all Defendants pursuant to section
10(b) of the Securities Exchange Act (the &#x201c;Exchange Act&#x201d;) and Rule 10b-5 promulgated thereunder, as well as additional claims
against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint purports to assert class action claims
on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October 31, 2022 and August 2,
2024.&#160; Plaintiff seeks unspecified damages.&#160; On May 5, 2025, a derivative shareholder complaint (the &#x201c;Derivative Complaint&#x201d;)
was filed against the Company and certain of the Company&#x2019;s directors and officers alleging derivative liability for the allegations
made in the Securities Complaint.&#160; The Defendants have not yet responded to the Securities Complaint, and they intend to vigorously
defend themselves against the plaintiff&#x2019;s allegations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
Company and other Defendants intend to defend vigorously against such
claims, however, there can be no assurances as to the outcome.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:MilestonePayment contextRef="c35" decimals="-6" id="ixv-7130" unitRef="usd">1000000</atnm:MilestonePayment>
    <atnm:NetSalesPercentage contextRef="c35" decimals="2" id="ixv-7131" unitRef="pure">0.02</atnm:NetSalesPercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-2114">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 3 - Leases &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#x2019;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The lease term for all of
the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At March 31, 2025, the Company
has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment. The
Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration
date of July 30, 2027 and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such as insurance,
utilities and maintenance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Supplemental cash flow information related to leases
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;156&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;153&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-28"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-29"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-30"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-31"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;2.3 years&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1.8 years&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#x2019;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands) &lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2025 (excluding three months ended March 31, 2025)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;475&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-32"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(83&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,415&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c0" id="ixv-7132">5 years 2 months</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseExpirationDate1 contextRef="c0" id="ixv-7133">2027-07-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-5" id="ixv-7134" unitRef="usd">600000</us-gaap:PaymentsForRent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-2126">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;156&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;153&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-28"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-29"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-30"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-31"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;2.3 years&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;1.8 years&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-7135" unitRef="usd">173000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c8" decimals="-3" id="ixv-7136" unitRef="usd">173000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" id="ixv-7137" unitRef="usd">2000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c8" decimals="-3" id="ixv-7138" unitRef="usd">2000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" id="ixv-7139" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c8" decimals="-3" id="ixv-7140" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" id="ixv-7141" unitRef="usd">3000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c8" decimals="-3" id="ixv-7142" unitRef="usd">3000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-7143" unitRef="usd">156000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c8" decimals="-3" id="ixv-7144" unitRef="usd">153000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c0" decimals="-3" id="ixv-7145" unitRef="usd">3000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c8" decimals="-3" id="ixv-7146" unitRef="usd">3000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" id="ixv-7147" unitRef="usd">2000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c8" decimals="-3" id="ixv-7148" unitRef="usd">2000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c28" id="ixv-7149">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c28" id="ixv-7150">P1Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c28" decimals="3" id="ixv-7152" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c28" decimals="3" id="ixv-7153" unitRef="pure">0.062</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-2382">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands) &lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2025 (excluding three months ended March 31, 2025)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;475&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-32"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(83&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,415&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c2" decimals="-3" id="ixv-7154" unitRef="usd">475000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c2" decimals="-3" id="ixv-7155" unitRef="usd">8000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="-3" id="ixv-7156" unitRef="usd">643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="-3" id="ixv-7157" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="-3" id="ixv-7158" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="-3" id="ixv-7159" unitRef="usd">1498000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c2" decimals="-3" id="ixv-7160" unitRef="usd">19000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="-3" id="ixv-7161" unitRef="usd">83000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="-3" id="ixv-7162" unitRef="usd">1000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="-3" id="ixv-7163" unitRef="usd">1415000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c2" decimals="-3" id="ixv-7164" unitRef="usd">18000</us-gaap:FinanceLeaseLiability>
    <atnm:OtherRevenueTextBlock contextRef="c0" id="ixv-2461">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 4  - Other revenue &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. There was no grant
revenue recognized for the three months ended March 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 7, 2022, the Company
entered into a license and supply agreement (the &#x201c;License Agreement&#x201d;) with Immedica Pharma AB (&#x201c;Immedica&#x201d;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#x201c;EUMENA&#x201d;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s contract
liabilities are recorded within Other revenue deferred &#x2013; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#x2019;s contract liabilities primarily consist of advanced payments from licensees. Long-term license revenue deferred was $35
million at March 31, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#x2019;s regulatory approval
of Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.&lt;/p&gt;</atnm:OtherRevenueTextBlock>
    <atnm:NonRefundablePaymentReceived contextRef="c36" decimals="-6" id="ixv-7165" unitRef="usd">35000000</atnm:NonRefundablePaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-6" id="ixv-7166" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c2" decimals="-6" id="ixv-7167" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-2488">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5 - Equity&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the Company
entered into the Capital on Demand&#x2122; Sales Agreement with JonesTrading Institutional Services LLC, &#x201c;JonesTrading&#x201d;, pursuant
to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock.
On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#x2122; Sales Agreement (the &#x201c;A&amp;amp;R Sales
Agreement&#x201d;) with JonesTrading and B. Riley Securities, Inc. (&#x201c;B. Riley&#x201d;). The A&amp;amp;R Sales Agreement modifies the
original Capital on Demand&#x2122; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares of common
stock are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the
&#x201c;Prior Shelf Registration Statement&#x201d;). On August 11, 2023, the Company filed a new registration statement on Form S-3 (File
No. 333-273911), which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024, to replace
the Prior Shelf Registration Statement, including a base prospectus which covers the offering, issuance and sale of up to $500 million
of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering,
issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold under the Amended
Sales Agreement. On March 31, 2025, upon filing of the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024,
the Company became subject to General Instruction I.B.6 of Form S-3, pursuant to which in no event will the Company sell its common stock
in a registered primary offering using Form S-3 with a value exceeding more than one-third of its public float in any 12 calendar month
period so long as its public float remains below $75 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company did not sell any
shares of common stock during the three months ended March 31, 2025. During the three months ended March 31, 2024, the Company sold 1.8
million shares of common stock, resulting in gross proceeds of $15.0 million and net proceeds of $14.7 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of stock option activity for the three months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.45&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;271&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.49&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.61&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercisable, March 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three months ended
March 31, 2025, the Company granted new employees options to purchase 25 thousand shares of
common stock with an exercise price ranging from $1.06 to $1.43 per share, a term of 10 years, and a vesting period of 4 years. The options
had an aggregated fair value of $28 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
option-pricing model include: (1) discount rate range from 4.0% to 4.5% (2) expected life of 6 years, (3) expected volatility range from
90.6% to 90.7%, and (4) &lt;span style="-sec-ix-hidden: hidden-fact-51"&gt;zero&lt;/span&gt; expected dividends. During the three months ended March 31, 2024, the Company did not grant any stock options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 31, 2025, the Board of Directors approved of the cancellation
of stock options to purchase an aggregate of 4.9 million shares of common stock held by certain current employees and directors that were
initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated Stock Plan. Such cancellations were
subject to the consent of the applicable holders of the stock options, which the Company received. The cancellation of these stock options
resulted in the recording of $8.7 million in stock compensation expense. During the three months ended March 31, 2024, the Company recorded
compensation expense related to stock options of $1.2 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2025
was $0.4 million related to unvested options, which is expected to be expensed over a weighted average of 2.3 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of restricted stock unit (&#x201c;RSU&#x201d;) activity for the three months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#x2019;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.8 million, was determined based on the stock
price on the dates of the grant and is being recognized over three years. The unrecognized compensation expense at March 31, 2025 of $0.2
million is expected to be expensed over 0.4 years. During the three months ended March 31, 2025 and 2024, the Company recorded compensation
expense related to RSUs of $0.1 million and $0.1 million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activity for the three months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.20&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.77&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c37" decimals="-6" id="ixv-7168" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c38" decimals="-6" id="ixv-7169" unitRef="usd">500000000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c38" decimals="-6" id="ixv-7170" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <atnm:AggregateMarketValueOfCommonStock contextRef="c39" decimals="-6" id="ixv-7171" unitRef="usd">75000000</atnm:AggregateMarketValueOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c22"
      decimals="-5"
      id="ixv-7172"
      unitRef="shares">1800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c22" decimals="-5" id="ixv-7173" unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <atnm:NetProceedFromIssuanceOfCommonStock contextRef="c22" decimals="-5" id="ixv-7174" unitRef="usd">14700000</atnm:NetProceedFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-2499">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of stock option activity for the three months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.45&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;271&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.49&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.61&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercisable, March 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c49"
      decimals="0"
      id="ixv-7175"
      unitRef="shares">5137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c49"
      decimals="2"
      id="ixv-7176"
      unitRef="usdPershares">6.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c50" id="ixv-7177">P7Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c44"
      decimals="0"
      id="ixv-7178"
      unitRef="shares">25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c44"
      decimals="2"
      id="ixv-7179"
      unitRef="usdPershares">1.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c44"
      decimals="0"
      id="ixv-7180"
      unitRef="shares">4891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c44"
      decimals="2"
      id="ixv-7181"
      unitRef="usdPershares">6.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c45"
      decimals="0"
      id="ixv-7182"
      unitRef="shares">271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c45"
      decimals="2"
      id="ixv-7183"
      unitRef="usdPershares">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c44" id="ixv-7184">P7Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c45"
      decimals="0"
      id="ixv-7185"
      unitRef="shares">152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c45"
      decimals="2"
      id="ixv-7186"
      unitRef="usdPershares">7.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c44" id="ixv-7187">P7Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c12"
      decimals="-3"
      id="ixv-7188"
      unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="c12"
      decimals="2"
      id="ixv-7189"
      unitRef="usdPershares">1.06</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c12"
      decimals="2"
      id="ixv-7190"
      unitRef="usdPershares">1.43</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="c40" id="ixv-7191">10 years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c0" id="ixv-7192">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EquityFairValueDisclosure contextRef="c2" decimals="-3" id="ixv-7193" unitRef="usd">28000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c41" decimals="3" id="ixv-7194" unitRef="pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c42" decimals="3" id="ixv-7195" unitRef="pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-7196">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c0" decimals="3" id="ixv-7197" unitRef="pure">0.906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c0" decimals="3" id="ixv-7198" unitRef="pure">0.907</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c43" decimals="-5" id="ixv-7199" unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c0" decimals="-5" id="ixv-7200" unitRef="usd">8700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c44" decimals="-5" id="ixv-7201" unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c45" decimals="-5" id="ixv-7202" unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c44" id="ixv-7203">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-2684">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of restricted stock unit (&#x201c;RSU&#x201d;) activity for the three months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c51"
      decimals="INF"
      id="ixv-7204"
      unitRef="shares">300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c51"
      decimals="2"
      id="ixv-7205"
      unitRef="usdPershares">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c46"
      decimals="INF"
      id="ixv-7206"
      unitRef="shares">300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c46"
      decimals="2"
      id="ixv-7207"
      unitRef="usdPershares">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EquityFairValueDisclosure contextRef="c46" decimals="-5" id="ixv-7208" unitRef="usd">1800000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c46" decimals="-5" id="ixv-7209" unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c47" id="ixv-7210">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c47" decimals="-5" id="ixv-7211" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c48" decimals="-5" id="ixv-7212" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-2763">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activity for the three months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.20&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable, March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.77&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c52"
      decimals="0"
      id="ixv-7213"
      unitRef="shares">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c52"
      decimals="2"
      id="ixv-7214"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c53" id="ixv-7215">P4Y5M15D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c55"
      decimals="0"
      id="ixv-7216"
      unitRef="shares">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c55"
      decimals="2"
      id="ixv-7217"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c54" id="ixv-7218">P4Y2M12D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="c55"
      decimals="0"
      id="ixv-7219"
      unitRef="shares">7</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice
      contextRef="c55"
      decimals="2"
      id="ixv-7220"
      unitRef="usdPershares">17.77</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm contextRef="c54" id="ixv-7221">P4Y</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c0" id="ixv-7222">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c0" id="ixv-7223">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c0" id="ixv-7224">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c0" id="ixv-7225">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c6"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c7"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c0"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c8"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c12"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c14"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c22"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c24"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c24"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c22"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c24"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c0"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c0"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c0"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c8"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities
      contextRef="c0"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities
      contextRef="c8"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c8"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c0"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c8"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="c2"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c49"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c44"
      id="hidden-fact-34"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c44"
      id="hidden-fact-35"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c45"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c45"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c47"
      id="hidden-fact-38"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c47"
      id="hidden-fact-39"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c47"
      id="hidden-fact-40"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c47"
      id="hidden-fact-41"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c47"
      id="hidden-fact-42"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c47"
      id="hidden-fact-43"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c52"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c54"
      id="hidden-fact-45"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="c54"
      id="hidden-fact-46"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c54"
      id="hidden-fact-47"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="c54"
      id="hidden-fact-48"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c55"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue
      contextRef="c55"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-51"
      unitRef="pure"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-7280">0001388320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-7281">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-7282">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-7283">--12-31</dei:CurrentFiscalYearEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
